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Abstract 
 
This project explores the dynamics of medical innovation using the development of 
deep brain stimulation therapy in paediatric neurology as a case study. Ethnographic 
research was conducted with a multidisciplinary clinical team developing a novel 
clinical service that uses deep brain stimulation (DBS) to treat children and young 
people with movement disorders. Interviews and observations were carried out to 
identify key challenges encountered by team members, and to explore the way in 
which team members attempt to manage these challenges in day-to-day clinical 
practice.  
Four key challenges were identified: coordinating multidisciplinary 
teamwork, identifying suitable candidates for deep brain stimulation; managing the 
expectations of patients and families; and measuring clinical outcomes. By exploring 
the strategies used by team members to overcome these challenges, this thesis 
develops the Complex Model of Medical Innovation which challenges prevalent, linear 
‘bench-to-bedside’ understandings of innovation. While scientific ‘discovery’ is one 
source of medical innovation, new therapies in medicine also emerge from 
technology transfer (the transfer of technology from one sector into another) and 
clinicians’ learning-in-practice (the ability of clinician to learn ‘on the spot’).   
Importantly, this thesis demonstrates that technology transfer, learning-in-
practice, and medical innovation in general are shaped by various socio-political 
trends. The activities of the multidisciplinary team and their novel DBS service, for 
example, have been shaped by the evidence based medicine movement, commercial 
interests, and a movement that promotes multidisciplinary approaches to paediatric 
service provision. A consequence of these influences is that the team subjects their 
patients to a broad clinical gaze. Adopting the Complex Model of Medical Innovation 
has important consequences: First, it draws attention to the innovative activities of 
clinicians, activities that may be worth disseminating in other contexts. Second, it 
highlights the role of existing social and material factors in shaping the development 
of new clinical services. The social impact of new technologies will be influenced by 
these contextual factors and cannot be attributed to the technology alone. 
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Preface 
 
This project was first conceived within the London and Brighton Translational 
Ethics Centre (LABTEC).  Established in 2008 and funded by a Wellcome Trust 
grant, the LABTEC initiative aims to explore the various social, ethical and clinical 
challenges arising from the translation of biomedical research into viable medical 
treatments (from ‘bench to bedside’). Two key principles underlie the LABTEC 
initiative. The first is a commitment to interdisciplinarity:  the individuals that 
constitute LABTEC come from diverse disciplinary backgrounds, including 
sociology, philosophy, law, and various health sciences.  The second principle is a 
commitment to “sociology in bioethics”: a conviction that an empirically-derived, 
in-depth knowledge of a clinical practice can inform more appropriate and more 
useful normative statements about such practices.  
Thus, the LABTEC initiative cultivates interdisciplinary research that has a 
substantial empirical component. Four PhD studentships were created in this vein, 
two to be hosted at King’s College London and two at the Brighton and Sussex 
Medical School. Reflecting a recent surge in interest among the social sciences, all of 
the studentships explore topics related to the neurosciences. While the specific 
topics of these studentships were being decided upon, a LABTEC co-applicant 
suggested that a particular paediatric team using deep brain stimulation would 
provide an excellent case-study. After my first and second supervisors approached 
the head of this team and secured his provisional approval, the studentship that has 
become this project was formally established. The studentship was titled “Deep 
brain stimulation and the treatment of children with dystonia” and was described as 
a project that would explore “clinicians’ perspectives on the clinical, social and 
ethical challenges of using deep brain stimulation”.  
In 2010 I was awarded the studentship. Although the scope of the project 
was set, I was granted a considerable freedom: For better or worse I was permitted 
to adopt a theoretical perspective that I felt would be most appropriate, and I was 
given the freedom to decide which specific aspects of the team’s work I would 
focus on. After a great deal of thinking and consultation, I decided to explicitly 
frame the project as an exploration of innovation in medicine.  
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Preface (continued) 
 
A brief note on nomenclature  
While putting this thesis together I have had to make a decision on how I would 
refer people receiving healthcare services. The available terms “patient” and “client” 
are both laden with symbolic baggage: each imply a particular mode of health care 
and a particular form of relationship between receivers and providers. (“Patient” is 
reminiscent of an earlier, ‘paternalistic’ era of health care, while “client” is associated 
with the move towards consumerism and individual choice.) Ideally I would have 
simply employed the same terminology used by the clinicians that feature in this 
project. For the most part, however, the clinicians in this project referred to their 
patients/clients by name, and during those few instances when a general term was 
required, clinicians switched between “patient”, “client” and “children” without any 
apparent logic. I did consider using “children” but some of the patients would be 
more appropriately described as “young adults”. So, in order to avoid clumsy and 
awkward phrasing, I have settled for the all-age-encompassing “patient”. When 
referring to individuals I have used pseudonyms.  
 
  viii 
Acknowledgements 
 
This project was funded by a Wellcome Trust Biomedical Strategic Award (grant 
number: 086034). I must begin by thanking the Wellcome Trust for their generous 
financial support. Throughout my time as a PhD student I have been able to focus 
my efforts on my PhD, without needing to take up any additional paid work.  This 
is a luxury that very few PhD students have. 
 I would also like to thank my student colleagues at King’s College London 
and Brunel University, London. At both institutions I have been surrounded by a 
warm group of students who have provided encouragement, support and coffee.  I 
would particularly like to thank James Porter and Gabby Samuel.  
 I have been extremely fortunate to have two excellent supervisors: Clare 
Williams and Steven Wainwright. Both Clare and Steve have been as enthusiastic 
about my project as I have, and I always came away from our supervision meetings 
feeling inspired. Clare has been especially brilliant. She has been pushy when it was 
needed, she has given me direction when I have floundered, and she has provided 
me with unfailing support over the last three years.  I cannot thank her enough. 
My family has also given me endless support and encouragement.  I thank 
my father, Peter, for reading sections of this thesis and for his very useful 
comments. (I apologise to him for my failure to purge this work of all split-
infinitives).  
 I’m forever grateful to my partner, Matthew.  Many of the ideas in this 
thesis are the product of discussions that we have had. He has helped me to make 
sense of my fieldwork findings and he has reviewed every chapter of this thesis. 
More importantly, he has provided me with constant encouragement and care, 
particularly when I have felt exhausted by it all.  
Finally, I would thank my participants for their time, curiosity, and 
tolerance.  They have shared a part of their professional and personal lives with me 
and they have exposed their activities to the scrutiny of an outsider. Consenting to 
do so would have seemed risky and they could have easily said ‘no’. By saying ‘yes’, 
they have provided me with a wonderful opportunity. I hope this thesis has made 
the most of this opportunity. 
 
 
  ix 
List of abbreviations 
 
ADL   Activities of daily living 
ANT   Actor-Network Theory 
AMPS   Assessment of Motor and Process Skills  
BFM/BFMDRS Burke-Fahn-Marsden Dystonia Rating Scale 
CDT   Child development teams 
COPM   Canadian Occupational Performance Measure 
DBS   Deep brain stimulation 
EBM   Evidence-based medicine 
FDA   Food and Drug Administration 
GAS   Goal Attainment Scale 
GMFM  Gross Motor Function Measure 
GPi   Globus pallidus interna (palladium) 
HDE   Humanitarian Device Exemption 
HTA   Health Technology Assessment 
IMMPACT Initiative on Methods, Measurement and Pain Assessment in 
Clinical Trials 
LABTEC London & Brighton Translation Ethics Centre 
MDT   Multidisciplinary team report 
MRI   Magnetic resonance imaging 
NBIA   Neurodegeneration with brain iron accumulation 
NHS   National Health Service (UK) 
NICE   National Institute of Health and Care Excellence 
PCT   Primary Care Trust 
PI   Principal Investigator 
PIL   Participant information leaflet 
PMDS   Paediatric Motor Disorder Service 
QoL   Quality of Life 
R&D   Research and Development 
REC   Research Ethics Committee 
STN   Subthalamic nucleus 
STS   Science and Technology Studies 
UPDRS  Unified Parkinson’s Disease Rating Scale  
  x 
Participant abbreviations 
 
Adm  Administrator of the PMDS team 
CD  Ex-Clinical Director of Paediatric Services 
CRF  Clinical research fellow 
Dr M.  Dr Martin, Paediatric neurologist (head of the PMDS team) 
JG  John Gardner (author) 
Mm  Patient’s mother 
Neur2  Second paediatric neurologist 
Nur  Specialist paediatric nurse 
OT  Occupational therapist 
Psy  Clinical psychologist 
PT1  Senior physiotherapist 
PT2  Junior physiotherapist 
S&L  Speech and language therapist 








1.1 Novel neurotechnologies: “Where great need meets great uncertainty” 
In 2003 the medical device manufacturer Medtronic gained regulatory approval to 
market their deep brain stimulation technology as a therapeutic intervention for 
dystonia. Other, more standard interventions for managing dystonia, a neurological 
disorder characterised by painful, crippling body postures, are generally considered 
to be crude and ineffective. Medications provide some relief for a small number of 
sufferers, but for many they are ineffective or the side-effects are intolerable. 
Ablative surgery, which involves carefully destroying a specific section of brain 
tissue, may have some therapeutic effect, but this is often short term: the surgery 
will need to be repeated, and as more brain tissue is incrementally destroyed, 
important functions will be irreversibly impaired. As the Nuffield Council on 
Bioethics’ recent report Novel Neurotechnologies (2013) states, dystonia is one of many 
neurological conditions for which there is “a great need” for new, safer and more 
effective therapies. There is a considerable hope among clinicians and sufferers, 
then, that deep brain stimulation will prove to be such a therapy. According to 
proponents it is adjustable and reversible (unlike ablative surgery), and it has proved 
to be remarkably effective in managing the symptoms of other neurological 
disorders such as Parkinson’s. Indeed, the Nuffield Council’s report identifies deep 
brain stimulation as one of several highly promising novel therapeutic innovations 
in neurology.  
The report also highlights the “great uncertainty” surrounding these 
promising innovations. Despite having undergone clinical trials as part of the 
regulatory approval process, there is a lack of useful data concerning the efficacy 
and safety of deep brain stimulation for dystonia. For example, while some sufferers 
have experienced a dramatic reduction in dystonic movements with deep brain 
stimulation, some experience no benefit whatsoever, and there is currently no body 
of literature that can be used to predict how an individual candidate may respond.  
And while the incidence of serious short-term adverse effects appears to be low, 
there is some uncertainty over the long-term effect of stimulating areas of the brain 
that may be implicated in cognition and mood. For these reasons, the Nuffield 
Council’s report suggests that the deep brain stimulation technique occupies a 
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tenuous half-way point between experimental therapy at one extreme and routine 
clinical intervention on the other.    
For clinicians who wish to provide deep brain stimulation therapy as a 
routine clinical intervention these uncertainties present considerable challenges. This 
thesis is based upon a study, using observations and interviews, of a specialist team 
of clinicians as they attempt to overcome such challenges. The team, which I will 
refer to as the Paediatric Motor Disorder Service (PMDS), is based in the UK and is 
one of a few teams worldwide that are currently providing deep brain stimulation 
therapy to children and young people with dystonia. This thesis explores several 
specific challenges encountered by PMDS team members, and it explores how team 
members attempt to manage and overcome these challenges during their day-to-day 
clinical work. The premise of this thesis is that the team’s response to these 
challenges is a vital part of the innovation process. The structure of the team is 
unique within a hospital setting, and team members engage in what could be called 
‘learning-in-practice’: they devise novel routines and practices that, they hope, will 
enable them to successfully utilise deep brain stimulation technology within a 
clinical service for children and young people with dystonia.  The activities of the 
team, then, represent an innovative attempt to address ‘a great need’ while managing 
‘a great uncertainty’.  
Obviously such learning-in-practice does not occur in isolation. PMDS team 
members are situated within a particular social and material context which 
constrains their activities, as well as providing them with various affordances. An 
aim of this thesis is to illustrate how the PMDS deep brain stimulation service has 
been shaped by such contextual factors, and thus to provide some insight into the 
dynamics of contemporary medical innovation. Specifically, this thesis will identify 
several key factors that have shaped the development of a deep brain stimulation 
service for dystonia. These include the evidence-based medicine and rationalisation 
of healthcare movement, commercial interests, pro-multidisciplinarity healthcare 
policy, the patient-centred healthcare movement, and a trend towards shared-
decision making in health care. Using the PMDS as a case study, I will illustrate how 
these factors can influence the way in which ‘promising’ new technologies become 
part of novel clinical services.   
 The research questions of this thesis will be clearly stated towards end of 
this introduction. In the meantime I will provide a more thorough overview of deep 
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brain stimulation and demonstrate why I believe it is worthy of sociological 
investigation. I will also provide a more thorough overview of the PMDS team that 
is the focus of this thesis, and the current policy climate as it relates to deep brain 
stimulation. I will then introduce a model of innovation developed by Piera 
Morlacchi and Richard Nelson (2011). This model provides a conceptual basis for 
this thesis, as reflected by the research questions. It also provides a useful starting 
point for developing what I will argue is a more comprehensive conceptualisation of 
medical innovation, which I will refer to as the Complex Model of medical 
innovation. 
 
1.2 Deep brain stimulation 
Deep brain stimulation (DBS) is a technique that reduces the symptoms of various 
neurological disorders by using a pacemaker-like device to deliver constant electrical 
stimulation to areas deep within the brain.  According to current models of the 
brain, such neurological disorders are the consequence of pathological or damaged 
brain structures which induce abnormal levels of neural activity. This activity 
disrupts normal signaling pathways within the central nervous system, leading to 
uncontrollable motor symptoms such as rigid and stiff muscles or shaking and 
flailing limbs (Montgomery & Gale, 2008). The exact way in which DBS alleviates 
such symptoms is not known. One explanation is that by swamping the problematic 
brain structures with electrical noise it essentially masks the pulsating, cyclic neural 
activity that would otherwise trigger the motor symptoms (Montgomery & Gale, 
2008). DBS is not, then, a cure. It does not repair abnormal brain structures and it 
does not prevent the progressive degradation of brain tissue associated with some 
neurological disorders. So while it may be effective in enabling patients to regain 
some control over the movement of their body, when electrical stimulation ceases, 
so does its therapeutic effect. 
 DBS is currently being used in several movement disorder therapies. Within 
the European Union and North America, regulatory agencies have permitted DBS 
therapies for Parkinson’s, essential tremor, and dystonia. Generally, due to the 
perceived risks and the high-cost of DBS, it is reserved for severe cases of these 
conditions where other, more usual treatments have failed to provide adequate 
therapeutic relief. Parkinson’s is by far the most common disorder treated with 
DBS: diagnoses of Parkinson’s are prevalent in developed countries, it is 
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progressive, and long-term medicinal treatment fails in up to two-thirds of patients 
(Marsden & Parkes, 1977: 348); hence, according to the device manufacturer 
Medtronic over 80,000 people world-wide are using DBS to manage the motor 
symptoms of Parkinson’s (Medtronic 2014).  
 
Figure 1.1: DBS system, implanted components 
 
Figure 1.1: An illustration showing the positions of the implanted DBS system components, 
including neurostimulator, extension wire, and lead (implanted into basal ganglia region of 
the brain).  
 
Some cases of epilepsy are also being treated with DBS, and recently researchers 
began exploring the ability of DBS to treat severe cases of psychiatric illnesses: in 
Europe, DBS has been approved for the treatment of severe obsessive compulsive 
disorder, and in both Europe and the US, pilot trials assessing DBS as treatment for 
depression have recently been completed. In the past, severe cases of these motor 
1: Introduction: “Where great need meets great uncertainty” 
 5 
and psychiatric disorders that failed to respond to medicine-based therapies would 
have been treated with ablative surgery. Proponents of DBS argue that unlike 
ablative surgery, DBS does not cause irreversible damage to brain structures and 
adverse effects are therefore less likely, or easier to manage if they do arise (Benabid 
et al., 1991; Limousin et al., 1995). 
Specialised technology is needed to deliver DBS. Electrical stimulation is 
delivered to the target areas within the brain by at least one lead. A neurosurgeon 
carefully threads the lead into the brain so that the electrodes at one end are placed 
within the target area. The other end of the lead is attached to a flexible extension 
wire, threaded under the skin from the top of the scalp, down the side of the neck 
to the chest (See figure 1.1, page 4). At this point it is attached to an implantable 
pulse generator (IPG), or neurostimulator, implanted under the skin (Talan, 2009:  
xiii). DBS therapies are either monopolar, where one lead is inserted on one side of 
the brain, or biopolar, where two or more leads are used to stimulate both sides of 
the brain. The specific brain area where the electrodes make contact depend on the 
condition being treated, but in motor disorders the target area is one of several 














The neurostimulator (figure 1.2) is very similar in appearance and function 
to a cardiac pacemaker, producing a constant electrical pulse, albeit at a much higher 
frequency than that used to regulate the beating of a heart. A battery makes up most 
of the bulk of the neurostimulator, and depending on the model is either 
Neurostimulator, 
 including battery 
Electrodes 
Insulated leads 
Figure 1.2: Deep Brain Stimulation hardware 
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rechargeable or non-rechargeable.  In rechargeable models the battery is recharged 
transcutaneously: the patient (or a caregiver) presses a recharging ‘paddle’ against 
the area of skin that covers the neurostimulator, ideally once a day for half an hour.  
Non-rechargeable models tend to be used for patients who may have difficulty 
adhering to a recharging schedule.  These batteries last between two and four years, 
after which the entire neurostimulator is surgically replaced.   
Once the components have been implanted within the patient, a clinician 
can programme the IPG via remote control: it can be switched on and off, the 
frequency of stimulation can be altered, and specific electrodes can be activated. It 
may take several weeks of trial and error adjustment before the most efficacious 
stimulation parameters for each particular patient have been determined (Ostrem & 
Starr, 2008: 322). In many cases (particularly with PD) the patient will be given a 
remote programmer enabling them to have some control over the implanted device. 
Importantly, after the device has been implanted and the initial optimal stimulation 
parameters have been identified, DBS patients require long-term skilled clinical 
attention: six-monthly follow-up assessments are necessary to ensure that 
stimulation parameters are indeed still optimal (they often require fine tuning); 
hardware failures, such as broken or migrating leads are not uncommon; and of 
course, for those patients with non-rechargeable stimulators, a neurosurgical team is 
needed to replace the stimulator at least every four years.  
 
The emergence of deep brain stimulation therapies offers an excellent opportunity 
to explore some of the tensions associated with biomedicine and society. On the 
one hand, as the Nuffield Council report states, DBS therapies have shown a great 
deal of promise. DBS therapy for Parkinson’s in particular is currently viewed as a 
sensible and generally effective intervention for patients who fail to respond to 
medicine-based therapies (Bell, Mathieu, & Racine, 2009; Deuschl et al., 2006: 578).  
Most Parkinson’s patients experience a reduction in the severity of the symptoms, 
and some patients have had dramatic improvement in their condition. Indeed, some 
commentators have heralded DBS as providing ‘a new life for people with 
Parkinson’s’ (Chou et al., 2012), and stories of previously housebound patients with 
debilitating symptoms subsequently regaining independence and self-confidence 
with DBS are not uncommon. Proponents also emphasise that because it does not 
damage brain tissue it is a favourable alternative to ablative therapies (Ardouin et al., 
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1999). And, despite the high cost of DBS, there is also emerging evidence to suggest 
that for the long-term treatment of Parkinson’s it is more cost-effective than the 
best alternative treatments (Bell, et al., 2009; Fraix et al., 2006). For these reasons, a 
great deal of hope and high expectations surrounds DBS (Talan, 2009).  
On the other hand there are, as I stated earlier, significant challenges for 
health professionals working with DBS therapies. First, despite the apparent success 
of DBS for treating motor disorders, it is associated with a range of adverse effects, 
some of which can be severe. There are those adverse effects that relate to the 
implantation of the components, such as intra-operative cerebral hemorrhaging and 
post-operative infection, and there are those related to the actual therapy itself, such 
as slurred speech and a range of so-called ‘psycho-social’ effects. In DBS therapy 
for Parkinson’s these include mood elevation, anxiety, aggression and cognitive 
dulling (Synofzik & Schlaepfer, 2011: 3-4). In the longer term, some DBS patients 
have experienced feelings of aimlessness, despair over the years lost to their illness, 
marital problems resulting from mood changes, and suicide (Agid et al., 2006; 
Schüpbach et al., 2006). It is not clear whether these long-term effects are directly 
linked to electro-stimulation itself or if they are the consequence of the major life 
changes resulting from the rapid transition from a severely impaired state to an able-
state. (Bell, et al., 2009). Second, there is a perceived lack of information regarding 
the efficacy of DBS therapies and the frequency and severity of these adverse 
effects. As I stated earlier, while many patients with Parkinson’s or dystonia will 
respond positively to DBS, some patients experience no benefit whatsoever, and 
currently it is not possible to identify into which of these two groups a prospective 
patient will fall (Schlaepfer & Fins, 2010; Synofzik & Schlaepfer, 2011).  
And third, like many novel biomedical developments, DBS is subject to a 
fair amount of media-generated hype. The media has tended to produce “over-
optimistic portrayals” of DBS, focusing on positive outcomes and dramatic, 
individual cases while neglecting to explore the actual, more subtle benefits for the 
majority of those undergoing treatment. (Gilbert & Ovadia, 2011: 2). Racine and 
colleagues (2007) argue that by reporting predominately on DBS ‘miracle stories’, 
the media is creating unrealistic expectations among the public and prospective 
patients, and thus producing additional pressures for clinicians delivering DBS 
therapies. This is particularly problematic with DBS as it often represents the last 
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hope for people with debilitating symptoms who have failed to improve with other 
available treatments (Bell, et al., 2009). 
Some commentators have also drawn attention to the role of commercial 
interests in disseminating DBS technology. The major producer of DBS equipment 
is the Minneapolis-based medical device manufacturer Medtronic. According to 
their most recent annual report, world-wide sales of DBS technology constituted a 
sizeable chunk of their USD 1.8 billion in net revenues in their neuromodulation 
division for the financial year (Medtronic, 2013).  Fins and Schiff (2010) argue that 
the interplay of market forces and scientific inquiry within DBS research has 
resulted in potentially dangerous conflicts of interest. Medtronic, for instance, has 
been accused of misusing a regulatory exemption in order to facilitate the 
dissemination of their DBS technology into a range of therapies (Fins et al., 2011). 
And, from a more philosophical perspective, DBS has been implicated in the 
‘continuous march of technologies that invade and transform the body’, bringing us 
closer to an era of ethically contentious intelligent design, cyborgs and 
mind/machine interfaces (Hester, 2007: 255). Such accounts render DBS a small 
but definite movement towards neurotechnologies with a potential to significantly 
effect that which we think of as ‘human’ (McGee and Maguire, 2007).    
Thus, DBS is not only the source of a great deal of hope, it is also the 
subject of apprehension. It exemplifies important tensions associated with 
biomedicine in contemporary society more generally: a conviction in technology-
orientated solutions, a drive to alleviate suffering, a suspicion of commercial 
interests, doubts over the ability of regulatory initiatives and anxiety over a 
precarious future. For these reasons DBS is an excellent topic of sociological 
investigation. For those of us who are interested in exploring the dynamics of 
medical innovation, such as how the social and technical aspects of medicine may 
shape one another, the relationship between developments in medicine and wider 
social and political context, and the ethical challenges presented by new medical 
technologies, DBS provides an illuminating case study. 
 
1.2.1 Deep brain stimulation in social science research 
A small body of work has explored the ‘social’ aspects of DBS.  Much of this has 
been conducted by French clinical teams as part of their post-operative long-term 
surveillance of patients receiving DBS for Parkinson’s (Agid, et al., 2006; 
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Schüpbach, et al., 2006). These follow-ups have involved standardised Quality-of-
Life and psychological assessments, along with “qualitative psychological 
observations backed-up by a semi-structured psychiatric interview” (Agid, et al., 
2006: 410). It has been these studies that have identified the various ‘psycho-social’ 
problems encountered by some “successfully” treated patients: marital problems, 
feelings of despair over the years lost to the illness, persistent negative anticipation 
of the future, and a loss of aim in life. Some patients, the authors note, have also 
experienced a sense of being dehumanised due to their reliance on a foreign, 
implanted mechanical technology; a feeling of being “an electronic doll” (Agid, et 
al., 2006: 412). Some of these same patients were interviewed by the sociologist Elsa 
Gisquet. Gisquet’s short report in Social Science & Medicine (2008) also highlights the 
day-to-day challenges faced by people with Parkinson’s whose motor symptoms are 
being successfully managed by DBS. Some, she noted, lamented their reliance on a 
specialised medical technology, others experienced troubling changes in mood 
which they attributed to the therapy, and some were frustrated that DBS was not 
providing greater relief. Gisquet goes on to suggest that DBS therapies may pose “a 
unique form of biographical disruption” for patients, and suggests that “a period of 
adaption is required so that patients become used to their new capacities and accept 
the limits of the treatment” (Gisquet, 2008: 1850).  
The experiences of these patients, and clinicians’ responses to them, have 
been more carefully interrogated by Baptiste Moutaud as part of his ethnographic 
study of one of the French clinical centres providing DBS (Moutaud 2011). 
Moutaud paid close attention to the way in which clinicians drew upon various 
explanatory models to make sense of their patients’ responses to DBS. He notes, 
for example, that the clinicians were able to carefully delineate patients’ psycho-
social problems as being a consequence of their inability to reintegrate into ‘normal 
life’, rather than being a direct side-effect of the stimulation. This enabled them to 
frame DBS as ‘successful’, and in the process they effectively drew upon and 
perpetuated a model of personhood characterised by a mind/body rupture (2011: 
186). Patients, in other words, were understood as having a successfully-managed 
neurological disorder, and as having a distressed mind that necessitated further 
psychological care. Moutaud also explored how patients themselves drewupon 
various models of personhood to make sense of their experiences. In contrast to 
their clinicians, some people with Parkinson’s attributed their psycho-social 
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problems to DBS and its direct effects on the brain. Moutaud argues (2011: 190) 
that these patients are, in effect, buying-into and reinforcing a naturalistic, 
neuroscientific discourse that equates behaviour and emotion with neural structures. 
Similarly, patients undergoing DBS for OCD (who were also included in Moutaud’s 
study) employed biological models to understand their illness. These patients made 
sense of their OCD in terms of pathological brain circuits rather than, say, drawing 
upon psychoanalytic models that relate OCD to obsessional neuroses.  Moutaud’s 
study, then, illustrates an interesting social consequence of DBS: it can influence 
how human actors make sense of health, illness and personhood. Indeed, like other 
neurotechnologies (as I will discuss further on), it has been implicated in 
perpetuating brain-based explanations of the self.   
Mautaud’s work demonstrates the value of an ethnographic study of a DBS 
clinical team. It provides the researcher with an opportunity to explore how DBS 
patients and their illnesses are rendered intelligible within actual clinical practice.It 
provides an opportunity, in other words, to witness how a medical innovation is 
implicated in the reshaping of self-perception, identity and notions of personhood.   
Morrison and Bliton are conducting similar sociological research with 
clinicians offering DBS to people with Parkinson’s at Vanderbilt University Medical 
Centre in Nashville, US.  As yet very little work has been published from this study, 
but Morrison and Bliton published an article in the American Journal of Bioethics (2011) 
in which they argue that such research can provide important insights into the ethics 
of new neurotechnologies.  Empirical research, they state, is necessary in order to 
identify those aspects of DBS that are ethically problematic. Indeed, they warn 
ethicists against presupposing which particular issues are ethically problematic 
without taking into account “the crucial dimensions of patient experience” 
(Morrison & Bliton, 2011: 27). Both Morrison and Bliton, and Gisquet (2008), argue 
that extensive examination of the perspectives of DBS patients is needed to guide 
future development of the therapy: “by focusing on outcomes important to patients, 
we become more sensitive to effects patients consider beneficial to their lives” 
(Morrison and Bliton, 2011: 28). For these authors, then, there is a clinical and 
ethical imperative for conducting qualitative empirical research into DBS therapies. 
This project will supplement this small body of work on the social aspects 
of DBS.  In a similar vein to the study of Moutaud, this project will use 
ethnographic methods to explore, among other things, the ways in which patients 
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and their illnesses are rendered intelligible during clinical practice.  And, in response 
to Morrison and Bliton’s argument, this project will also draw on empirical 
observations to reflect upon current discussions on the ethics of deep brain 
stimulation. However, rather than focusing specifically on the experiences of 
patients (as suggested by Morrison and Bliton), this project will focus on the 
perspectives of clinicians, and it will explore their clinical interactions with patients. 
 
1.3 The Paediatric Motor Disorder Service: A multidisciplinary DBS 
service 
The case study for this project is the Paediatric Motor Disorder Service (PMDS). As 
stated earlier, it is using deep brain stimulation technology to provide a therapy for 
children and young people with severe forms of dystonia at a large children’s 
hospital in the UK. The team was established in 2007 by Dr Martin (pseudonym), a 
consultant in paediatric neurology. Dr Martin had become familiar with DBS 
therapy for dystonia via his association with a French team that at the time was 
providing DBS for a range of motor disorders in adults and a small number of 
children (It now also conducts DBS for psychiatric disorders in adults.) Dr Martin 
was awarded a substantial grant from an NHS hospital trust which provided 
sufficient funding to establish a team that could specialize in the management of 
complex motor disorders, and could offer DBS as a key therapy. By the time this 
pool of money was exhausted the service was receiving enough referrals to become 
self-sufficient.  
 The initial NHS grant provided Dr Martin with the sufficient degree of 
financial flexibility to create a team structure that he felt would be most appropriate 
for offering DBS for dystonia in a paediatric context. Consequently, the PMDS was 
established as a multidisciplinary team, and during the duration of this project it 
included nine team members in addition to Dr Martin. These were:  
 
• An additional neurologist (a clinical fellow in paediatric neurology) 
• A clinical nurse specialist  
• Two physiotherapists (PTs) 
• An occupational therapist (OTs) 
• A clinical psychologist 
• A speech and language therapist (S&L) 
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• A therapy assistant 
• A clinical research fellow (training to become a paediatric neurologist)  
Aside from Dr Martin and the clinical research fellow, all members of the team are 
female. This ‘core’ team also worked closely with two neurosurgeons at a nearby 
hospital (where the DBS system implantation is carried out), and with several MRI 
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currently the PMDS is one of only two groups that specializes in providing DBS 
exclusively for children and young people with dystonia. It is also the only group 
that has this multidisciplinary structure: the other prominent specialist team (based 
in Fort Worth, Texas) does utilize the services of a physiotherapist, an occupational 
therapist, a neuropsychologist and a ‘child life specialist’, but their specific roles 
differ from those of the PMDS members. The PMDS is therefore unique, and along 
with the Texan team, it is perceived to be pioneering DBS therapy for dystonia in 
children and young people. More specifically it is pioneering the use of DBS to treat 
a particular category of dystonia, secondary dystonia (which will be described 
further on), that is more common in children than adults. 
 The normal patient pathway through the PMDS (see figure 1.3, page 12) is 
as follows. First, the families of new referrals are sent a questionnaire that explores 
the patient’s level of disability, their medication regime and history of clinical 
interventions. Next, the patient and supporting family members attends a screening 
clinic at the hospital, during which one of the neurologists and several other 
members of the team (generally the occupational therapist and a physiotherapist) 
undertake a preliminary assessment of whether or not the patient is a suitable 
candidate for DBS. This may involve undertaking diagnostic procedures if the 
patient arrives with an unclear diagnosis. If they are a good candidate the patient 
will return at a later date to undergo a series of scans (MRI and PET imaging), an 
information session about DBS, and a regime of pre-surgical assessments, which 
may take several days to complete. These assessments are used to confirm that they 
are indeed a suitable DBS candidate, and to produce a ‘baseline’ measurement of the 
severity of their condition which can later be used to determine the effectiveness of 
the intervention. A range of features are assessed:  
 
• Impairment: the degree to which different regions of the body are affected 
by the motor disorder);  
• Gross motor function: the degree to which the disorder affects the patient’s 
ability to perform ‘major’ movements, such as standing, walking, sitting 
upright;  
• Occupational performance: the ability of the patient to undertake common, 
day-to-day tasks, like brushing teeth; 
• Cognitive: the ability of the patient to perform basic cognitive tasks; 
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• Speech and language: the ability of the patient to verbally communicate. 
This may also include assessing the patient’s ability to chew and swallow 
food items.  
 
The assessment regime is then followed by a goal setting session involving 
the patient, their supporting family members, and most members of the PMDS 
team. During this session the team attempts to identify the family’s goals and to 
ensure that such goals are realistic. The patient and their family are then given 
several months to decide whether or not, in light of these ‘realistic goals’, they 
would like to continue to proceed with DBS. If they do, the patient will undergo 
surgery to have the device implanted at a nearby linked hospital, before being 
brought back to the PMDS for a week of post-surgical recovery as an inpatient in 
the neurology ward of the children’s hospital. It is during this time that the 
stimulator device is activated. From then on the patient and their supporting family 
members will be required to regularly return to the PMDS so that the stimulator 
parameters can be ‘fine-tuned’ and the assessment regime can be repeated. 
Let me now provide a brief overview of the roles of each of the PMDS 
team members (more substantial descriptions will be provided during the course of 
this thesis). The neurologists are responsible for assessing the various MRI and PET 
images in order to determine whether the structural and functional features of the 
patient’s brain will permit the use of DBS: is there, for example, an appropriate, 
intact target area for the electrodes? The neurologists will also work with the 
surgeon to plan the surgical insertion trajectory for electrodes. Again, this involves 
consulting the MRI and PET images. During the patient’s post-operative follow-ups 
it is usually the neurologists who decide upon the stimulation parameters. 
Additionally, the neurologists are also responsible for prescribing and managing the 
patient’s medication from the time of their initial screening: generally, patients are 
on a plethora of medications to manage the symptoms. During the patient’s time 
with the PMDS the specialist nurse is largely responsible for liaising with families 
and helping them to manage their child both before and after the surgery, liaising 
with the surgical team, and coaching the neurology ward staff on how to manage 
DBS inpatients. The nurse, together with the neurologists, is responsible for 
managing any infections that occur. The nurse also leads the DBS information 
session with families. The regime of pre-surgical and post-surgical assessments are 
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carried out by the therapists: the physiotherapists assess gross motor control, the 
occupational therapist assesses the patient’s ability to undertake various activities of 
daily living (self-feeding, hygiene, etc), the speech and language therapist assesses 
the patient’s ability to eat (chew and swallow) and to verbally communicate, and the 
psychologist assesses the patient’s cognitive abilities. The psychologist will also 
work with patients and their families to help manage anxiety, stress and depression 
throughout their time with the PMDS. The therapy assistant provides support to 
the therapists, often helping to set up assessments and record information. In 
addition to carrying out the assessments the therapist will also consult with families 
on how to manage their home life. This may involve helping them work with 
appropriate technologies such as assistive communication devices or mobility aides. 
Importantly, within the PMDS, it is the therapists who direct the goal setting 
session with patients and their families: during the regime of assessments they 
become familiar with the family; a familiarity which they draw upon when helping 
families to set realistic expectations.  
The clinical research fellow is training to become a specialist in paediatric 
neurology, and to this aim, he works alongside the neurologists as an ‘apprentice’. 
His training also requires him to complete a PhD (in addition to his already-
completed medical degree), which involves conducting a research project with the 
team. His particular project involves determining whether or not there is a 
correlation between electrode placement within the target structure of the brain and 
symptom control.  
Thus, the team is roughly divided into two sections: the ‘medical section’, 
which involves the neurologists, the nurse and the clinical research fellow, and the 
‘therapy section’, which includes the therapists, the therapy assistant, and the clinical 
psychologist. The ‘official’ domain of the former group is brain structure and brain 
function assessment, DBS hardware management, and infection management, while 
the domain of the latter is assessing and assisting the patient’s day-to-day functional 
abilities, and managing the expectations of patients and families. 
 
1.3.1 Dystonia and the PMDS cohort 
Dystonia is defined as “a neurological syndrome characterized by involuntary, 
sustained, patterned, and often repetitive muscle contraction of opposite muscles, 
causing twisting movements or abnormal postures” (Jankovic 2007). It can occur 
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seemingly at random in people of any age. While in many cases it may be limited to 
a specific region of the body (focal dystonia, such as cervical dystonia that affects 
the muscles of the neck), in some cases it affects large sections of the body 
(generalized dystonia).  And, in some people dystonia is ‘brought on’ only when 
they attempt particular movements, while in others dystonic movements are present 
at rest. It is often exacerbated by stress and anxiety (Geyer and Bressman 2006). In 
more severe cases, the twisting movements and the resulting abnormal postures are 
intensely painful and severely debilitating. Although the exact pathology of dystonia 
is unknown, dystonia, like other movement disorders, results from abnormal neural 
activity in the structures that make up the basal ganglia, a region deep within the 
brain that is responsible for motor control.  
 Generally dystonia is classified as either ‘primary dystonia’ or ‘secondary 
dystonia’. Primary dystonia is used to describe cases where the dystonia (either focal 
or generalized) is the only neurological condition present (Geyer and Bressman 
2006). It is characterized by an absence of any identifiable brain lesion or structural 
abnormality, and in many cases it is associated with one of several specific genetic 
mutations, such as the DYT1 or DYT6 mutations (although it is not known how 
these specific mutations result in dystonic movements). Primary generalized 
dystonia is often ‘early-onset’, appearing in children who, up until that point, appear 
to have had normal motor system development. At first, dystonic movements are 
restricted to a particular area of the body, often the feet, before ‘spreading’ to other 
regions of the body over a period of several years until it appears to plateau (Marks 
et al. 2009).  As this happens the child becomes increasingly disabled (especially as 
dystonia spreads to the trunk and upper limbs) and the child will require a great deal 
of care and assistance. Estimates of the prevalence of early on-set primary dystonia 
range from 24-50 cases for every million people (Defazio 2010). In this chronic 
form the dystonia itself is not life threatening, but it is not uncommon for such 
individuals to enter into a seizure-like state called status dystonicus.  In this state, 
which can last anywhere from a few hours to several months, dystonic movements 
become so severe that life-threatening complications may ensue, such as renal and 
respiratory failure. Patients with status dystonicus often require management in an 
intensive care unit (Manji et al. 1998). 
Secondary dystonia is used to describe cases where the dystonia results from 
some sort of brain injury.  It is characterized, then, by the presence of a brain lesion 
1: Introduction: “Where great need meets great uncertainty” 
 17 
that is rendered visible with MRI or PET imaging techniques. Depending on their 
exact location these brain lesions can interfere with a number of brain functions, so 
it is not unusual for individuals with secondary dystonia to have a number of 
neurological conditions such as spasticity and cognitive difficulties. A common 
cause of secondary dystonia is brain trauma received around the time of birth. In 
these individuals (who are classified as having a ‘cerebral palsy’), dystonia will often 
present alongside spasticity, muscular-skeletal abnormalities and low muscle tone, 
leading to what clinicians refer to as a ‘complex motor disorder’.  Generally 
secondary dystonia is not progressive.  In children, cerebral palsy is the most 
common cause of dystonia (Marks et al. 2009).  
 There is a subset of secondary dystonia that is progressive however.  This is 
heredodegenerative dystonia, where dystonia is one of manifestation of a genetic 
abnormality that results in the slow and progressive destruction of the structures 
that make up the basal ganglia area of the brain.  A large proportion of these are 
metabolic disorders referred to as Neurodegeneration with Brain Iron 
Accumulation (NBIA). Here, the individual’s inability to produce an essential 
enzymatic protein results in the build-up of particular metabolites within structures 
of the basal ganglia. These metabolites destroy the brain tissue, leading to a gradual 
increase in neurological conditions such as dystonia and spasticity until the point of 
death, which may occur several decades after the original diagnosis (Gregory and 
Hayflick 2005).  Generally as afflicted individuals progressively deteriorate and their 
bodies become increasingly contorted and disfigured, they experience prolonged 
periods of intense physical pain. These NBIA conditions are incurable. Thankfully, 
they are very rare.  
 Both primary and secondary dystonia, particularly less severe cases, can be 
adequately managed with medicine-based therapies (such as benzodiazepines and 
anticholinergics), but there is subset of cases where medicines fail, or where the 
individual is unable to tolerate medication side-effects. It is this subgroup that will 
be considered for deep brain stimulation. At this point in time clinicians believe that 
the most efficacious electrode target area for managing the symptoms of dystonia is 
the globus pallidus internus (GPi) structure within the basal ganglia (Ostrem and 
Starr 2008).   
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Table 1.1: The PMDS patient cohort 
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The Dystonia Medical Research Foundation states that by 2010 around 1000 
individuals worldwide had received DBS therapy for dystonia (Dystonia Medical 
Research Foundation 2010).  Most of these are adults with primary dystonia, and 
according to the small number of reports within published literature DBS has 
proven to be effective in managing their condition. Some of these patients have 
experienced a dramatic improvement, regaining their ability to walk unaided after 
being wheelchair bound for several years (Ostrem & Starr, 2008; Vercueil et al., 
2001). As with other DBS therapies, however, there is considerable variation in 
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improvement rates, with some patients receiving no beneficial effects whatsoever. 
Generally dramatic improvements are far less likely in patients with secondary 
dystonia – according to the very small number of available reports. In these 
patients, if the dystonia itself is alleviated the presence of additional neurological 
disorders such as spasticity and contractures (which do not improve with DBS) will 
limit the degree of functional gain experienced by the patient (Marks et al. 2009).  
By the end of 2012 the PMDS had provided DBS therapy to approximately 
80 children and young people with dystonia. Approximately half of this cohort are 
patients with secondary dystonia, a quarter have primary dystonia, and a quarter 
have some form of heredodegenerative disorder (see table 1.1, page 18). In line with 
the predominantly adult DBS outcomes reported in the literature, the primary cases 
have tended to respond better than secondary cases and several have regained their 
capacity to walk unaided after having been wheelchair bound. DBS is offered to 
patients with a heredodegenerative disorder as part of palliative care: it is intended 
to help alleviate some of the intense pain caused by dystonic contortions rather than 
enable the patient to regain some function. Because that PMDS is the only service 
of its kind within the UK it receive referrals from around the country, including 
Northern Island, Wales and Scotland. The costs of the procedure, as we will see 
below, are covered by the NHS.  Each year the team also accepts a small number of 
‘private’ patients from overseas, a high proportion of whom are from the wealthy 
Gulf states. 
 
1.4 UK policy on DBS therapy for dystonia 
In 2003 DBS therapy for primary dystonia was approved in the US, and therapies 
for both primary and secondary dystonia were approved in the EU. In both 
jurisdictions the therapies are approved for individuals who are seven years and 
older and who have failed to respond to medicine-based therapies.  In the US the 
therapy was approved under the US Food and Drug Administration’s (FDA) 
Humanitarian Device Exemption (HDE).  This form of approval is granted to 
device-based therapies for conditions that affect a small population of individuals; 
populations that are too small to warrant the lengthy and expensive clinical trials 
required to obtain ‘full’ approval. HDE approval, then, does not depend upon the 
demonstration of efficacy but device manufacturers must nevertheless conduct 
small clinical investigations in order to demonstrate that their device ‘does not pose 
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an unreasonable or significant risk of illness or injury’ (U.S. Food and Drug 
Administration 2010). In the EU DBS therapy for dystonia does have ‘full’ 
approval, but the criteria for ‘full’ device approval differ from those of the FDA. 
Indeed, ‘full’ approval does not require a demonstration of efficacy: in addition to 
demonstrating a device’s safety, manufacturers must demonstrate that the device 
performs satisfactorily (i.e, that it does not malfunction)(NCoB 2013: 134). Hence, 
despite obtaining regulatory approval there is as yet no substantial body of evidence 
that demonstrates the efficacy of deep brain stimulation therapies for both primary 
and secondary dystonia.  
Nevertheless, the UK’s National Institute for Health and Clinical Excellence 
(NICE) supports the use of deep brain stimulation therapy for dystonia (both 
primary and secondary). Referring to the small number clinical reports in the 
literature, existing NICE guidelines state: 
 
Current evidence on the safety and efficacy of deep brain stimulation for tremor 
and dystonia… appears adequate to support the use of this procedure (NHS: 
National Institute for Health and Clinical Excellence 2006: 1). 
 
Thus, the NICE guidelines have contributed to the establishment of a context that 
is largely supportive of those who wish to offer DBS therapies for dystonia in the 
UK. In December 2013 the NHS Commissioning Board published a National 
Clinical Commissioning Policy for DBS for movement disorders in adults for the 
population of England. The policy affirms that the evidence supporting DBS is 
sufficient, and states that funding for DBS (including DBS for dystonia) will be 
provided by the Commissioning Board via the appropriate Health Resource Group 
(NHS Commissioning Board 2013).   
 This national policy has followed a heated debate over the effectiveness of 
DBS. Prior to the national commissioning policy, the decision about whether or not 
to fund DBS for dystonia was made by regional Specialist Health Commissioning 
Groups. These groups were responsible for recommending which specialist services 
would be funded by the Primary Care Trusts (which have since been replaced by 
Clinical Commissioning Groups) within their jurisdiction. Most regional groups 
followed the NICE guidelines and released policy statements stipulating their 
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willingness to support DBS therapies for dystonia. As with the NICE guidelines 
these statements drew on the available data produced by the small number of 
clinical investigations to justify their support, but they also stipulate the limitations 
of such data, and state the need for further evidence. The following quote from the 
Specialist Services Commission Group of Wales exemplifies this:  
 
“Whilst all of the studies demonstrate the benefits of DBS in the treatment of 
dystonia, all of the studies have relatively small samples, and limited evidence is 
available on the long term outcomes of dystonia.” (Health Commission Wales 
(Specialist Services): 2009: 10)    
 
One specialist service commissioning group, however, stated that these 
same studies did not provide sufficient grounds for recommending DBS for 
dystonia. The East Midlands Specialist Service Commissioning Group policy on 
DBS stated: “the use of DBS for non-Parkinson’s tremor, dystonia and pain 
disorders is not supported due to a lack of robust evidence.” (East Midlands 
Specialised Commissioning Group 2011: 2). Since most Primary Care Trusts (PCTs) 
within the UK did provide funding for their patients to receive DBS therapy for 
dystonia, the policy of the East Midlands Specialist Service Commissioning Group 
led to what The Dystonia Society (which actively supports DBS therapies) described 
as a DBS “postcode lottery” (The Dystonia Society 2013). The issue became the 
source of some controversy and was the subject of a Channel 4 News Item (4 News 
2012). The Dystonia Society enrolled Lord Macdonald and several MPs including 
Stephen Dorrell, the chair of the Health Select Committee, in a campaign pushing 
for a National Commissioning Policy that would force all PCTs to align their 
position on DBS. The campaign appears to have been a success. Now, all adults 
who meet eligibility criteria will receive funding for DBS for dystonia, Parkinson’s, 
or essential tremor. The total cost of DBS for dystonia is around £80,000 per 
patient over ten years.1 £35 000 of this covers hardware and surgical costs, and the 
remainder covers pre and post-surgical assessments.  
                                                 
1 This cost of £80,000 pertains to paediatric cases receiving a non-rechargeable neurostimulator 
which requires replacement every two-to-four years. For adult cases, the cost is around £5,000 less 
(over ten years).  This is because adults undergo a less rigorous, and thus cheaper, regime of pre- and 
post-surgical assessments. (Medical Services Advisory Committee 2008; Yianni et al. 2005).    
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As yet there is no national commissioning policy for paediatric DBS, so the 
PMDS receives their revenue directly from individual Clinical Commissioning 
Groups. New referrals will only be accepted if they are accompanied by a letter of 
guarantee from their Commissioning Group stating that the funding for the therapy 
has been approved. In the past, Primary Care Trusts within the East Midlands area 
had refused to provide funding, and several families that were wishing to peruse 
DBS with PMDS had moved postcodes in order to fall within another jurisdiction.  
Thus, while the NHS policy environment is generally supportive of DBS 
therapy for dystonia, this ‘postal code lottery’ controversy highlights that potentially 
precarious position of DBS services, particularly a service that provides DBS to 
children. There is still some doubt as to the reliability of the small amount of 
evidence of the efficacy of DBS. 
 
1.5 Conceptualising innovation in medicine 
It is because of this tenuous evidence-base and the associated uncertainty that the 
Nuffield Council’s report described DBS as occupying a realm that is somewhere 
between established clinical therapy and clinical research.  Indeed, deep brain 
stimulation therapy can be described as an innovation in-progress, and for this 
reason the novel PMDS provides an excellent case study by which to explore the 
dynamics of innovation in contemporary medicine. In this thesis I use this case 
study to build upon a model of medical innovation proposed by Piera Morlacci and 
Richard Nelson (2011). Their model provides a useful starting point for this thesis, 
and as we will see in this section, the research questions of the project derive from 
it. There are, however, limitations with the Morlacchi-Nelson model.  It is by 
addressing these limitations and thus building upon their model that this thesis 
makes a novel theoretical contribution to medical sociology. I will introduce the 
Morlacchi-Nelson model by way of a critical overview of a prevalent understanding 
of medical innovation. 
 
The linear, ‘bench-to-bedside’ model of innovation 
Several commentators have argued that an oversimplified, inadequate understanding 
of medical innovation is common among members of the public, various policy 
circles, and parts of the biomedical community (Gelijns and Rosenberg 1994; 
Hopkins et al, 2007; Morlacchi and Nelson 2011). According to this understanding 
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medical innovation is largely a linear process that begins with basic science and 
culminates with a diagnostic or therapeutic application. Here, scientific research 
generates novel knowledge about the body or a disease that leads to the 
development of (or is translated into) a new drug or device.  This drug or device 
then progresses through various stages of clinical trials (during which it is 
incrementally modified), gains regulatory approval, and is subsequently incorporated 
into clinical practice as a finished product (see figure 1.4).   
 
Figure 1.4: A linear model of medical innovation 
 
 
Morlacchi and Nelson (2011) argue that prevalence of this unidirectional, ‘bench-to-
bedside’ understanding of medical innovation has several unfortunate 
consequences. First, the linear model implies that useful therapeutic and diagnostic 
advancements ultimately have their genesis in basic biomedical research. 
Consequently basic biomedical research has received vast amounts of funding from 
governments and agencies, while “other important activities like clinical and health 
services research have been largely neglected” (Morlacchi and Nelson 2011: 512). 
Second, the linear model assumes that clinicians will adopt a drug or device in a 
uniform and predictable manner, as intended by the drug or device’s manufacturer. 
The model does not account for the various ways in which the local specificities of 
clinical contexts may influence how a drug or device is used, and while it presumes 
that clinicians must acquire a new skill set to use the tool, it does not account for 
clinicians’ ‘learning-in-practice’ as a generator of novelty. Learning-in-practice as a 
source of innovation in its own right, is overlooked (Morlacchi and Nelson 2011).    
 We can add more criticisms to those of Morlacchi and Nelson. The model 
assumes something akin to what economists have referred to as demand-pull. Here, 
the innovation process is perceived to be driven by and oriented towards a pre-
identified market demand for, say, a therapy for a particular illness. Innovation, 
then, is perceived as a means of producing solutions to known problems. The wider 
transformative implications of medical innovation processes, such as their impact 
on the professional and institutional structures within medicine (c.f. Pasveer 1989) 
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and their capacity to shape understandings of disease, illness and the body (c.f. 
Martin 1999; Joyce 2006), are disregarded. As the economist de Laat argues, markets 
are the result of the innovation enterprise, rather than an a priori determinant (de 
Laat 2000: 190). The linear model, in other words, ignores the fact that medical 
innovation may entail a constant re-conceptualisation of the problem being 
addressed and often involves an ongoing negotiation of what constitutes a 
satisfactory endpoint. As Brown and colleagues have demonstrated, prospective 
‘endpoints’ are actively constructed and often contested during innovation 
processes (Brown et al. 2000).     
 In a similar vein to Morlacchi and Nelson, other scholars have criticized 
what they refer to as the narrative of a ‘biotech revolution’ (Nightingale and Martin 
2004; Hopkins et al. 2007).  According to this narrative (which presupposes a linear 
model of innovation) biotechnological advancements have the potential to produce 
a vast array of new, highly effective drug therapies and thus “bring about radical 
changes in healthcare” (Nightingale and Martin 2004: 564).  Yet, as Hopkins and 
colleagues argue (2007), the available empirical evidence suggests that the narrative 
is overblown. While there have been considerable changes in the way in which the 
pharmaceutical industry is organized, there has not been a significant, 
corresponding rise in the emergence of useful new drug-based therapies. Indeed, 
Nightingale and Martin argue that the perpetuation of the biotech revolution 
narrative is itself part of the innovation process: it has a performative function as it 
is used to create high expectations and facilitate the formation of pro-biotech 
alliances, thus enabling innovators to gain access to valuable resources such as 
funding, people, and intellectual property (2004: 566). 
 
The Morlacchi-Nelson model of medical innovation 
Based on their empirical exploration of the development of the Left Ventricular 
Assist Device (LVAD), Morlacchi and Nelson (2011) have put forward an 
alternative model of the development of new medical therapies (see figure 1.5, page 
26). They state that while the generation of new knowledge regarding a disease or 
the body is an important component, medical innovation is also the result of two 
other factors: an improvement in the ability to design and use new medical technologies, and the 
ability of health professionals to learn-in-practice.  Improvements in the ability to 
design and use new medical technologies often results from technology transfer: the 
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horizontal movement of a technology, perhaps from an area of industry into 
healthcare, or within healthcare from one clinical specialty to another. ‘Exogenous’ 
advances in electronics, computing and composite materials, for example, have 
brought about considerable changes in diagnostics and clinical therapies. Learning-
in-practice refers to the new skills and knowledge acquired by healthcare workers as 
they attempt to integrate a technology or a drug into an actual, useful, day-to-day 
therapy or diagnostic tool.  This is not, however, just a matter of becoming a 
‘competent’ user via familiarisation with an instruction manual or protocol. 
Learning how to use a technology often entails acquiring tacit knowledge or 
embodied ‘know-how’ that can only be learned through day-to-day clinical practice.   
Learning-in-practice is also a source of novelty in its own right. Successfully 
integrating a technology into a useful therapy or diagnostic tool in clinical contexts 
that are inevitably ‘messy’ often requires health professionals to make impromptu, 
ad-hoc adjustments and thus to learn ‘on-the-spot’. Indeed, many of the day-to-day 
challenges associated with integrating a technology or drug into clinical practice will 
be unforeseen. Thus, as Hopkins and colleagues state “the benefits of new 
technologies do not come from only possessing firm specific assets or 
competencies, but instead require the dynamic capability to effectively transform 
them.” (2007: 568) 
Morlacchi and Nelson point out (2011: 523) that while the relative influence 
of technology transfer, learning-in-practice, and knowledge on the innovation 
process will differ according to the medical therapy in question, all three elements 
interact strongly. While learning how to work with the technology, for example, 
healthcare workers may provide feedback to the manufacturer on how it could be 
improved (2011: 516):  via a process of constant communication between healthcare 
workers and manufacturers the technology undergoes a series of incremental 
adjustments. Additionally, while working with new technologies, healthcare workers 
may acquire a new understanding of the underlying disease. This may subsequently 
inform further learning-in-practice and developments in the technology (2011: 520-
21). According to Morlacchi and Nelson’s model, then, medical innovation is a 
cumulative and incremental process involving ongoing negotiations between 
clinicians, those involved in designing and manufacturing the technology or drug, 
and those working on advancing understandings of disease and the body.   
 





Figure 1.5: The Morlacchi-Nelson model of medical innovation 
 
Adapted from Morlacchi and Nelson 2011 
 
This ‘Morlacchi-Nelson model’ provides a useful starting point for a sociological 
conceptualization of medical innovation and it is a useful starting point for this 
thesis.  First, it draws attention to the role of local specificities in shaping how a 
technology or drug is actually implemented in a clinical service. Technologies, for 
example, are immersed in “relations of other technologies, practices and know-how, 
and it is through their localization in heterogeneous networks that they emerge and 
evolve” (Morlacchi and Nelson 2011: 523).  In other words, the way in which a 
newly introduced technology or drug is understood and is implemented will depend 
on the pre-existing material and social context (Callon 1987; Latour 1987: Berg 
1998). As a result, a technology or drug will seldom be adopted in a uniform and 
predictable manner across clinical contexts.  
Second, the complex model also takes into account the transformative 
nature of innovation. Technologies and practices are mutually constituting and 
interdependent (Morlacchi and Nelson 2011: 521).  Health professionals, for 
example, may respond to the challenges and opportunities presented by a new 
technology by bringing in additional complementary tools and protocols, thus 
actively altering the material and social context within which they work. The 
introduction of a technology, then, can prompt further changes within a particular 
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clinical context. Additionally, Morlacchi and Nelson illustrate that the process of 
innovation often involves the formation and consolidation of novel alliances 
between various professions: the development of the LVAD, for example, involved 
the formation of close ties between cardiac surgeons and engineers (2011: 516).   
A third reason why Morlacchi and Nelson’s model provides a useful starting 
point for a sociological conceptualization of innovation is that it portrays innovation 
as being what complexity theorists have referred to as an ‘emergent property’ 
(Antonelli 2009; Antonelli and Ferraris 2011). An emergent property is generated by 
the numerous interactions within a collective (or an assemblage) of agents. All 
agents within the collective contribute to the emergent property, and the property 
cannot, therefore, be reduced to the activities of any one agent. As Morlacchi and 
Nelson illustrated, the evolution of useful LVAD-based therapies has been a 
collective process involving a network of clinicians (cardiologists, and cardiac 
surgeons), engineers and industrial scientists. The resulting therapy cannot be 
attributed to the activities of any one of these groups, but has, rather, emerged out 
of and has been shaped by, the various and ongoing interactions between them. 
Innovation, then, is a collective process, involving what is often an extensive 
network of agents from a range of disciplinary and professional backgrounds. 
 
1.6 Research questions 
Morlacchi and Nelson’s model provides a conceptualization of medical innovation 
that avoids both technological determinism and social determinism. Progress in 
medicine cannot solely be attributed to either technological (or pharmaceutical) 
advancements or the dissemination of particular understandings of a disease and/or 
the body. Rather, innovation entails what Science and Technology Studies (STS) 
theorists have referred to as the mutual co-construction of both the technological-
material and social domains: technological artefacts both shape, and are shaped by, 
the social relations within which they are embedded (Faulkner 2009). In this thesis I 
adopt a version of Morlacchi and Nelson’s model of medical innovation in order to 
provide a conceptual framework for exploring deep brain stimulation in paediatric 
neurology.  We can, therefore, conceptualize the development of a DBS service for 
children and young people with dystonia as involving: the transfer of DBS 
technology from one clinical area (Parkinson’s therapy) into another; the learning-
in-practice activities of PMDS team members as they learn to adapt the technology 
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into a clinical service for dystonia; and particular understandings of dystonia and the 
motor system, which influence how the technology is adopted, and may also evolve 
or change in the process. By adopting this model, we are drawn to specific areas of 
inquiry if we want to explore the development of a DBS service for dystonia. 
In addition to noting how particular understandings of dystonia and the 
motor system are, along with development of deep brain stimulation technology, 
implicated in the development of novel a service, we are also encouraged to explore 
the role of PMDS clinicians’ learning-in-practice; how it is that they identify and 
learn to manage the challenges in their day-to-day clinical activities. Thus, this leads 
to the first three research questions of this thesis: 
 
1) What factors have shaped the development and dissemination of DBS 
technology? 
 
2) According to PMDS team members, what are the challenges 
associated with the integration of DBS technology into a therapy for 
children and young people with dystonia? 
 
3) How do members of the PMDS team attempt to overcome these 
challenges in clinical practice?  
  
The first of these questions relates to the development and transfer of technology 
and the second and third relate to learning-in-practice. Addressing these will enable 
us to explore how a specific group of clinicians perceive and manage the ‘great 
uncertainty’ associated with a promising neurotechnology as they attempt to meet a 
‘great need’. For example, it will enable us to see how a team of clinicians develop a 
clinical service when there is a lack of information regarding the efficacy of DBS, 
and where media hype has tended to generate unrealistic expectations among 
patients and families. Importantly, addressing these questions will also enable us to 
see the various types of day-to-day work that are entailed in medical innovation; 
work that is necessary to create a service from a newly available technology but is 
generally overlooked in accounts of medical innovation. By doing this we will also 
see how it is that social and technical change can occur in medicine; how it is that 
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the introduction of a technology into a clinical service can entail wider social and 
technological changes.   
However, in the process of addressing these questions, this project will also 
reveal what I believe to be a limitation with the Nelson-Morlacchi model. While the 
model does account for the role of local contextual social and material factors in 
shaping the way in which new clinical therapies emerge, it does not account for the 
influence of what could be called ‘macro’ factors. Indeed, it gives the impression 
that the ‘innovative’ clinical sites in which new clinical services are being developed 
are independent of wider social and political trends, examples of which could be 
healthcare policy initiatives, emerging health-related movements, or prevalent 
approaches to thinking about and dealing with ethical dilemmas in medicine. Such 
socio-political trends tend to traverse individual clinical and research sites, and while 
they will seldom influence each site in a uniform or predictable way, they may 
nonetheless encourage particular patterns of innovation. As Faulkner has put it 
(2009: 24), such trends can constitute “powerful structuring forces that affect the 
capacity of groups to shape a technology” (And we can infer their capacity to 
integrate technologies into new therapeutic or diagnostic services). Faulkner gives 
several examples of these structuring forces relating to device innovation: the close 
intermeshing of the medical device industry and the healthcare state (or what Clarke 
and colleagues (2003) have referred to as the BiomedicalTechnoService Complex), 
the emergence of assertive user-groups and the associated framing of patients as 
active, autonomous citizens, and medical device regulation and device classification 
systems. State policies related to health service provision may also be an example: 
Stuart Blume has illustrated how changes in the US Medicare system facilitated the 
growth of cochlear implants (Blume 2010).  The ‘culture of images’ identified by 
Kelly Joyce in her account of the development of MRI is also an example of a 
socio-political trend (Joyce 2006). Joyce argues that the popularising of images 
brought about by the emergence of television, film and computers in the 1970s 
encouraged engineers to produce diagnostic machines that displayed biomedical 
data as images rather than sets of numbers. Another example of a ‘macro’ trend 
which relates to clinical innovation more broadly is what Keating and Cambrosio 
(2003) have referred to as the transformation of medicine into biomedicine. This 
trend manifests in the emergence of what they refer to as biomedical platforms: 
configurations of healthcare policy, architecture, machines, infrastructure, reagents, 
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protocols and ‘ways of thinking’ that render disease (and health) intelligible in terms 
of an array of biological entities (cellular markers and oncogenes, for example). 
They argue that these platforms have become common place in Western medical 
settings such as hospitals and have a structuring effect on clinical research and 
innovation.      
 In light of this limitation I recommend that an amendment to the 
Morlacchi-Nelson model of medical innovation is necessary. In addition to 
technology transfer, learning-in-practice, and understandings of disease, we can add 
what could be termed the ‘socio-political climate’ to the list of interacting factors 
that generate and shape the innovation of new therapies. Here ‘socio-political’ is 
used in a very broad sense, referring to trends that are not limited to particular, 
discrete clinical settings. Generally (but not necessarily) such trends will have 
become macro ‘structuring forces’ by being encoded in some sort of policy, perhaps 
in national healthcare policy, or in a regulatory agency classification system for 
example. I will refer to this amended Morlacchi-Nelson model as the Complex 
Model of Innovation. By exploring the history of the development of deep brain 
stimulation and the ‘learning-in-practice’ activities of the PMDS, this project will 
expose several socio-technical factors that are shaping medical innovation as it 
relates to deep brain stimulation. As the economist Cristiano Antonelli argues, 
learning is only possible in the “limited spectrum of techniques and conditions, both 
external and internal” to the locale of clinicians, and an analysis of their learning 
process “makes it possible to appreciate the role of a variety of contextual 
constraints in shaping the process.” (Antonelli 2009: 631). So, in the process of 
addressing the first three research questions, this project will also address the 
following: 
 
4) What socio-political trends influence the development of the PMDS’s 
deep brain stimulation service? 
 
By demonstrating how the activities of the PMDS are influenced by socio-technical 
trends, this project will validate The Complex Model of Medical Innovation and 
thus make an original theoretical contribution to medical sociology.    
 Additionally this project will also shed some light on current discussions 
regarding the impact of new medical technologies. Some commentators have 
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suggested that new medical technologies tend to reify reductive, biomedical model-
based understandings of disease and the body (Corea 1985, Klein 1991; Brown and 
Webster 2004). As Webster states, many new medical technologies have enabled the 
medical gaze to peer deeper into the body, thus facilitating the emergence of health 
identities based around biomedical criteria (Webster 2002). Commentators have also 
associated new neurotechnologies with this ‘reification’ of the biomedical model. As 
Singh states, new neurotherapies have been implicated in the emergence of brain-
based explanations of the self (Singh 2013), or what some commentators have 
referred to as the creation of ‘cerebral subjects’ (Ortega 2009; Vidal 2009). 
Moutaud’s (2011) observation that some patients receiving DBS made sense of their 
own behaviour and emotion in terms of their neural networks (and the effect of 
DBS on these networks) is an example of this ‘neurologisation of personhood’.  
Indeed, a significant body of social science work has explored the recent rise 
of neuroscience and its cultural impact (c.f. Pickersgill and Van Keulen 2011; Rose 
and Abi-Rached 2013). As Pickersgill and Van Keulen argue, the neurosciences 
have become an influential and prestigious branch of biomedicine. The tools of 
neuroscience (particularly neuro-imaging technologies) and neuroscientific models 
are increasingly influencing the way in which the ‘classical questions’ (such as the 
nature of human agency and the demarcation between normal and pathological) are 
being addressed (Pickersgill and Van Keulen 2011: xii).  
Sociologists exploring this cultural impact have suggested that a plurality of 
neurological-based understandings of the self and personhood are being 
constructed and drawn-upon in various clinical settings. Rose, for example, has 
traced the emergence of the neurochemical self, in which individuals are rendered 
intelligible in terms of their brain chemistry (2003; 2007). According to this 
understanding, the brain (and thus the individual) is malleable and open to 
improvement via carefully administered psychopharmacology. Indeed, this model of 
the individual is implied (and perpetuated by) psychopharmacological interventions. 
Fein (2011) argues that there has also been an emergence of contrasting brain-based 
explanation of the self: the neurostructural self. Drawing on her study of people 
diagnosed with an autism spectrum disorder, she argues that this particular brain-
based understanding of personhood equates the self with a brain that is largely a 
fixed material system governed by physical laws. The neurostructural self is 
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predictable, and in contrast to the neurochemical self, it is “not open to intervention 
and optimisation” (Fein 2011: 27).     
 Such work has shown that the neurosciences, neurotechnologies and neuro-
interventions have spawned various brain-based explanations of the self, health and 
illness. The tools and models of neuroscience have the capacity, then, to 
substantially influence the way in which people make sense of themselves and the 
world around them. In this particular project I will be studying a team that relies 
heavily on neuro-imaging technologies; a team which also puts electrodes into the 
brains of patients. It therefore represents an excellent opportunity to explore the 
social impact of the neurosciences in a particular context. More specifically, it 
provides an opportunity to explore how bodies, patients and illnesses are actually 
‘constructed’ and rendered intelligible within a clinical setting providing a novel 
neuro-therapy. Are PMDS patients, for instance, ‘reduced’ to biomedical entities? 
Are PMDS patients and their illnesses rendered intelligible in terms of neural 
networks? This leads us to the fifth research question of this thesis. 
 
5)  How are dystonia and patients rendered intelligible during their time 
with the PMDS?  
A fruitful way to address this question is to explore the nature of the clinical gaze of 
PMDS team members. Do they, for example, exercise the objectifying medical gaze 
identified by Foucault (1963), whereby a patient - and ultimately ‘health’ and 
‘disease’ - are rendered intelligible in terms of their body’s (or brain’s) inner shapes, 
forms and textures? Or do they exercise a more extensive gaze that takes into 
account a patient’s experiences and interpretations, for example? 
 
1.7 Summary of thesis chapters 
Using Morlacchi and Nelson’s work as a precedent this thesis is based on a 
methodology that includes both historical and ethnographic methods. It includes an 
historical overview of the development and dissemination of deep brain stimulation 
and I use interviews and observations to explore the day-to-day activities of PMDS 
team members.  
In the following ‘Methodology’ chapter I provide an overview of these 
methods (including their limitations) and I justify why they were chosen.  I will state 
that the methods reflect a particular theoretical approach to exploring and making 
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sense of the social and technical world known as material semiotics.  I outline the 
basic tenets of material semiotics, describe the implications of these tenets for 
sociology, and then illustrate how they entail a set of ethnographic methods: 
observations and interviews. Importantly, I argue, a material semiotics approach 
requires the researcher to explore the role of non-human actors, such as objects, 
instruments and the built environment, in shaping, constraining, enabling and 
transmuting human action.  Additionally, I describe the range of factors that shaped 
the overall scope of this project. These include the process of gaining site access 
and the NHS Research Ethics Committee approval process - both of which placed 
constraints on the data collection process. I conclude this chapter by outlining the 
major challenges encountered by the PMDS that were identified during data 
collection, each of which becomes the focus of subsequent chapters.  
   The remainder of the thesis is loosely structured according to the research 
questions outlined above. Chapter 3, ‘A History of Deep Brain Stimulation’2, 
addresses the first research question. It provides an historical account of deep brain 
stimulation, illustrating the plurality of interests involved in the development and 
stabilisation of deep brain stimulation technology. In doing this, I identify several 
key socio-political trends which have influenced the innovation process and which 
have also shaped the environment within which the PMDS team operates.  
Chapters 4, 5 and 6 address the second and third research questions. Using 
data from the interviews and observations each of these chapters focuses on one 
specific challenge encountered by the team and illustrates how members of the team 
attempt to overcome that challenge. We will see that these challenges and the team’s 
responses to these challenges reflect particular socio-political trends. These chapters 
will also illustrate how, in order to manage the challenges, the team has brought in 
tools, protocols and perspectives from different professions, most notably, 
physiotherapy and occupational therapy. Chapter 4, ‘Coordinating 
Multidisciplinarity’, explores the first challenge: coordinating multidisciplinary 
teamwork. There has been a trend within healthcare policy to encourage 
multidisciplinary service provision with healthcare. Yet as various commentators 
have illustrated, overcoming disciplinary and professional boundaries is challenging. 
                                                 
2 The bulk of this chapter has been published as: Gardner, J. (2013). A history of deep brain 
stimulation: technological innovation and the role of clinical assessment tools. Social Studies of Science 
43(5): 707-728. 
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In this chapter I illustrate how the team attempts to overcome these challenges. 
Specifically I will explore the role of the built environment of the hospital, their use 
of a collective diary and regular team meetings. We will also see that the PMDS 
exercises what could be called a ‘broad’ clinical gaze, aspects of which will be 
examined in the following chapters.  
Chapter 5, ‘Body work & identifying dystonia’, explores the challenge of 
identifying suitable candidates for deep brain stimulation. I illustrate that for the 
PMDS this challenge involves differentiating dystonia (which does respond to DBS) 
from other manifestations of neurological pathology, such as spasticity and muscle 
weakness (which do not respond to DBS).  In order to do this the team relies on 
what I refer to as the body work of the physiotherapists: the ability to use their own 
bodies as a means of generating useful clinical information. Such work, I argue, 
requires the careful construction of an ensemble involving bodies, objects and texts, 
and is an important part of the innovation process.  
 Chapter 6, ‘Managing expectations’, explores how the team attempts to 
manage the expectations of patients and supporting family members. I will begin 
this chapter by providing some background on the emergence of patient rights and 
‘respect for autonomy’ in healthcare. These have placed a burden on health 
professionals to disclose information in a way that is accessible to patients, and to 
respect patient’s wishes. I will illustrate how, in an attempt to overcome this 
challenge, team members use a goal setting session with patients and supporting 
family members. This goal setting session is based around the use of a specific tool 
adopted from occupational therapy which works very much like a script: it delegates 
particular roles to team members, the patient, and family members; and in doing 
this, it encodes particular power relations. Importantly it does this in a way that 
generates what could be considered an ethically favourable mode of 
communication.  
 In Chapter 7, ‘Measuring Clinical Outcomes’, I explore the challenge of 
generating ‘robust evidence’ on the safety and efficacy of DBS. I will begin by 
stating that in an era increasingly dominated by evidence-based medicine (a socio-
political trend), clinicians and researchers are required to generate ‘objective’ 
evidence of a therapy’s efficacy and safety.  For the PMDS team, measuring the 
impact of DBS is particularly challenging due to what team members feel is the 
inadequacy of the widely-accepted clinical assessment tool in neurology for 
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measuring dystonia. In order to overcome this challenge the team has adopted what 
they believe to be a more appropriate tool from occupational therapy. I compare the 
two tools, illustrating how each of them enables data to be extracted from patients, 
and I argue that they encode different understandings of disease. I will argue that 
the team’s adoption of the tool from occupational therapy reflects a general shift in 
many areas of clinical practice towards tools such as Quality of Life measures that 
attempt to measure the ‘social’ aspects of illness.  
In the final chapter I argue that the team’s strategies for managing these 
challenges can be seen as innovations in their own right; they are, I will argue, 
examples of strategies that are vital to establishing new therapeutic or diagnostic 
services but are often overlooked in accounts of medical innovation. I will also 
argue that they provide a specific illustration of how the emergence of new 
technologies can prompt wider social and clinical changes in medicine. Bringing 
together the findings from each chapter, I will then discuss the key socio-political 
trends which have influenced the development of deep brain stimulation and the 
team’s attempts to produce a clinical service. From this I will outline the ‘The 
Complex Model of Innovation. I will then relate my observations on the ‘broad’ 
clinical gaze of the PDMS to current discussions on the relationship between new 
neurotherapies and biomedical-model derived understandings of disease and the 
body. PMDS patients, I will argue, are ‘enacted’ in multiple ways. I will then discuss 
how the findings from this thesis can be used to ‘guide the future of DBS’, referring 
to recommendations put forward by the Nuffield Council and a group of 
neuroethicists. I conclude the thesis by outlining some fruitful avenues of further 






2 Methodology: Exploring innovation in medicine 
 
2.1 Introduction 
Several schools of thought within the social sciences, particularly those that have 
been inspired by ethnomethodology, maintain that social order is the 
accomplishment of everyday interactions between individuals. Through talk and 
action, individuals make sense of, and compose group activities, and from these 
activities emerges what we refer to as ‘society’. Thus, society is a product; it is the 
ongoing consequence of the heterogeneous interactions between numerous and 
diverse individual agents. From this perspective, then, cohesion and social order 
(and disorder) are the effect of the practical reasoning and actions of negotiating 
individuals. Accordingly, scholars such as Harold Garfinkel and Harvey Sacks 
argued that if we wish to gain insight into how and why particular social patterns 
exist, we must observe the everyday, often mundane interactions of individual 
agents. 
I adopt a conception of society that is similar to that of Garfinkel and Sacks 
and consequently the methodology of this project reflects their commitment to 
exploring the every-day, mundane interactions of individuals. The advantage of such 
an approach is that it enabled me to see the ‘messiness’ of using deep brain 
stimulation as a therapy in paediatric neurology. As John Law states (2004: 18-19) 
ethnographic methods allow the researcher to see the diverse, ‘ragged’, and 
contingent ways in which knowledge is created and decisions are made, rather than 
having to rely upon the ‘clean’ narratives of fact-finding and discovery often 
perpetuated in prepared accounts. And importantly, according to the Morlacchi-
Nelson-derived model of innovation that underpins this project, such ethnographic 
methods (in addition to historical methods) enable us to explore the activities that 
constitute medical innovation. In particular they enable us to explore Learning-in-
practice: how clinicians perceive the challenges associated with their work, how they 
bring together a host of tools, resources and knowledge to overcome such 
challenges, and how, in the process, they contribute to the construction of emergent 
phenomena. (Ethnographic methods, then, enabled me to address the second, third 
and fourth research questions, and provide some insights to address the fifth 
research question).    
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While this project has much in common with other ethnographic studies, it 
differs in one major respect. Traditionally, ethnographic studies have tended to 
focus on the interactions of human actors (it is the ‘communicative, perceptual, 
judgemental and other accommodative work’ of ‘persons’ that ‘establish, maintain, 
restore or alter society’, as Garfinkel puts it (1963: 187-188)). When non-human 
elements are included, they tend to be rendered as tools that simply facilitate human 
action, or as blank canvases upon which humans impart meaning.  In this project I 
explore the materially-situated nature of human action. Rather than seeing objects 
and the built environment as mere tools for human action or receptacles for 
meaning, I am assuming that human action is prompted, transmuted, hindered and 
transformed by non-human objects in ways that cannot be reduced to the intentions 
of other human agents. This assumption reflects a particular ontological stance 
which, following John Law (2007), I shall refer to as material semiotics. Again, this 
also aligns with the co-constructionist perspective that underpins the Morlacchi-
Nelson-derived model of innovation (and thus this thesis).  
This chapter will provide an outline of material semiotics and will illustrate 
how a material semiotics ontology entails a set of ethnographic methods.  It will also 
illustrate how such methods have been used in the field of medical sociology. The 
methodology and design of this project is not informed by my material semiotic 
conception of the world alone, however. Like all knowledge-forming endeavours, 
this project has been shaped by a host of influences, most notably the NHS 
research ethics committee approval process and the specific research site, which 
have imposed restrictions on the specific methods of data collection that can be 
used. Thus, before outlining the ontological justification of the design of this 
project, this chapter will describe how these various factors have shaped the design 
of this project.   
 As I have alluded to several times thus far, this project also includes a 
historical research component. This enabled me to identify the various factors that 
have influenced the development and dissemination of DBS technology, and thus 
address question one. This chapter, however, deals with the ethnographic methods 
and practicalities of accessing the field site: I have reserved the discussion of the 
materials and methods of the historical research for the following chapter, where 
the results of the research are also presented.   
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2.2 Gaining site access 
The PMDS is based at a large children’s hospital in the United Kingdom – it is this 
hospital that is the research site for this project. In order to maintain anonymity of 
the team and my participants, I cannot provide too many details about the hospital. 
Suffice to say it is a multilevel complex that contains staff workstations and meeting 
rooms on the top floor, outpatient clinics on the ground floor, and various wards in 
between, one of which is the neurology ward (more details about the hospital built 
environment are provided in chapter four). All clinical work with patients takes 
place within the various spaces of this hospital, except for the surgical procedure to 
implant the DBS system: this takes place at a nearby linked hospital with the 
appropriate neurosurgical facilities.  
Luckily securing provisional access to this case-study site did not prove to 
be too difficult. This is largely due to the work of my first and second supervisors 
who, during their initial scouting of the team as a possible case-study site for the 
studentship, were able to establish something of a rapport with the head of the team 
and ‘gatekeeper’, Dr Martin (pseudonym). During this time, Dr Martin indicated 
that he would be happy for the members of his team to be involved in the project 
(pending the consent of individual team members).  
While securing provisional access to the site was not difficult, it was still 
necessary to negotiate the specific terms on which site access would be granted. 
Shortly after I began the project my first supervisor took me to the field site to meet 
Dr Martin. During this meeting Dr Martin voiced a couple of concerns about the 
project. First, he was concerned that the findings of the project could misrepresent 
the activities of the team, and that he, or some of his staff, could be misquoted. To 
allay these concerns I told him that my intention was not to assess the team’s 
activities, and that he and other members of the team would have some control 
over the data that would be used in the project. Specifically, team members could 
ask to have any data pertaining to them withdrawn after three months of their 
participation (no participants made such a request). We also agreed that it would be 
appropriate for Dr Martin to act as my clinical co-supervisor. In this role he was 
able to clarify any queries I had regarding clinical details of DBS and dystonia, and 
he was be able to guide my access to his team members and patients. We felt at the 
time that such a compromise would not prevent me from exploring the team 
members’ perspectives of their work, nor would it prevent me from addressing the 
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research questions. As Hammersley and Atkinson point out, such adjustments to 
project design are often necessary to secure access from even the most cooperative 
of gatekeepers (2007: 59).  
Like all gatekeepers Dr Martin was bound by his own commitments, and as 
a result he was impelled to direct the scope of the research. Aside from expressing a 
commitment to protecting the reputation of his team, Dr Martin also expressed a 
concern for the wellbeing of his patients. It was important, he stated, that my data-
collection methods did not unnecessarily interfere with this team’s ability to work, 
or place undue stress on patients and their families. After some discussion we 
agreed that two data-collection methods would be feasible: interviews with team 
members and observations of specific interactions, including interactions with 
patients. While this is not the ideal methodology entailed by a material semiotics 
conception of the world (as I will illustrate further on), we nevertheless felt that 
these methods would enable me to collect the data necessary to address the research 
questions of this project. Thus, during this initial meeting, the data collection 
methods of the project had been set.  
Several months later my supervisor and I returned to the fieldwork site to 
meet with other members of the PMDS team. Eight members including Dr Martin 
turned up (two could not be pulled away from clinical duties). I introduced my 
supervisor and myself and I then gave a brief presentation to the team on what it 
was that I was hoping to do.  I made a point of emphasising that, if they agreed to 
participate, they would have some control over the data they contribute, and that 
the design of the project would ensure that as little as possible of their normal work 
would be disrupted.  After the brief presentation I asked team members if they had 
any questions or concerns. The only concern that was raised was about time. One 
member asked if my project was going to take up much of Dr Martin’s time, adding: 
“we already have enough difficulty getting hold of him when we need him”.  I 
replied that it should take up very little of his time, and repeated that aside from the 
interviews, the project as a whole should not take members away from their normal 
work duties.  Generally team members seemed interested and curious in the project 
and said that as long as it didn’t take too much of their time, they would certainly 
consider participating. At this stage, then, I was ready to begin putting together the 
various documents required to get ethics approval 
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2.3 The NHS Research Ethics Committee approval process 
Because this research was taking place within the National Health Service the 
project required a “favourable opinion” from an NHS research ethics committee 
(REC). Once I had some idea of the data collection methods I would use and 
PMDS team members had indicated that they would consider taking part, I 
compiled the documents required for REC approval. Within this documentation I 
was able to argue that the specific data-collection methods that had been selected 
would not, according to a specialist health professional (Dr Martin), unnecessarily 
disrupt the team’s work, nor cause undue stress to patients and their 
family/caregivers. It was also necessary to explicitly stipulate the aims of the 
fieldwork. Thus, I stated that my aims were to explore the challenges encountered 
by team members, and to explore how they attempted to overcome these challenges 
in day-to-day clinical practice (these later became the first and second research 
questions of this thesis) I felt at the time that such aims were specific enough to 
satisfy the research committee but sufficiently general that I could explore any 
issues that arose during the fieldwork. In total, I was required to submit twenty-one 
different documents to the Research Ethics Committee. These included: 
 
• A REC application form outlining the project design, the ‘scientific 
justification’ of the project, the main ‘ethical issues’ arising from the project 
design, how the informed consent of participants would be obtained. 
• A project protocol/overview (around 6 000 words), which was an abridged 
version of the above. 
• Participant information leaflets (PILs) for each of the data collection 
methods (interviews, and observations), including specialized participant 
information sheet for participants less than 16 years of age (Appendix 2, 
pages 240-251). 
• Consent and forms for participants involved in each of the data collection 
methods, including as assent form for children and young people under 16 
(Appendix 3, pages 252-256). 
• The CVs of my supervisor and myself. 
• Proof of Brunel University’s indemnity/insurance coverage, proof that 
Brunel University was my ‘sponsor’, and a letter from the Wellcome Trust 
proving that they were funding the project.  
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It took just over six months to compile this documentation. I was able to model my 
participant information leaflets (PILs) and consent forms for adults on those 
produced by other members of the LABTEC team. The PIL for participants under 
16 years of age was based on the model prescribed in Alderson and Morrow’s The 
Ethics of Research with Children (2007).  As a consequence, the PIL reflects Alderson 
and Morrow’s belief that children as young as five can make informed decisions 
regarding participation in research (and that children 16 years and under can legally 
give their informed consent), and that such decisions should be guided by their 
parents or caregivers. Consequently the PIL for children and young people contains 
all information necessary for informed consent to be obtained, and is intended to be 
read by children and their parents together.   
Several weeks after the above documentation was submitted my first 
supervisor and I met with the NHS REC. Committee members asked us to clarify a 
few points, and we were informed that the committee had granted the project 
provisional approval. A few minor changes would have to be made before a 
‘favourable opinion’ would be granted: pictures would have to be added to the PIL 
for participants under 16, and assent, rather than consent, was to be obtained from 
all participants under 16 years of age. Aside from these minor recommendations the 
REC had no problem with the design of the research or the data-collection methods 
being used, probably due, at least in part, to Dr Martin’s support. A month later I 
resubmitted the amended children’s PIL containing cartoon pictures that I drew 
myself. Full approval from the REC was obtained on the 13th of February 2012 
(the letter of REC approval confirmation is appended to this thesis – Appendix 1, 
pages 237-239). I was therefore permitted to conduct interviews with health 
professionals and observe specific interactions including consultations involving 
young patients. 
Once I had been notified of REC approval I had to obtain clearance from 
the Research and Development Department (R&D) of the specific NHS Trust 
overseeing the hospital where the research was taking place.  In short, while the 
REC assessed the overall project, the R&D assessed me: In order to gain clearance I 
had to undergo an enhanced police check and obtain Occupational Health 
Clearance, the latter requiring me to receive an assortment of vaccinations to ensure 
I would pose no biological risk to patients.  R&D clearance also required the project 
to have a Principal Investigator (PI) who was employed by that particular Trust. The 
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role of the PI was to ensure that I adhered to the Trust’s policy and that all 
necessary reports were completed. Luckily, Dr Martin agreed to this role, and on the 
4th of April 2012 I was informed that I had an ‘Honorary Research Contract’ with 
the Trust and I was permitted to begin conducting research within the children’s 
hospital. 
The honorary contract, however, did not enable me to conduct research at 
the hospital where the actual surgical implantation of the DBS system takes place. 
This hospital was under the jurisdiction of a different trust and would therefore 
require the approval of a separate R&D department. A local PI employed within 
that particular trust would also be required. The only possible contender was the 
neurosurgeon, but due to his workload he was reluctant to undertake this role. 
Unfortunately this meant that I was unable to include the neurosurgeon and his 
interactions with patients in this project. (I was, however, able to discuss 
neurosurgical issues with the neurologists, one of whom would often sit in on the 
neurosurgical operation, and the clinical research fellow, whose PhD was exploring 
the placement of DBS electrodes within the brain). In effect, then, the necessity of 
having R&D department approval defined the research site and limited the scope of 
the project.  
The design and focus of this project, therefore, is the product of multiple 
influences. Before I discuss the data collection methods in more detail and describe 
the actual data collection process, I will now outline what could be called the 
material semiotics ‘metaphysics’ of this project. This, as we will see, has implications 
for the specific methods used.   
 
2.4 An ethnography of every thing: material semiotics 
Material semiotics has emerged from two domains of enquiry: Science and 
Technology Studies (STS), particularly in the form of Actor-Network Theory, and 
Deleuzian-inspired assemblage-theory, which is most clearly articulated in the work 
of Manuel DeLanda (2002, 2006). It has no heritage in the work of Marx, Weber or 
Durkheim, and consequently many of its key tenets seem at odds with more 
traditional sociology: ‘social’ is simply the association of any entities; non-human 
objects can be ‘actors’, and spatial and temporal scale are the consequence of 
associations between actors, to name a few oddities. The goal of this section is not 
to give an exhaustive account of material semiotics, but rather to explain its key 
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tenets and outline how it can be used in sociology. In order to do this I will rely 
heavily on the work of three proponents. Using Manuel DeLanda I will articulate 
what could be called the underlying metaphysics of material semiotics, and with the 
work of Bruno Latour, I will illustrate how this metaphysics translates into a 
sociology methodology. Referring to the work of Annemarie Mol, I will then 
illustrate how this approach can be applied to medical sociology. 
 
2.4.1 The ontology of material semiotics 
The central tenet of material semiotics is a commitment to relationality. The 
intelligibility of an entity, or how we come to perceive and understand an entity, is 
not the result of some inner essence or nature, revealing itself to the objective 
observer. Rather, the intelligibility of any entity (an inanimate object, an individual, a 
social institution) is the consequence of its interaction (or association) with 
numerous other entities.  Each entity has capacities for interaction; qualities that become 
perceptible only when it is prompted, jostled, or moved by another (DeLanda 
2006). As associations form, particular capacities of interaction are realised or 
enacted, and thus the associating entities become intelligible. It is only by being 
immersed in an assemblage with other entities, therefore, that an entity acquires a 
perceptible form. In Laboratory Life (1986), Latour and Woolgar argue that the 
process of scientific ‘discovery’ that takes place within a laboratory involves noting 
how an entity of interest (such as the hormone Thyrotropin Releasing Factor, or 
TRF) responds when placed within various, carefully arranged material assemblages. 
Laboratory technicians attempt to create a list of the entity’s qualities by enacting its 
various capacities for interaction.  
Importantly, the intelligibility of an entity will differ depending on the 
assemblage in which it is immersed. Each entity has innumerable capacities for 
interaction, only a few of which will be enacted, or realised, in any one assemblage. 
We might think of an individual as having a capacity to act rationally (however we 
may define the term), a capacity to experience a range of emotions, and innumerable 
capacities to physically engage with the material world: to move bipedally, for 
instance.  The combination of capacities that are enacted will depend on the 
individual’s wider context. A supermarket may prompt an individual to rationally 
appraise a food product according to its cost and perceived value; a theatre 
production may prompt particular emotive responses among members of the 
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audience; and a set of stairs will induce an individual to move bipedally. Generally, 
an entity is defined according to a few of its qualities for convenience (such as 
colour, shape, mass), but its potential for expressing other qualities means that it will 
always escape any attempt to determine its essence (DeLanda 2006). We may define 
a human as a ‘rational actor’ for pragmatic or political purposes, but any definition 
will reflect, at most, only a select set of a human’s capacities for interaction. Any 
intelligible entity, then, possess perceivable characteristics that are the result of 
being immersed within a particular assemblage, and it will have an indefinite 
number of un-actualised capacities that may later be realised, or enacted, if the entity 
becomes part of a novel assemblage (DeLanda 2006; 2002: 72).  
DeLanda refers to this as relation between an entity and the assemblage in 
which it is immersed as relations of exteriority. While each entity is rendered intelligible 
through its association with other entities, it cannot be reduced to this relationship. 
Its potential to express qualities, its capacities for interaction, will always exceed 
those that are actually being expressed at any one time.  An example are the amino 
acids that combine to form the hormone TRF: the same amino acids have the 
capacity to combine in other combinations creating hormones or peptides with 
different effects. We might also think of the ability of an individual to adopt 
different roles within different social contexts or professional organisations. An 
individual’s potential, then, always exceeds any one of the various roles that they 
may undertake. To put this another way, component parts cannot be reduced the 
function they may have within a larger structure. DeLanda contrasts this relations of 
exteriority with relations of interiority, a conceptual relationship between the social 
‘whole’ and its ‘parts’ that has been prevalent in social sciences, most blatantly in 
representations of society as an organism (DeLanda 2006: 9). Here, each part is 
constituted by the relations it has to the social whole. In its crudest, functionalist 
manifestation, it is only because of its relationship to the social whole that a part 
exists. With the relations of exteriority model that underlies material semiotics, 
society is not a seamless whole, nor does it determine the shape, activity, or 
intelligibility of its constitute parts. Society is, rather, the consequence of numerous, 
heterogeneous assemblages: it is the temporal product of the enactment of an 
enormous number of capacities for interaction and the elision of many more.  
This does not entail methodological individualism, however. Structures can 
possess properties that cannot be reduced to their component parts. As multiple 
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entities assemble, many expressed capacities combine and interact, and subsequently 
come to have a novel affect that cannot be attributed to any one entity. These are 
emergent properties (DeLanda 2002). Emergent properties are not logically necessary: 
they do not exist because they serve a particular function. Rather, they are 
continually obligatory: they are the consequence of complex dynamics and relations 
between parts (and within parts) that do not necessarily have a specific higher order 
objective (DeLanda 2006). They are, essentially, unintended consequences. Thus, it 
is possible for assemblages to act or express properties that differ from the actions 
and intentions of the individuals and components that constitute them.  
This holds true for all assemblages, whether they be nation-states, 
institutions, individuals, the body, organs, or DNA. Obviously DNA possesses 
capacities for interaction (such as inducing the formation of proteins) that cannot be 
reduced to its constituent nucleotides. An individual, too, can be seen as the 
emerging product of an assemblage of what could be called subpersonal 
components (DeLanda 2006): acquired beliefs, prejudices and ideas, learned 
embodied-dispositions and habitual responses, ambiguous desires, and a host of 
various biological processes. Different combinations of these will be enacted in 
different contexts, and the overall effect of a combination (the individual) cannot be 
reduced to any one constituent component. The individual is the emergent product 
of an assemblage, and the individual is also a component in other assemblages (such 
as social or professional organisations). And by participating in ‘larger’ assemblages, 
the individual may of course be prompted to adopt new, or hone existing, 
subpersonal components: they may acquire an additional set of political beliefs or 
develop new practical skills that resonate with their existing beliefs, skills, desires (or 
fears) (DeLanda 2006). In this light, socialisation can be seen as a process of 
immersing individuals within assemblages that configure their various subpersonal 
components.  
Individuals, then, are both networks in themselves, and ‘actors’ in other 
networks; they are the ‘effect’ of associations between entities, and subsequently 
they come to have an ‘affect’ on others. Any intelligible entity is both the 
consequence of a network or assemblage of components (other entities), and a 
component in other assemblages or networks. They are an ‘effect’, that can 
subsequently have an ‘affect’. And while an entity may contribute to the 
perpetuation and delineation of a larger assemblage, its capacities for interaction (its 
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potential, enabled by its constituent components) will exceed this role, or any other 
one role.  According to a material semiotics perspective, society is constituted by 
these heterogeneous actors that are both actors and networks (or actor-networks).   
 
2.4.2 A sociology informed by material semiotics 
If intelligibility is the effect of an assemblage, then the sociologist should refrain 
from making a priori assumptions about the nature of entities that constitute 
society. Instead sociologists should explore how such entities are rendered via their 
associations with other entities. According to Latour (2005) this is achieved by 
identifying the ‘actors’ within a network. Here, however, an ‘actor’ does not refer to 
the origin of an action, nor does it refer to a subject possessing intentionality. 
‘Actor’ refers to an entity that is made to move, to have an affect, by other actors; it 
is a point of confluence where a series of actions is translated into another type of 
action (Latour, 2005: 46). Michel Callon’s example of the space of calculability within a 
strawberry market illustrates this (Callon, 1999). In the Salogne region of France, 
text-book neo-liberal economic theory was used to guide the formation of a market: 
merchandise was physically arranged so that its weight and quality were clearly 
delineated and comparable, yet information pertaining to its production and origin 
were deliberately hidden and partitions were constructed between growers and 
buyers. Transactions were displayed on a large electronic board, formal 
measurement standards were adopted, and digressive bidding was used. 
Consequently, buyers had little choice but to base their decisions on the data 
displayed to them and engage in decentralised and ‘rational’ exchange. The resulting 
‘rational’ buyer was not the cause of the action; they were prompted to act in this 
way by a wider network of electronic display boards, physical partitions, formalised 
measurement tools and so on. These cannot be called the ‘cause’ of the resulting 
action either: they were carefully arranged by other actors, such as the graduate in 
economics who had been employed by local authorities to create the market and 
who, in turn, would also have been prompted by others. Each actor was made to 
move (or to express a capacity for interaction), to have an affect, by other actors, 
and consequently action was transferred, altered, distributed, and translated along a 
concatenation of actors.  
Importantly, as Callon’s example illustrates, this definition of ‘actor’ does 
not exclude non-humans. Physical, inanimate objects, transmute, constrain, guide, 
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and prompt the action of other entities, including humans. As Annemarie Mol puts 
it, human action is not just culturally and historically situated, it is also materially 
situated (Mol, 1999: 75). Consequently, the sociologist should refrain from making a 
priori judgments about which type of entity can have agency.3    
Latour has advocated a ‘follow the actors’ approach to sociology (Latour, 
2005). Rather than presupposing the existence of particular structures, such as the 
individual, class, the state, the sociologist should seek to explore how these are 
enacted in networks, that is, how they emerge in specific contexts. If social 
structures are not the result of some higher function they may serve, (that is, if they 
are continually obligatory rather than logically necessary), then ‘thought’ alone 
cannot explain their existence and form. Here, then, Latour proscribes an empiricist 
method for exploring the social world that is not dissimilar to that of the 
ethnomethodologists; a commitment to exploring how every-day practices generate 
those things that constitute society. The key difference, as we have seen, is that the 
sociologist must not focus exclusively on the interactions between humans. 
 
2.4.3 Material semiotics and medical sociology 
For the sociology of medicine this method can be used to illustrate how medical 
practices, often laden with technologies and material objects, collectively generate 
                                                 
3 This entails a notion of ‘social’ that differs from that usually adopted in the social sciences. For a 
sociology informed by material semiotics, ‘social’ is defined as the associating of entities: It is the 
transferring and translating of action from one entity to another. As Latour has noted (Latour, 2001), 
this conception was articulated by a contemporary of Durkheim, Gabriel Tarde, who made no 
distinction between the social and the material: when two or more things are brought together, it is a 
social phenomenon: “everything is a society and that all things are society” (Tarde, quoted Latour 
2005: 218). This is perhaps the most significant point of difference between material semiotics and 
more traditional sociology. Traditional sociology has tended to posit the existence of a social realm 
that is distinct and a priori to the world of material things. For Durkheim, social reality is constituted 
by ‘social facts’. These have an independent existence beyond the actions of individuals: they inform 
individual behaviour, they can explain collective behaviour, and they provide society with some 
rigidity (Durkheim, 1982). Here, society is seen as the cause of associations between people. 
Although Weber may have rejected this type of positivism, he nonetheless reified the existence of a 
distinct social realm with his neo-Kantian notion of verstehen: if social change is to be explained, 
then it is necessary to understand the rationale of human actors. Tarde, however, argued that if 
sociologists postulate the existence of a distinct social realm, they will overlook much of the stuff 
that society is actually made of (Tarde, 2010). 
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many of those things that interest the sociologist: the body and body-parts, agency, 
the individual, and so on. The work of Annemarie Mol (2002) is perhaps the best 
example of an account that explores how both human and non-human actors 
collectively participate in the production of intelligibility in medical practices, and it 
is her work that will form the basis of the argument here. Importantly she has used 
this method to illustrate not only how intelligibility is produced, but also how 
multiplicity and conflict can arise; different material and/or cultural contexts 
(assemblages) can generate distinct renderings of an entity, as different capacities for 
interaction are realised. In some cases, this can result in conflict. 
Employing the approach proscribed by Latour, Annemarie Mol undertook 
what she referred to as an ‘ethnography of atherosclerosis’. This became the basis of 
her book The Body Multiple (2002). Here she reports on her observations of specific 
interactions that rendered lower-limb atherosclerosis intelligible within the hospital. 
She noted that even within the one hospital, the intelligibility of atherosclerosis 
varied: in different sites, distinct assemblages of humans and non-humans would 
enact4 a distinct atherosclerosis. In consultation room, atherosclerosis is the inability 
to walk a certain length on flat ground without pain. In the pathology lab, 
atherosclerosis is a thickening of deposits on the inside of blood vessels, but only 
after the construction of a delicate assemblage: the preparation and staining of a 
blood vessel cross section on a slide, carefully placed under a microscope. And in 
the vascular clinic, atherosclerosis was rendered intelligible as restricted blood flow 
and a loss of blood pressure, as enacted by the ultra-sound emitting Doppler 
apparatus and accompanying pressure cuff. Each of these sites contained a different 
assortment of human and non-human actors, and each, then, enacted a distinct 
atherosclerosis. In other words, different capacities for interaction were realised in 
different locations.  
                                                 
4 Mol uses the term ‘enactment’ to replace ‘social construction’. The problem with the latter, she 
argues, is it implies that the ‘constructed’ entity has obtained a degree of durability. ‘Enact’ conveys 
the short temporality of such ‘constructions’: a body might be constructed as a biomedical entity in 
one specific context, but this may have very little influence in other contexts were it is enacted 
differently  (Mol 2002; 32-33). By emphasizing the generally short temporality of enactments, 
sociologists are encouraged to explore how it is that some enactments do actually become more 
durable than others; how it is, for example, than some enactments come to be seen as more ‘valid’ 
than others.   
2: Methodology: Exploring innovation in medicine 
 
 49 
Mol argues that far from being unified and homogenous, medical practices 
are complex, divergent and messy, and tend to produce multiple entities (Mol, 
2002). What may be considered the same disease can, in fact, multiply in various 
parts of the hospital. Often this multiplicity is unproblematic, particularly if the 
various enactments remain tethered to the site in which they are produced. But 
alongside this multiplicity, however, are practices that seek to produce an overall 
singularity and coherence: Mol notes how some renderings of atherosclerosis were 
discarded or ignored by clinicians (if they appeared contradictory), how narratives 
were used by health professionals to link, say, the pain in the leg with arterial 
deposits, and how some enactments were simply ‘translated’ into others. Some 
assemblages, then, become more durable than others. An ‘informed’ patient may be 
presented with a singular, coherent account of their affliction, but such an account 
is an achievement; the consequence of ordering and sorting, ranking and 
prioritising.  
Mol, then, draws attention to the way in which disease and the body are 
rendered intelligible in medical practices, how potentially conflicting accounts can 
be produced, and how such conflict is overcome. She has illustrated how 
assemblages produce an intelligible body, how the body can be rendered intelligible 
differently by various assemblages, and importantly, she has illustrated how 
particular renditions may supplant others in order to give the impression of a 
singular, coherent reality. Reality is the product of assemblages, and if such a reality 
appears singular and coherent, it is because multiplicity has somehow been elided.  
 
2.5 Material semiotics and the collection of data  
Many of the assumptions underlying material semiotics are synonymous with the 
key tenets of Garfinkel’s approach and ethnographic inquiry, such as: a rejection of 
positivism (the idea that universal laws, or an appeal to a transcendental reality, can 
be used to explain social phenomenon); a commitment to studying practices ‘in situ’ 
(rather than in some sort of artificial or experimental setting); a tendency to conduct 
in-depth small scale studies involving a few cases/contexts; and a commitment to 
prioritising agents themselves and the meanings they attribute to their actions and 
their surrounding world (Hammersley and Atkinson 2007: 3, 7). These tenets reflect 
a belief that human action is culturally and historically situated, and that social forms 
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and structures emerge from such action. Understanding such action therefore 
requires exploring the rich, complex and messy milieu in which it takes place.  
This project employs these key tenets of ethnographic inquiry. As I have 
argued, however, this project also assumes that human action is materially situated: 
So for this project, to the above list of tenets common to ethnographic inquiry, I 
append a commitment to including within this sociological exploration the 
interactions between human agents and non-humans. In this project such an 
approach can be used to explore: how, in the process of developing a DBS service, 
PMDS team members bring together a range of tools, bodies and knowledge into 
an assemblage; how these assemblages render various entities (such as the dystonic 
patient) intelligible, thus enabling the production of useful clinical knowledge; and 
how potentially conflicting renderings of an entity are negotiated or managed. 
 
2.5.1 Methodology issues with material semiotics in practice 
Before I outline the specific data collection methods it is necessary to introduce two 
potentially problematic issues arising when a material semiotics-informed 
methodology (or an adjusted ethnography) is put into practice. The first potentially 
problematic issue relates to the specific methods of data collection.  Ideally the 
researcher would immerse themselves in the field for a long period of time, ‘living 
with the tribesmen’, to quote Latour and Woolgar (1986: 28). In collecting the data 
that became the basis for Laboratory Life (1986), Latour undertook a twenty-one-
month programme of participant observation within the selected laboratory.  He 
was employed as a research assistant, enabling him to participate in, and experience 
first-hand, practices within the lab. He was also granted free access to the 
laboratory’s archive, papers and documents, many of the scientists’ discussions, and 
he undertook formal interviews with scientists (1986: 39).  Latour and Woolgar 
argue that such prolonged immersion within the field enabled them to witness the 
‘craft’ of science; that is, the actual day-to-day, often mundane, often messy 
practices that constitute the production of scientific facts. In situ observations are 
necessary, as many aspects of this ‘craft of science’ are not presented in scientists’ 
own presentations of their work (1986: 28-29). Interviews and documentary analysis 
alone, then, are insufficient. Similarly, Mol’s The Body Multiple is based on data 
collected from over 300 observations of consultations (2002: 2).  
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Ideally for this project I would have undertaken a similar quantity of 
fieldwork. I would have immersed myself within the field site for a long period of 
time, observing members of the medical team as they interact with each one 
another, their patients and their material environment. I would have viewed 
communications between the team and other agents, and I would accessed the 
medical records, clinical assessment tools and so on that members of the team use 
to diagnose and manage children with dystonia. As Pawson has stated (1999), 
however, there is often a divergence between what is ‘ideal’, and what is possible 
(the ‘real’) in research practice, and as I illustrated earlier, the practicalities of doing 
fieldwork with the PMDS prohibit the sort of prolonged field-site-immersion 
undertaken by Latour. However, although I did not ‘live with the tribesman’, I 
believe that the my methods nevertheless enabled me to witness the ‘craft’ of using 
deep brain stimulation to treat children with dystonia. The observations in particular 
(as we will see further on) were particularly useful in this regard.   
This brings me to the second potentially problematic issue regarding a 
material-semiotics informed methodology. Latour implies that the role of 
sociologist is to create a sociological account via extrapolation from the field alone. 
The sociologist, he argues, must refrain from making a priori assumptions about the 
nature of entities in the world, or what constitutes ‘reality’, as these are being 
generated and negotiated ‘in the field’5. Ideally, if I were to have followed suit, I 
would have immersed myself in the research site, having jettisoned prior 
assumptions about the body and the brain, the roles of clinical staff, dystonia and 
the deep brain stimulation technology. Much like the romanticized version of a mid-
20th century anthropologist, I would approach the research site as if it were a 
strange and exotic culture where various artefacts are produced and become 
implicated in wider systems of exchange and meaning. I would extrapolate all that is 
important to the inquiry from the field itself. Indeed, in their seminal Laboratory Life 
                                                 
5 “Your task is no longer to impose some order, to limit the range of acceptable entities, to teach 
actors what they are, or to add some reflexivity to their blind practice… You have ‘to follow the 
actors themselves’, that is, try to catch up with what the collective existence has become in their 
hands, which methods they have elaborated to make it fit together, which accounts could best define 
the new associations that they have been forced to establish… sociology has to be fully relativist.” 
(Latour, 2005: 11-12)    
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(1986), Latour and Woolgar claim that this naïve, intrepid researcher is the basis for 
their ‘anthropology of science’. 
 
We envisage a research procedure analogous with that of an intrepid explorer of 
the Ivory Coast, who, having studied the belief system and material culture of 
“savage minds” by living with tribesman, sharing their hardships and almost 
becoming one of them, eventually returns with a body of observations which he 
can present as a preliminary research report. (Latour and Woolgar, 1986: 22)  
 
I argue that such an ultra-relativist position, however, is problematic. If it were 
possible to thoroughly purge oneself of all a priori assumptions, the world would 
appear as an incomprehensible mess. As Silverman puts it, without a prior 
conceptual orientation, “one would not recognize the ‘field’ one was trying to 
study” (Silverman, 2001: 72). At the very least a researcher requires a starting point, 
some sort of focus to anchor their initial inquiry.  A realistic goal is not to dispense 
with prior knowledge of the topic area, but to be aware of, and reflect upon, any 
bias that such knowledge may entail (Dey, 1993: 63-64).  What might seem like a 
sensible starting point for the researcher may turn out to be highly contested by 
those within the field, or completely irrelevant.  The key, then, is to approach the 
field with an “open mind”, not an “empty head” (Dey, 1993: 63).  For Mol, 
‘atherosclerosis’ provided an initial starting point and a means of discerning which 
particular phenomena would be the focus of her inquiry. By entering the field with 
some ideas about what atherosclerosis is and what it might be, she equipped herself 
with a means of engaging with those within the field and a means of keeping her 
project to a manageable size (Mol had received basic training in medical school and 
studied text books and journal articles on atherosclerosis while undertaking the 
study (Mol, 2002: 1,3). And obviously, as Mol demonstrates, adopting 
atherosclerosis a priori as an initial starting point did not mean that it was taken to 
represent an unproblematic aspect of nature, nor did it render her insensitive to the 
divergent ways in which actors in the field understood atherosclerosis. Indeed, it 
was her ontological starting point and not a naivety of the topic matter that 
compelled her to be attentive to the ways in which such seemingly taken-for-granted 
concepts could be contested, disrupted, or reified by practices within the field.  
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My goal, then, was to enter the field with as much knowledge of the topic 
matter as possible. Prior to beginning fieldwork I attempted to read as much 
material on deep brain stimulation as I possibly could (some of this material has 
featured in the introduction of this thesis). From this material I acquired some 
understanding of the DBS technology, the regions of the brain and the pathology of 
various neurological disorders, and I became familiar with at least a few of the 
seemingly infinite number acronyms used by members of the team. My familiarity 
with the literature, then, meant that my participants and I had at least some 
common points of understanding, and it meant (I assume) that I had some 
credibility in their eyes. To borrow a term from Collins and Evans, I acquired (or 
attempted to acquire) an interactional expertise: a sufficient level of “expertise to 
interact interestingly with participants and carry out sociological analysis” (Collins 
and Evans 2002:  254)6. My primary research questions were also particularly 
important in this regard: they provided me with an initial framework for 
determining which participants to include in the project, which particular practices 
might be worth focusing upon, and in the case of interviews (as I will explain 
further on), which questions to ask. I tried my best, then, to avoid entering the field 
as a naïve, intrepid researcher. Before I provide a description of fieldwork activities, 
let me address some of the methodological issues of the specific data collection 
methods that I used. 
 
2.5.2 Methodological issues relating to interviews and observations 
Interviews and observations each have their limitations as data-collection methods. 
By using both in-depth semi-structured interviews and observations I hoped to 
sufficiently overcome the limitations specific to each method. Obviously, like all 
data collection methods, interviews do not provide the researcher with a transparent 
view of reality or a set of truths. Interviews elicit participants’ perspectives on their 
world, and during the course of interviews, participants actively shape their 
responses according to commonsense devices for making sense of their 
environment. On this point I adopt what Silverman refers to as the constructionist 
perspective on interviews (Silverman 2001: 95); during an interview, both the 
                                                 
6 Interactional expertise is in contrast to no expertise, which is insufficient for undertaking 
sociological analysis, and contributory expertise, which is the expertise required to contribute to that 
field which is being studied (Collins and Evans 2002). 
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researcher (interviewer) and the participant (interviewee) actively engage in the 
construction of an account of the world. The interviewer brings a set of concerns to 
the interview (which reflects their worldview and background knowledge of the 
topic), and prompts the interviewee to address these concerns through a particular 
line of questioning. The interviewee responds by offering details of their 
experiences, but in doing so, constructively adds to, takes away from, and 
transforms the facts and details (Holsteim and Gubrium, in Silverman, 2001: 95). To 
adopt a material semiotic parlance, interviews are a means where interviewer and 
interviewee actively construct an assemblage. Both prompt and respond to each 
other, bringing together and relating a range of semantic elements within an account 
that subsequently provides intelligibility to the aspect of the world in question. 
Importantly, in the process of co-producing an account, both the interviewer and 
interviewee share and draw upon common, learned tools for interacting and 
communicating meaning (Cicourel, 1964: 100). Latour refers to such tools as ‘plug-
ins’ (2005: 207): circulating clichés, gestures, turns of phrase and so on that actors 
can ‘plug-into and download’ in order to articulate themselves and the world around 
them. Here, then, familiarity with the topic matter, a shared understanding of such 
‘plug-ins’, and an ability to relate to, and engage with participants are not hindrances 
to the collection of data (as is implied by the ‘intrepid researcher’ fallacy), but 
necessary prerequisites.  
Thus, during interviews I attempted to prompt participants into articulating 
their perspectives on various aspects of using DBS to manage children with 
dystonia, enabling me to address the research questions. Additionally, a key 
component of participants’ perspectives was not just ‘what’ they said, but also ‘how’ 
they said it. I used interviews to explore how members of the PMDS team and 
associated health professionals employed circulating tools, points of reference, and 
norms in order to convey their understandings of their work. 
While interviews enabled me to see how participants thought about their 
work, observations enabled me to see what they actually do. Observation as a 
method reflects the theoretical position that social forms and structures emerge 
from the every-day activities of actors: people do not ‘come to terms’ with 
phenomena; they actively constitute them (Silverman, 2001: 74).  From a material 
semiotics perspective, observations enable the researcher to explore how routine 
and mundane practices assemble various entities, and how the resulting assemblages 
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enable the expression of particular capacities of interaction (while preventing the 
expression of many more). Observing consultations enabled me to witness first-
hand the practices that assemble the patient in a wider network of entities: health 
professionals, medical technologies, clinical assessment tools, and so on. Just as 
Annemarie Mol observed (2002) how various practices rendered atherosclerosis 
intelligible within the consultation room, I used observations in order to see how 
the body, dystonia, and the patient are ‘enacted’, or rendered intelligible, in every-
day clinical practice. (Additionally, Dr Martin stated that in order for me to gain a 
coherent insight in the way in which his team works it would be necessary to 
observe several consultations involving patients.) 
 
2.6 Conducting fieldwork: Observations and interviews 
I began my fieldwork with the PMDS immediately after I received an Honorary 
Research Contract from the R&D department of the hospital trust. My strategy was 
to undertake five or six observations of team meetings before conducting interviews 
or observing any interactions with patients. As we will see, I used these initial team 
meetings to identify some of the various challenges encountered by PMDS team 
members.  I was then able explore these challenges in detail during subsequent 
interviews, and I was able to request to observe specific interactions with patients 
where these challenges are addressed 
 
2.6.1 Observing team meetings in the field 
In the second week of April 2012 I began undertaking observations of team 
meetings.  For the first six months I attended as many as I could.  I would arrive 
five minutes before the scheduled start time and sit in one of the many chairs lining 
the parameter of the room. During meetings I used hand-written field notes to 
record data.  The reason for this is that I suspected an ethics committee would 
object to the taking of audio or video recordings on the grounds that these would 
be too invasive: with handwritten field notes I could easily omit any data that could 
be used to identify participants, and I would more easily ‘blend-in’ with other 
members of the team.  
My rough strategy for taking notes was based on a few points of guidance 
provided by Hammersley and Atkinson (2007: 141-147). My goal was to record as 
much activity as possible, in as much concrete detail as possible, particularly during 
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the initial observations. In order to do this, I created my field notes in two stages. 
The first stage took place during the observation. Here, I made very concise notes 
comprising key words and phrases and brief descriptions: “jottings, snatched in the 
course of action” (2007: 143). These were intended to trigger my memory during 
the second stage of note taking which took place immediately after the observation. 
Generally this first stage was not too challenging and I was able to check my brief 
jottings against the comments added to the agenda/minutes that were displayed on 
the wall and were being created as the meeting progressed. But the informality of 
the meeting did present challenges. Sometimes, on occasions when several team 
members were talking at once, I became perplexed and failed to note anything at all.  
Often a ‘course of action’ had been added to the meeting minutes but I could not 
follow how the team actually arrived at that decision.   
I used the brief notes made in stage one to “trip-off a string of images in the 
mind” (Hammersley and Atkinson 2001: 143), enabling me to write a more 
substantial and detailed reconstruction of the observed interaction (stage two). The 
advantage of this two-stage process is that by delaying the extensive note taking 
until after the observation I was less likely to miss details of the interaction. For this 
strategy to work, however, it was necessary that the second stage take place 
immediately after the observation while the rich detail of the interaction was still 
accessible in my mind. This was not difficult: I wrote-up my field notes immediately 
afterward in a café near the hospital. Generally I found that for every one-hour of 
observation, It took me a further two hours to write up my field notes in full.  
As Hammersley and Atkinson point out, as ethnographic research 
progresses emerging themes become apparent and the project becomes more 
focused as a result (Hammersley and Atkinson, in Silverman, 2001: 70). From very 
early on in the meetings I was able to discern the key challenges encountered by the 
team in their day-to-day work and thus hone my fieldwork as a result.  Much of the 
discussion revolved around several key issues. One of these was the coordination of 
the team itself: a great deal of meeting-time was taken up discussing what could be 
referred to as “coordinating multidisciplinarity”. Others included: deciding which 
patients were suitable candidates for DBS, managing expectations of patients, 
managing infection, measuring the effectiveness of DBS, and disseminating the 
clinical outcomes and research of the team to the wider clinical community. These 
were similar to the challenges that had been identified in the literature on DBS and 
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no doubt my attention had been drawn to these by my background reading, but 
given the amount time the PMDS team spent discussing these issues, I decided that 
I could indeed delineate them as being ‘major challenges associated with the day-to-
day application of DBS into paediatric neurology’.  I honed my fieldwork strategy to 
explore how these challenges manifested in the clinical practice of the team, and 
how the team managed these challenges in their day-to-day work (thus addressing 
my first and second research objectives). As I will illustrate further on, I decided to 
use the interviews and the observations of interactions with patients as a means to 
explore these specific issues in more detail.  
Aside from ‘routine’ team meetings I also had the opportunity to observe 
‘academic’ team meetings (a full list is displayed in table 2.1, page 58).  This term 
was used by team members to describe either a meeting with a visiting clinician 
working in a related area (usually an area of paediatric neurology), or a meeting to 
review a potentially useful academic paper. Both types were especially useful to 
observe.  In the former, the team and the visiting clinician would compare services, 
discuss difficult clinical cases, explicitly state the challenges they faced, and provide 
detail on how they managed these challenges in practice. In the latter type of 
meeting the team identified papers for review that could shed light on a particular 
clinical challenge: a team member would present the paper, and the team would 
then discuss its merits and its applicability to the team’s day-to-day practice. In both 
types of academic meetings the challenges encountered by the team and their 
methods for overcoming these challenges were explicitly articulated. These meetings 
provided vital data and confirmed that I had, indeed, chosen to focus on the correct 
issues. By the time I had observed five or six meetings I had created the list of 
challenges that I would focus upon in more depth and consider as specific topics 
for the substantive chapters of this thesis: coordinating multidisciplinary teamwork, 
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1 Routine 120  
2 Academic 150 With paediatric neurologist from Texas 
3 Routine 70  
4 Academic 90 Discussion on paper on DBS for 
childhood dystonia written by another 
centre 
5 Routine 100  
6 Routine 80  
7 Academic 60 With obstetrician from Australia. 
Discussion about causes of cerebral 
palsy 
8 Routine 80  
9 Routine 60  
10 Routine 60  
11 Routine 75  
12 Routine 60  
13 Routine 45  
14 Routine 55  
15 Routine 60  
16 Academic 60 Review of paper detailing new clinical 
outcome measure 
17 Routine 60  
18 Routine 180 First team meeting after three week 
delay 
19 Academic 60 Discussion of two complex clinical 
cases 
20 Routine 90  
21 Academic 180 Discussion of alliance with statisticians 
22 Routine 60  
 
2.6.2 Observing interactions with patients and family members 
Thus, once I had identified the challenges, I asked team members if I could observe 
interactions, including interactions with patients and family members, where these 
specific challenges were addressed. Team members identified two patients who 
would be involved in PMDS activities in the coming months, one of whom would 
undergo a full pre-surgical assessment regime. Here I will describe the process of 
obtaining consent and assent from these patients before describing my method for 
capturing data during the interactions.  All names provided below are pseudonyms. 
The first patient was Kyle, a twelve-year old with dystonic cerebral palsy.  At 
that time he had recently had the DBS system implanted and was an inpatient in the 
neurology ward. The neurologist suggested that I observe her working with Kyle 
and his parents as she showed them how to operate and recharge the DBS system. 
On the day of the interaction I arrived at the neurology ward an hour before this 
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scheduled meeting and Dr Martin introduced me to Kyle’s mother and father who 
were sitting in a private room.  Kyle, I was told, was attending the hospital school 
and would return in thirty minutes. Dr Martin left me to speak with Kyle's parents 
alone, and after initial introductions I provided them with an adult’s and young 
person’s participant information leaflets (PIL), explained the purpose of my project, 
and described, specifically, what participation would involve. I then asked them if 
they had any questions, if they were interested in participating, and if they would be 
happy for me to ask Kyle if he would like to participate. They both stated that they 
were more than happy to participate, and that Kyle usually enjoyed having extra 
people around. I gave them copies of consent and assent forms and said that I 
would collect them just prior to the upcoming consultation (thus giving them 
additional time to read the PIL).  I then left the private room where I was met by 
the occupational therapist (OT) and Kyle who had just returned from school. The 
OT introduced me to Kyle, and I explained my project (in simple terms) to him and 
asked if he would like to participate. He smiled, and using the communication 
device attached to his motorised wheelchair indicated ‘yes’. I asked him if he had 
any questions (to which he indicated ‘no’), and as we accompanied him back to his 
parents, I told him that he could talk about it more with his mum and dad, and that 
if they did want to participate, they could sign the forms that I had given them.  I 
left Kyle with his parents and I returned around fifty minutes later with the 
neurologist (not Dr Martin) to see if they were happy to participate. They were, and 
they handed me their signed consent and assent forms. 
The second patient, Carl (pseudonym), was a sixteen year-old with 
suspected but undiagnosed secondary dystonia. He was a candidate for deep brain 
stimulation and would be undergoing all necessary pre-surgical assessments and a 
goal setting session: the team decided this would provide me with an excellent 
opportunity to observe them as they attempt to manage some of the challenges I 
had identified during team meetings. I first met Carl on the morning of his first set 
of assessments.  He was sitting in the waiting area of the outpatient clinic, typing on 
his laptop, with his mother seated next to him. The psychologist had introduced us, 
and said that one of the other team members would return in twenty minutes to 
collect them for the first assessment.  Carl and his mother had been told of my 
project several days earlier and they had said they were interested in participating. I 
provided them with PILs, described my project and what participation would entail, 
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and asked if they had any questions. Carl had no problem with speech and was 
articulate, and said that he would be happy to participate. Both him and his mother 
signed consent forms, and I waited with them before we were collected for the first 
of his assessments.  
Again, during my observations of the interactions involving Kyle and Carl, I 
used the ‘two-step’ process of creating field notes (Hammersley and Atkinson 
2007). In addition to capturing what was ‘said’ by participants, however, I also 
wanted to record as much of the non-verbal action as possible. Indeed, an 
observational method informed by my particular theoretical stance (material 
semiotics), necessitated that I capture the interactions between bodies, objects, 
technologies and the physical, built-environment. Although there is a significant 
body of ethnographic studies focusing on interactions between humans, non-human 
objects, and the build environment, very little guidance is provided within sociology 
literature on how the researcher can record such interactions.  The design theorist 
John Zeisel (2006) provides some useful guidance. He states that maps and 
accompanying notation are a convenient way to analyze several people in one 
setting (2006: 200-203). Following suit, I created annotated maps of the physical 
setting in which the observed scenes take place. During the interaction I created a 
quick floor plan of the setting, noting the location of tables and chairs, the position 
of various participants (PMDS team members, patients, family members), and the 
position of various equipment and tools that were used. I also used ‘trigger’ words 
or concise phrases to note how and when various tools, equipment and other non-
human objects were used. During stage two of the note-taking process these initial 
scribblings were expanded into a more coherent and detailed account.  
Zeisel also suggests that researchers should stay attentive to several types of 
‘physical traces’ that indicate how participants interact with their environment. 
These include various displays of the self, where objects are employed to personalize a 
space or associate a space with a particular group; adaptations for use, where 
participants add props to enable a space to be used in a particular way; public 
messages, such as official signs or graffiti which communicate to people how a space 
should be used; and by-products of use such as wear-and-tear of a surface, or physical 
remnants, which indicate how a space or an object has been used (2006: 170-179).  
These traces can be used to infer how a material environment shapes particular 
actions and how human participants mould and utilise their environment. My 
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original intention was to take note of all of these types of physical traces, but as I 
undertook the research I found that it was the first two (‘displays of the self’ and 
‘adaptations for use’) that I tended to notice. Perhaps because I was already near-
overwhelmed with data as the interactions took place that I failed to note any 
instances of ‘public messages’ or ‘by-products of use’.  
Using this method of noting and recording data I observed most members 
of the team as they worked with patients and families. (A full list of the specific 
interactions that I observed is presented in table 2.2). Observing these interactions 
enabled me to see how team members, in a ‘messy’, clinical setting, managed several 
of the challenges that I had identified during the team meetings:  how they selected 
candidates for DBS, how they attempted to manage the expectations of families, 
and how they measured clinical improvements. Importantly, it also enabled me to 
see how various assemblages ‘enact’ the patient and dystonia.  
 
 Table 2.2: Observations of interactions involving patients 
Observation Interaction Participants Duration 
(min) 
1 Teaching family how to 
recharge DBS system 
Neurologist  
Patient  
Patient’s mother  
Patient’s father 
30 







3 Fine motor skills 
assessment, assessment of 







4 Speech and intelligibility 
assessment 
Speech and language 
therapist,  
patient patient’s mother 
40 
5 Goal setting session prior 







6 Scoring of impairment Two physiotherapist 
Occupational therapist 
Speech & language 
therapist 
90 
7 Scoring of functionality Occupational therapist 120 
Table 2.2 illustrates the observations of interactions that were undertaken as part of 
this project. Note that several of the interactions involved more than one 
assessment or exam.  





2.6.3 Interviews with clinicians 
All members of the PMDS team were interviewed once, except for the clinical 
research fellow who was interviewed twice.  Interviews lasted between 45 and 90 
minutes and all participants were happy to have the interviews audio-recorded. To 
ensure that they did not feel pressured to participate (which was a possibility, given 
that the leader of their team was also Principal Investigator for the project), all team 
members were told that their decision to participate would be kept confidential. In 
addition to members of the team I also interviewed a consultant clinical geneticist 
who was the Head of Clinical Services at the hospital when the PMDS team was 
established. In this role she liaised with the head of the PMDS team and had 
extensive knowledge of the institutional environment in which the team worked. (A 
full list of interviews conducted is represented in table 2.3, page 63). 
By conducting most of the interviews towards the end of the data collection 
process I was able to address issues that had been raised during both types of 
observations. Importantly, I was able to address the key challenges I had identified 
during the observations of team meetings. I also found it particularly useful to 
recount actions that I had observed during interaction with patients and then ask 
participants to explain to me what was going on. Thus, the specific interview 
questions differed for each participant, but in general the interview topic guide that 
I prepared (and which can be found in Appendix 4, pages 257-259) addressed the 
following issues: 
 
• The participant’s specific role within the team 
• The training and experience required to undertake his/her role within the 
team 
• The challenges of identifying candidates for DBS 
• Managing patient expectations and getting informed consent 
• The challenges associated with measuring clinical improvements 
• The benefits and challenges of working within a multidisciplinary team 
• Safety and risks associated with DBS implantation 
• Working with families 
• Communicating with patients. 




The interviews were semi-structured and above issues were addressed by-way of 
open-ended questions. This enabled me to seek clarification, ask for specific 
examples, and redirect the interview if new, potentially important issues were raised.  
 
 Table 2.3: Full list of interviews 
Interview Participant Duration 
(min) 
1 Ex-head of clinical services of children’s hospital  50 
2 Clinical research fellow  90 
3 Therapy assistant   70 
4 Team administrator  60 
5 Specialist nurse   55 
6 Occupational therapist   80 
7 Speech and language therapist  45 
8 Physiotherapist – A 45 
9 Physiotherapist – B  60 
10 Psychologist  45 
11 Neurologist – B 55 
12 Neurologist – A (Dr Martin)  45 
13 Clinical research fellow (2nd interview) 55 
Table 2.3 illustrates all interviews conducted as part of this project. All interviews 
were audio recorded.  
 
It appeared that participants enjoyed the opportunity to express their points of 
view, and all stated that they would be happy for me to approach them with further 
questions if need be. On several occasions after an interview had formally ended the 
participant would go on to elaborate on issues that had been raised, perhaps feeling 
more relaxed now that they were no longer recorded. In such instances, I asked 
participants if it was okay for me to make quick hand-written notes of what they 
had said. A professional transcriber transcribed all audio recordings. I also read each 
transcript thoroughly while listening to the audio recordings to correct any errors. 
 
2.6.4 Other fieldwork activities 
Aside from the ‘formal’ methods of data collection outlined above I was involved in 
other activities on site (table 2.4). These included what I refer to as ‘information 
sessions’ with individual team members. One such session involved the nurse who 
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showed me the presentation she gives to families who are considering undergoing 
DBS and the presentation on DBS and infection she gives to nurses working on the 
ward.  
 
Table 2.4: Other fieldwork activities 
Activity Type of activity Individuals 
involved 
Type of notes 
taken 
1 Demonstration of presentation 
on DBS given to families   
Nurse Two-stage note 
taking process 
2 Demonstration of presentation 
on DBS and infection given to 
ward nurses   
Nurse Two-stage note 
taking process 







4 PMDS team away day 
Feedback session 
All PMDS team 
members 
General impressions 
noted at end of 
activity 
5 Demonstration of props and 







Another session involved the occupational therapist (OT) who showed me the 
various tools and props they use to communicate with patients with poor speech. 
The team administrator and nurse also showed me how she put the weekly team 
schedule together (which was particularly useful to see – as we will see in the 
following chapter is one strategy for managing the challenge of multidisciplinarity).  
During these sessions I recorded data using the two-stage note taking processes 
outlined above. 
I was also invited to team social events, one of which was the annual ‘away-
day’.  During this event the team discussed various ‘non-clinical’ issues, such as: the 
overall direction and goals of the team, possible research projects and collaborations 
with other groups; and the content and format of their website format. Rather than 
take ‘full’ field notes using the two-stage process I simply recorded my general 
impressions at the end of the day. At this event I was allocated 45 minutes to 
provide a feedback session to the team.  Here, I articulated my understanding of the 
major challenges encountered by the team and how the team was attempting to 
manage these challenges, and I illustrated how I was using and presenting the data 
that I had so far collected. Members of the team clarified a few points, and indicated 
that they were satisfied with the picture I had presented.   




2.7 Data analysis and identifying key themes 
Analysis was an iterative process and took place as I was collecting data.  All 
interview transcripts and field notes were transferred to NVivo9 data 
storage/analysis software, which I then used to code the data immediately after it 
was uploaded. As I indicated earlier, my research objectives compelled me to 
maintain surveillance of any challenges that the team was encountering in their day-
to-day work. After five of six observations of team meetings I had identified what I 
took to be the major challenges of the team: coordinating multidisciplinary 
teamwork; selecting candidates for DBS, managing expectations of families, and 
measuring clinical improvements. I therefore created thematic codes that would 
enable me to quickly locate any discussions or actions related to these particular 
challenges. I was able to use the feedback session to check with participants that the 
challenges I had identified (and that had become the basis for much of my codes), 
were in fact, representative of their work. As my stock of data increased I quickly 
noticed that many of my initial codes were too general. So, I had to create ‘sub-
codes’ and subsequently recode data collected earlier. For example, the code 
‘measuring clinical improvements’ was divided into the sub-codes ‘BFM scale’,  
‘AMPS scale’, ‘BADS scale’, and several others. This ‘enriching’ of my codes 
corresponded to my increased familiarity with the activities of the team.  
Indeed, the codes tended proliferate throughout the data collection process. 
Each additional observation or interview tended to reveal a new theme that might 
be of interest, and although I became aware that the project would most likely focus 
on several key challenges encountered by the team, I did not want to preclude any 
potential avenues of inquiry. In one of the later interviews, for example, I asked a 
participant if she found it difficult working with children very severe motor 
disorders. She replied that it was essential to have a good sense of humour. When 
she said this, I thought about the numerous times I had witnessed team members 
laughing, often in potentially stressful circumstances. Thankfully I had noted these 
instances in my field notes even if I had not considered it to be a theme worth 
coding. I subsequently went back over all my collected data and coded all instances 
where members of the team were using humour. My analysis, then, involved a 
continual re-evaluation of earlier data in response to findings from more recently 
collected data. 
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Thus, by the end of the analysis period, the data had been organized around 
the key challenges encountered by the team. Within each of these are a plethora of 
codes that pertain to participant discussions of that challenge, or specific, practical 
methods of managing that challenge. I felt that I had sufficient data that all four of 
these challenges could become the basis for a chapter of this thesis. There is, then, a 
chapter that explores each of the following challenges encountered by the team: 
 
 Coordinating multidisciplinarity (Chapter 4) 
 Selecting candidates for deep brain stimulation (Chapter 5) 
 Managing expectations of families (Chapter 6) 
 Measuring clinical improvements (Chapter 7) 
 
Each will show how PMDS members have ‘innovated’ to overcome the challenge, 
and together with the chapter on the history of DBS that precedes them (the 
following chapter), they will provide a comprehensive illustration of medical 
innovation.  
In addition to these challenges I have identified other themes that could be 
considered to traverse all of these challenges. These included themes such as the 
role of humour in managing tension, the role of the clinician’s body in generating 
useful clinical knowledge, and what could be called socio-political factors: the 
influence of evidence-based medicine, the influence of a ‘patient-centred’ mantra 
within healthcare, and concerns about how this encourages autonomous decision 
making among patients. 
 
 
2.8 Conclusion: producing a sociological account from an irreducible 
world      
In this methodology chapter I have highlighted some of the many factors that have 
collectively shaped this project (such as negotiations with the gatekeeper, Dr Martin, 
and the NHS REC approval process). I have also illustrated how the project has 
been influenced by a set of beliefs about the nature of the world in which we live; a 
set of beliefs that have been adopted from material semiotics. And, I have also 
shown how data collection and analysis was shaped by my research questions and 
background reading on the topic, leading to the identification of four ‘key 
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challenges’ encountered by the PMDS team which form the structural basis for the 
thesis. 
Before we move on however, it is important to keep in mind a caveat. As 
Law has stated (2004), much of the world does not lend itself to neat sociological 
accounts. It is naïve to think that the phenomena of the world can be reduced to 
language and conveyed in text; some phenomena will escape our faculty of 
comprehension, and even a miniscule aspect of the world contains a near-infinite 
detail that, if it were to be captured faithfully in an account, would require an 
enormous amount of time and text (George Luis Borges illustrates the crippling 
futility of any such attempt in ‘Funes the Memorious’ 1970)7. Inevitably, then, any 
manageable account of any aspect of the world, even one that seeks to foreground 
complexity and uncertainty, is stylized in some way. My goal with the proceeding 
chapters, therefore, was to produce an account that is akin to a useful map. As 
McGrail puts it in his description of a good Actor-network Theory account: 
 
A good map makes no secret of the fact that it has left-behind a near infinite 
amount of the detail and complexity of the original terrain, but at the same time it 
can never be divorced from it – it can never relax its empirical grasp… A map is 
stubbornly situated, but at the same time it is built upon rigorous, intelligent, and 
pragmatic abstraction (McGrail 2004: 128-129). 
 
 
                                                 
7 “Funes not only remembered every leaf on every tree of every wood, but even every one of the 
times he had perceived or imagined it... I suspect, nevertheless, that he was not very capable of 
thought. To think is to forget a difference, to generalize, to abstract. In the overly replete world of 





3 A history of deep brain stimulation8  
 
3.1 Introduction 
In order to put the innovative activities of the PMDS team in context, it is necessary 
for me to describe some of the historical developments that have enabled such a 
team to exist in the first place. In this chapter I will illustrate how the DBS 
technology has emerged from an entanglement of various actors and has been 
shaped by several socio-political trends (In other words, this chapter will be used to 
address the first research question9 and to provide some insights that can address 
the fourth research question10). Aside from enabling me to provide a more coherent 
picture of medical innovation, this foray into the historical development of DBS will 
also shed light on some of the challenges encountered by the team in their day-to-
day activities.  
While overviews of the development of DBS are not uncommon in the 
scientific literature, they are seldom little more than a means of introducing the 
technology to readers. As such, they tend to be brief, relying on a few key historical 
events to provide some sense of context. As Hariz et. al. point out (2008), the 
common narrative of these overviews is that DBS was first developed in 1987 by a 
team treating patients with tremor at Grenoble, France. Alim-Louis Benabid and his 
colleagues were using electro-stimulation to identify the correct area of the brain to 
undergo ablative surgery. In doing this, they noted that high-frequency electro-
stimulation was, on its own, therapeutic and subsequently DBS was adopted as a 
means for treating medically refractory motor disorders in many parts of the world. 
And as time went on, the narrative goes, the psychiatric side effects identified in 
some patients encouraged explorations of DBS as a possible treatment of 
psychiatric illnesses.   
                                                 
8 This chapter (with some adjustments to the introduction and discussion) has been published as: 
Gardner, J. (2013). A history of deep brain stimulation: technological innovation and the role of 
clinical assessment tools. Social Studies of Science 43(5): 707-728.   
9 Research question 1: What factors have shaped the development and dissemination of DBS 
technology? 
10 Research question 4: What socio-political trends influence the development of the PMDS’s deep 
brain stimulation services? 
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While the details of such narratives may not necessarily be wrong, they tend 
to give a misleading impression of the nature of medical and scientific innovation. 
Much of the scientific literature presents DBS as if it is an inevitable outcome; the 
consequence of continuous development driven by good science, beneficent 
medicine and committed specialists. Consequently, knowledge is presented as 
something that is discovered, and innovation as the inevitable, neutral incorporation 
and application of this knowledge (thus reifying the linear model of medical 
innovation). Many scholars have been critical of such narratives. Generally, such 
criticisms point out that various social forces shape the development and 
application of technologies, and such technologies are not, then, value-free and 
neutral. As Brown and Webster argue (2004), medical innovation is complex and 
reflects a wide-range of distinct and competing interests. Much of the work 
undertaken in science and technology studies and the sociology of medicine has 
sought to identify exactly how particular interests shape the development and 
application of technology, and how these technologies subsequently reify or disrupt 
particular norms and institutions. A recent example of such work is Stuart Blume’s 
account (2010) of the development of the cochlear implant. From the late 1960s 
onwards several groups were attempting to develop an implantable hearing device. 
These groups had differing views on how such a device should work, faced 
considerable hostility from their colleagues, and had to compete for funding. Some 
were not averse to using media hype in order to secure the resources they needed, 
much to the disdain of other hearing specialists. Competing groups formed alliances 
with rival device manufacturers, one of which provided the necessary resources to 
conduct clinical trials and gain regulatory approval. Once approved sales of the 
device failed to rise, partly due to the high costs associated with its implantation. 
Competing companies therefore formed an additional alliance to lobby the US 
government to have the device covered by Medicare. Blume’s account highlights the 
many diverse actors involved in innovation: competing scientists and engineers, the 
media, industry, regulatory agencies, lobby groups, patient advocacy groups, and 
governments. As Faulkner states, this plurality of interests, both public and private, 
is characteristic of medical innovation within neo-liberal economies (Faulkner, 2009: 
7).  Brown and Webster argue that technologies emerge from, and are an integral 
part of, heterogeneous networks made up of professions and institutions, users and 
citizens, governments, regulatory agencies and commercial industry. Technological 
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innovations have to work within and through these networks by resonating with 
pre-existing values or interests. Their capacity to do this, to be co-opted, moulded, 
and perpetuated by various actors, determines their success. No technology “ever 
speaks for itself” (Brown and Webster 2004: 38).   
Indeed, as this chapter will illustrate, this plurality of interests and the 
formation of alliances is characteristic of the development of deep brain stimulation 
technologies. Deep brain stimulation has its origin in the neurostimulation 
techniques developed within a sub-speciality of neurosurgery: stereotactic 
neurosurgery (also known as functional neurosurgery). During a brief era of intense 
learning-in-practice, neurosurgeons within this speciality produced much of the 
knowledge and material infrastructure from which deep brain stimulation therapies 
later emerged.  We will also see the importance of technology transfer in the 
development of device-based therapies: the first neurostimulators were modified 
cardiac pacemakers. As this technology was transferred, alliances were formed 
between neurosurgeons and commercial industry, particularly with the medical 
device manufacturer Medtronic. This chapter will suggest that the material qualities 
of the technology facilitated its rapid dissemination. As de Laet and Mol have 
illustrated (2000), flexible technologies can disseminate more easily than those that 
impose a particular type of usership.  We will also see that the advent of medical 
device regulation had a major impact on the development and dissemination of 
neurostimulation therapies. In effect, it directed the development of 
neurostimulation technology towards therapies for conditions such as Parkinson’s 
which could be ‘objectively’ quantified with clinical assessment tools. I will also 
argue that the commercial utility of such clinical tools in the era of device regulation 
and evidence-based medicine is one reason why they have become prominent. This 
has facilitated the diffusion of particular techniques for manipulating bodies to 
extract data, techniques that are currently employed by the PMDS team.  In this 
chapter, then, we will explore the particular conjunction of circumstances that have 
enabled the emergence of teams such as the PMDS, and we will see how some of 
the elements that constitute the context of the PMDS have been shaped by a range 
of historical actors. 
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3.2 Materials and methods 
The data for this chapter has been gathered from a range of resources. Scientific 
papers from 1930 onwards relating to electro-stimulation, neurostimulation, 
neuromodulation and deep brain stimulation were sourced from a range of 
neurosurgical, neurological, psychiatric journals, as well as engineering and 
bioengineering publications. Data was also gathered from scientific papers relating 
to the development of clinical assessment tools for movement disorders published 
from the 1970s onwards. Newspaper articles, press releases, transcripts of FDA 
panel hearings and meetings (available online), and secondary historical documents, 
and accounts produced by engineers (Shatin et al. 1987; Mullett, 1987) Metronic 
medical advisors (Coffey 2001; 2008) and numerous clinicians, particularly the 
neurosurgeons Philip Gildenberg (2000; 2005; 2009) and Adrian Upton (1986, 
Upton & Lazorthes, 1987) were also included. These documents were critically 
analysed in order adhere to Lampland and Star’s proscription for interrogating naive 
“stories of inevitable technological development” and instead identify how both 
deep brain stimulation and standardized, clinical assessment tools emerged from, 
and were shaped by, an entanglement of actors (Lampland and Star, 2009). Thus, 
these papers were used to identify the various social actors, political and institutional 
pressures, and biomedical developments involved in the development and 
stabilization of deep brain stimulation. 
 
3.3 The development and stabilisation of deep brain stimulation 
Much of the recent scientific literature on DBS provides a brief overview of the 
therapy’s history. As Hariz et al point out (2010), the common narrative of 
these overviews is that DBS was first developed in 1987 by a team treating 
patients with essential tremor and Parkinson’s at Grenoble, France. Yet, many 
clinicians had been aware of the therapeutic effects of electro-stimulation of 
the brain, or neurostimulation, for several decades prior to this and 
neurostimulation technologies had been in development since the 1960s. 
 
3.3.1 The rise and near demise of stereotactic neurosurgery 
Since the 1930s clinicians had been using electrodes to explore the function of 
various areas within the brain and to identify areas for ablative therapy. Ablative 
therapy involves the deliberate, precise destruction of particular areas within the 
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brain that are thought to be malfunctioning. The first such procedure, the 
“Montreal Procedure”, was developed by the neurosurgeon Wilder Penfield in the 
1930s to treat epilepsy. Here, patients were kept awake while a surgeon would 
stimulate different areas of their cerebral cortex with an electrical probe. By noting 
the patient’s response when stimulating various regions, the surgeon hoped to 
locate, and subsequently destroy, the particular area of implicated in the patient’s 
seizures (Penfield, 1936). In 1947 an apparatus was developed that enabled 
clinicians to use this technique to explore and ablate areas deeper within the brain.  
The stereotactic apparatus (figure 3.1) brought about the emergence of a new 
neurosurgical speciality, stereotactic neurosurgery, within which the skills, 
equipment and knowledge were developed that would later enable deep brain 
stimulation to emerge and a therapy.   
 The stereotactic apparatus delineates the brain as a three-dimensional system 
of Cartesian coordinates.  When used in conjunction with imaging technologies, any 
point within a patient’s central nervous system can be designated as a set of three 
numbers. Surgeons can then plan their procedure to carefully avoid vital areas and 
navigate their way to areas deep within the brain (Spiegel et al., 1947). As a result of 
the apparatus the mortality rate associated with neurosurgery plummeted (from 15% 
to 1%) and stereotactic neurosurgery went through a period of rapid growth: within 
ten years it was being practiced in over forty centres worldwide (Gildenberg 2000).  
 
Figure 3.1: A stereotactic apparatus 
 
            An artist’s rendition of the stereotactic apparatus. (From Coffey 2008). 
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This rapid growth was fuelled by a large demand for ablative therapies, the only 
means available to provide relief from a range of otherwise untreatable neurological 
conditions. During the period of rapid growth, stereotactic surgery was used to treat 
various psychiatric disorders (psychosurgery), movement disorders, and chronic 
pain. Following Penfield’s technique and guided by the stereotactic apparatus, 
surgeons would use electro-stimulation to identify possible target areas deep within 
the brain that were thought to be implicated in the condition, and if they were 
satisfied with the corresponding effect on the patient, the area would be carefully 
destroyed. Prior to the introduction of antipsychotic medications in the mid 1950s, 
this and the much cruder frontal lobotomy were the only treatments available for 
patients with psychiatric disorders; disorders that were considered to be a huge 
financial burden on society, particularly in the US (Mashour et al., 2005). Similarly, 
prior to the introduction of levodopa in 1968, medicines were largely ineffective in 
managing the symptoms of Parkinson’s, a condition that affects around three in 
every 1000 individuals. Parkinson’s became the main condition treated with 
stereotactic surgery, with approximately 25 000 surgeries by 1968 worldwide 
(Gildenberg 2000). 
This large body of otherwise untreatable patients provided stereotactic 
neurosurgeons with a great deal of work and ample opportunity to engage in what 
Morlacchi and Nelson (2012) refer to as ‘Learning-in-practice’.  While attempting to 
identify the most effective means of treating each individual patient, stereotactic 
neurosurgeons were able to explore the effects of stimulating areas deep within the 
brain. As the neurosurgeon Gildenberg puts it, it brought about:  
A period of unrivalled empirical human experimentation… From the beginning, 
the philosophy was to use every insertion of an electrode into the brain as an 
opportunity to study neurophysiology… The information obtained in the operating 
room was valuable to help localise the electrode position, and the information 
obtained about pathophysiology was used to develop new indications and targets 
for stereotactic surgery (Gildenberg, 2000: 299, 301) 
 
Surgeons continued to hunt for more effective target areas for ablation, and in the 
process they created a body of knowledge based on the effects of stimulating 
different areas within the brain. In patients with motor disorders it was noted that 
lower frequency stimulation of particular areas could exacerbate symptoms, while 
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higher frequencies could reduce symptoms (Mundinger, 1965; French et al, 1962). 
In patients with Parkinson’s, the subthalamic nucleus (STN), now the main target 
for deep brain stimulation, was identified as one such area:  
The subthalamic nucleus was not readily activated by low frequency stimulation… 
but there was suppression noted when values of 120 to 300 c.p.s were reached. 
(Nashold & Slaughter 1969: 243) 
 
Noting the therapeutic effect of higher frequency stimulation, some surgeons 
carried out chronic stimulation on their patients. Electrodes were left in situ and 
protruding from the skull for several weeks, enabling the surgeons to identify and 
lesion the optimal areas for ablation in an incremental fashion (Sem-Jacobsen 1966; 
Nashold & Slaughter 1969).  
By the end of the decade, however, this era of experimentation, and indeed 
the stereotactic specialty as a whole, almost came to an end. After the introduction 
of levodopa in 1968 neurologists were reluctant to refer Parkinson’s patients to 
neurosurgeons: the reservoir of severally affected, otherwise untreatable patients 
willing to undergo ablative surgery was drastically reduced. Compared to surgical 
treatments, levodopa was inexpensive, safe (non-invasive), remarkably effective in 
reducing the severity of Parkinson’s symptoms, and it quickly became the first-line 
treatment for diagnosed patients. Indeed, when it was first introduced it was 
believed to be a panacea for Parkinson’s; a therapy that would control symptoms 
indefinitely without any major side-effects (Gildenberg 2000). Additionally, 
neurosurgeons were discouraged from treating psychiatric conditions by a public 
campaign that lumped their stereotactic procedures with the frontal lobotomy.  A 
figurehead of the campaign, the psychiatrist Peter Breggin, told the US Senate 
Subcommittee on Health that psychosurgery has “no empirical or rational basis…”, 
“attacks and mutilates brain tissue that has nothing demonstratably wrong with it” 
and that it can be used to “subject the individual to the control of others” (Breggin, 
1972: 381). Using examples of surgically treated restless housewives and hyperactive 
children, he argued that psychosurgery was a political tool used to placate 
minorities. Breggin’s criticisms were taken-up by US representative Cornelius 
Gallagher and a commission was established to further investigate his claims. 
Despite the commission’s findings that psychosurgery appeared to be of great 
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benefit to individual patients the political climate led most neurosurgeons to 
abandon the field (Valenstein, 1997).  
Thus, by the middle of the 1970s levodopa and a hostile political climate 
had brought about the near-demise of stereotactic neurosurgery. A few academic 
centres remained open in the US and Europe to provide relief to the small number 
of patients with chronic, untreatable pain, and those with movement disorders that 
would not respond to the new levodopa medications. The skills, knowledge and 
equipment that had been developed during the ‘era of experimentation’ were 
maintained in these few centres. As the next section will illustrate, it was within 
these centres that deep brain stimulation therapy would have its genesis. The 
particular material infrastructure (such as the stereotactic apparatus) and the 
knowledge-base of these centres, the exploratory ethic of the clinicians working 
within them, and as we will see, technological developments in cardiac pacemaking, 
led to the development of the first neurostimulators. 
 
3.3.2 The genesis of the neurostimulator 
During the period of ‘unrivalled experimentation’ neurosurgeons had noted the 
therapeutic effects of high frequency neurostimulation. Electro-stimulation was not 
a therapy on its own, however. The lack of sufficient technology is no doubt a 
reason for this: electrodes had to be externalized, protruding from the head in order 
to link with a power source which at the time were large, cumbersome and certainly 
not implantable. As Morlacchi and Nelson point out (2011), new medical therapies 
often arise from the transfer of technological artefacts from one sector into another. 
This was certainly the case with neurostimulation therapies. In the early 1960s the 
then fledging medical device manufacturer Medtronic introduced the first, 
commercially available cardiac pacemaker. These small, mobile power sources 
quickly disseminated throughout the US fuelling the company’s rapid growth, and 
by 1975 Medtronic’s annual turnover was over USD 100 million. From this industry 
came the components and finance required to produce neurostimulation 
technologies: in effect, the development of the neurostimulator piggybacked on the 
success of the cardiac pacemaker. 
The adaptability of cardiac pacemaker technology was first demonstrated by 
neurosurgeons attempting to treat chronic intractable pain in the late 1960s. 
Although medicines had become the first-line treatment for psychiatric disorders 
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and Parkinson’s, drug-based therapies for various forms of chronic pain remained 
elusive. This small pocket of patients provided neurosurgeons with an opportunity 
to continue exploring the effects of neurostimulation and to trial neurostimulation 
as a therapy in its own right. The Wisconsin based Norman Shealy was the first 
neurosurgeon to adapt cardiac pacemaker technology into a therapy for chronic 
pain. Electrodes were implanted within the spinal cord of a group of patients and 
connected to an implanted Medtronic pacemaker modified to produce the higher 
frequency of stimulation required to modulate the perception of pain (Shealy, 
Mortimer, & Reswick, 1967: 490). At that time, standard, battery-powered 
pacemakers were unable to produce the necessary frequency of electrical pulses 
required to interfere with the conduction of pain. Shealy used a modified Medtronic 
“RF” (Radio Frequency) system where energy (in the form of radiowaves) is 
transferred through the skin to an implanted receiver. Shealy reported his 
‘promising’ results to colleagues at a conference in 1969, many of whom were 
sufficiently convinced to offer the therapy at their own centres. (Shatin, et al. 1986). 
Similarly, a Californian team used pacemakers to stimulate areas deep within the 
brain. Hosobuchi and his team had been using stereotactic-guided ablative surgery 
to provide relief to patients with chronic pain. Deep brain stimulation was trialled 
on a few patients who failed to respond satisfactorily to ablative therapy: electrodes 
were stereotactically implanted within the thalamus and connected to a pacemaker 
(Hosobuchi et al. 1973).  Hosobuchi reported that pain was sufficiently masked in 
three of his four original patients. 
Soon there was sufficient interest among neurosurgeons treating chronic 
pain to encourage the medical device industry to develop a specific neurostimulator 
device. Medtronic was the first to do so in 1968, followed by Avery Laboratories in 
1972 and then Cordis, the second largest producer of pacemakers behind Medtronic 
(Rossi, 2003: 10). As Shealy had illustrated, many pacemaker components such the 
power source, the circuit board, and the device casing could be adapted into 
neurostimulation therapies, and pacemaker producers were able to use their existing 
manufacturing skill set to produce many of the neurostimulator components (Stuart, 
2012). Companies subsidized the development and production of these components 
with returns from the highly lucrative pacemaker market (Upton, 1986). Medtronic 
officially established a neurological division in 1975 and it was while marketing its 
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device for the treatment of pain that Medtronic trademarked the term “Deep Brain 
Stimulation” (Coffey, 2009).  
During the 1970s these neurostimulators disseminated throughout specialist 
centres within the US and Europe and were incorporated into therapies for a range 
of conditions. These were conditions that had previously been shown by 
neurosurgeons undertaking ablative surgery to respond to electro-stimulation: 
various motor disorders, cerebral palsy, epilepsy, schizophrenia, and severe 
depression. Different areas of the nervous system were stimulated: the spinal cord, 
the cerebral cortex, and within those centres that had retained the ability to carryout 
stereotactic surgery, areas deep within the brain such as the thalamus. The well-
known US neurosurgeon Irving Cooper, for instance, used the newly developed 
neurostimulators to stimulate the cerebellum and deep brain as treatments for 
cerebral palsy, epilepsy or dystonia in around 200 patients (Cooper and Upton, 
1978, Cooper et al., 1980). Up to 200 patients were treated, the results of which 
were good and “worthy of immediate notice” (Rosenow et al., 2002). In Germany, 
Fritz Mundinger used Medtronic neurostimulators to stimulate areas within the 
thalamus to treat dystonia, arguing that the reversible nature of the treatment made 
it preferable to ablation (Mundinger, 1977). This statement was echoed by Orlando 
Andy of Mississippi who was using stimulation of areas within the thalamus to treat 
nine patients with Parkinson’s who had failed to respond to levodopa therapy 
(Andy, 1983). At Tulane University Robert Heath adopted Medtronic 
neurostimulators into his treatments for psychiatric disorders, particularly 
schizophrenia, reporting that some of these patients subsequently became symptom 
free (Heath 1977; Heath et al 1980). In Southampton UK during the late 1970s, 
Brice and McLellan were using DBS to treat a small number of patients with 
multiple sclerosis–associated intention tremor. They reported that some of their 
patients improved significantly: one patient initially totally disabled, was 
subsequently able to “feed herself, light her own cigarettes, fasten her own buttons, 
and control bed light and radio” (Brice and McLellan, 1980).   
In a recent retrospective, Philip Gildenberg, a stereotactic neurosurgeon at 
the time, gives us some idea as to why neurosurgeons were receptive to 
neurostimulation technology. The introduction of levodopa for the treatment of 
Parkinson’s in 1967 had left a work void for functional neurosurgeons with training 
in stereotactic techniques. Neurostimulation provided an opportunity, for some 
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neurosurgeons at least, to utilize their skills and equipment and provide potentially 
effective surgical treatments for other conditions or for those few patients with 
Parkinson’s who could not tolerate levodopa (Gildenberg, 2009: 14). The skills, 
knowledge and tools that had been developed during stereotactic surgery’s earlier 
period of rapid growth could easily be transferred into deep brain stimulation 
therapies: the stereotactic apparatus in conjunction with imaging technologies were 
used to identify target areas and plan the surgical procedure necessary to implant 
permanent electrodes; intra-operative stimulation was often used to ensure that the 
correct target area had been located; and these target areas were often the same as 
those that, in the past, would have been ablated. Neurosurgeons, then, had the 
necessary skill set, and the technology provided them with a vehicle for intervening 
in complex neurological conditions in an era when drug-based therapies tended to 
dominate.  
This dissemination was enabled by the flexibility of the technology. As 
Faulkner argues, the material qualities of a device interact in more or less flexible 
ways with social actors, impinging upon their possibilities for adoption and usage 
(2009: 18). The material qualities of neurostimulation technology, such as its small 
size, its biocompatibility and its ability to deliver precise electrical stimulation to a 
region decided upon by the clinician, permitted its adoption into a range of 
therapies. This is not to say that the diffusion of the device was unproblematic. 
Problems with components were not unusual and these were subject to incremental 
modifications: the electrodes used in deep brain stimulation could fray and turn on 
their axis (Siegfried & Shulman 1987); complications arose from lead implantation 
and the power source could fail (Shatin et al 1986). In the 1980s some of these 
difficulties were overcome. Lithium batteries enabled the production of a 
neurostimulator that could be implanted for several years while providing the 
necessary level of on-going stimulation. New neurostimulator leads were produced 
based on endocardial (pacemaker) leads, and a device was created that could be 
programmed via a wireless console programmer. Again, these incremental 
developments were the result of technology-transfer from the on-going financially 
lucrative improvements associated with the pacemaker (Shatin et al 1986).  
Additionally, it is likely that the diffusion of the neurostimulator was linked 
to the success of a cardiac pacemaker in a broader sense. As Blume argues, the 
cardiac pacemaker gave ‘the notion of an implantable device legitimacy and appeal’ 
3: A history of deep brain stimulation 
 
 79 
(2010: 34). It enabled clinicians to significantly improve the lives of a large body of 
patients and was heralded as a major advancement in modern medicine. This 
encouraged wider acceptance of implantable devices among the public, and no 
doubt encouraged those working in neurostimulation to emulate the success of this 
pacemaker. 
 
3.3.3 Medical device regulation 
During this period clinicians reported that many of their patients were responding 
well to neurostimulation therapies. In 1978 Cooper stated there had been a clinical 
improvement in the majority of the 700 patients who had undergone cerebral 
stimulation for the treatment of either cerebral palsy or epilepsy (Cooper and 
Upton, 1978). Orlando Andy reported that the results of stimulating the thalamus at 
high frequencies in nine patients with motor disorders were “fair to excellent” 
(Blomstedt & Hariz, 2010: 431); and Heath, reporting on a study of 38 patients, 
argued that those with depression, those with “behavioural pathology consequent to 
epilepsy, and those with psychotic behaviour consequent to structural brain 
damage” responded well to neurostimulation of the cerebellum (Heath, et al 1980: 
243).  
Yet in this area prior to medical device regulation it was not exactly clear 
what constituted a ‘clinical improvement’ or a ‘fair to excellent’ outcome. In effect, 
the opinion of a clinician was sufficient to determine whether a medical therapy was 
effective, and thus whether or not the use of a medical device could be justified. 
This reflected the sentiment of the early 20th century when ‘efficacy’ was 
considered “a matter of opinion, not a fact” (Bodewitz et al., 1989). With the advent 
of medical device regulation, however, ‘efficacy’ was delineated as something that 
should be objectively verifiable, thus necessitating clinical assessment tools and 
outcome measures that would enable the quantification of a patient’s response to an 
intervention.  Here we will see that there were few such tools for the conditions 
being treated with neurostimulation, and subsequently, neurostimulation therapies 
such as deep brain stimulation for chronic pain were not approved in the new 
regulatory climate. 
In 1976 after seven years of political debate, the US Congress passed the 
Medical Device Amendments to the Federal Food, Drug, and Cosmetic Act, thus 
granting the FDA authority over all medical devices. This was in response to a spate 
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of device failures: between 1960 and 1970, medical devices were implicated in 
10,000 injuries and over 700 deaths, and between 1972 and 1975, over 22,000 
potentially defective pacemakers were recalled by manufacturers (Foote, 1978). The 
intention of the amendments was to provide a “reasonable assurance of safety and 
effectiveness for all devices” (Foote, 1978). With pharmaceutical regulation the 
gold-standard for determining efficacy became the double blind trial. With medical 
devices, which are often not amenable to double-blind trials, the FDA stated that 
efficacy would be determined “on the basis of well-controlled investigations, 
including clinical investigations where appropriate, by experts qualified by training 
and experience” (Foote, 1978). Consequently, efficacy was rendered as something 
objectively verifiable: it would have to be demonstrable to an FDA appointed panel 
of experts that were not directly involved in the treatment in question. 
In regard to neurostimulation technology used in deep brain stimulation and 
cerebral stimulation therapies, the FDA decided that clinical trials would be 
necessary before it could be marketed (Coffey and Lozano, 2006). Medtronic, 
Avery, and Neuromed, the three manufacturers of neurostimulation technology, 
were offered time to perform the necessary trials and produce the required 
documentation. All, however, eventually declined. The probable reason for this is 
provided by Adrian Upton, a UK-based neurologist. A major problem in the 
application of neurostimulation, he stated, was the lack of standardized, quantifiable 
measures for determining the effectiveness of the treatment (Upton, 1986). Pain, for 
instance, was especially difficult to measure. In a recent summary of 
neurostimulation treatments for pain, Coffey and Lozano refer to the:  
paradox of pain – its simultaneous reality and subjectivity makes the assessment of 
pain relief therapies susceptible to observer- or patient-related influences... 
Unintentional cues, learned responses, or knowledge that a treating physician… is 
conducting the assessment can affect how patients rate analgesic treatments 
(Coffey and Lozano, 2006). 
 
Irving Cooper’s neurostimulation therapies, including his deep brain stimulation 
therapies, were also problematic in this regard. Despite Cooper’s belief that they 
“yielded promising clinical results”, the lack of uniform objective evaluations to 
quantify and measure clinical improvement meant the “true benefit” could not “be 
elucidated” (Rosenow et al., 2002).  
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Thus, DBS and other neurostimulation treatments were not amenable to 
clinical trials because the conditions being treated were not quantifiable: there were 
no generally accepted clinical assessment tools that could be used to demonstrate 
clinical improvement. The clinical trials that were now needed to demonstrate 
efficacy and safety were also expensive, and Upton stated that the costs of further 
development would need to be offset by a large market (Upton and Lazorthes, 
1987). Upton specifically referred to Parkinson’s as a potential market for 
neurostimulators. The problem with Parkinson’s, he claimed, was an over-reliance 
on medications and the promising findings of earlier neurostimulation treatments 
for movement disorders were therefore being overlooked (Upton, 1986). 
 
 
3.3.4 The Unified Parkinson’s Disease Rating Scale: generating immutable 
mobiles 
By the mid-1980s neurostimulation was in a precarious position. On the one hand, 
there was the medical device industry with the manufacturing skill set necessary to 
produce the neurostimulator technology and there were neurosurgeons with the 
expertise required to incorporate the technology into working therapies. On the 
other hand, the new regulatory climate had effectively put a halt on the 
dissemination of many neurostimulation therapies and the market for the 
technology was restricted. In effect, medical device regulation established the FDA 
as what Latour (1987) refers to as centre of calculation. It was endowed with the 
responsibility of assessing efficacy and safety of therapeutic interventions, and as a 
result it became a gatekeeper, either preventing or permitting dissemination of new 
device-based therapies. A distance was created between the point of therapeutic 
intervention (the clinic or the research site), and the point at which efficacy and 
safety of those interventions are assessed (an FDA appointed panel of experts). 
Such distance was deemed necessary to reduce the influence of bias on the 
assessment of an intervention and thus provide a level of protection to patients and 
consumers. Yet, as Latour points out, for a centre of calculation to function this 
distance must be traversed; the two points must, somehow, be brought together. 
This can be achieved via the production of immutable mobiles: renderings of 
entities of interest that are capable of circulating between the two locations without 
losing their meaning in the process (Latour, 1987).  
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As this section will illustrate, clinical assessment tools are a means of 
generating immutable mobiles and creating an equivalency of meaning between the 
sites of intervention and the FDA, thus enabling the latter to act as a centre of 
calculation. In the mid-1980s such a tool was developed for one particular condition 
that was known to respond to neurostimulation: Parkinson’s. This tool, along with 
several other developments, encouraged Medtronic to pursue regulatory approval 
for an application of their neurostimulation technology: deep brain stimulation 
therapy for Parkinson’s.  
In the mid-1980s at University Hospital in Grenoble, France, a team led by 
Alim-Louis Benabid was using ablative therapies to treat cases of Parkinson’s, 
dystonia and a few psychiatric conditions that had failed to respond to drug-based 
therapies. The team was one of the specialist centres that had retained the 
stereotactic tools and skill-set developed during the subspecialty’s period of growth.  
For each patient a stereotactic apparatus was used in conjunction with imaging 
technologies to identify the areas for ablation and to plan the surgical procedure. 
Additionally, intra-operative electro-stimulation was used to ensure the correct area 
had been located, and like others before him, Benabid noted that higher frequency 
stimulation could reduce some of the motor symptoms of Parkinson’s. Benabid set 
about trialling chronic neurostimulation as a therapy in its own right. Importantly, 
Benabid and his team had been using neurostimulation to treat chronic pain and 
were familiar with the equipment and methods that would be required to provide 
chronic stimulation: “We had the method. We had the electrodes. We had the 
stimulating leads.” (Benabid, in Talan, 2009: 41). From 1987 onwards Benabid used 
Medtronic equipment to trial deep brain stimulation of areas within the thalamus to 
treat tremor in patients with either Parkinson’s or essential tremor, some of which 
showed complete relief (Benabid  et al., 1987). While Benabid and his team were 
repeating what others had done a decade earlier, a particular conjunction of 
circumstances meant that Benabid’s work was to have a far greater influence. 
Firstly, Benabid’s team coupled deep brain stimulation to Parkinson’s at a 
time when clinicians were looking for a surgical alternative to levodopa-based 
therapies. Clinicians were becoming aware that while medications such as levodopa 
are initially effective in managing the symptoms of Parkinson’s, they lose their 
effectiveness in the long run.  By the mid-1980s a reservoir of severely affected 
Parkinson’s patients with symptoms no longer adequately managed with 
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medications had emerged. Alternative therapies were needed, and neurosurgeons 
were beginning to revisit pre-levodop-era stereotactic surgical procedures (Bergman 
et al., 1990, Laitinen et al., 1992).   
Secondly, the accidental discovery of a neurotoxin led to the production of 
primate models of Parkinson’s. The resulting studies enabled Benabid to 
consolidate particular areas deep within the brain as effective targets for DBS. In 
two separate incidents (1976 and 1983) recreational drug users inadvertently 
manufactured and ingested a compound that left them with severe Parkinson’s 
disease-like symptoms. The substance was identified as MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine), and an autopsy later revealed that it has destroyed the 
dopamine producing cells of the substantia negra, the same area that degenerates in 
Parkinson’s (Porras et al., 2012). Subsequently, MPTP was used to create the first 
non-human primate models of Parkinson’s (Chiueh et al., 1984; Langstorm et al., 
1984), enabling new avenues of research into the underlying pathology; research 
that would have been unethical on afflicted human subjects. One such avenue of 
research produced a model of a pathological chain of neural activity in which the 
sub-thalamic nucleus (STN) and the globus pallidus  (GPi) are overactive (DeLong, 
1990). By surgically ablating these areas researchers at Johns Hopkins University 
noted that they could reduce the induced-Parkinson’s symptoms in primates 
(Bergman, 1990). The STN had first been identified as an effective target in late 
1960s (Nashold & Slaughter 1969), but the resulting model now provided a 
scientific rationale, prompting Benabid to direct his attention to the area as a target 
for deep brain stimulation.  
And thirdly, Benabid and his team coupled deep brain stimulation 
treatments to Parkinson’s at a time when the disease could be quantified. In 1987, a 
consortium of movement specialists established the Movement Disorder Society 
and produced the Unified Parkinson’s Disease Rating Scale (UPDRS). Their 
intention was to create a comprehensive and flexible system that would replace the 
numerous and idiosyncratic scales being used at various Parkinson’s research sites 
(Fahn and Elton, 1987). The variability of the scales in use at the time made 
comparative assessments difficult: the unified system would standardize clinical 
assessment across centres (Goetz et al., 2003). The UPDRS has five parts, each 
using a scale system to determine the severity of particular Parkinson’s symptoms, 
including mentation, behavior and mood, speech and swallowing, facial expression, 
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tremor at rest, rigidity and finger tapping. For each symptom a number from 0-4 is 
used to assess severity (0 being normal or unaffected, and 4 being the most severe), 
and an overall score for each of the five parts of the UPDRS can be assigned to the 
patient. The severity of a patient’s Parkinson’s, therefore, can be represented with a 
series of numbers. In order to ensure that these numbers are equivalent across 
contexts, the Movement Disorder Society produced a teaching video-tape, 
specifically designed to aid new researchers and those conducting multicentre trials 
(Goetz et al., 1995). The resulting equivalence would enable patients to be 
compared before and during treatment, across research centres, and would thus 
permit the calculations required to determine efficacy.  
Given there was now a considerable demand for surgical treatments and a 
tool had become available to quantify Parkinson’s, it is not surprising that 
Medtronic enthusiastically aligned themselves with the Grenoble-based French 
team. In the early 1990s Benabid presented his results to Medtronic. Engineers at 
Medtronic had recently conducted studies to assess the use of their stimulation 
technology to manage pain, but these were abandoned due to the lack of any 
definitive results (The findings were eventually published in Coffey 2001). Benabid’s 
work illustrated that the same technology could be used to treat Parkinson’s and 
that the results could be demonstrated to regulators: “Changes in movement are 
pretty obvious… pain is something that is not so obvious” (Medtronic engineer, 
quoted in Talan, 2009). Subsequently, Benabid was employed by Medtronic to 
design international (Europe and US), multi-centre clinical trials assessing DBS for 
the treatment of Parkinson’s. The STN or the GPi were to be tested as target areas, 
both of which were supported by the newly developed model of deep brain 
function. The trials were funded by Medtronic and the UPDRS was used in all sites. 
Over the next few years 113 people with Parkinson’s and 83 with essential tremor 
were involved in the trials (Talan, 2009). 
 
3.3.5 Clinical trials & FDA approval 
In a laboratory trial, complexity is elided by having a few metabolic parameters 
‘stand in’ for health; parameters that can be measured, counted and used in the 
construction of factual statements (Latour 1986, Mol 2008.). Similarly, this 
purification is required in clinical trials involving bodies. The UPDRS (like outcome 
measures in general) enabled the purification and inscription required to ‘construct’ 
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factual statements regarding the efficacy of deep brain stimulation. Because the 
UPDRS was adopted in all of Medtronic’s DBS clinical trials, all patients were 
subjected to the same standardized regimes of examination, quantification and 
comparison. Each patient, regardless of their unique personal histories or social 
context, was rendered as a set of comparable numbers representing the severity of 
their symptoms. 
This quantification and the elision of messy and cumbersome personal 
detail, therefore, had three important functions. Firstly, it enables calculation: it 
permits each participant to become a nexus linking the deep brain stimulation 
technology to a clearly delineated region of the brain in a manner that could be 
clearly measured: the effect of deep brain stimulation on particular regions of the 
brain the STN or the GPi could be determined by noting and comparing the 
numerical changes associated with each body. Secondly, these numerical renderings 
of the impaired body are mobile: they can be collected, pooled together, charted, 
graphed, compared and computed, and these resulting inscriptions can then be 
circulated as ‘proof’ or ‘evidence’, with much more fluidity than fleshy bodies. 
These mobile numerical inscriptions are also immutable: they hold the same 
meaning across particular centres, enabling the establishment of a common 
language. Thirdly, as Porter has made quite clear, by eliding personal detail, such 
renderings are imbued with an authority resulting from their supposed objectivity 
(Porter, 1994). The UPDRS, therefore, was an essential part of an apparatus for 
producing facts, in an era when ‘efficacy’ is institutionally deemed as something 
objectively verifiable. In effect, through a process of purification and inscription, 
the UPDRS created the immutable mobiles that bridged the distance between the 
point of treatment (the clinic) and the point of assessment (the FDA) that had been 
created with the advent of medical device regulation. 
In March 1997 UPDRS-derived data were presented to the FDA’s 
Neurological Devices Panel Advisory Committee by consultants managing the trials 
on behalf of Medtronic. The intention was to gain approval for the “Medtronic 
3382 DBS lead and the Medtronic ITREL stimulation system for the suppression of 
tremor due to essential tremor or Parkinson’s; unilateral or bilateral.”(1997). Slides 
of the results were shown to the panel and explained by a consultant who drew 
attention to both individual improvements in UPDRS and statistical analyses of 
overall UPDRS data. He stated that there was a statistically significant reduction in 
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tremor and global disability and that the efficacy of the treatment appeared to be 
greater than that of available medications. There was more to the panel hearing than 
the presentation of numerical data, however. A portion of the hearing was reserved 
for members of the public to voice their opinion. Four individuals spoke to the 
panel, all in support of the therapy. The testimony of these four speakers 
highlighted the day-to-day difficulties of living with a movement disorder, and the 
hope and expectation that had been invested in the deep brain stimulation therapy. 
Two were representing patient advocacy groups and two were being successfully 
treated with DBS therapy as part of the clinical trial (three of the four had also been 
brought to the hearing by Medtronic).  
At the end of the hearing members of the panel expressed their initial 
impressions. All members believed the efficacy of DBS had been demonstrated. 
Some, however, said they were not convinced of its safety: although no major safety 
issues had been identified, potential adverse effects could not be ruled out (1997). 
As one member put it: “unless the side effect slaps you in the face or is quite 
profound, you may not find subtle effects like the neurological changes” (Premarket 
Notification, 1997). As a result of the panel’s findings the FDA formally approved 
the use of unilateral deep brain stimulation for the treatment of essential tremor and 
Parkinson’s. For the latter, however, it could only be used in patients with severe 
tremor, due to uncertainty regarding possible adverse reactions. Medtronic 
continued to sponsor trials exploring the longer-term effects of stimulation and in 
2002, confident that sufficient evidence of safety had been demonstrated, the FDA 
approved DBS for more general cases of Parkinson’s. In 1998 the same clinical 
trials were used by Medtronic to gain the CE mark for their technology, thus 
permitting the use of DBS to treat Parkinson’s within the European Union. 
 
3.4 Discussion: the shaping of DBS  
Within ten years of being approved for the market within the US over 40,000 
individuals had been treated with DBS for Parkinson’s or essential tremor (Talan, 
2009) and DBS had gone from being a marginal therapy to an “effective”, “standard 
and accepted treatment for Parkinson’s disease” (Montgomery & Gale, 2008). 
Currently, Parkinson’s patients can undergo deep brain stimulation therapy at 
specialist centres in North America, Australia, the UK and much of Europe. In their 
2010 annual report, Medtronic highlighted a 9% increase in net revenues from the 
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previous year in their neuromodulation division (from USD 1.4 billion to 1.5 
billion), driven largely by a substantial increase in demand for their DBS technology 
in both Europe and the US (Medtronic 2010). 
DBS for Parkinson’s, then, has proven highly lucrative for Medtronic. 
Medtronic is attempting to replicate some of this success by developing DBS as a 
treatment of other conditions. While Parkinson’s is by far the most common DBS 
indication, a small number of patients have now undergone DBS for the treatment 
of dystonia, epilepsy and obsessive-compulsive disorder and depression. Again, the 
flexibility of the technology has enabled it to be easily adapted to other treatments: 
as one financial analyst recently put it, “deep brain stimulation provides stimulating 
a market… because with a single platform, companies can address several diseases 
with large populations” (Stuart, 2012). In 2003 Medtronic DBS technology was fully 
approved for the treatment of dystonia within the European Union and partially 
approved within the US. Like Parkinson’s, many of the symptoms of severe 
dystonia are clearly visible: pathogenic neural activity causes limbs to become rigid 
and bodies to become painfully contorted. The rate of severe dystonia is 
significantly lower than that of severe Parkinson’s, and so the resulting trials using 
Medtronic equipment were smaller in scale. As with Parkinson’s, standardized 
clinical assessment tools have been co-opted in order to generate the immutable 
mobiles necessary to demonstrate efficacy to regulatory agencies. The Burke-Fahn-
Marsden Dystonia Rating Scale (BFM), like the UPDRS, uses a series of numbers to 
indicate the severity of symptoms (Burke et al., 1985). Medtronic sponsored trials 
assessing DBS for epilepsy and obsessive-compulsive disorder have also adopted 
clinical assessment tools that produce computable, mobile, impersonal renderings of 
the patient. Thus, the medical device industry has been, and remains, a major driver 
of DBS development and stabilization. Indeed, we could say that commercial 
industry and motivation for profit have been a major socio-political factor in the 
emergence of deep brain stimulation therapies. (We will return to this point in the 
final chapter of this thesis). 
Professional interests have also driven the innovation process. With the 
‘rebirth’ of DBS neurosurgeons with training in stereotactic techniques are once 
again gaining access to a pool of patients with conditions inadequately managed 
with medications. In 1990, stereotactic surgery “was the realm of a relatively small 
group of subspecialists” (Gildenberg, 2000: 309). By the end of the 1990s “more 
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stereotactic surgery was being practiced by more neurosurgeons than ever before, 
and stereotactic techniques made inroads to become needed skills for every 
practicing neurosurgeon” (Gildenberg, 2000: 309). Importantly, diffusion has been 
driven by an increasing realization of the limitations of drug-based therapies. As 
Ackerman points out, neurologists are far more inclined to recommend surgical 
therapies to patients in the present day. Indeed, in the majority of present day 
centres offering deep brain stimulation centres, patients are managed by teams that 
include both a neurosurgeon and a neurologist (Ackerman, 2006: 111).  
As this historical overview has shown, the development and stabilization of 
deep brain stimulation therapies was contingent upon the co-development and 
diffusion of standardized methods of rendering the affected body. By eliding 
complexity and foregrounding specific phenomena as ‘significant’, clinical 
assessment tool, and the immutable mobiles they produce, can have a commercial 
utility. This particular case study suggests that this utility has facilitated their 
diffusion. The UPDRS, for example, has been adopted throughout Europe and 
North America and is now considered the gold-standard reference scale for 
Parkinson’s.  Between 1994 and 2003, out of all articles using a Parkinson’s rating 
scale well over two-thirds were using the UPDRS, and the scale was used in most 
clinical trials of both drug and surgical treatments for Parkinson’s. Consequently, 
US and European regulatory agencies have come to rely on the UPDRS (Goetz, et 
al., 2003: 740). The diffusion of such tools is part of what several authors have 
referred to as the rationalization of healthcare of which the evidence-based 
medicine (EBM) movement is a significant component (Porter, 1995; Hunter, 2003; 
Wehrens and Bal, 2012). Indeed, EBM and rationalization can be seen as another 
major socio-political tendency that has, via the redefinition of ‘efficacy’ that 
occurred with the advent of medical device regulation, influenced the innovation 
pathway of DBS. Rationalization has involved a move towards pre-defined 
processes aimed at improving efficiency, an emphasis on quantitative over 
qualitative characteristics, and creating uniformity over multiple sites (Ritzer; 1996).  
Proponents of EBM are wary of a clinician’s experience alone and argue that clinical 
practice should be guided by trials that have objectively determined the effects of an 
intervention. Timmermans and Berg (2003) state that this process of rationalization 
in healthcare began in the 1980s, driven by attempts to reduce unnecessary 
interventions and limit healthcare costs, and facilitated by the emergence of 
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information technologies. This case study suggests that commercial and professional 
interests have also assisted this process. The emergence of clinical assessment tools 
and outcome measures, facilitated by companies in alliance with particular health 
professionals, is an important part of this rationalization process: they enable 
‘efficacy’ to be verified by a third party; no longer is it a clinician’s ‘matter of 
opinion’ (Bodewitz et al., 1989).   
This historical overview has also shown that the necessity of clinical 
assessment tools in the era of regulation can shunt the development and application 
of a medical device towards a particular therapeutic intervention. In effect, medical 
device regulation not only restricts which devices can be marketed, it also limits 
which illness can be treated with devices. This was the case with the use of 
neurostimulation to treat chronic pain. Standardized clinical assessment tools did 
not exist and an evidence-base for the therapy could be produced. Consequently, 
Medtronic directed its resources towards treatments for other conditions. There is 
therefore a financial incentive for both the medical device industry and 
pharmaceutical industry to open up new avenues for innovation by promoting the 
development of standardized clinical assessment tools. In 2002 a consortium of pain 
specialists held the first meeting as part of the Initiative on Methods, Measurement, 
and Pain Assessment in Clinical Trials (IMMPACT). The aim of the initiative was to 
develop “consensus reviews and recommendations for improving the design, 
execution, and interpretation of clinical trials of treatments for pain” (Dworkin, 
2005). Importantly the initiative has sought to develop a standardized clinical 
assessment tool, as the current “variability in outcome measures across clinical trials 
hinders evaluations of the efficacy and effectiveness of treatments” (Dworkin et al., 
2005). Johnson & Johnson, Pfizer, Bristol-Myers Squibb and Boehringer Ingelheim 
sponsored the initiative. 
 
3.5 Implications for the PMDS 
In this chapter we have explored some of the factors that have shaped the 
development and dissemination of DBS technology, thus addressing research 
question one. In doing so, we have also identified several socio-political factors that 
have influenced the innovation process. One of these is the influence of commercial 
interests which has led to alliances between commercial industry and entrepreneurial 
clinicians. The PMDS team, which was established in 2007 (five years after the 
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approval of DBS for dystonia) also liaises closely with Medtronic. The team uses 
Medtronic DBS technology and regularly communicates with Medtronic 
representatives: Medtronic requests feedback on clinical outcomes and offers advice 
and support on any technical issues that arise.   
The PMDS team is also characteristic of many centres offering DBS 
therapies in that it involves a close alliance between neurology and neurosurgery.  If 
DBS were not available, many of the PMDS patients would not be considered for a 
neurosurgical treatment. Indeed the DBS technology has enabled stereotactic 
neurosurgeons to participate in providing therapeutic relief, via the PMDS, to a 
group of otherwise untreatable patients. In a sense, then, the PMDS is 
representative of the new alliances that are forming between neurologists and 
neurosurgeons as clinicians explore alternatives to medicine-based therapies for 
neurological disorders.   
The second major socio-political factor that has influenced the innovation 
of DBS is the emergence of EBM and rationalization. As we will see in the 
following chapters (particularly chapter 7), this has major implications for the 
PMDS team as they work to develop a DBS service for children and young people 
with dystonia. They are inclined to demonstrate the effect of DBS using 
standardized, clinical assessment tools. Given that Medtronic used the Burke-Fahn-
Marsden-Dystonia Rating Scale (BFM) when obtaining regulatory approval for DBS 
as a treatment for dystonia, it is perhaps not surprising that this is one of the tools 
used by the PMDS. Indeed, the BFM has become the widely accepted means of 
measuring and comparing the severity of dystonia before and after implantation of 
the DBS system.  As we will see in chapter 7, this creates challenges for the team: 
the scale was developed specifically for primary dystonia, and team members believe 
that it fails to capture meaningful improvements in patients with secondary 
dystonia.  
In this chapter we have explored the conjunction of circumstances that 
enable teams like the PMDS team to exist. In the remaining chapters, we will 
‘zoom-in’ on the activities of the PMDS team members as they utilize the DBS 





4 Coordinating multidisciplinary team work  
 
4.1 Introduction: The challenge of multidisciplinary team work 
I began my fieldwork by observing the team’s routine weekly meetings and their 
less-frequent academic meetings.  During the very first observation several features 
of the meeting caught my attention. At that time they struck me as peculiar, but I 
soon realised that they were characteristic of most of the PMDS team meetings. The 
first of these was the way in which members of the team referred to, and spoke 
about, their patients.  While there was some talk about MRI images, brains, the 
basal ganglia, electrodes and stimulation parameters, much more time was devoted 
to talking about a child’s progress at school, their relationship with their siblings and 
parents, their mood, and their ability to access computers, iPads or assistive 
technologies.   Interestingly, such considerations had a bearing on the decisions that 
were made during the team meeting; they were certainly not immaterial to clinical 
decision making. The patients who were being discussed, then, were not the 
impersonal biomedical entities that have been the subject of so much critical 
attention from social scientists. Given the various professional backgrounds of 
those involved in the team, I should not have found this surprising: proponents of 
multidisciplinarity (or ‘interprofessionalism’) in healthcare have argued that it leads 
to more ‘comprehensive’, ‘patient-centred’ approach.  
This brings me to the second feature of the meetings that struck me as 
peculiar: the seemingly significant proportion of meeting-time that was devoted to 
discussing what could be called administrative issues. Much of the talk pertained to 
aligning the weekly schedules of various team members, chiding team members for 
failing to complete and circulate reports, planning how to secure necessary 
resources and clinical working space from the hospital, and bemoaning the length of 
the meeting itself (which was seldom completed within the allocated one-hour slot). 
My understanding of these discussions is that they reflect the difficulty of 
coordinating teamwork; a task which is no doubt complicated by the 
multidisciplinary nature of the team, but is essential, proponents argue, if a 
‘comprehensive’, ‘patient centred’ approach to healthcare is to be achieved.  
  So, from very early on during my observations I became aware that 
multidisciplinary teamwork is not easy, and that certain strategies are used within the 
PMDS to coordinate the activities of various team members. The product of these 
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coordinating activities is a particular rendering of the patient: a patient who is 
understood as more than just a biomedical entity - at least during team meeting 
discussions. In this chapter, I will flesh out this relationship between the techniques 
for managing and coordinating multidisciplinary teamwork, collaboration, and a 
specific way of ‘enacting’ the patient. Before I do this however, it is necessary to 
provide some background on multidisciplinary service provision in healthcare more 
generally.       
 
4.1.1 Multidisciplinarity in health service provision 
For the last two decades various health professionals and policy makers have 
actively promoted multidisciplinary team-based service provision within health care.  
Advocates have argued that multidisciplinary (or ‘interprofessional’) teams are a 
means to ensure that safe, efficient and patient-centred outcomes can be 
accomplished (Department of Health 2000; Kennedy 2001). Teams that include 
individuals from a range of professional backgrounds, it is argued, can tap into a 
range of disciplinary perspectives and are more likely to provide a comprehensive 
assessment of a patient’s needs, and are thus better suited to help the patient decide 
upon the most appropriate course of action.  As Fins and colleagues argue (2010), a 
pro-teamwork discourse is a defining feature of healthcare reform in the UK. This is 
perhaps best illustrated by the Department of Health’s 2008 ‘next stage review’: A 
High Quality Workforce, which states that achieving the NHS’s goal of delivering 
“high quality care for patients and the public… requires an effective team of 
professionals across clinical, managerial and supporting roles” (Department of 
Health 2008: 8). Indeed, this pro-multidisciplinarity movement can be seen as an 
emerging socio-political trend in healthcare, a trend that has had a real influence on 
the provision of social services. 
 The trend has become encoded in legislation. In amongst this rhetoric are 
several policy initiatives which have prompted greater levels of interprofessional 
collaboration. Many of these pertain to the provision of primary, community-based 
care for those with psychiatric illnesses, chronic illness, people with disabilities, and 
the elderly (D’Amour et al. 2005).  The 1990 NHS and Community Care Act, for 
example, stipulated that psychiatric nurses were required to assess a patient’s needs 
for social care, leading to collaborations with psychologists, counsellors and 
occupational therapists (Leathard 2003: 14).  Similarly, the Health Care Act 1999 
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created ‘pooled budgets’ for health and social services, enabling local authorities and 
health authorities to merge services.  This enabled the formation of ‘rapid response 
teams’ that could provide emergency care for people at home, and ‘integrated home 
care teams’ to help people live more independently, both of which might consist of 
nurses, care workers, social workers, therapists and GP’s.  Such policy initiatives 
created an environment where it was common for occupational therapists, for 
example, to liaise with social workers, physiotherapists, and doctors. Child 
Development Teams (CDT) are a good example of this form of collaboration. 
There are currently over 300 Child Development Teams in the UK, one for each 
district. The intention of these teams is to assess, diagnose and help manage 
children with developmental delays and disabilities in a community setting. 
Typically, these teams involve occupational therapists, physiotherapists, a 
paediatrician, a speech therapist, and a social worker, and most teams also have 
access to a child psychiatrist (McConachie et al 1999).   
Generally teamwork within hospital settings has tended to involve a less 
diverse array of professionals. (Hospital medicine, as May and colleagues (2006) 
point out, has tended to be less interested in the ‘comprehensive’ approach to 
dealing with illness). Surgical teams are commonplace, and are orientated towards 
supporting the actions of the lead-surgeon. Critical care is also provided by 
multidisciplinary teams, generally made of made up of nurses and doctors with 
various clinical specialisms. And since the 1990s, multidisciplinary teams, also made-
up of doctors and nurses with various specialisms, have emerged as the 
predominate method of delivering oncology services (Department of Health 2010).  
Various authors have highlighted the difficulties of establishing and working 
within interprofessional healthcare teams. As early as 1992 Hardy and colleagues 
identified five categories of barriers to joint working.  These included: structural and 
procedural issues, such as differences in planning procedures and budgetary cycles 
that may prevent, for example, effective collaboration between health and social 
services; financial factors such as the cost of establishing and maintaining the 
appropriate administration and communication infrastructure (it was the structural, 
procedural and financial barriers to health and social services collaboration that the 
Health Care Act 1999 sought to remove); status and legitimacy issues that can exist 
between the different authorities responsible for providing services (such as NHS 
and appointed local authorities); and professional issues, such as the difficulty in 
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aligning diverse professional perspectives, expertise and skills, and the problems 
associated with professional self-interest.   
This last of these, ‘professional issues’, has received considerable attention. 
Pietroni noted that the language and values that characterise disciplines can hinder 
the ability of inter-professional communication (Pietroni 1992). In effect, there can 
be a degree of incommensurability between different professions, each of which can 
be said to represent a distinct community characterised by particular expertise, 
language and tools (Fournier 2000). Other authors have noted that traditional 
hierarchies of professional authority can also impede the intended benefits of 
teamwork from being achieved.  This has been noted particularly in hospital teams. 
In multidisciplinary critical care teams, for instance, doctors tend to have a far 
greater influence on clinical decision-making than the nurses (Coombs 2003; 
Coombs and Ersser 2004). During their ethnographic studies of several clinical 
sites, Coombs and Ersser (2004) noted that a patient’s course of action was 
generally decided upon by doctors based on their biomedical understanding of the 
body. Nurses, who had often acquired a very detailed knowledge about the patient’s 
family and the patient ‘as a person’ had very little input.  This, Coombs and Ersser 
argues, constituted a ‘medical-hegemony’ in clinical decision-making (2004: 245).    
There are, then, considerable challenges to multidisciplinary team-based 
health service provision. Such teams are an intersection of professional worlds, each 
characterised by distinct tools, understandings and practices. According to current 
policy discourse (or the current ‘socio-political trend’) this diversity is necessary for 
effective service provision, but in actual clinical practice, this diversity threatens to 
undermine the ability of such teams to function effectively.  The existence of 
multidisciplinary teams, then, is dependent upon strategies that both preserve 
diversity and coordinate diverse activities towards the achievement of the aims of 
the team as a whole.  In what follows, I will explore some of the strategies that bind 
the various members of the PMDS team together and coordinate their diverse 
activities towards the provision of a DBS service. Specifically I will explore several 
key ‘binding’ elements: the built environment of the hospital which was 
intentionally designed to foster multidisciplinary activities; the creation and 
circulation of a schedule which coordinates the activities of team members; and the 
weekly team meetings, which provide a forum for prompting individuals to align 
with team strategy and a structured space for multidisciplinary decision-making. 
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First, however, I will explore why the PMDS team was established as a 
multidisciplinary team in the first place. The socio-political trend towards 
multidisciplinary service provision is, in paediatric healthcare, underpinned by a 
particular model of ‘normal’ childhood development. The PMDS structure, along 
with the built environment of the hospital and the current NHS tariff structure all 
reflect a particular understanding of ‘normal’ childhood development and can be 
seen as manifestations of this socio-political trend. 
 
4.2 The clinical justification for a multidisciplinary PMDS 
The composition of the PMDS team reflects a particular understanding of motor 
system development. According to this understanding the new born child has a 
motor system that is largely unusable but semi-pluripotent. Through constant 
sensing of and interaction with the material environment, a child’s motor system 
becomes highly specialised and adapted, providing the child with a capacity to move 
their body and negotiate space (“fine” & “gross motor function”). Importantly, this 
involves and stimulates cognitive development: it involves, for example, the 
development of spatial awareness and the ability to anticipate the consequence of 
particular bodily actions. Generally a child’s progress is indicated by well-known 
developmental milestones: crawling, sitting upright, standing, learning to walk, and 
so on. If development is unimpeded the child will learn how to use their body and 
obtain the necessary cognitive skills to conduct a vast range of culturally mediated 
and meaningful activities: riding a bicycle, using a keyboard, brushing teeth 
(“occupational” tasks). Dystonia, like other childhood physical disabilities, is 
perceived to be problematic because it inhibits the child’s ability to engage in the 
sort of social and physical interactions and educational opportunities that are 
considered necessary for healthy development. In effect, it ‘locks’ the body, 
rendering it insensitive to the physical environment and unresponsive to the child’s 
will. Elements of the child’s motor system will fail to become honed and adapted, 
and this will consequently stunt some aspects of cognitive development.  DBS 
promises to unlock the body and enables a child (supported by therapists) to engage 
in the interactions that are necessary for healthy development and meaningful living. 
As the Clinical Research Fellow states:  
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The way I see it is that the DBS unlocks dystonia so the therapists can get in and 
give you the functional recovery… it allows you to get some more intensive 
therapy. (Clinical research fellow, interview). 
 
Accordingly, the PMDS was deliberately composed by Dr Martin to include a set of 
professionals with the skill-sets to identify how dystonia may be hindering various 
aspects of development, and how such hindrances might best be managed: a 
physiotherapist with the ability to examine the impact of dystonia on fine and gross 
motor function; an occupational therapist to examine the impact upon the child’s 
ability to conduct “occupational” tasks; a psychologist to assess cognitive skills; and 
a speech and language therapist to examine talk and verbal communication, 
swallowing and feeding [interview].  
 Clinical exigencies dictated which other professions would be included in 
the PMDS. Neurologists were included within the team due to their knowledge of 
brain structures and medications: the former is drawn-upon to identify the DBS 
target and plan the implantation procedure, and the latter is necessary to advice on 
patients’ medication regimes.   
   This understanding of childhood development and the corresponding 
belief that a multidisciplinary approach is the appropriate method of service 
provision for children with disabilities is prevalent within the UK. It has had a 
considerable impact on child health and social welfare policy which consequently 
have facilitated the establishment of the PMDS as a multidisciplinary team in several 
ways. Firstly, as stated above, multidisciplinary Childhood Development Teams are 
the common means of delivering health services to children with severe disabilities 
in community settings throughout the UK.  Within these teams it has become 
commonplace for occupational therapists, physiotherapists, speech and language 
therapists and doctors to work together with clients (McConachie et al 1999). The 
PMDS physiotherapists and the occupational therapists had worked in such settings 
prior to joining the PMDS team, and were familiar each other’s professions. Indeed, 
in this respect, the PMDS mimics a model of service provision that has been in 
existence for several decades, albeit in community setting.   
 Second, current NHS commissioning policy also reflects the notion that 
multidisciplinarity is the preferable mode of service provision for children. Tariffs 
for an intervention are generally higher for a child than for an adult. For example, 
the base tariff for adult’s first attendance to a neurology outpatient consultation is 
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£225; for a child, the same service has a tariff of £400.  And, a hospital that delivers 
a specialist service intervention for a child will receive a 50% ‘top-up’ on the adult 
tariff (2012-13 Tariff Information Spreadsheet). This, according to the ex-Clinical 
Director of Children’s Services, is based on the recognition that a child may need 
the support of a greater range of professionals (Interview). This commissioning 
policy has, then, reduced some of the financial hindrances to multidisciplinary 
service in paediatric service provision. It has enabled the PMDS to become a self-
sufficient multidisciplinary service, and it has enabled them to employ their own 
administrator. (As we will see further on in this chapter, the administrator plays an 
important role in coordinating and ordering the activities of the team).  
 Third, this ideal of multidisciplinary paediatric service provision has also 
influenced the design and construction of clinical spaces. Specific hospitals uc as he 
work place of the PMDS have been built in order to encourage multidisciplinary 
activities. In the following section, we will explore how the built environment of the 
PMDS team has been designed to encourage multidisciplinarity, and we will explore 
how it actually influences their activities. 
 
4.3 The children’s hospital: materialised multidisciplinarity 
Various authors have explored the relationship between medical knowledge, 
hospital design, and biomedical practice (see Prior 1988, Keating and Cambrosio 
2003, Adams, 2008). The gist of the matter is captured by Prior (1988). He argues 
that the spaces that constitute the built environment of a hospital should be seen as 
a social product: the physical form of a hospital, such as the layout of the beds and 
the location of amenities, embody particular understandings about the patient and 
disease (along with engineering considerations, aesthetics etc.). And importantly, 
Prior argues, such spaces are not merely an inert backdrop to human interaction. 
Rather, their symbolic and material dimensions guide, restrict and facilitate 
particular human interactions, and thus encourage particular forms of biomedical 
practice. Drawing on the work of Foucault (1978), Prior argues that hospital 
architecture therefore contributes to the production of particular forms of clinical 
work. 
Using Prior’s conceptualisation we can draw an interesting link between the 
architecture of the children’s hospital where the PMDS is based and the 
multidisciplinary activities of the PMDS team. The design of the recently built 
4: Coordinating multidisciplinary team work 
 
 98 
hospital reflects the belief that multidisciplinary service provision results in better 
health-outcomes for patients and consequently, the built environment of the 
hospital itself encourages (but does not cause) teamwork and multidisciplinarity. 
Here, I will illustrate these points with extracts from interviews with several 
participants, one of whom was the Clinical Director of Children’s Services and 
participated in the design of the hospital. Three aspects of the hospital will be 
explored: the open-plan office space, the ward design, and the greater hospital itself. 
 
The office space 
One aspect of the hospital that was specifically designed to encourage a team-based 
approach is the office space. The office space of 150 clinical and administrative staff 
are located on the same floor. Along one side are seven or eight enclosed offices, 
while the remaining space is open-plan.  As the Clinical Director explains: 
We were keen to try and bring teams together, because people had come from little 
boxy offices, all over the place, and often very isolated. What we did was to [have] 
areas for teams.  So there’s a neurology bay, a cardiology bay, a nephrology bay and 
so on. (Clinical Director, Interview)  
 
When teams were moved into the office area they were allocated, they could then 
decide how they wanted to use it: 
What some specialties did was put the secretarial staff, who are in their offices all 
day, in the closed offices, so they would have a bit more peace and quiet and get on 
with their audio typing and so on. Clinicians, who were coming and going all the 
time, were put in the open plan offices. Other specialties did it the other way 
round. They put the secretaries outside and the consultants took the closed offices. 
My own view is that it worked best when the clinical teams were in the open plan 
area, because they saw each other more, they could talk to each other more, they 
could provide support.  (Clinical Director, Interview). 
 
All members of the PMDS team including the administrator occupy roughly the 
same area of open plan office (figure 4.1, page 100). This is largely at the behest of 
the team leader, Dr Martin (Dr M), as illustrated by the following team meeting 
extract. Here team members are discussing relocation from one end of the office to 
the other:  




Dr M: Can we begin by talking about the move?  I really don’t want us to be 
scattered around the place. We need to know where we are going. 
Nurse: We need one of us to push [an administrator] for a common space 
 
Sitting together enables team members to easily consult with one another about 
cases, and according to one member, it also helped to facilitate a positive social 
atmosphere: 
It really does encourage people talking to each other and because you’re more 
visible, it encourages ease of access.  It breaks down the barriers of, ‘Oh I’ve got to 
go to and knock on someone’s door.’  I think it does pull the team together… 
Socially it’s lovely because we all get to chat with each other.  It’s not quite as 
productive as it could be, for that reason there. (Clinical research fellow, Interview) 
 
Indeed, one member of the team stated that she would prefer not to sit with the 
others as it resulted in constant interruption.  
Importantly, sitting together in an open-plan space gives team members an 
opportunity to constantly check and coordinate their schedules. The administrator 
who, as I will illustrate further on, is responsible for producing a weekly team 
schedule, felt that it was particularly helpful for her work.  Here she recounts a 
previous seating arrangement where team members were more scattered: 
 
Some of us were in every single lobby scattered around.  I think we work - I 
certainly work - a lot more efficiently [when] I can see all of them.  If I had a quick 
question or someone’s on the phone and I’ve got a quick query -  I would have to 
[say], ‘Oh let me write that down and when I can find that person then I’ll call you 
back.’   It’s a lot easier if I just access my team, have them sitting around me. 
(Administrator, Interview).      
 
Thus, we can see that one aspect of hospital’s design that was intended to 
encourage and support a team-work based approach has been successful, at least for 
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The wards in the hospital were also intentionally designed to facilitate 
multidisciplinarity and a team-based approach to service provision.  During the 
design of the hospital focus groups consisting of clinicians from a range of 
professions (nursing, physiotherapy, occupational therapy) were consulted on the 
ward layout (Clinical Director, Interview).   
 As a result the wards were designed to be flexible spaces where a range of 
varied services could be brought to the bedside of the child, rather than the child 
having to be transported around different departments of the hospital.  
So that’s thinking along a multidisciplinary route, you’re acknowledging that the 
child actually may need to be seen by a number of different clinicians… And the 
way the building is designed, the services come to the child. Any bed should be able 
to support any type of service… wherever possible, the services should be taken to 
the child rather than the other way round (Clinical Director, interview) 




As the Clinical Director states, creating this ‘child-centred’, flexible space require 
investing in a particular technical infrastructure.   
So we invested a lot of money in portable equipment, portable ultrasound screens, 
portable x-rays and so on…. A German manufacturer that could provide these 
pendants where the power sockets are on columns that come down out of the 
ceiling, so that you can put the bed in the middle of the space and people can 
actually look after the child round all four sides of the bed (Clinical Director, 
Interview).    
 
Flexibility, then, is enabled by a configuration of various technical and material 
elements. The tools of particular professions must be sufficiently mobile to move 
from one bed to another, and the ward itself must provide sufficient space for a 
team of clinicians to access the bed.  Obviously, other medical and social 
considerations also influenced the design of the hospital. Limiting cross-infection 
and promoting interactions between children were two concerns that were explicitly 
mentioned by the clinical director: 
And there are tensions pulling in both directions.  You need to have [beds] 
sufficiently far apart that you minimise the risk of cross infection.  But if they’re too 
far apart, actually the children may as well be in their own bays, because they can’t 
talk to the child next door.     
 
After the DBS system has been surgically implanted a patient will spend seven days 
in the neurology ward receiving a course of antibiotics, but overall PMDS patients 
do not spend a great deal of time on the ward. Patients with DBS hardware-related 
infections and patients with status dystonicus will also be brought into the ward 
until their condition is under control. These patients require various medications 
and are managed predominantly by the ‘medical group’ within the PMDS team (the 
neurologists and nurse). Therapists will also individually visit these patients, perhaps 
to provide advice to family members and ward staff on how to physically handle the 
patient, or to conduct a quick assessment (the PT, for example, may need to screen 
for musculoskeletal contractures while the patient is heavily medicated). In this 
respect the configuration of the ward has indeed permitted a multidisciplinary space, 
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enabling members of the PMDS team to carry out necessary tasks at the bedside of 
the patient. 
 
The greater hospital  
Most of the PMDS activities with patients, however, take place in other parts of the 
hospital.  Many of the pre- and post-surgical assessment activities that therapists 
conduct with patients require privacy or a large area of space with a specific set of 
resources.  
 The hospital was designed so that it contains a diversity of spaces and 
resources. Each ward contains a play area with toys and small desks and chairs for 
in-patients and their siblings to draw and interact with one another.  Each ward also 
contains a kitchen area adjacent to the play area.  Here, the families of in-patients 
can prepare food and hot drinks while watching children play. These areas of the 
wards mimic a generic domestic, open-plan kitchen-living area space.  The hospital 
also contains a school with full-time teachers.  This is located in a large mezzanine 
area of the hospital that overlooks a nearby park. It too resembles a ‘generic’ school 
environment: student artwork, alphabet and multiplication-table posters are littered 
across the walls, and it contains desks and chairs of various sizes.  The clinical 
director explains that these features reflect a belief that the hospital is not treating 
individual children, it is ‘dealing with families’:  
You always have to remember that a child is part of a family and anything that 
happens to the child has ramifications for siblings and parents… 
The decisions we made when we were setting up the school is that actually if we’re 
really going to help the children who are in hospital, we need to think holistically 
about the whole family and we need to think about the siblings who can sometimes 
almost be more traumatised by what’s gone on than the child who’s sick… The 
hospital school will take siblings as well as the children so they don’t miss a week’s 
schooling.  They are doing something that’s actually quite fun and keeping them 
absorbed and engaged. (Clinical Director, interview)  
 
We can also see these features of the hospital as reflecting what could be called a 
‘clinical concern’ for children’s wider social context. Features of normal domestic 
and schooling scenes have been recreated within the hospital with the intention of 
minimising disruptions to the stable family unit. 
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Importantly for the PMDS team, these areas can be adapted without too 
much difficulty into the spaces required for conducting pre- and post-surgical 
assessments.  For example, (as we will explore in greater depth in chapter 7), one 
assessment involves observing and quantifying the patient’s ability to undertake 
tasks of daily living, such as brushing teeth, preparing cereal, or washing dishes. The 
kitchenettes – although not specifically designed as places of assessment – contain 
the appropriate arrangement of facilities for this assessment with patients who are 
less severely disabled. Other assessments require the child to attempt drawing and 
writing tasks.  These can be conducted in the play areas or the school, both of 
which contain desks and chairs of appropriate sizes.   
The hospital also contains a large gymnasium. This large room contains a 
variety of resources: inflatable balls, toys, adjustable desks and benches, padded 
floor mats of various sizes and plinths and hoists for moving severely disabled 
patients. The gym was designed to be an area for providing rehabilitative assistance 
to children and contains plenty of open space for gross-motor function activities 
(walking, running, jumping). For the PMDS, the gym also provides a suitable 
location for assessing gross motor function (as we will see in chapter 4), and for 
other assessments which require open space, such as the assessment of impairment.  
Here, plinths and hoists are essential for placing severely disabled patients into the 
body-positions required to conduct the assessments, and the available toys can be 
used to entice younger children to participate.          
Thus, the recreation of domestic and educational settings and the provision 
of a gymnasium affords a variety of clinical activities: the various spaces that 
constitute the greater hospital are easily adapted into the spaces required by PMDS 
team members. To put it concisely, a diversity of spaces permits diversity of 
professional practice and consequently, many of the clinical practices that 
characterise each of the professions within the PMDS can take place under the 
same roof.  
The greater hospital, along with the office and ward spaces, constitute what 
could be called a materialisation of a pro-multidisciplinary and pro-teamwork 
ideology. A particular socio-political trend in health service provision that 
encourages multidisciplinary team work (and which corresponds to a particular 
understanding of ‘normal’ childhood development) has been embodied within the 
physical structure of the hospital. Obviously this does not induce multidisciplinary 
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teamwork in a deterministic fashion, but it no doubt enables and prompts 
individuals to participate in multidisciplinary activities. As Prior argues, space is an 
active ingredient in producing and reproducing social practices (1988: 91), and the 
children’s hospital, then, can be seen as actively configuring the multidisciplinary 
activities of the PMDS team. This hospital provides some material durability to 
multidisciplinarity. 
 
Disrupting multidisciplinarity? Moving services to a new location 
The importance of the specific built environment for the team’s activities is 
illustrated when team members discuss moving some of the activities to a new 
location. A steady rise in the number of patients for the hospital as a whole is 
placing increasing pressure on available resources. In order to relieve some of this 
pressure, managers within the Trust are encouraging the PMDS to move many of 
their activities with patients to newly refurbished spaces within a new neurology 
centre located within the neighbouring adult hospital. (This corresponds to what 
Hardy and colleagues (1992) referred to as a financial constraint to 
interprofessionalism.) This move was the focus of much discussion during team 
meetings; the therapists in particular felt that it hindered their ability to work: For 
example: 
 
OT: Okay, so the new neurology centre - I’ve taken a couple of kids there, the 
more functional ones, and both [the PT] and I are of the opinion that 
much more equipment is needed if we are able to work with these kids 
safely. I’m going to put forward a list with the minimal equipment we need. 
We need a plinth; we need a ceiling track hoist… We have been assigned 
rooms where other people don’t want these things.   
Dr M: Do they have computers?  
OT: Yes but they don’t work yet. They also don’t have phones. Some of these 
things are just small things but we need them. There are no benches and I 
don’t think one of the rooms is large enough.  
 
As the above discussion illustrates, the OT perceives the rooms to be inadequately 
resourced to conduct her assessments with patients, particularly patients who are 
more severally disabled. Although the two hospitals are relatively close and 
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connected by a corridor, the distance from one to the other is also a considered to 
be a problem: 
 
OT: I’m reluctant to send all patients there. For instance, Carl would take 
twenty minutes to walk there [because of his movement disorder], where as 
it would take you and me five minutes. And with Bridget, by the time we 
had gone back and forth between locations [to conduct assessments], it 
had taken us three hours to do what we could have done in one! 
S&L: That is where transfer services should provide a wheelchair. 
OT: But many patients like Carl refuse to use them! 
 
Members of the team also worried that the move would threaten the effective 
administration of the team. Some duties currently undertaken by the PMDS 
administrator (which we explore in the next section) would need to be delegated to 
the new centre’s administrator. This particular issue was discussed during the team’s 
‘away day’ (for which I did not take full field notes): team members stated that the 
new administrator would lack the knowledge of the team’s ‘idiosyncrasies’ and their 
unique patient cohort; knowledge that is required to effectively coordinate room 
bookings with team members’ schedules and a patient’s clinical needs. Dr Martin 
replied that team members could inform the new administrator of the ‘blocks of 
time’ that they would need for a specific patient some time in advance. The 
therapists responded that this would not provide the flexibility that is required when 
dealing with such a variable cohort of patients: it is often very difficult to predict 
how long an assessment with a patient will take. This is an example of what Hardy 
and colleagues (1992) referred to as a procedural barrier to interprofessional 
practice; the planning and scheduling procedures of the new centre are mismatched 
with the workings of the team. 
 These discussions provide some insight into the types of pressures that can 
disrupt the activities of the team.  Despite the suitability of the children’s hospital 
for multidisciplinary teamwork, resource constraints and administrative 
complications threaten the PMDS’ ability to fully utilise it.   
 
4.4 Managing the PMDS dairy: crafting a programme of actions 
The second ‘binding’ strategy of the PMDS that we will explore is the team’s use of 
a collective diary.   Much like any diary it lists the times and locations of upcoming 
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PMDS activities: the arrival and departure times of patients, the clinical activities of 
each team member, and the various locations where clinical activities will take place 
can all be represented on the diary. Any team member can consult the schedule and 
decipher which patient they are meeting, which other team members will be 
accompanying them, what activity will be taking place, and what room has been 
booked for them. During my fieldwork I noticed that it was often displayed during 
team meetings (via a projection system). It was consulted, debated and altered, and 
it was clear from these discussions that team members placed a great deal of 
importance on the diary. Indeed, it was a constant point of reference for members 
of the team who planned their own schedules to align with it.    
The diary can be seen as what Actor-Network theorists have referred to as a 
programme of actions (Akrich and Latour 1992; Latour 1992).  This is an entity that 
functions as a set of instructions or a script, detailing how other entities (human and 
non-human) should act and inter-act at specific times and locations so that an 
overall specific output can be achieved. Software programmes, for instance, 
stipulate how the diverse components of a machine should interact so that a 
particular task, or set of tasks, can be completed. A successful programme of 
actions, then, enables the various unique capacities of a range of diverse entities to 
be coordinated and orientated towards the achievement of a set of collective goals. 
This is the intention of the PMDS diary: it stipulates the actions and interactions 
required from a heterogonous group of professionals so that each new referral can 
be adequately screened, and so that each DBS patient can be suitably assessed and 
managed. By doing this, the diary provides a degree of structure and routine to 
PMDS activities. As team members consult the diary week after week, a diverse 
group of professionals, patients and their family members are enrolled in and 
perform the institutional routines that characterise the PMDS, while (ideally) 
achieving the aims of the team as a whole. An example of a common week of 
PMDS events from the diary is illustrated in figure 4.2, page 107. 
Creating and updating the diary, then, is obviously an important task.  It is 
an ‘ordering’ process, where a diverse array of elements must somehow be 
coordinated into a single programme of actions.  In this section we will explore this 
ordering process.  It is undertaken by the team’s administrator and the nurse 
together, usually several times a month, during what they refer to as a ‘scheduling 
session’. It is a challenging task. As the administrator stated during an interview, it is 
4: Coordinating multidisciplinary team work 
 
 107 
her ‘biggest challenge’: patients with very different requirements must be booked in 
to see health professionals who have different tasks to perform, some of which 
require several hours to complete. Patients cannot simply be booked in to pre-
defined 30 minute time slots, for instance. Using interview extracts and notes from 
an observation of one of these sessions I will illustrate some of the complexities that 
must be anticipated, coordinated and ordered by the nurse and administrator in 
order to create a coherent diary. I will also argue that the ordered diary emerges 
from what Carmel (2013) has referred to as craft work. Craft work, according to 
Carmel, is characterised by two features: the application of different knowledges, 
and practical reflexive interaction with the object being crafted.  
 
Figure 4.2: Section of the near-complete PMDS schedule  
 
 
Institutional factors that influence the PMDS schedule 
Scheduling sessions usually take place at the nurse’s desk in the middle of the 
PMDS team seating area of the open plan office. The task is carried out on a 
computer so that the nurse and administrator can easily access and move between 
several patient databases and the Microsoft Outlook software programme with the 
‘Calendar’ feature that contains the diary.  
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 At the beginning of my observation of a scheduling session I noted that 
they do not begin with a blank schedule: before any additional data has been added 
to it, it already displays a great deal of information. Firstly, the schedule contains a 
particular format that reflects, to some degree, the institutional routines of the 
greater hospital. Working days and working hours are clearly delineated: Monday to 
Friday, 8am until 6pm. All PMDS activities must be allotted into this conventional 
and institutionally defined temporal structure. Secondly, various activities have 
already been entered within this pre-defined temporal structure, each indicated by a 
coloured ‘block’.  These are the standard clinical activities that take place every 
week, largely regardless of ‘contingencies’. These also reflect various institutional 
pressures. For example, as consultants employed by the NHS Trust, both 
neurologists are obliged to conduct a daily round of the neurology ward (9am to 
10am), and Dr Martin is obliged to run a neurology screening clinic on Monday 
afternoons.  Other routine weekly activities include the PMDS screening clinics on 
Thursday and Friday mornings and the neurosurgeon’s visit on Friday afternoon.   
Importantly, these blocks of activity have been colour-coded using a system 
devised by the administrator and nurse. The colour of the block indicates the impact 
it will have on the scheduling of additional activities, and thus, by implication, it 
indicates the importance of the individual involved.  During an interview the 
administrator explained the colour codes:  
Red is important meetings or activity that is not flexible, that is important for the 
whole team to take into consideration when scheduling patients. Dr Martin’s 
[screening] clinic on a Monday afternoon means that he will not be available to see 
PMDS patients at that time… Green means that that particular member of staff is 
not available for that period of time but they’re not like a doctor. These are [things] 
that don't necessarily affect the timetabling of patients but are useful for others to 
know. (Administrator, interview) 
 
At the beginning of the scheduling session the diary is already loaded with meaning:  
it reflects particular institutional patterns and it contains colour codes that indicate 
the importance and availability of various team members. Thus, while the MO 
Calender spreadsheet provides affordances (empty spaces) for scheduling additional 
clinical activities, these meaningful elements also present a degree of obduracy; they 
influence when and where additional clinical activities can be allotted. Creating a 
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workable programme of actions for the PMDS, then, requires that the nurse and 
administrator carefully respond to these meaningful elements while they add 
additional layers of meaningful elements. It could, in other words, be described as a 
process of “crafting”, where the nurse and administrator mindfully respond to the 
medium they are working with, as it evolves and responds to their actions (Carmel 
2013). 
 
Knowledge of team members’ capacities 
The first information that the nurse and administrator add to Calendar spreadsheet 
pertains to the availability of team members. Crafting a workable programme of 
actions requires knowledge of the capacities of each of the agents that will perform 
it (Akrich And Latour 1992). In regards to the scheduling process, the nurse and 
administrator require an understanding of the professional role of each team 
member, and importantly, an awareness of their availability to carry out PMDS 
activities. As the administrator states, each member of the team has their own 
individual commitments that need to be considered before patients can be 
scheduled:   
The biggest challenge for me, with it being a multidisciplinary team, is diary 
scheduling. You’ve got eight professionals who take leave, go to conferences, have 
their own research and other things that they do… (Administrator, interview).   
 
Once the nurse and administrator are aware of the availability of team members 
(which they can often check by simply asking team members seated nearby), they 
carefully note these details on the diary for each week. Along the top of the diary 
the administrator uses a series of coloured bars and text to note the availability of 
professionals for that day (figure 4.3, page 110). Again, the colour of reflects the 
importance of the team member: red for more important team members whose 
absence will likely affect the PMDS activities that can be scheduled for that day, and 
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Figure 4.3: Section of schedule indicating team member availability 
 
 
Financial considerations and knowledge of families 
Once these details have been added, the nurse and administrator can then ‘book in’ 
patients for that week.  The first set of patients to be booked in is the new referrals. 
These will be booked into the routine weekly PMDS screening clinics on Thursdays 
and Fridays.  Screening clinics are used to identify new DBS candidates from the 
many referrals received by the team and thus ensure that the team generates 
sufficient revenue.  Indeed, revenue generation determines how many patients and 
clinicians will be ‘allotted’ into these clinics, as illustrated by the following team 
meeting abstract: 
 
PT: For it to be financially viable [with that tariff], we need to see two new 
patients in a slot. We won’t be making any money [from that specific 
screening clinic], but it enables us to weed out some of the patients and 
initiate needed actions.  
 
The tariff for this activity is £511. This must cover the cost of: A neurologist, who 
is required to assess, among other things, the patient’s medicine regime; and a 
therapist (either an occupational therapist or physiotherapist), who is required to 
assess the patient’s functional concerns. Consequently, when ‘booking in’ new 
referrals the administrator and nurse ensure that: 
 
Adm: Dr Martin sees two new patients every Thursday morning and [Neurologist 
2] sees two new patients on Friday mornings. One therapist is also present 
(Observation notes).  




Two new referrals will be allotted into these clinics on each day along with a 
neurologist and one of the available therapists. These details are entered into the 
diary and the clinic is coded ‘purple’.  Additionally, only new referrals that have a 
‘letter of guarantee’ from their PCT that states a willingness to fund the DBS service 
will be booked in to these clinics. As the extract from the scheduling session 
illustrates: 
 
Adm: This patient here, heaps of information has been sent to us but no letter of 
guarantee yet. We can’t book them in until we get one (Observation notes).  
  
Next, the nurse and administrator must book-in patients requiring pre and post-
surgical assessments. Because these assessments can take a great deal of time and 
require many team members they can be difficult to align with the other elements 
on the schedule:  
Trying to fit a child in for a review [post-surgical assessment] at a time when all of 
the required people are available within a set timeframe, and when you’ve got 
several hundred kids on our service now, many of whom are now being reviewed – 
it can be a struggle.  But that’s something that we just have to come to terms with.  
It’s not going to get any easier (Administrator, interview).   
 
The nurse and administrator consult the PMDS DBS database which contains all 
patients and indicates the date of their last visit to the PMDS. From this the nurse 
and administrator can identify those that are due for an assessment.  These names 
can then be ‘cut & pasted’ into the schedule, if an appropriate space with the 
necessary time and staff members can be found.  However as the following excerpt 
from the scheduling session indicates, the nurse and administrator must also take 
into account other concerns:  
 
Adm: Friday’s are [the patient’s] day off college, so that works well for him.  They 
come in from [county] so mid-morning onwards would be ideal. It is a 
three-hour round trip. 
Nurse:  It will have to be 11am. 
Adm: That will do. It is not too early for them.   
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When finding an appropriate time in the schedule the nurse and administrator 
consider various details about the family and the patient, such as schooling 
commitments and their living location. Those families that have to travel some 
distance will be booked into Trust-provided accommodation, the availability of 
which will also affect the scheduling of patients. Obviously, then, the scheduling 
process requires the nurse and administrator to know such details about families. 
Both, in their wider roles within the PMDS, do acquire this personal knowledge of 
families and they are able to draw on this during the goal setting session. Indeed, 
knowing the families quite well is “the nature of the service’”. The administrator, for 
instance, states: 
I’m the first point of contact for the patients… some of them end up talking to me 
quite a lot if they make contact with the team quite a lot…. . I do my best to go 
down and meet as many of the patients as I can because obviously that is the 
nature of the service. (Administrator, interview). 
 
Drawing on clinical knowledge 
Clinical knowledge is also needed when crafting a workable programme of actions, 
and it for this reason that the nurse is involved in the process.  Before pre- and 
post- surgical assessments can be placed within the schedule the nurse needs to 
ensure that the clinical needs of the patient can be met by the available staff. As she 
explains:  
Our administrator, she doesn’t understand all the illnesses, whereas I know their 
clinical details, what they’re coming in for, what clinical need they have. [That’s 
why] I need to help arrange the whole diary and everyone’s life within the service. 
(Nurse, interview). 
 
This extract provides an example: 
 
Adm:  They cancelled their previous appointment because it was his brother’s 
first day at school. 
Nurse: It is a three-year review so [the physiotherapist] will want to see him.  
 
The assessment will be ‘booked’ once a time period within the schedule has been 
found that is manageable for families and corresponds with the availability of the 
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staff members required. Here, then, the nurse and administrator take note of the red 
and green coloured ‘blocks’ within the schedule to determine which staff members 
are available.  The assessments are coloured white on the schedule to indicate that 
many of the staff members will be involved (text is added to note which specific 
staff are involved). The sessions are also given a blue and white ‘hashed’ border to 
indicate that the booking details have not yet been sent to the family, (These are 
changed to a blue-only boarder once the administrator sends these details: figure 
4.4) 
 
Figure 4.4: Schedule section with group assessment (‘long review’ in white) 
 
 
By this stage the diary is almost full.  The remaining free time can be used by 
members of the team to complete paper work, but often emergency bookings will 
occupy these times. Emergency bookings might be made for patients with 
infections, status dystonicus, or with suspected hardware failures, or for patients 
who have inexplicably deteriorated.   
 Interestingly, aspects of the built environment facilitate the scheduling 
session and the process of ‘ordering’. Throughout the scheduling session the open-
plan arrangement of the office enables the nurse and administrator to check details 
with some other members of the team. Here is an example from the session I 
observed: 
 
Nurse:  [Physiotherapist!] You have a very busy day!  [Patient] needs to come in for 
an injection. 
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PT1: Sedation is going to take 30 minutes. Can you book her in for 3:30? I don’t 
finish until six so it doesn’t matter if it runs past five.  
 
By examining the diary crafting process we can see how the itinerary of activities of 
the PMDS is shaped by a broad range of concerns, not just the clinical needs of the 
patient. Creating the diary requires the administrator and nurse to draw on their 
knowledge of the capacities and availability of each team member, personal 
knowledge of families, and a clinical understanding of the patient’s requirements. 
These ‘complexities’ must be coordinated with an institutionally-defined timeframe, 
institutional obligations and funding pressures.  It is via this process of crafting that 
the administrator and nurse create a PMDS programme of actions: a diary that 
describes and prescribes the actions required from each team member so that the 
overall goals of the PMDS team can be achieved. We can say that, as team members 
adhere to and enact the schedule, the PMDS as a multidisciplinary service is 
‘performed into being’.  
 Of course, it would be naive to suggest that the product of the scheduling 
session is a ‘completed’ diary which is diligently adhered to by all members of the 
team.  The diary is constantly subject to alteration as families cancel meetings and 
emergencies arise, and team members inevitably engage in what Akrich and Latour 
(1992) refer to as antiprogrammes11 such as taking sick leave, and sometimes the 
nurse and administrator have simply not been able to anticipate what a particular 
patient requires from the PMDS. As the administrator explains:  
Sometimes we make the right decisions and sometimes we don’t. And [team 
members] email us to say, ‘Why have you put this patient in here?   I need to see 
them at that review and I’m on annual leave.’  If you’ve just spent three hours 
going through the diary, making all these changes, and then you get an email saying, 
‘Well that’s not going to work, that’s not going to work,’ it can be a bit, you know, 
it makes you feel a bit deflated sometimes, because then we have to go back and do 
it again.  But it’s, it’s just all par for the course really. (Administrator, interview). 
 
                                                 
11 Individual actions that do not correspond to those of the collective. 
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4.5 The team meeting: A forum for group decision making 
The third ‘binding’ feature of the PMDS that we will explore is the weekly team 
meetings.  These are scheduled for every Monday between 9:30am and 10:30am, 
although during the time I was conducting fieldwork it was common for meetings 
to be postponed or cancelled, and those that did take place were seldom completed 
within the hour. Indeed, it was not unusual for a meeting to take two hours long (to 
the obvious frustration of team members). The team meeting had several purposes. 
It provided a forum to: discuss current clinical cases and decide upon an 
appropriate for course of action for each case; to assess which new referrals should 
be allocated a slot in the PMDS screening clinic; and to address any concerns that 
individual team members may have about the service as a whole. In effect, the team 
meetings represented a regular, structured time for multidisciplinary decision 
making - a feature that commentators have argued is vital for effective 
multidisciplinary service provision (West and Slater 1996; Housley 2003). And, the 
team meeting also provided a structured time to talk about and resolve any tensions 
that threaten to upset the functioning of the team as a whole.  In this section, we 
will draw on extracts of my observation notes from various team meetings to 
explore both these features.   
The meeting room where PMDS meetings took place was one of the few 
enclosed rooms in the open-plan office space. Team members sat around two tables 
that had been pushed together in the centre of the room. The exact seating 
arrangement differed from meeting to meeting, although Dr Martin would sit in one 
of the chairs closer to the door (he often arrived several minutes after everyone 
else). A large projection screen was attached to one wall of the room, at the head of 
the tables, which was used to display various documents and images via the 
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Figure 4.5: A common team meeting seating arrangement 
 
 
The meetings were informal: there was no chairperson and the meetings 
initially seemed to me to be rather disorderly.  The meetings did follow a structure, 
however. An agenda was projected on the screen where it could be seen by all team 
members. The agenda was a Microsoft Word document, and as team members 
worked their way through the various agenda items and various clinical cases, one 
member of the team would add comments and actions to each point on the 
document. Thus, the agenda was converted into the meeting minutes as the meeting 
progressed and each member of the team could observe and scrutinize the actions 
as they were inscribed in the document. Several different team members undertook 
the minute taking role throughout the fieldwork period: the administrator, the more 
senior physiotherapist, the psychologist and the speech and language therapist 
(notably, neither of the neurologists ever did this task).  In the absence of a 
chairperson, no one individual kept the team moving through the agenda points or 
coordinated the utterances of the other members, and it was not uncommon for 
several team members to be talking at the same time or for discussions to jump 
back and forth from one action point to another.  
A direct, upfront style of communication was a common characteristic of 
team meetings and several members of the team, particularly the occupational 
therapist, and the senior physiotherapist, appeared to be unafraid to express their 
4: Coordinating multidisciplinary team work 
 
 117 
opinions. This no doubt reflected what several team members later described to me 
as the “strong personalities” within the team. As an outsider, it seemed to me that 
this created rather tense exchanges within the meetings. I was explicitly told during 
the course of my fieldwork, however, that: “team members get on very well, even if 
it does not always seem so” (Therapy assistant, interview). Indeed, in addition to the 
seemingly terse exchanges, there was often a great deal of humour in team meetings. 
In amongst clinical discussions it was not unusual for team members to share 
comical stories from their work. In one meeting, for example, the nurse told the 
team that one of their older, more functional inpatients had managed to sneak his 
girlfriend into the neurology ward for the night, much to the chagrin of the ward 
nurses. Stories such as this were often a source of amusement for the team and no 
doubt managed to diffuse some of the tension.   
 
The authority of Dr Martin during team meetings 
The lack of a chairperson and the informality of the meetings are not indicative of 
an absence of authority, however. Dr Martin’s authority as team leader was 
expressed in other ways. He would often put forward utterances that reasserted his 
position as team leader; utterances which also had the effect of, at least discursively, 
‘unifying’ the team. In the following extract Dr Martin responds to the frustrations 
voiced by several team members over the limited time available to conduct research. 
Dr Martin states that research is part of their obligation to conduct clinical audits:     
 
Dr M: We need to be very clear about what research means. Research is about 
audits. Everybody has to participate in audits. It is mandatory within the 
NHS. We have to put in audit time each week, and this can then help us to 
reflect on the business of delivering this service. When we collect data, we 
are doing an audit and that provides information that enables us to make 
changes in how we manage patients in the future. 
 
In this utterance Dr Martin’s use of the pronouns “we” and “us” discursively unites 
individual team members in order to remind them that their individual research 
activities are part of the collective work of delivering “this service”.  
Dr Martin would sometimes step in to quell tensions during the meeting.  In 
the following extract the speech and language therapist is visibly frustrated with the 
long duration of the team meeting:   




S&L: Why are we going through these [patients] again? We went through them 
at the last meeting! 
PT1: We are doing them again because no one can remember where we left off!  
Okay we need to go through and find where we left off last time. 
Dr M: Just calm down! Relax! I have to leave soon, and before I go I want some 
alterations to be made to the agenda. You need to add these details to 
Rebecca....   
 
During meetings it was common for team members to express frustration at 
decisions made by hospital management. The decision to move some of the PMDS 
activities to the Neurology Centre in the adjacent hospital was often discussed: as 
we saw earlier, team members felt that the new centre was inadequately resourced 
for PMDS activities.  In these discussions Dr Martin would often play a diplomatic 
role: he would articulate the perspective of ‘management’ and suggest a 
compromise. In the following extract Dr Martin responds to the other team 
members concerns that the new centre is poorly resourced: 
 
Dr M:  We want to give the new centre the opportunity to step up…  From a 
management perspective, everybody agrees that we should be actively 
involved in the new centre. Usually, when these sorts of shifts occurs, it is 
necessary to slow the work down a little while people become accustomed 
to the new location… We need to adopt a pragmatic approach to this. We 
need to try an invest time in the centre and push for them to provide the 
equipment we need. They will be willing to set up the environment so it is 
safe and useful.   
 
Again Dr Martin constantly employs the use of “we” to discursively unite individual 
members of the team and direct them towards a particular, collective strategy for 
dealing with the dilemma. It is in this way, by attempting to ease tensions and 
orientating team members towards collective strategies, that Dr Martin displayed 
authority during team meetings. We can also see that these actions are an attempt to 
manage some of the challenges of delivering a multidisciplinary service.   
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Coordinating team documents 
The meeting also provides an opportunity for members to discuss the management 
of team documents.  Team documents contain information that is relevant to most 
members of the team, and may require profession-specific inputs from several team 
members. They are, in a sense, ‘multidisciplinary’ documents: information from a 
range of professions is pooled-together within one portable document under the 
heading “Paediatric Motor Disorder Service”.  Two examples include the ‘PMDS 
Parent Questionnaire’, which is sent to all new referrals and contains a range of 
questions about the patient’s medication regime, communication skills, mobility and 
so on, and the  ‘Multidisciplinary Team (MDT) Report’ that is completed for each 
patient and which involves a summary and set of recommendations from each 
PMDS clinician. The MDT report is sent to the child’s local community services. 
The circulation and completion of these documents is an important aspect of the 
effective functioning of the team: they are part of what Law has referred to as the 
network of heterogeneous entities that constitute an organization (Law 1992). 
 The importance of these documents is revealed by discussions that took 
place during team meetings.  Generally such discussions were negative in tone. For 
example, team members complained that questionnaires were not being sent to all 
new referrals or were not be adequately completed by parents. This threatened their 
ability to make effective use of clinical time with patients: 
 
OT: I have quite a few things to put on the agenda… Firstly, questionnaires. It 
seems that they are not being sent out regularly. We had a patient here and 
the family said they had not received the questionnaire. Personally, I have 
decided that I’m not going to see a patient unless they have filled it in: it 
takes too much time – it is a waste of clinical time – if I have to cover 
those issues and ask those questions with them while they are here. I spend 
so much time with that patient when it should have taken much less time.  
Psyc: Yes, we really need to make sure that all families receive the questionnaire! 
 
The slow rate at which patients MDT reports were being completed was also 
lamented by members of the team. In several meetings the more senior 
physiotherapist chided other team members for failing to complete their sections of 
the reports, resulting in a backlog of semi-finished reports (outstanding reports are 
listed at the end of the agenda). Here is an example: 




PT1:  Look; I know this is a contentious issue but we need to discuss this. Some 
reports are getting on for five months. Jane’s for instance.  
Nurse: That was delayed because we were waiting on some information from the 
family. 
PT1:  No! She just needs the neuro exam added.  
Dr M: Can I just say that the chances of me doing those [outstanding] reports 
today is negligible.  
PT1:  I know, but they have been on the agenda for months.  
Neuro: [Directed at Dr M.] Well, just do Jane’s report today then.  
 
In most cases these frustrations were directed at the ‘medical’ members of the team, 
specifically the neurologists. In one meeting the physiotherapist suggested sending 
out various components of the report separately to local community services.  
Another team member replied that fragmenting the reports in this way might be 
counterproductive, as there is not necessarily a clear distinction ‘medical’ and 
‘therapy’ elements within the PMDS service:  
 
PT1: I think we are going to need to send out separate reports, given that it is 
taking so long for the medical notes to be added to them. 
Nurse: But where would you put the pain report? 
PT1: Well, if you can complete it in a month or two, they can be sent out with 
the therapy reports.  
Nurse: That would be difficult: the medical stuff and the therapy stuff often 
overlap. Recommendations often need to go together. 
PT1:  I know, but some of my recommendations need to be read by people 
quickly. They can’t be sitting there, unread for months.   
 
These discussions illustrate that getting all team members to actively contribute to 
the production and circulation of PMDS team documents was challenging. And as 
the above extracts illustrate, the team meeting provided a forum were the 
importance of such multidisciplinary documents could be reaffirmed and where 
team members could be reminded of their obligations to complete and circulate 
such documents. 
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A space for group decision making 
Of course the main activity that takes place during team meetings is the discussion 
of clinical cases and clinical decision making. As Centellas and colleagues have 
argued (in press), team meetings can provide an opportunity for multidisciplinary 
teams to engage in an “interactive process that facilitates interdisciplinary 
collaboration by aligning different disciplinary identities” around a particular case 
“without necessarily blurring or softening disciplinary identities or local meanings” 
(In press).  In this section we will use extracts of these discussions to illustrate how 
multidisciplinarity is enacted within team meetings. We will see how the team 
meeting provides a forum in which different types of specialist knowledge and 
expertise are articulated and filtered into the decision-making process. As this 
happens, disciplinary boundaries are demarcated, and a ‘composite’ account of the 
patient produced.   
During discussions various team members articulate a knowledge of clinical 
cases that reflects their particular area of expertise.  In the following extract several 
members of the team discuss Emma, who has a complex and severe movement 
disorder and had a DBS system implanted several years ago.  The physiotherapist’s 
appraisal of the case is presented in terms of her ‘movement control’ and her 
‘functional’ ability – both of which reflect the physiotherapist’s focus on gross 
motor function:  
 
PT1: She has been deteriorating. Her selective movement control is certainly 
getting worse.  
Dr M: Has she grown? Because there is a mechanical disadvantage that can arise 
when you grow but the muscle can’t compensate with the new mass…   
PT1:  I was getting her to lie on her tummy and lift her leg – it seems to me that 
the signal is just not getting through. It is not simply about weakness. 
Qualitatively, her dystonia is getting worse and functionally she is 
deteriorating. 
Neuro: We had to adjust her stimulation parameters. She wasn’t responding well to 
higher stimulation doses.  
Dr M: Yes, with higher stimulation there is the possibility of inducing 
Parkinsonian symptoms. 
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We also see from this extract that the neurologists (which includes Dr Martin) 
employ a different lexicon when proffering an understanding of Emma; terms like 
‘stimulation’, ‘stimulation parameters’ and ‘voltage’ were often used by the 
neurologists when discussing cases, indicating that managing the implanted DBS 
system was part of their role within the PMDS.  Typically the neurologists would 
also provide reports on patients’ medications regimes, brain imaging results, and 
provide a summary of surgical procedures – all of which align with a biomedical 
understanding of the patient. The following extract is an example of this. Here a 
teenage patient named Chris appears to have had a DBS system malfunction and 
will require surgery: 
 
Dr M: There is a problem with the [DBS] connection. His left arm became very 
dystonic and I have admitted him and I’m glad that I did that because he 
went into status dystonicus. [The neurosurgeon] came over and we went 
over the images and it seems the extension wire and the electrode 
connection has become adrift.  When I changed the stimulation parameters 
I managed to get him out of his status dystonicus, and I have put him on a 
tiny bit of [medication].  His status dystonicus – it was frightening for the 
ward team, but at least they got to see the DBS at work when I managed to 
pull him out of it.  
 
Not surprisingly the psychologist’s contribution to discussions tended to include 
utterances pertaining to mood or cognition. In the following extract we can see her 
employ specific terminology (such as suicidal ideation) that reflect her disciplinary 
expertise. Here the team discusses Jimmy a potential DBS candidate who is 
uncertain about whether or not to proceed with DBS.   
 
Psyc: Well, he is an interesting one really.  He has personality and behavioural 
issues. I think he is lonely and he has poor self-esteem.  He has never had 
suicidal ideation but he definitely wishes he wasn’t alive, which is not the 
same as ideation. His family says that what happened to him was an 
accident, but it may have been an extreme move to seek attention… He 
and his family are very unsure about DBS. 
 
Similarly, the contributions of other team members reflected their particular area of 
specialty. For example the speech and language therapist: “When I last saw her I 
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noted that she speaks very quickly. Once she gets speaking she has trouble 
stopping”, and: “She has some freezing when eating, but there is no danger with her 
swallowing…” The nurse’s contributions were similar to those of the neurologists 
and tended to refer to DBS hardware, medications and surgical procedures (she 
would also refer to patients’ pain).  
 During meetings, team member draw upon their distinct disciplinary 
commitments to bear upon their understanding of the patients being discussed. As 
Centellas and colleagues have argued (in press), this has the effect of demarcating 
the professional identity of each team member. Importantly, as clinical cases are 
discussed and team members make their particular contributions, a composite 
picture of the patient emerges: a patient that is understood in terms of their gross 
motor function, stimulation parameters, mood and self-esteem, feeding capacity, 
and functional ability.  Together, team members enact a patient that is more than 
just a biomedical entity.   
 In addition to contributing their own discipline-specific understandings to 
discussions, team members would also draw upon an awareness of patients’ families 
and wider social circumstances. All members of the team appeared to display and 
contribute such awareness. No doubt this reflected a familiarity with families that 
developed during the considerable amount of time they spend with the PMDS 
(particularly during pre- and post-surgical assessments).  In some discussions, for 
instance, team members vocalised the opinions or worries of a family or family 
member. In the following extract the team is discussing how to move forward with 
Jimmy, the patient described above by the psychologist:  
 
Psyc: …he and his family are very unsure about DBS. 
PT: Clinically, you want to offer him DBS. He is the sort of case that responds 
well.  
Dr M: I have met him! I think he would make a great candidate for DBS. 
OT: His family is reluctant because we can’t tell them exactly how he will 
respond. 
Psyc: I think we should put him in touch with another family [that have had 
DBS]. They still won’t be able to get the sort of certainty they want though. 
Neuro: Let’s put them in touch with Colin. That will give them a broad range of 
what to expect.  
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As the extract demonstrates the team members would like Jimmy to precede with 
DBS, but in consideration of the family’s perspective they decide to put him in 
touch with the family of one of their other patients.  
 In some discussions team members will draw upon their understanding of a 
patient’s relationship with siblings and parents. The following extract pertains to 
Ioannis, a patient around five years of age who has been displaying a great deal of 
agitation. There has been some uncertainty as to what is causing the agitation: 
 
Dr M: We need [the psychologist] to have a discussion with the family. The family 
is in distress – let me tell you what has been going on. Ioannis has been 
waking up early in the morning, screaming and soiling himself, and then in 
the evenings they are having trouble getting him into the bath. I think there 
is a large behavioural component to what is going on: I think he is 
intensely jealous of his [slightly] younger brother who is running around, 
playing…  It is difficult for the family but I told them we can’t use 
medications inappropriately. We will bring him into the ward for four or 
five days, and if he doesn’t kick up such a fuss here in front of strangers 
then we know it is a behavioural issue. I witnessed his interactions with his 
family. It is clear that it is one of those classic situations where he is spoiled 
on the one hand but there is a huge emotional entanglement on the other.  
 
It was not uncommon for the wellbeing of a family to be taken into account when 
deciding upon a course of action for a patient.  In the example presented below the 
team decides to keep a patient (Arivinder) in the ward to provide some relief to the 
family, at least until the family can access some support services: 
 
Dr M: I have been talking to his dad. Dad doesn’t want to take him home only 
for him to have another episode and for everyone to be completely 
demoralised.  
PT1: Is he dischargeable? 
Dr M: He is on par with others who have been discharged, so yes. 
OT: But he fluctuates every day.   
Neuro: His family seem a little bit happier in hospital.  
PT1: When Arivinder is bad, his dad holds him while the nurse gives him some 
medication. At home his dad has to do it all by himself. 
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Dr M: It is better, then, to wait and not discharge him now until he has access to 
[support group].  
PT1: In terms of actions this week? 
Dr M: Just waiting and watching. Lets see if he goes to school.  We can fill in a 
sleep chart and monitor his dystonia and sleep patterns. 
PT2:  I will contact home services [community support group]. 
 
Indeed it was not uncommon for team members to refer to a patient’s access to 
community services, or to decide upon a course of action that involved contacting 
support services.  Schooling, a patient’s performance at school, and relations with 
peers were also talked about. In the following extract team members discuss the 
possible causes of William’s changes in mood: 
 
Dr M: [The dystonia in] his legs are much better. I put him on double 
[stimulation] contacts and I reduced the right lead voltage to avoid 
dyskinesia in his face. 
S&L: His speech was good. 
Psyc: And he seemed cheerful when he was here.  
Dr M: On that point, it would be interesting to see whether his mood problems 
are because now, even though his dystonia has improved with DBS, he still 
can’t keep up with his peers at school. This could be making him frustrated 
and stressed. Prior to DBS, he could always attribute his inability to keep 
up with dystonia.  Perhaps now that he has DBS, he and others are placing 
too much expectation on him. This is in contrast to the changes in mood 
resulting directly from stimulation itself. 
Psyc: His dad certainly does not think it is directly a result of the stimulation… 
you would think the school would be understanding and make allowances 
for him.   
 
Thus, schooling, family dynamics and the availability of community services were 
often discussed. References to these elements are used to help ‘understand’ the 
patient and thus inform decision making.  Within team meetings, then, patients were 
enacted not just in terms of gross motor function, pain, medication regimes, 
stimulation parameters, functional abilities and so on, but also as individuals within 
a wider network that includes families, schooling and peers, and community 
services. Unsurprisingly, discussions and decision-making that involved these 
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frames of reference tended to draw on prevalent social norms. For example, team 
members make judgements on whether a patient has an ‘overly dependent’ 
relationship with a parent leading to ‘emotional entanglement’ (as with the case of 
Ioanis above). Schooling and interaction with peers are talked-about as things that 
should be encouraged, and it was common for team members to make assessments 
and recommendations based on their perceptions of age-appropriate behaviour.  A 
good example of this is the case of Carl, a 16 year old patient who is about to have 
the DBS system implanted:  
 
PT: I really think Carl should have a non-rechargeable battery.  I was really glad 
when [the psychologist] agreed with me!  Dr Martin has been pushing for 
him to have a rechargeable battery.  A non-rechargeable battery would be 
much better for Carl – he is at that age where he will want to go out and 
do things. He can’t be expected to routinely be at home to recharge his 
battery.  
Psyc: Let’s contact his family and let them know [that that’s what we advise]. 
They should know that they don’t have yet another big decision to make 
on their own. 
 
Thus, in addition to providing a regular structured time for addressing tensions that 
could threaten the functioning of the team, team meetings provide a forum for 
multidisciplinary decision making. They provide team members with a space to 
articulate their particular understanding of the patient; understandings which reflect 
their disciplinary expertise and their familiarity with the patient’s social and family 
circumstances.  As various team members contribute to a discussion, a clinical case 
is rendered intelligible in terms of a wide variety of elements, from brain imaging 
and stimulation parameters to relationships with parents and performance in school. 
Inevitably, in PMDS team meetings these ‘patient-centred’ discussions involved 
drawing on particular understandings of ‘normal’ childhood and teenage 
development.   
 
4.6 Discussion: The broad remit of the PMDS clinical gaze 
In The Birth of the Clinic (1963/2003) Foucault describes the emergence of what he 
referred to as the medical gaze of modern medicine. This gaze, he argued sought to 
delineate and define the body in terms of its concrete shape and form, and its 
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emergence signalled the birth of the biomedical model of disease and the body in 
which a patient’s social circumstances are largely elided or considered irrelevant to 
clinical decision-making (Fox 2012: 143).   
  Within the PMDS team meetings something quite different to Foucault’s 
medical gaze is in operation. Biomedical considerations are certainly mentioned 
within team meetings and without a doubt such considerations influence a great 
deal of PMDS clinical decision-making, but social considerations are also 
foregrounded.  In addition to talk about brain images, medication regimes and 
surgical considerations, PMDS team members devote considerable discussion to 
non-biomedical considerations: schooling, relations with peers, family dynamics, a 
patient’s mood, and so on.  Indeed, we could say that the PMDS casts a broad 
clinical gaze over their patients; a gaze that extends from the inner concrete shapes 
and forms of the brain, to the subjective thoughts and emotions of their patients, 
and to the internal dynamics of domestic life.12  Like the medical gaze described by 
Foucault, there are normative consequences for those subjected to the broad clinical 
gaze of the PMDS. Patients are, in effect, subject to a broad surveillance where they 
are inevitably compared to various norms and where clinical action is undertaken 
with the intention of upholding such norms – the decision to implant a non- 
rechargeable neurostimulator in Carl so that he can “go out and do things” like a 
normal teenager is an example of this. 
 We can see here, then, how the PMDS engages in what could a 
‘comprehensive’, ‘patient-centred approach’ to service provision that has been 
promoted by proponents of interprofessionalism and multidisciplinarity.  Bourret 
(2005) has argued that particular forms of clinical work emerge from various 
collaborative arrangements. He illustrated how the development of new forms of 
molecular clinical practices in breast cancer genetics was predicated upon the 
emergence of multidisciplinary teams involving biologists and particular clinical 
specialists.  These novel clinical practices (which constitute what could be called a 
clinical molecular gaze) emerged from the pooling of the heterogeneous resources 
from these disciplines and the subsequent blurring of disciplinary boundaries 
                                                 
12 This is in notable contrast to the multidisciplinary oncology teams explored by Coombs and Ersser 
(2004), where nurses’ understandings of patient ‘as a person’ were very much ignored in favour of 
doctors’ biomedical knowledge.  
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(Bourret 2005: 57). Similarly, we can see here how a particular ‘comprehensive’ 
clinical gaze has emerged from a specific form of multidisciplinarity collaboration.   
What I have attempted to illustrate is that this type of collaboration is an 
achievement: it requires a great deal of work. Teams such as the PMDS (or indeed 
any organisation) do not simply exist in the ‘order of things’; rather, they are 
brought into being and are maintained through various practices of socio-technical 
organising (Alcadipani and Hazzard 2010). I have explored several of these practices 
such as the careful arrangement of the built environment which was purposefully 
designed to encourage multidisciplinarity, the diary scheduling session which is used 
to enrol each individual team members into an collective itinerary of actions, and 
the team meetings itself, which provides a forum for reminding individuals to 
contribute to and circulate the various team documents that are necessary for 
effective functioning of the team. There are, of course, numerous other practices 
that have the effect of maintaining and unifying the multidisciplinary PMDS team. 
For example, team members regularly socialise together at a pub, which no doubt 
reinforces a sense of group friendship and trust.  The team also maintains a 
webpage as part of their NHS Trust website which delineates the team and presents 
it to the public as a “comprehensive service”. (This can be seen as an example of 
what Gieryn refers to as boundary work (1983): a rhetorical effort to assert the 
remit of the team and distinguish it from other services). And importantly, tools and 
protocols used within the PMDS can have a ‘unifying’ influence: some assessments, 
for example, can be carried out by several members of the team, and some may 
require several team members to work together (the goal setting session which we 
will explore in chapter 6 is a good example of this): such activities tend to blur 
disciplinary boundaries during clinical practice (Carmel 2006). The PMDS can be 
seen as the on-going consequence of these everyday practices of ordering and 
unifying, and it is upon these types of practices that the broad, ‘patient-centred’ and 
‘comprehensive’ clinical gaze is predicated.  
 Foucault argued that the modern medical gaze was encoded in, and thus 
perpetuated by, various institutional arrangements: It was not simply a mode of 
perception and reasoning that existed solely in the minds and practices of observers 
and doctors (1963/2003: 109). Similarly, Bourret argues that that the emergence of 
collaborative clinical teams (and thus a specific form of clinical work) in breast 
cancer diagnosis reflects various governmental and professional stipulations that 
4: Coordinating multidisciplinary team work 
 
 129 
explicitly encourage multidisciplinarity (2005: 58).  In this chapter I have indicated 
that the barriers to multidisciplinarity for the PMDS team are perhaps not as 
imposing as those encountered in other areas of health and social service provision. 
There is, it seems, a prevalent pro-multidisciplinary socio-political trend promoting 
multidisciplinary teamwork, particularly in paediatric settings. This trend is reflected 
in a favourable tariff structure which has reduced the financial boundaries for teams 
such as the PMDS, and of course the structure of the hospital itself, which permits 
particular forms of multidisciplinary by providing diverse spaces for diverse clinical 
activities as well as spaces that encourage collaboration. Such arrangements provide 
‘institutional weight’ and durability to the PMDS team and their comprehensive, 
‘patient-centred’ clinical gaze. Indeed, we can assume that the successful emergence 
and stabilisation of teams such as the PMDS is shaped by, and depends upon, their 
ability to resonate with such institutional arrangements.     
In the discussion of this thesis I will situate these observations on the 
multidisiciplinarity work of the PMDS within a discussion of medical innovation 
more generally. In the meantime we will explore how the PMDS manages three 
specific challenges associated with the introduction of deep brain stimulation 
technology into paediatric neurology. These challenges, as I stated in the 
methodology, were often discussed by team members during team meetings, 
particularly during the academic team meetings that took place on Fridays.  As we 
explore each challenge, we will see other instances of this patient-centred clinical 
approach; indeed, while exploring how the team manages the expectations of 
patients and families (Chapter 6) and how they measures clinical outcomes (Chapter 






5 Body work and diagnosing dystonia 
 
5.1 Introduction: The challenge of diagnosing dystonia 
Well over half the patients who attend the PMDS for deep brain stimulation have 
secondary dystonia. In these patients, many of whom have cerebral palsy, dystonic 
movements often co-exist with spasticity, muscle weakness, and contractures, as 
well as cognitive and communicative difficulties. Of these various manifestations of 
neurological pathology, it is only dystonia that can be directly managed with deep 
brain stimulation. In its ‘pure’ form, the spasms and shaky movement that 
characterise dystonia easily distinguish it from other motor signs. Spasticity, for 
example, appears as stiffness and rigidity, the consequence of the excessive 
contraction of a muscle or muscle group. Yet the clinical presentation of many 
PMDS patients, some of whom are the most severe cases in the UK, is complex. In 
these patients it is not unusual for both dystonia and spasticity to occur in the same 
regions of the body (‘mixed hypertonia’) and distinguishing the two becomes 
clinically difficult (Lebiedowska et al. 2004). Consequently, it is often unclear which 
motor sign is causing the patient the greatest discomfort or has the greatest impact 
on motor function. This is further complicated by the presence of permanent 
muscular-skeletal abnormalities, or contractures, which can also restrict a patient’s 
movement and produce painful posturing.   
 This presents a challenge for the team. In order to determine if DBS will be 
of any benefit to a patient, they must be able to distinguish dystonia from other 
manifestations of neurological pathology, and they must be able to determine to 
what degree dystonic movements are detrimentally affecting the patient. If, for 
example, a patient has both spasticity and dystonia but it is predominately spasticity 
that is creating difficulties for the patient, then DBS will be of little use. There are 
no technological solutions to this challenge. MRI and PET may render neurological 
abnormalities visible, but the images they generate cannot be used to distinguish the 
various effects of these abnormalities. Current clinical measurement tools are also of 
limited use as they lack the sensitivity necessary to identify and capture subtle 
differences (Gordon et al. 2006).    
 The PMDS’ solution to this problem is to rely on the embodied knowledge 
and tactile skills of the two physiotherapists. During an initial interview with 
patients and during the subsequent regime of pre-surgical baseline assessments, the 
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physiotherapists conduct an examination of gross motor function and a 
musculoskeletal screening, both of which are used to identify the various 
manifestations of neurological pathology and to assess the degree to which dystonia 
affects the motor functioning of the patient. In order to conduct these examinations 
the physiotherapists must use their own bodies to extract sought-after clinical 
information from the bodies of patients. In this chapter we will explore how the 
physiotherapists use a set of corporeal skills to produce useful clinical information. 
We will see that they use their bodies to encourage patients to comply with the 
examination, and we will see that they rely on a carefully honed sense of touch to 
differentiate dystonia from spasticity. Extracts from field notes taken during my 
observations of both a gross motor function examination and a musculoskeletal 
screening will be used as examples. I will identify and describe two modes of what 
several authors have referred to as body work (Brown et al. 2011; Maseide 2011): 
communicative body work, and what Moreira refers to as sensorial reflexivity (2004). As we 
will see, these modes of body work contribute to the production of clinical 
knowledge that enables the team to identify suitable candidates for DBS and to 
predict how these patients may actually benefit from the therapy. Within the PMDS 
team the successful adoption of DBS into paediatric neurology requires the body 
work of physiotherapists. This chapter will illustrate, then, that body work is a vital 
component of knowledge production within clinical contexts, and is an important 
and much overlooked component of medical innovation. 
 
5.2 Perspectives on the role of body in knowledge production 
Within the broad and diverse field of philosophy there have been several schools of 
thought that have emphasized the absolute centrality of the body in processes of 
knowledge production.  What these diverse schools have in common is a rejection 
of Cartesian dualism, which, in various manifestations, has tended to underlie a 
great deal of western thought, particularly the school of analytical philosophy, and 
to some extent, traditional sociology. Descartes argued that the body and bodily 
senses were a fallible and untrustworthy source of knowledge. Knowledge and 
beliefs (or at least those worth having and acting-upon) are, rather, the domain of 
the mind: they are explicitly present in consciousness and they are the product of 
reflective, sceptical and reasonable deliberations (Shusterman 2012). The effect of 
Cartesian dualism is that the role of the body and bodily-sensations has been largely 
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elided from accounts of knowledge production, scientific endeavour and medical 
progress. Knowledge, in other words, is portrayed as disembodied. 
 Various forms of ‘non-Cartesian’ philosophy have sought to affirm the 
centrality of the body. In general terms these schools of thought argue that we 
experience the world within and through our bodies. Our bodily sensations shape 
our perceptions, feelings and thoughts, and it is from these that useful knowledge 
emerges.  The pragmatism of William James and John Dewey is an example of this 
line of thinking. For Dewey and James, a great deal of productive and useful mental 
activity takes place below an individual’s conscious awareness - implicit, non-
discursive and vague, and guided by incorporated habit (Shusterman 2012). Such 
activity informs beliefs and enables useful, pragmatic bodily action. In a similar vein, 
the phenomenological perspective has emphasized the centrality of corporeal 
sensation to informing action and beliefs. Merleau-Ponty for example argued that 
our perception of the world, how we come to understand it and thus act within it, 
derives from our embodied dispositions (Crossley 2012). We learn how to sense the 
world via our bodies; how to see, hear, feel, smell the world, and it only via these 
sensations that that we can act within, and form knowledge of, the world. Merleau-
Ponty (1962) referred to these acquired ways of sensing-and-acting as habits. They 
are collectively shared and transmitted and importantly they become sedimented or 
ingrained in the body as embodied dispositions. According to this line of thinking, 
then, different cultures or different professional groups can be characterised by their 
particular (perhaps idiosyncratic) embodied dispositions (or habits of sensing-and-
acting) that generate specific forms of knowledge. According to both pragmatism 
and phenomenology the notion that a disembodied mind can occupy some sort of 
Archimedean point, from which various truths about the world can be deciphered, 
is a myth.  
Similarly, various scholars within STS have illustrated the role of the body 
and embodiment in the production of scientific knowledge.  This work (and indeed 
the field of science and technology studies more generally) has offered an alternative 
explanation of scientific progress to that put forward by positivist and rationalists 
philosophers of science (c.f. Reichenbach 1938; Popper 1959; Hemple 1966) that 
has tended to portray scientific knowledge as “abstract, universal and placeless” 
(Henke and Gieryn: 2008: 343), (and, of course, body-less). In contrast, various STS 
scholars have sought to highlight the artisanal, craft-work nature of scientific activity 
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and knowledge production, a key component of which is the tacit and embodied 
knowledge of scientists (Knorr-Cetena 1981; Lynch 1982; 1985; Collins 1987).  
Generally, tacit knowledge has been defined as unwritten knowledge and skills that 
circulate within scientific communities, a sort of ‘feel for the game’, that enables 
individuals to utilize technical apparatuses together with more formal forms of 
scientific knowledge to generate meaningful scientific statements. Such knowledge, 
according to Polayni’s (1962) influential description, cannot be directly 
communicated or codified.  For Lynch, tacit knowledge is incorporated into the 
specific practices of scientists and “plays a central role in the evaluation of 
experiments and experimental results” (Cambrosio and Keating 1988: 245).  
Collins’s definition of tacit knowledge includes manual and perceptual skills, such as 
“the ability to make a throat swab and see relevant shapes under the microscope” 
(1987: 336). These various theorists emphasize the importance of tacit knowledge, 
or acquired habits of ‘sensing-and-acting’ in transforming local specificities 
(laboratory apparatuses and materials) and formal rules (such as scientific protocols) 
into novel and explicit scientific statements about the world. According to the 
translation model of science put forward by Latour and Woolgar (1986; Latour 
1987), tacit and embodied skills are a vital component of the chain of 
transformations between various forms of matter (reagents, raw materials), 
inscriptions (diagrams, marks, tables and curves), and explicit propositions (Callon 
1995).  Indeed, according to this model embodied and tacit knowledge enables the 
generation of meaningful semiotic elements (utterances and texts), from material 
elements. The production of knowledge, then, is dependent upon, and shaped by, 
the embodied ‘sensing-and-acting’ skills of scientists.  
In this chapter I will argue that the embodied ‘sensing-and-acting’ capacities 
of the physiotherapists are essential to the work of the PMDS team.  Importantly, 
the physiotherapists use these embodied sensing-and-acting skills to translate what I 
will call momentary affects into meaningful semiotics elements: they use their own 
acquired perceptual skills to decipher various, temporarily-induced bodily 
movements within their patients, which they then verbally articulate and/or inscribe 
in particular texts. The meaningful utterances and texts subsequently enable the 
team to confirm whether or not the patient is a good candidate DBS, and to help 
predict how that patient will respond to the therapy. Here, then, I will be adopting a 
model of clinical work that is similar to the translational model of scientific 
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knowledge production put forward by Latour and Woolgar (1986). Useful medical 
documents or clinically-useful propositions about the patient emerge from a chain 
of interactions (or an assemblage of heterogeneous elements) involving the 
embodied skills and knowledge of the physiotherapists, the body of the patient, a 
carefully arranged material environment, and the application of formal protocols 
 
5.3 The clinician’s body in medical sociology 
Scholars within medical sociology and the sociology of health and illness have 
tended to focus on the bodies of patients and those subjected to clinical discourses 
and practices, rather than the bodies of those working within the health practices. In 
this regard, drawing on a flourishing of work within sociology more generally, 
scholars have analysed the body as a malleable marker of identity, a vehicle for 
particular types of lived experiences, a sexed and sexualized object used to oppress 
women or non-heterosexuals, and as the focus of various disciplinary practices 
aimed at creating governable subjects (Shilling 2007). It has been explored as a site 
of contestation between ‘objective’, technology-derived representations and the 
‘subjective’ experiences of patients (Rhodes et al 1999), and as a patched-together 
assortment of various enactments (Mol 2002). Yet, there has been comparatively 
little work exploring the role of the clinician’s body in clinical practice.  
 The exceptions can be roughly divided into two groups, each illustrating a 
different aspect of what has been called body work,13 or the corporeal work, 
conducted by health professionals.  First, there are studies that have explored the 
communicative body of those working in health care.  Here scholars have explored the 
way in which health professionals use their body to help encourage the compliance 
of patients within clinical interactions. Brown and colleagues (2011), for example, 
have explored how clinicians use their bodies to convey information to patients, 
usually as a complement to verbal language, within the context of gynae-oncology. 
For many of the patients included in the study, whether or not they trusted a 
clinician depended a great deal on the clinician’s bodily actions and gestures. 
Particular forms of body movement and presentation inspired trust and confidence 
in patients, thus facilitating clinical practice. In a similar vein, Måseide (2011) noted 
                                                 
13 Generally the term ‘body work’ refers to work done to the body of others (Twigg et al 2011). Yet 
several authors (Brown et al 2011; Måseide 2011) have used the term to refer to the corporeal work 
conducted by health professionals. It is in this sense that I will use the term.   
5: Body work and diagnosing dystonia 
 
 135 
how clinicians used their own bodies to help instruct patients how to use and move 
their bodies during examinations. Respiratory physiological examinations, for 
example, require patients to physically interact with technical equipment in a precise 
(and challenging) fashion. In order to encourage patients to do this, clinicians would 
often use bodily gestures in addition to verbal instruction, and if this were done 
successfully, the interaction would generate a textual artefact that could 
subsequently be used to inform further clinical action. Måseide illustrated that 
communicative body work, therefore, was essential to ensuring the success of the 
examination, and suggests that clinical examinations can be seen as “mutually 
constituting processes between various agents, bodies and body modes” (2011: 
297).   
 These studies suggest that the body is an important instrument for 
communicating with patients and thus enabling clinical interactions to produce a 
desired output.  The second aspect of the body work explored by several scholars is 
what Moreira (2004) has referred to as sensory reflexivity. Sensory reflexivity refers to 
the sensing-and-acting habits acquired by health professionals via training and 
clinical experience; the learned perceptual skills and embodied dispositions that are 
often difficult to verbally articulate and communicate, but are nevertheless a vital 
component of clinical practice. Drawing on Merleau-Ponty’s work, Harris (2011) 
illustrates that conducting even the most routine, mundane clinical activities such as 
inserting a cannula requires a tactile competency that can only be acquired through 
bodily practice, and can easily be disrupted if, say, a new type of cannula is 
introduced. Perhaps the most thorough examination of this embodied sensing-and-
acting within a clinical interaction is Moreira’s exploration of neurosurgical practice 
(2004). The neurosurgeons in Moreira’s study had, via training and clinical 
experience, carefully attuned their tactile and visual senses to particular phenomena 
within the fleshy bodies of their patients. Only by learning how to sensorially 
register these particularities within the patient could they then act upon them and 
thus conduct the surgery. Importantly, Moreira illustrates that these sensing-and-
acting abilities of surgeons are dependent upon a wider array of carefully arranged material 
and semiotic elements. First, the patient had to be carefully prepared before surgery: 
medicated, shaved and physically positioned so as to expose specific body regions. 
And secondly, elements within the operating theatre, such as surgical tools, texts, 
lighting, and other theatre staff, were precisely arranged, thus creating a layered 
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space that, Moreira argues, enabled, channelled and constrained the actions of the 
surgeon. The carefully arranged material and semiotic elements enabled and 
endorsed particular actions; or to put this in another way, they created particular 
sensory affordances for the surgeon to act upon. Moreira points out, then, that both 
the surgeon and the patient are the subject of this wider surgical assemblage: the 
patient’s body is configured to present particular sensory affordances, while 
simultaneously the surgeon is configured as a particular sensing-and-acting surgeon-
body.  
 As these authors have demonstrated, clinical work is not something that is 
simply done to, or done with, a subjectified patient body, it is also something that is 
done via, or done through the bodies of those working within health care. 
Communicative body work and sensory reflexivity are elements of what could be 
called the craft work of clinical practice: the local and often ad-hoc work which 
brings together patients, various technological apparatuses and more formal or 
codified forms on knowledge (such as clinical protocols) in such a way that a 
diagnosis or assessment can be achieved, or a therapeutic intervention can be 
conducted. As we will see in this chapter the process of deciphering dystonia within 
the PMDS requires the physiotherapists to engage in both communicative body 
work and to utilize their particular, carefully honed sensing-and-acting capacities (or 
sensorial reflexivity). In order to conduct the Gross Motor Function Measure 
(GMFM) and the musculoskeletal screen, the physiotherapists use their own bodies 
to instruct and guide the patient on how to position and move their body in such a 
way that it presents particular opportunities to examine specific parts of the 
patient’s motor system.  In order to take advantage of these opportunities, the 
physiotherapists employ their tactile sensibility to ‘feel’ and thus identify spasticity, 
muscle weakness, contractures and dystonia. Importantly, as Moreira (2004) argues, 
this body work is enabled by a carefully constructed material and semiotic space. 
 
5.4 Using the body to diagnose dystonia 
A brief overview of the GMFM and muscular-skeletal screen 
The physiotherapists use two assessment tools to identify dystonia and to attain 
some idea of its impact upon the posture and motor function of the patient. These 
are a manual musculoskeletal screening and a specific means of examining gross 
motor function called the ‘Gross Motor Function Measure’ (GMFM). Parts of both 
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of these assessments may be conducted during the initial interview with potential 
new patients, in which case they are used to help select appropriate DBS candidates. 
During subsequent pre-surgical baseline assessments, both the musculoskeletal 
screening and the GMFM will be conducted in full and the information they 
produce will be used to confirm that a patient is indeed an appropriate DBS 
candidate, and to help predict how that patient may respond to DBS.  
 Musculoskeletal screening can involve any number of standard examinations 
of muscle strength, joint movement, muscle bulk and reflexes. The intention of the 
screening is to evaluate a patient’s motor system and locate abnormalities that are 
causing motor dysfunction. Various regions of a patient’s body can be explored 
one-by-one and specific sets of examinations can enable the clinicians to decipher if 
an abnormality is located in a particular part of the peripheral motor system 
apparatus (such as muscles and neuro-muscular junctions) or the central motor 
system apparatus (pyramidal system, the basal ganglia, or the cerebellum) (Reeves 
and Swanson, 2008). Conducting many of the examinations requires the 
physiotherapist to engage in a great deal of physical work with the patient. They 
may be required to manually move a joint or place their body weight upon parts of 
the patient’s body, and in many cases they must be able to ‘feel’ particular 
phenomena within the body of the patient. Particular manifestations of neurological 
pathology, for example, have a signature ‘feel’, but this is perceptible only if the 
patient’s body is manipulated in a specific fashion. Within the PMDS the 
physiotherapists use neuromuscular screening to physically detect and locate 
spasticity, muscle weakness, contractures and dystonia. As we will see further on, 
conducting an effective musculoskeletal screening requires the physiotherapist to 
possess a carefully honed tactile sensibility.    
 The GMFM was developed in the 1980s specifically to assess children and 
young people with cerebral palsy (Russell et al. 1989). According to the authors it 
can be used to obtain detailed information on a child’s motor skills, to measure 
motor skill changes over time, and as a means of assessing the impact of posture 
aides and braces. In order to conduct the examination the client must attempt a 
range of ‘gross motor’ movements, which include lying, rolling, sitting, crawling, 
kneeling, running and jumping, as prescribed by a GMFM manual (Russell et al. 
2002). Specifically, the client must attempt 88 separate tasks, ranging from the very 
easy such as turning their head while laying their back, to the more difficult such as 
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jumping forward 30cm with both feet simultaneously. As this is done, the 
physiotherapists provide a score for each task using a four-point scale, where zero is 
‘does not initiate’ and three is ‘completes’.  From these individual task scores an 
overall score is calculated. This reflects the client’s motor function capability (what 
they can do), rather than their performance (what the child does do) in everyday 
settings. Importantly, in addition to quantifying a client’s motor function, 
physiotherapists can use the tool for guiding clinical decision-making and 
intervention planning (Tieman et al. 2005). As the assessment is carried out it can 
provide physiotherapists with an opportunity to interpret the possible causes of 
gross motor function impairment and this can then be used to decide upon an 
intervention.   
 It is in this respect as a guide for intervention planning that the GMFM is 
particularly useful for the PMDS.  The therapists use it as a means of assessing and 
quantifying their patients’ gross motor function, and along with the musculoskeletal 
screen, as a means of identifying the possible cause of patients’ motor function 
impairment. As one of the physiotherapists explains, this is not a function of the 
tool itself; rather, it is a matter of the physiotherapist’s interpretation: 
The GMFM actually only gives you a number.  It doesn’t tell you why somebody 
can’t do something. And that’s what the professional who’s doing it brings to the 
interpretation.  I would be disappointed if somebody did a whole GMFM and 
couldn’t tell me why they thought the child was having some difficulties. The 
professional carrying out the GMFM interprets as they go about it, from analyzing 
the quality of movement, and then linking that to the [muscle screening] - if I know 
a child has weakness around the hips, it wouldn’t surprise me that they’d have 
trouble standing on one leg. (Physiotherapist 1, interview).  
 
Together the musculoskeletal screen and the GMFM enable the PMDS 
physiotherapists to ‘decipher’ dystonia from other manifestations of neurological 
pathology, and to produce an overall picture of how each manifestation is impacting 
upon a patient’s gross motor function. As one physiotherapist indicates, this 
information enables the team to assess the suitability of DBS for that patient:   
And it will give us an idea of what they’re able to do, what they’re not able to do 
and how the dystonia is preventing them doing something, or whether it’s actually 
weakness, because we need to decipher if they’re unable [for example] to stand up, 
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is it the dystonia that’s impacting that? Or is it more weakness? And then obviously 
from our clinical experience, we know that DBS isn’t going to directly influence 
weakness. So it’s just kind of deciphering. (Physiotherapist 2, interview) 
 
In order to successfully conduct both the musculoskeletal screen and the GMFM, 
the physiotherapists use a range of tools and props. As the following section will 
illustrate, these tools and props constitute part of a material terrain that configures 
particular interactions between the bodies of the physiotherapists and the patient, 
enabling the generation of sought-after clinical information. In order to explore this 
in some detail, we will follow a specific case: Carl, a 16 year old patient with 
secondary dystonia. Carl is accompanied by his mother, and the assessments are 
conducted by both PMDS therapists.    
 
The importance of spatial organization: Constructing a material terrain 
The musculoskeletal screen and the GMFM take place in the hospital gymnasium. 
Importantly for the physiotherapists, the gymnasium is large enough with 
sufficient open space for the patient to perform various GMFM tasks (one 
task, for example, requires the patient to run ten metres in a straight line). The 
gymnasium also contains adjustable couches and benches, height-adjustable 
desks, mats, several inflated balls of various sizes and an area that has been 
delineated with a pattern of floor markings (see figure 5.1, page 140).      
Before Carl’s assessment begins, the physiotherapists set about adjusting 
and arranging many of the objects within the gymnasium, creating a material spatial 
configuration in which the musculoskeletal examination and GMFM can be 
conducted.  Aspects of this resulting distribution of material objects are prescribed 
by the GMFM manual are therefore (ideally) uniform across all GMFM 
assessments.   As the physiotherapist states:  
The GMFM is quite defined about having something at waist height and defines 
what there is. Various height adjustable benches and tabletops and all those kinds 
of things [are required] (Phsyiotherapist 1, interview)  
 
Thus, just prior to beginning Carl’s assessment, one of the physiotherapists asks him 
to stand next to the couch which she then adjusts so that it is at his waist height. 
The bench is also adjusted so that as Carl sits on it his feet will be placed squarely 
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on the ground.  Meanwhile the other physiotherapist pulls two floor mats together 
and places them nearby, thus providing several metres of padded floor space. 
  
Figure 5.1: Gymnasium containing objects used during the GMFM and 




Some elements within the gymnasium have been permanently arranged in 
accordance with the GMFM manual.  The most obvious example of this is the set 
of guiding floor markings, a series of lines of various lengths and a circle which have 
been painted on the floor in the middle of the gym. These can be used to help guide 
the patient perform various GMFM tasks such as walk in a straight line or jump a 
specific distance. Rather than having to mark out lines and distances during each 
examination, the physiotherapist arranged for a set of guiding markings to be 
painted permanently on the floor of the gym.  During an examination, then, a 
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patient can simply be instructed to ‘jump from inside the circle to the line’.  As the 
physiotherapist states: 
The GMF are the main lines that are down there…  I mean the idea [of the 
markings is] that there’s quite set criteria in the test that the patient has to adhere 
to. For instance, if they walk along the line, they have to have their foot on the line, 
they can’t step off.  So having the facility set up ready to go.  And also having them 
predetermined, it means we’re all using the same marks each time.  Before we had 
the lines painted on, we often had to push two mats together and measure it every 
time and get children to walk between the mats… But you can imagine there is an 
error that would potentially affect the child’s score.  So it’s obviously its faster for 
us and more professional looking, but it also means all the professionals are using 
exactly the same test criteria to score the children on.  So that’s the advantage of 
those. (Physiotherapist 1, interview).  
 
These guiding floor markings, along with the adjusted bench and couch and 
the padded floor mats, create part of a material terrain, a spatial organization of 
objects which enables the GMFM and musculoskeletal screen to take place.  As we 
will see this terrain permits particular forms of body work as it constrains, prompts, 
guides and channels the actions and interactions of the physiotherapists and the 
patient. Specifically, we will see that this material terrain participates in the 
production of momentary affects which are subsequently translated by the 
physiotherapists into utterances and texts. 
 
Communicative body work: from text and words to corporeal movement 
Carl’s assessment begins with the GMFM.  From the very start it is apparent that 
the examination takes place in a terrain that is both material and semiotic: as well as 
the material objects noted above, there is considerable verbal communication, 
various texts are read out aloud and other texts are created. For the GMFM to 
precede and generate sought-after clinical information, Carl must perform each of 
the 88 tasks in the manner instructed by the GMFM manual. It is the role of the 
physiotherapists to translate the events as described within the text of the manual 
into actual events within the gymnasium. Much of this is done via verbal 
instruction, but these instructions are not word-for-word those of the manual; 
rather, they are the physiotherapists’ interpretation, translated into language that is 
more appropriate for a 16 year old patient. Words such as ‘prone’ and ‘supine’, for 
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example, are translated as ‘lie flat on your belly’ or ‘lie flat on your back’. At one 
point the manual stipulates that it is imperative that the child attempt as well as they 
can to complete each task.  The physiotherapist explains this to Carl as ‘getting 
points:’ 
 
Carl:  What if I can’t do [a task]? 
PT1: It is okay.  We are just screening. We are just trying to find out what you 
can and can’t do…It’s about getting as many points as you can. 
 
The physiotherapists do not rely on verbal instructions alone, however.  In 
order to ensure that the events within the gymnasium proceed as stipulated by the 
GMFM they use their own bodies to communicate the instructions within the 
manual to Carl. Indeed for many of the tasks they use both verbal and corporeal 
communication to instruct Carl how to position and move his body, often in 
reference to the objects that constitute the material terrain. Below is an example 
where the more junior of the two physiotherapists (PT2) uses her body to instruct 
Carl on how to perform ‘Task 41’ , which requires moving from ‘prone’ to ‘4-point, 
weight on hands and knees’. (The other physiotherapist watches and provides a 
score for Carl’s attempt): 
 
PT2:  I want you to lie down on your front, flat on the mat facing me and then 
get up on all fours. Like this [She lies face down on the floor flat (prone), 
and then picks herself up so that she is resting on her knees and hands (4-
point)]  
Carl:   [Repeats the task without noticeable difficulty] 
 
Similarly, ‘Task 63’ requires the patient to move from standing position to a 
squatting position without using their arms. Again the physiotherapist uses her body 
and her own verbal translation of the text to instruct Carl:    
 
PT2:   Now you have to do a squat. Let me show you – you have to get your 
bottom lower than your knee. [From an upright position, she slowly bends her 
knees, with her arms extended out in front of her for balance until she is in a squatting 
position].  
Carl: Does it matter if your bottom touches the ground? 
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PT2:  No, just as long as you don’t fall back on it. 
Carl:  [Completes the task with noticeable difficulty]. 
 
Here the physiotherapist uses her body to demonstrate how the task should be 
performed. In effect she embodies a small part of the GMFM text; she enacts it 
with the intention that Carl will mimic her and do the same. Throughout the 
assessment the physiotherapists use their bodies in this way; as a means of corporeal 
communication that will, ideally, enable the descriptions within GMFM text to be 
enacted by the corporeal movements of the patient.    
Generally throughout the assessment this corporeal communication and 
verbal communication are used together as a means of complementing one another. 
In the process, both bodily movements and words can acquire specific meaning 
within the assessment. Indeed, verbal utterances are indexical to the 
physiotherapist’s body movements and the other material and discursive elements 
that constitute the diagnostic space. Examples of this are the physiotherapist’s 
instructions on how to perform ‘Task 45’, which requires the patient to ‘crawl 
reciprocally forward for 1.8m’:  
 
PT2:  The first thing we are going to do is the commando crawl. Get down on 
that mat for me.  You need to pull yourself along and keep your body very 
low, to the end of the second mat [which is approximately a distance of 
1.8m]. 
Carl:   [Looks puzzled]. 
PT2:  Okay, this is what I mean. [She then gets down on the floor so that she is 
resting on her stomach and elbows. She then uses her elbows and knees to 
propel herself forward.]  Remember to keep low.   
Carl:  [Carl, without speaking, gets down on the floor and does this same with some difficulty] 
PT 2:  Remember to keep low! 
 
As she does this her utterances acquired specific meaning for Carl. The ‘commando 
crawl’ and ‘keeping low’, descriptions that initially caused confusion, are equated 
with specific corporal form and movement; they acquire specific referents within 
the assessment. By using her body to complement verbal instructions, she is, in 
effect, participating in the production a meaningful semiotic world. Performing each 
task involves a series of translations from semiotic elements to corporeal-material 
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elements within gymnasium. Parts of the GMFM text are articulated as verbal 
utterances or bodily movements by the physiotherapist, and if the patient is 
compliant, he will position and move his own body as best he can in accordance 
with these verbal and bodily articulations of the text.   
The result of this chain of transmutations, then, is that the patient will adopt 
a series of GMFM prescribed body postures and movements. Importantly these 
postures and movements are prescribed in relation to other material elements of the 
assessment; the patient is channelled into a series of specific relations with other 
objects or the guiding lines on the floor. Task 47 requires the patient to climb on 
hands and knees up four steps, and tasks 26 and 27 require the patient, seated on 
the mat, to reach for a toy placed 45 degrees behind their left and right sides. These 
resulting body-object ensembles configure the patient’s body in such a way that enables 
the physiotherapists to extract useful clinical information: The patient’s body is 
coaxed into specific positions that enable either one of the physiotherapists to 
scrutinize particular aspects of the patient’s motor function.  
To put this in another way, the ensemble produces particular momentary 
affects: temporary corporeal phenomena that are registered by (and thus ‘affect’) the 
observant physiotherapists. Examples of momentary affects include Carl’s inability 
to move his body to perform a set task, or as we will see further on, specific bodily 
movements that are registered via the carefully honed tactile skills of the 
physiotherapists. These momentary affects are generated by a collective of elements: 
it involves the careful arrangement of material objects, the compliant patient, and 
the active and attentive physiotherapists.14  
Importantly, these momentary affects will be captured and translated into 
more durable modes of representation such as a text. As the following examples 
show, while the junior physiotherapist (PT2) instructs Carl, the other 
physiotherapist (PT1) watches carefully and provides a score for his performance on 
the GMFM score sheet.  The first example, Task 72, requires the patient to walk 
forward ten steps carrying a large object with two hands.   
 
                                                 
14 Or to use material semiotics terminology, we could say that momentary affects are particular 
capacities for interaction which are enacted by the carefully arranged assemblage involving bodies 
and objects within the gymnasium.   
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PT2: Okay, now I want you to walk holding this ball. Do you remember these 
[inflatable balls]?  I was an 80s child and they were common in my time.  
Now, let’s use these lines on the floor. Walk between them all the way to 
the end.   
Carl: [Picks up the large, inflatable pink ball which has two small handles on either side and 
walks to the end of the guiding lines.  Despite appearing a little unsteady he does this 
without any obvious difficulty]  
PT1: Easy peazy! No problems there [She scribbles a 3 on the GMFM score sheet.]  
 
Here we see the translation of corporeal movement and semiotic elements within 
the assessment. In this case Carl’s bodily movements, movements that entail 
negotiating other material elements within the gymnasium, are translated by the 
physiotherapist into a number (3) that is subsequently inscribed on the score sheet 
adjacent to the specific task number (72).  This process creates a text with a specific 
meaning that derives from the relationship between the assigned scores and the task 
numbers. In this way the momentary affects generated within the ensembles are 
translated into a more durable, textual representation of the patient’s motor 
capabilities.    
Task 56 requires the patient to stand upright and still for three seconds. 
Tasks 55 and 54 require the patient to stand upright, holding on to a bench with 
one hand and lift the right foot off the ground, and then the left foot of the ground. 
Again, PT2 provides instructions while PT1 makes a note of the score: 
 
PT2: Now, stand next to the couch. Just stand there for 20 seconds, as still as 
you can.  
Carl: [Stands next to the couch, but his shaking body makes it difficult for him to keep 
balance. Several times he has to adjust his feet to keep himself from falling].  
PT1: How much effort does it require to stand still? 
Carl: It is hard to stand still. I can’t stand still at all.  
PT2: Now, put your hand on the couch, and try and see if you can lift the 
alternate foot. 
Carl: [Does this with the left foot with some effort]… 
PT2: One, two, three, well done. 
Carl:  [Tries with the right foot, but keeps having to place his second hand on the bench to stop 
himself from falling].  
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PT1: Carl, would you mind taking off your t-shirt? I want to see what is 
happening with your spine.  
PT2 [According to the GMFM manual] you get three goes on each foot. Try standing on it. 
One, two, three, four, five… 
Carl: This is the problem, when I try and stand on this [right] foot.  
PT2: Your left foot moves [flails] around and throws you off balance, doesn’t it.  
Carl: Yes.   
 
This particular ensemble has enabled the physiotherapists to capture useful clinical 
information in addition to a numerical GMFM score. The shape of the couch 
enables Carl to attempt to stand upright, first on one leg and then on the other as 
instructed by the physiotherapists, and this has led to the generation of two notable 
momentary affects: his twitching spine and flailing left foot. The physiotherapists 
provide a brief description of these in Carl’s notes – again, momentary affects are 
translated into a more durable form.  At a later time these notes will help inform the 
team’s prediction of how Carl will respond to DBS.  
 
 
Sensing and acting: from corporeal movement to text and words 
Once the GMFM is completed, Carl and the physiotherapists have a short break 
before beginning the musculoskeletal screen. By this stage the physiotherapists have 
an idea of which particular areas of the motor system are causing difficulties for 
Carl, and this information is used to decide which areas of his musculoskeletal 
system will be screened. Carl’s shoulders, pelvis hips, knees and ankles will be 
screened for range of movement, muscle weakness, spasticity, and contractures, and 
this will, ideally, enable the physiotherapists to decipher the presence of dystonic 
movements.  
 The screen takes place on the adjustable couch. As it progresses Carl is 
instructed to adopt a number of body-positions, each enabling a particular aspect of 
the musculoskeletal system to be screened. Much like the body-object ensembles of 
the GMFM, in each one of these positions the material form of the couch 
participates in moulding and supporting the patient’s body in such a way that it can 
be scrutinized: the adjusted couch participates in configuring the patient’s body so 
that it will generate momentary affects for the physiotherapists. However, unlike the 
GMFM, the physiotherapists themselves become corporeally involved in the 
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ensemble. Indeed, the musculoskeletal screen constitutes a body–body–object ensemble. 
Here is an example of one such ensemble during which the physiotherapist is 
examining the range of movement of the hip joints:  
 
PT2: I will see if there is any asymmetry… [Directed at PT1].  Now, Carl, lie in 
your tummy on the couch.  
Carl: [Does as is instructed] 
PT2: [Stands at the base of the couch and holds both of Carl’s ankles, one in each hand. She 
then splays his legs apart in one steady movement, before bringing them back together 
until they are slightly crossed over]. 
 
Within these ensembles the physiotherapist’s body serves two purposes. The first is 
as a means of physically manipulating Carl’s body, as illustrated above, in such a way 
that it will divulge particular information. When testing for range of movement or 
smoothness of movement (which can be used to detect spasticity) the patient is 
instructed to remain passive and the physiotherapist will support and move a part of 
the patient’s body in a specific fashion. The physiotherapist is actively using her 
own physical body, then, to prompt the patient’s body to divulge useful clinical 
information. Standard techniques of musculoskeletal screening, outlined in various 
user manuals and learned by physiotherapists as part of their training, describe how 
the physiotherapist should use their body in this way. For example, many 
examinations require the physiotherapist to apply ‘overpressure’ to a particular joint, 
which involves gently flexing or extending a joint beyond its usual range. While 
doing this the physiotherapist is instructed to “be in a comfortable position”, use 
their “body weight or the upper trunk to produce the force, rather than the intrinsic 
muscles of the hand, which can be uncomfortable for the patient”, and in order to 
accurately direct this force, ensure that the their “forearm is positioned in line with 
the direction of the force”. All force should be “applied slowly and smoothly to the 
end of the available range” (Ryder 2011: 9).   
 In some cases the patient will take a more active role: when testing for 
muscle weakness, for example, a patient will be instructed to attempt to move a 
limb while the physiotherapist uses her own body weight to create resistance. Here 
is a specific example from Carl’s assessment. Carl is seated upright on the couch 
with his legs dangling off one end.  The physiotherapist is exploring his muscle 
strength in his quadriceps: 





PT2:  Carl, I’m going to try and hold your feet down and I want you to try as 
hard as you can to extend your leg. [She moves to the end of the couch and holds 
both his feet, one in each hand]. 
Carl: [Slowly extends his legs, with noticeable effort, while the PT exerts pressure]  
PT2:  [Talking to PT1]  There is a bit of loss at inner range – I think it was the 
jerkiness. 
PT1: That fits with the movement disorder. 
 
This example also illustrates the second purpose of the physiotherapist’s body 
within the ensemble: to physically register particular momentary affects generated 
by the moulding and manipulating of Carl’s body. As various physical manipulations 
take place the physiotherapist uses a carefully honed tactile sensibility to assess 
muscle strength, smoothness of movement, and movement range, and thus help 
identify motor system abnormalities. Here then, the body-body-object ensembles 
are enacting motor system abnormalities as particular bodily sensations. During an 
interview the junior physiotherapist described how particular abnormalities ‘feel’ 
when she is conducting a screen with a patient.  
If you take a knee, to see if a child or a young person has spasticity, you bend the 
knee very quickly you’ll suddenly get like a bony block, it will feel like a bony block 
but it’s not a bony block, but it’s like a catch.  And then it will release and you will 
be able to bend it a bit further. Now that is spasticity. Whereas if you have the leg 
that’s straight and you’re about to bend it and you struggle to bend it throughout 
range, but you don’t get one of these fast bends where you get a stop, then that’s 
high tone…  Sometimes you might get a leg and bend it and you’re feeling any 
resistance but it’s really floppy, so you would call that as low tone.  And then other 
times you’ll try and bend a knee and you can’t flipping bend it because the 
quadriceps are kicking in, which is dystonia, it’s literally kicking in   and stopping 
you bending [their knee].  It’s completely rigid and you can’t bend it 
(Physiotherapist 2, interview)   
 
Indeed as the physiotherapist points out, various motor system abnormalities have 
their own ‘signature’ feel.  This “bony block that is not a bony block” sensation of 
spasticity, which can only be detected when the muscles are passively moved at high 
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velocity, is often described as the ‘clasp-knife’ response (due to the similarity with 
the rapid increase of, and then rapid decrease of, resistance when closing a folding 
pocket knife) (Burke et al. 1970).  Similarly, the difficulty in bending a knee through 
its range of movement due to high tone (or hypertonia) is been referred to as ‘lead-
pipe rigidity’. These are, of course, descriptions of specific, collectively generated 
momentary affects. 
 During Carl’s assessment the physiotherapists are drawing upon a sensorial 
understanding of the motor system and its abnormalities.  This tactile capability has 
been acquired during their professional training and has no doubt been honed in 
clinical practice. In effect, they have acquired a body that is tuned to particular 
sensorial affordances, just as the neurosurgeons described by Moreira (2004) 
become sensitive to numerous visual and tactile sensorial differences within an 
operating theatre. To borrow Latour’s parlance, they possess a body that has learnt 
to be affected by and moved by a set of contrasts that many other bodies would fail 
to register (Latour 2004). And importantly, as we have seen above it is only within 
specific body-body-object ensembles that this sensorial capability is realized: the 
body of the physiotherapist is, in effect, configured as a clinical information-
gathering apparatus by the specific corporal-material elements that constitute the 
ensemble. Of course it may not always be clear to the physiotherapist what it is that 
they are sensing, in which case they may ask the patient for some clarification. At 
one stage during Carl’s assessment, for example, the physiotherapist asks Carl “are 
you ticklish or is this the involuntary movement”, to which Carl replied that it was 
the former. And, at another point when Carl is pushing up on his toes while leaning 
against the couch, he is asked to which of his lower legs feel weak, to which Carl 
replies “both”.      
 Indeed verbal communication, whether it be instructions or questions 
directed at Carl, are necessary for the screening process to proceed smoothly.  But 
throughout the screening there is also a great deal of talk between the 
physiotherapists. The more junior physiotherapist who is leading the screening 
vocally articulates her tactile sensations to the other physiotherapist. For example, 
during an exam of the hip region: 
 
PT2: I’m getting intermittent pulling, twitching at the abduction. 
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And again, during another examination of the hip which requires Carl to lie on his 
back, holding and his knee in a flexed position while the physiotherapist splays his 
legs: 
PT2: I got some resistance there, and the abductor switched on. 
PT1: I think it is those intermittent jerks.  
 
And during and examination of the range of notion of his left knee: 
PT2: Ahh – there is a catch here.  
 
Here, then, the physiotherapists are again adding a meaningful layer of semiotic 
elements to the assessment activities. Groups of words are used to articulate 
particular sensations (or momentary affects) that as a result acquire a discursive 
existence as ‘intermittent jerks’, a ‘catch’, or ‘some resistance’. Specific collectively 
generated momentary affects are therefore translated into utterances. These 
utterances are then inscribed in text: both physiotherapists jot down some of these 
utterances along with their interpretations (‘muscle weakness’ ‘spasticity’ and so on) 
in handwritten notes, so that by the end of the screening they have produced a 
document that provides a textual picture of various aspects of the Carl’s motor 
systems and its abnormalities. There has been, therefore, a series of transmutations 
from physical phenomenon to utterance to text, in which the embodied knowledge 
of the physiotherapist, her ability to physically mould and manipulate the patient 
and her honed tactile sensensibility have been essential.    
 At the end of Carl’s screening the physiotherapists explain their findings to 
both him and his mother.  He does indeed have dystonic movement that affect the 
gross motor function in parts of his upper body, and in his left leg, and he has 
dystonic posturing in his feet.  But, the main problem for Carl, the physiotherapists 
inform him, is muscle weakness around the pelvis.  
 
PT1: Carl, the hip abductors and hip extensors are an issue. The main issues are 
around your pelvis, it is due to muscle weakness.  Maybe we could teach you to do 
some exercise that could help you there.  
   
5: Body work and diagnosing dystonia 
 
 151 
5.5 Discussion: the body as an inscription device 
If we are to avoid reifying a Cartesian-like division where the patient body is the 
subject of a disembodied medical discourse, it is necessary to explore how health 
professionals use their own bodies in everyday clinical practice. As the example 
presented here illustrates, the body of the patient is entwined in clinical practices 
that that are done with, or done via, the body of the clinician. Indeed, the 
physiotherapists demonstrate what could be called an embodied knowledge of the 
motor system and motor disorders: a somatic memory and awareness of how to 
corporeally engage with patients, and how aspects of a motor disorder or a ‘normal’ 
motor system should feel, or visually appear, when the patient’s body is placed in 
particular positions or made to move in a particular way. Many elements of the 
physiotherapists’ somatic awareness of the motor system may be expressible in 
language (the ‘clasp-knife’ description of the tactile sensation of spasticity is an 
example of this) but this is not a knowledge that resides entirely within a cognitive 
domain and it is not, then, wholly and fundamentally shaped by the reflective 
deliberations of the mind. Merleau-Ponty’s notion of corporeal schema, as articulated 
by Crossley (2001), is useful here. Crossley describes the corporeal schema as 
learned embodied ‘know-how’. It is a pre-reflective understanding of how to move 
the body and register the surrounding world: a “perspectival grasp upon the world 
from the ‘point of view’ of the body” (2001: 102) that is inseparable from practical 
action and enables reflective thought. Within the PMDS the corporeal schema of 
the physiotherapists, their ability to use their own bodies to manipulate the body of 
the patient so that they can then register and differentiate the various manifestations 
of neurological pathology, is vital for identifying DBS candidates and helping to 
predict how individual patients may respond to DBS therapy. For the PMDS, 
therefore, the physiotherapists’ embodied knowledge and corporal skills are an 
important component in the process of creating and operating a DBS service.  
Merleau-Ponty’s notion of corporeal schema is intended to counter the 
Cartesian model of knowledge production. The example presented here suggests 
that cognitive deliberations are just one component in the production of clinically 
useful knowledge regarding a patient (and thus just one component of the processes 
that constitute ‘innovation’).  Indeed, it is perhaps more useful to describe such 
clinical knowledge as an emergent product. It emerges from a series of coordinated 
interactions involving various heterogeneous elements and cannot be attributed to 
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the activities of any one of these elements (such as the sceptical and reasonable 
deliberations of mind of the clinician). In Carl’s case the final GMFM score and the 
physiotherapists’ written notes, which together contain useful clinical information 
about Carl’s motor system, are an example of this. Their production required a 
careful arrangement of material objects and technical apparatuses (such as the 
adjustable couch and the guiding floor markings), the afflicted body of the patient, 
the embodied knowledge of clinicians, and the application of formal protocols (such 
as the GMFM). These ensembles produced the enactments from which more 
durable clinical information could be obtained. The resulting clinical knowledge 
about Carl’s motor system cannot be attributed to any one of the elements within 
these interactions: rather, it the consequence of all the various elements as they 
jostle, shape, constrain and enable one another.15   
  Latour (1987) has argued that the production of scientific knowledge within 
the laboratory involves a series of transformations between various states of 
physical matter, and between physical matter and textual inscriptions. He has 
termed those apparatuses that transform physical matter into the textual inscriptions 
(graphs, lines, and tables) that subsequently become the basis of scientific 
propositions as inscription devices. (1987: 68). We have seen that the assessment of 
gross motor function involves a similar series of translations between material and 
semiotic elements, the product of which is a text; a set of inscriptions and 
interpretations that together form a durable and circulate-able representation of the 
patient’s motor system. This process of inscription, however, is not conducted by a 
technological device as in Latour’s conception of the laboratory. Rather, it is the 
trained and highly configured body of the physiotherapist that enables this 
                                                 
15 In this chapter we have focused exclusively on the body work of the physiotherapists. Of course, 
other members of the PMDS team also have their particular corporal schema, or an embodied 
knowledge of how to use their bodies within clinical contexts, that reflects their own professional 
trajectories. The neurologists, for example, have no doubt acquired a perceptual skill that enables 
them to interpret the various shades of grey within an MRI image, and the speech and language 
therapist may utilize an aural sensibility that is not possessed by other member of the team. While 
various elements of embodied knowledge and some corporeal skills will be shared by all members of 
the team, it reasonable to suggest that the PMDS is characterized by multiple clinician bodies, each 
with their own acquired habits of sensing-and-acting, and each capable of engaging in particular 
forms of body work with patients.   
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translation to occur, and in this regard, it is appropriate to say that by using their 
bodies in this way, the physiotherapists are acting as an inscription device.  Indeed, this 
inscription work cannot be delegated to a non-human technological apparatus, 
because no technology is capable of distinguishing dystonia from other 
manifestations of neurological pathology.    
In the following chapter we will see how the clinical knowledge produced 
during the GMFM and muscular screen are, along with other knowledge and 
considerations, utilised during a goal setting session with Carl. The representation of 
his motor system as inscribed in the physiotherapists’ notes is used as a means of 
predicting how Carl will respond to DBS, and thus as means of informing him and 
his mother of what they can expect after the DBS system has been implanted and 
activated. Interestingly, we will see how this knowledge helps them to manage a 
challenge that results from a particular socio-political trend: the emergence of 






6 Managing the expectations of patients & families 
 
We’re dealing with people’s hopes and expectations.  They often come to us with 
very raised hopes that we are the team that can offer something new and life 
changing, and then obviously in some of our cases, we are actually breaking the 
news to them that the outcomes we expect are not what they were hoping for. It 
means that they feel a loss all over again (Physiotherapist, interview). 
 
6.1 Introduction: the challenge of managing expectations 
Families arriving at the PMDS for the first time have varying degrees of knowledge 
about deep brain stimulation. Many families have made use of the Internet to access 
information and arrive at the hospital with “reams of paper and are very 
knowledgeable about [DBS],” while other families arrive with “absolutely no 
knowledge whatsoever” (Clinical research fellow, interview). Because of the novelty 
of DBS, however, the information available to patients (and indeed health 
professionals) concerning the effectiveness of DBS as a means of managing 
dystonia is limited. Many of those families that do undertake research into DBS 
have obtained information from the popular media which has tended to focus 
almost exclusively on those clinical cases that have done very well (particularly cases 
where a wheelchair bound child has regained an ability to walk unaided) thus giving 
an over-optimistic portrayal of DBS therapy (Racine, et al. 2007). This creates a 
challenge for the team: 
There’s often misperceptions, the problem is the press reports the case studies that 
do well, so there can be perception that DBS will get my child to walk.  Because 
actually that’s what you read about in the press… We had one child who six weeks 
after his surgery, was in the press, starting to walk again. And that’s a very worrying 
thing for us… Managing the expectations - that can become very difficult.  (Clinical 
research fellow, interview). 
 
It is not uncommon, then for families to arrive at the PMDS with unrealistic 
expectations about the effectiveness of DBS in managing the symptoms of dystonia.  
No doubt this ‘false hope’ is exacerbated by the vulnerability and desperation of 
some of the severely affected patients and their families (Marks et al. 2009). 
Generally by the time families are being considered for DBS, they have already tried 
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a range of other treatment options without meaningful success, and DBS represents 
something of a last hope for improving the child’s quality of life.  
 The challenge is complicated by the lack of a comprehensive body of 
medical literature that can be used to predict how individual patients will respond to 
the therapy. A nascent body of literature does provide some indication of the 
efficacy of using DBS to manage dystonia. Reports of small clinical studies 
involving mixed cohorts of adults and children with generalized primary dystonia 
state that, on average, subjects will experience a 50% improvement in motor 
symptoms, and that one third will experience at least an 75% improvement 
(Vidailhet et al. 2005). Improvements in patients with secondary dystonia appear 
less dramatic, averaging 24%, with a great deal of variation between individual 
patients (from 0% to 71%) (McClelland et al. 2011). The PMDS team does use 
these figures to provide some guidance to families who are considering DBS: during 
a “DBS information session” the specialist nurse will present families with these 
percentages (“everyone wants to know the percentages!”) but she also emphasizes 
to families that children will fall outside these ranges. Generally, however, the 
literature is considered of minimal use in predicting the outcomes of individual 
patients and thus in guiding the expectations of specific families. As we will see in 
the following chapter there is scepticism among the team and other DBS centres 
about the specific scales used to measure clinical improvement and generate these 
official percentages (Gimeno et al. 2012; Marks et al. 2009), and most of the PMDS 
patients have secondary dystonia, thus falling within the group for which the 
improvement figures are highly variable and therefore almost meaningless.   
 This presents a major challenge for the team: how can the expectations of 
desperate families be managed when the literature provides so little guidance on 
predicting how an individual patient is likely to respond? Solving this dilemma and 
ensuring that families have realistic expectations about the benefits of DBS is 
important for several reasons. Firstly, it helps protect the reputation of the team by 
reducing the chances that they will be accused of failing to deliver an (unrealistic) 
clinical result. As Dr Martin puts it: “If you paint the most optimistic picture, you 
are setting yourself up for certain failure.” (Team meeting). Secondly, in order for 
families to make an informed decision about whether or not to proceed with the 
highly invasive procedure, it is necessary for them to comprehend the likely 
consequences of DBS therapy. In an era when facilitating patients’ autonomy and 
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enabling patients’ capacity for decision making are heralded as fundamental to 
ethical medical practice, managing the expectations of patients can be seen as an 
ethical challenge. Indeed, the ethicists Bell and colleagues (2009) have argued that 
conveying the risks and benefits to vulnerable patients in order to ensure that 
informed consent can be obtained is one the key ethical challenges associated with 
all deep brain stimulation therapies.  In this chapter we will see how the team 
attempts to manage this particular ethical challenge of managing the expectations of 
patients, and thus obtain their informed consent. The chapter will illustrate how 
members of the PMDS team, specifically the occupational therapist and one of the 
physiotherapists, use a tool known as the Canadian Occupational Performance 
Measure (COPM) to convey the potential benefits of DBS to families. This tool has 
been adopted from occupational therapy; it was designed to facilitate a patient-
centred approach to healthcare, and its introduction into paediatric neurology and 
the specialty of deep brain stimulation by the PMDS team is novel. It therefore 
represents an innovative attempt to manage one of the challenges associated with 
the introduction of new medical therapies: managing patient expectations in the 
absence of a useful body of literature. As we will see, the COPM facilitates a 
particular mode of patient decision making. Before we explore this tool and how it 
is employed by the team, it is necessary to provide some context on a socio-political 
trend within healthcare that promotes patient involvement in decision-making and 
patient autonomy in medical practice. This context will enable us to see the 
historical circumstances that have brought about the need for such tools, and it will 
also enable us to see why the consequences of implementing this tool in clinical 
practice are of interest to sociology.   
 
6.2 Decision making and patient autonomy in healthcare  
Over the last one hundred years or so there has been a transformation in the 
decision-making role of patients within medical contexts. In the early part of the 
20th century, an era dominated by what commentators often refer to as the 
‘paternalistic’ approach, it was health professionals (or more specifically, male 
doctors and surgeons) who decided what course of action was most appropriate for 
their patients (Coulter et al. 1998). This approach assumed that both the health 
professional and the patient had the same goals but that only the doctor was 
sufficiently informed to decide how to achieve these goals. In effect, the views and 
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preferences of these patients were considered largely irrelevant. Over the course of 
the century, however, new approaches to decision making have emerged 
accompanied by much-bandied notions of ‘patient choice’ and ‘patient autonomy’. 
According to this socio-political trend, the role of the health professional is to 
communicate their clinical knowledge and their professional opinion effectively to 
the patient, so that the latter can be sufficiently informed to decide.  Decision-
making is the prerogative of the patient, and the health professional is expected to 
ensure that the patient’s expectations are not unrealistic. 
 There is still considerable variation in the level of patient-involvement in 
decision-making in actual contemporary clinical practice.16 Generally, however, 
policy makers and bioethicists are endorsing those that entail a greater level of 
patient involvement. NHS policy, for example, stipulates that patients should be 
given choice of hospitals, should be encouraged to participate as ‘partners’ in 
treatment decisions, and should also be seen as users who can meaningfully 
contribute to the development of health services (NHS England commitment to shared 
decision making 2013) 
 Various arguments have been put forward to explain the movement away 
from paternalistic decision making approaches and the subsequent embracing of a 
discourse of consumer choice. For example, Annandale (2002) suggests that it is 
useful to frame the emergence of patient choice discourse as a manifestation of 
what Beck has referred to ‘reflexive modernity’, where new parameters of risk and 
uncertainty permeate everyday life. In such conditions individuals become more 
aware of the fallibility of authority and ‘established’ knowledge, and thus become 
more critical. (In medical contexts, this awareness has no doubt been facilitated by 
media coverage of various medical scandals that have indicated that the goals of the 
medical professionals did not always align with those of their patients.) 
                                                 
16 Commentators have defined three models of patient involvement in decision making in clinical 
contexts (Morgan 2008). The first, ‘professional choice’, is very much synonymous with the paternalistic 
approach of previous times, where decisions are made by solely by health professionals.  The second, 
‘shared decision making’, refers to the sharing of information between health professionals and the 
patient, and both parties then decide upon a course of decision making together.  And the third, 
‘consumer choice’, is where health professionals dispense information to autonomous patient-
consumers, who then decide on a course of action according to their own goals and values. As 
Morgan (2008) points out, all three of these approaches to decision making occur in a contemporary 
clinical practice, but seldom in a pure form. 
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Empowerment of the individual is at the heart of this reflexive modernity, and the 
language of consumerism fits in with this (Annandale 2002). Accordingly, 
individuals are encouraged to assess benefits and risks and reflexively choose a 
course of action that aligns with their own goals and values, whether they be at the 
supermarket or in a clinical context.  In a world characterized by risk and fallibility, 
the patient has been framed as an active consumer, capable of appraising and 
deciding upon the course of action that will best achieve his or her aims.  
 This has no doubt been facilitated by the emergence and increasing 
authority of the field of bioethics which has emphasised the importance of patient 
autonomy.  Bioethics as a distinct intellectual pursuit had its birth in the US during 
the 1970s. In light of a series of public medical controversies, early proponents of 
the field wanted to provide some guidance to health professionals working in 
ethically problematic situations. Philosophers (bioethicists at that time were 
predominately philosophers or theologians) attempted to systematize bioethics by 
developing a set of principles that could be applied in any such situation by health 
professionals without training in ethics or philosophy. Beauchamp and Childress’s 
Principles of Biomedical Ethics (1977) is by far the most influential product of this.  The 
four ‘principles’ outlined by Beauchamp and Childress (respect for autonomy, 
nonmaleficence, beneficence and justice) have become the standard toolkit when 
engaging with ethical issues in medicine and biomedical science in both the UK and 
US. (Wolpe 1998). Although the authors have emphasized that no one principle 
should be considered a priori more important than any others, in the process of 
being incorporated into actual health care practices the principle of autonomy has 
become the most dominant. Wolpe (1998) argues that it has become the default 
principle; the principle that is appealed to when two or more principles may come 
into conflict (such as autonomy and justice).  
 The principle of respect for autonomy stipulates that patients can decide 
upon a course of action with an understanding of what that action would entail and 
without undue controlling influences that might dictate their decision. This 
necessitates, they argue, that health professionals disclose information in a way that 
is accessible to patients while checking that patients comprehend what is being said 
to them (Beauchamp and Childress 2001). These are the elements of informed 
consent, and the informed consent process is the means by which the autonomy of 
the patient can upheld in clinical practice.  
6: Managing the expectations of patients & families 
 
 159 
 Wolpe (1998) provides several reasons for the emerging dominance of 
autonomy over other principles. First, it resonates with the atmosphere of liberal 
individualism that has been so dominant, particularly in the US, for the last fifty 
years. Patient autonomy aligns with notions of self-governance, liberty, individual 
choice and freedom, often heralded as the foundational values of the US. Secondly, 
autonomy is relatively easy to codify and implement within institutional settings via 
the process of informed consent. In contemporary clinical settings, which are 
inevitably large and bureaucratic and where patients and health professionals are 
often strangers to one another, the informed consent process has been 
institutionalised as the means of establishing some sort of trust. Wolpe argues that 
in an era where structural impediments prevent more informal bonds between 
health professionals and patients, informed consent, much like any contractual 
arrangement, aims to ensure that both parties satisfy their obligations to one 
another: health professionals will disclose the risks and benefits of a course of 
action and refrain from placing undue pressure or presenting misleading 
information, and patients will assess these risks and benefits and decide according to 
their goals and values.  The regulatory guarantor that this interaction will take place 
has become the participant information leaflet and the informed consent form 
(Wolpe 1998). By stipulating that such forms are read and signed by patients and 
health professionals prior to an intervention, institutions such as the NHS can 
demonstrate that they are respecting patient autonomy and are thus engaging in 
ethical conduct, in a way that would not be possible with the principles of, say, 
justice or beneficence.  
The movement towards patient involvement in decision making has also 
had an impact on the rights of children and young people. The United Nations 
Convention on the Rights of the Child (1989) stipulations that children and young 
people have the right to express their opinions freely, and that these opinions 
should be given due weight (according to their age and maturity) when making 
decisions that directly affect them. Additionally, the Convention also respects the 
rights and duties of caregivers to “provide direction to the child… in a manner 
consistent with the evolving capacities of the child” (UNCRC Articled 14 and 15). 
These UN stipulations have had considerable impact on government policy around 
the world - at least according to official government reports (Alderson and Morrow 
2011). In contemporary health contexts in many Western Countries (including the 
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US and UK), this balance between children’s right to express their opinions and 
caregivers’ rights to provide direction to their child is captured in an informed 
consent arrangement whereby permission is obtain from caregivers and assent is 
obtained from the child (Ross 2006).  This arrangement assumes that children under 
the ages of 16 (or 18 in some contexts) are unable to provide consent as they lack 
the capacity to make an informed, autonomous decision. Thus, overall permission is 
obtained from caregivers, and children are provided with an opportunity to either 
comply or disagree with a decision. Current NHS policy, for instance, states that 
permission for an intervention must be obtained from a caregiver for all children 
and young people under the age of 16. In some circumstances a caregiver can give 
also give consent for a treatment if the child has refused, but this would likely be 
decided “in the courts” (NHS Choices 2012). 
 The field of bioethics and its principles approach to ethics, therefore, has 
facilitated the socio-political trend towards greater patient involvement in medical 
decision-making. The emergence of this ‘patient choice’ and ‘patient autonomy’ 
approach has placed new pressures on health professionals. They now have a 
responsibility to ensure that information, particularly the risks and benefits of a 
course of action, is disclosed to patients in accessible language (Morgan 2008). They 
have a responsibility to ensure, then, the expectations of patients regarding the 
effects of a course of treatment are realistic; a task that is particularly tricky when 
the treatment being offered is relatively new. 
 
6.3 Criticisms of the dominance of autonomy 
The framing of patients as ‘consumers,’ or rational, autonomous actors has also 
resulted in challenges. Indeed principlism approach to ethics (and particularly the 
emerging dominance of ‘autonomy’) have received considerable criticism from the 
social sciences. Generally such criticisms point out that rather than simply enabling 
patients to act, principlism imposes a set of decontextualised norms upon patients. 
Principlism (particularly the principle of autonomy) and the corresponding 
emergence of a discourse of ‘consumer choice’ within medicine assume that 
individuals are, and should act as, independent rational agents regardless of their 
context. This ‘atomistic’ conception ignores the fact that individuals are socially 
embedded. As Fox and Swazey stated some time ago: 
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In the prevailing ethos… the value of individualism is defined in such a way and 
emphasized to such a degree, that is virtually severed from social and religious 
values concerning relationships between individuals; their responsibilities, 
commitments, and emotional bonds to one another; the significance of the groups 
of the social communities to which they belong; and the deep inward as well as 
outward influence that these have on the individual and his or her sense of moral.  
(1984: 358) 
 
As various clinical institutions are configured to respect the autonomy of 
these independent and rational agents, patients find that they have little choice but 
to engage in this type of decision making. This can cause additional distress for 
patients. Rothman (1986), for instance, interviewed mothers who were presented 
with the decision to undergo amniocentesis after speaking with a genetic counsellor. 
The focus on individual ‘autonomous’ decision making within this context had the 
effect of isolating women at a time when building connections with a support 
system and her child was very important (Rothman 1986).  Similarly Morrison, who 
also studied how autonomy is enacted within the context of genetic counselling, 
noted that the strategies employed by genetic counsellors tended to place the 
burden of decision making on the individual mother, while the mother’s wider 
social relationships with others, relationships that could have provided support and 
guidance, where largely elided (Morrison, 2008).   
In a similar vein, Mol has criticized the ‘logic of choice’ that underlies the 
patient-consumer discourse, noting that it fails to account for the absolute 
dependency of the patient and their body (particularly the afflicted body) on a 
plethora of other social and material entities (personal relations, medicines, etc). The 
patient is bound by such dependency, and cannot simply choose with the freedom 
of a consumer in a supermarket (Mol, 2008).  
The notion that children and young people are unable to provide consent 
has been criticised by some commentators, most notably Alderson and Morrow 
(2011). Alderson and Morrow’s make two key points. First, Alderson and Morrow 
argue that  even young children are capable of a sufficient level understanding that 
permits them to make ‘informed decisions’, as long as information is provided to 
them in an accessible form and that they have guidance and support from parents 
or caregivers. Second, relying on support and guidance from family members should 
not be equated with an inability to provide consent. Alderson and Morrow highlight 
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the myth of the autonomous, independent decision maker that seems to underlie 
the notion of informed consent.  Adults, they argue, often rely on the guidance and 
direction from others, particularly family members, when making difficult decisions 
about treatment, and this does not mean that they are any less capable of giving 
consent.  
In short, social scientists have criticized the emerging dominance of 
autonomy and consumer choice as an imposition of liberal individualism within the 
realm of health care. Such criticisms aim to illustrate that there is no such thing as 
an objective, value-free panacea to ethical dilemmas in medicine (c.f. Corrigan 
2003). Accordingly, we should remain open to other approaches to decision making 
and other strategies for managing difficult ethical challenges in clinical practice, 
particularly those that are attentive to, and foster, the socially embedded nature of 
patients.     
 This is where empirical social science can provide some useful insights into 
the debate. In the contemporary clinical contexts within the UK and US, health 
professionals are expected to disclose particular information and ensure that 
patients have realistic expectations about the effects of the treatment, and patients 
are expected to become involved in decisions about their treatment.  It is important 
to explore how these responsibilities are enacted (or not enacted) within various 
clinical settings for two reasons. Firstly, it can enable us to see whether the emerging 
dominance of the principle of autonomy does, inevitably, lead to the imposition of a 
particular mode of patient involvement in decision-making within actual clinical 
practice. Are patients provided with little choice but to act as rational, autonomous 
agents, abstracted from their social context, as Rothman (1986) and Morrison 
(2008) illustrated?  And has the informed consent process really replaced more 
informal bonds between health professionals and patients, as suggested by Wolpe 
(1998)? And secondly, empirical research can draw attention to the emergence of 
novel ways of managing these dilemmas. Clinical practice is inevitably messy and 
often unpredictable (particularly in new areas of medicine such as deep brain 
stimulation), and health professionals and patients may have to engage in ad-hoc 
solutions to immediate challenges. Such circumstances are a source of innovation.  
I have undertaken such an empirical investigation and in this chapter we will 
see how the PMDS team has created a novel way of disclosing information to 
patients regarding the likely effects of deep brain stimulation therapy. The Canadian 
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Occupational Performance Measure (COPM) is used as a means of managing the 
expectations of families so that they can make an ‘informed’ decision about whether 
or not to proceed.  Interestingly, as we will see, as PMDS team members and 
families use the COPM, the socially-embedded nature of the patient is scrutinized 
and brought to the forefront:  The potential effects of DBS therapy are discussed in 
terms of a patient’s dependency on a wider array of social and material entities, and 
it is this dependency that is used as the basis of deciding wither or not to go ahead 
with the therapy. Ultimately, patients and their families are still expected to appraise 
the risks and benefits and decide whether or not to proceed based on their own 
goals and values, but this involves enacting, rather than eliding, the patient’s social 
embedded-ness. As we will see, however, for the COPM to work as intended, team 
members must engage in a great deal of ad-hoc work. 
 
6.4 Informing families on the effects of DBS 
Patients who have been identified as potential candidates for deep brain stimulation 
will spend a considerable amount of time with the PMDS service. It is not unusual 
for candidates to undergo the equivalent of three days of pre-surgical assessments, 
thus providing families and team members with an opportunity to become familiar 
with one another. According to members of the team, the process of informing 
families about the effects of DBS, and thus re-adjusting the unrealistic initial 
expectations of families, takes place throughout this pre-surgical assessment period.  
There are, however, specific sessions dedicated to the management of expectations 
and the disclosure of information to families.   
 The first of these, the ‘DBS information session’, is not unlike standard 
information sessions provided to patients for many medical interventions, and I will 
only briefly outline it here. The DBS information session is conducted by the 
specialist nurse and includes the patient and their supporting family members. This 
usually takes place near the beginning of a family’s time with the PMDS, shortly 
after the patient has been designated as a candidate, and it is not unusual for the 
same family to undergo the information session more than once as there is quite a 
bit of information to convey. During the session the nurse will communicate a body 
of information that has been agreed upon by PMDS team members. This includes 
detail of the DBS device, the surgical procedure, how to take care of surgical 
wounds, how to recharge the device, how the scars on the scalp and the torso will 
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appear, and how quickly the patient’s hair will grow back after the procedure (“lots 
of kids always ask about their hair” Nurse, interview). The session is also used to 
explain and illustrate the efficacy of DBS (as a percentage defined by the literature), 
and the rates of adverse reactions, including cerebral haemorrhage and infection, 
and what each adverse reaction would actually entail for the patient (in the case of 
infection, for example, the DBS system will have to be removed). A PowerPoint 
presentation with some text and plenty of pictures (many of previous patients who 
have undergone DBS) is used to illustrate these various details, and families are 
given an opportunity to play around with dummy DBS equipment.  
 The information session is used for illustrating to families what the surgical 
procedure and post-surgical recovery entails, and for demonstrating the rates and 
consequences of adverse effects, but it is not used to explain how DBS will affect 
the specific motor symptoms of individual patients. Families, then, will leave the 
information session with little knowledge about how DBS therapy will specifically 
benefit their particular child. Indeed, despite the nurse emphasising that DBS is not 
a cure, families may still hold unrealistic expectations about how DBS can help their 
child.  The team attempts to deal with this particular challenge in the second type of 
session dedicated to managing patient expectations: the goal setting session. The 
goal setting session is novel; it is the team’s unique response to the challenge of 
gaining informed consent for a new and uncertain medical therapy, and for this 
reason, it forms the basis for the rest of this chapter. 
 
6.4.1 The goal setting session 
The goal setting session is a semi-structured interview involving the patient, their 
supporting family members, and two or three members of the PMDS team (usually 
the occupational therapist and the physiotherapist). The aim of the session is to 
communicate to families how DBS is likely to benefit the patient and to 
quantitatively measure a family’s perceptions of the patient’s abilities. Usually, the 
session is held in one of the larger consultation rooms that are also used to carry out 
some of the pre-surgical assessments and which have sufficient space for the people 
involved. Generally the goal setting session takes around an hour.  
 The goal setting session takes place soon after the patient has undergone the 
required pre-surgical assessments (which include the GMFM muscular-skeletal 
screen we explored in the previous chapter), and usually several months before the 
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scheduled surgery to have the DBS system implanted. As we will see this timing is 
important as it enables team members to form (during the pre-surgical assessments) 
their own expectations about how DBS will benefit a particular patient. The session 
is structured around the use of the COPM, a tool that has been adopted from 
occupational therapy. 
 
The Canadian Occupational Performance Measure (COPM) 
The COPM is a standardized, semi-structured interview that was developed by a 
team of Canadian occupational therapists led by Mary Law in the 1980s. Originally 
it was designed as a tool for therapists to measure and quantify changes in a 
patient’s functional abilities over time, such as before and after a therapeutic 
intervention. During the interview patients and their families are asked to identify at 
least five key tasks of daily living (such as washing the dishes, brushing teeth) that 
the patient would like to improve. For each task they are then asked to rate, on a 
scale from one to ten, the importance of the task to them, their ability to perform 
that task, and their satisfaction with their ability. From these set of numbers an 
overall average is calculated. In order to help maintain consistency (and ensure that 
scores can be compared), users of the COPM are provided with a manual 
containing a set of instructions and a standardized score sheet. 
The COPM, then, measures the patient’s self-perception of their abilities. 
According to the authors the logic behind this focus on self-perception is that the 
clinically important aspects of an affliction are how it impacts on the actual, day-to-
day life of the patient. It is this impact that should be measured (and ideally 
reduced), and not those aspects deemed important by health professionals who may 
have very little understanding of the experience of living with the affliction (Law et 
al. 2005). We can see here how a particular normative orientation has been 
incorporated into the tool; an orientation that attaches a heavy weighting to broader 
“functionings” of a patient. Accordingly, both ‘disease’ and the treatment of disease 
should be understood and assessed according to their impact on those aspects of a 
patient’s life that the patient feels are important. The tool embodies what 
occupational therapists refer to as the patient-centred approach of their discipline. 
Use of the tool in occupational therapy is widespread: the authors state that 
it is now used in over 35 countries (Law et al 2005). The PMDS, however, is the 
only DBS service that utilizes the tool as part of their routine clinical practice. It was 
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introduced around 18 months after the establishment of the team largely due to the 
initiative of the OT: it was, she states “embedded in my training” (OT, interview) 
and she used it in the community prior to joining the PMDS. While the team uses 
the COPM as a means of measuring changes in patients’ abilities (along with several 
other outcome measures), the primary reason for introducing the tool was to help 
set realistic goals for patients. The introduction of the tool was a pragmatic response 
to a specific clinical challenge 
In the process of being adopted into the PMDS it has undergone a degree 
of modification. As Berg argues in relation to clinical protocols, its introduction has 
altered local clinical practices, but the tool itself has also been altered by local 
factors: it is both transformative and transformed (Berg 1998). First, within the 
PMDS patients and families are asked to identify the five or more daily living tasks 
that are important to them prior to the goal setting session. Indeed, they are usually 
asked to identify these tasks very early on during their time with the PMDS, so that 
they can then attempt to perform these tasks as part of their pre-surgical 
assessments. And second, the COPM in its original form was intended to involve 
one therapist and one patient. In the team’s version, the patient and their supporting 
family members will be involved (usually both parents), and two or three team 
members will conduct the session together. Usually this includes the occupational 
therapist (OT) and physiotherapists (PTs), who by the time of the session have an 
idea of how the individual patient may actually respond to DBS, and sometimes the 
psychologist, particularly if the patient has experienced depression. In this way the 
COPM has been modified to suit the aims and the environment of PMDS. 
As we will see below, the COPM provides a script that coordinates the 
activities of the individuals involved. In order to ensure that the COPM functions as 
intended, team members must engage in ad-hoc work in order to enrol patients and 
families in the script. This may involve using props, and often involves the use of 
humour.  Importantly, the COPM script encodes a set of power relations and designates 
positions of authority to those involved in the goal setting session. By ascribing a 
spokesperson’s role to patients and families, it encourages their active involvement - 
although this is highly configured by team members. Consequently, I will argue, the 
‘patient-centred’ logic of the COPM prompts a particular mode of communication 
that can be seen as ethically favourable, and it enacts the patient as a socially-embedded 
entity. 




The COPM as a script 
Despite its flexibility, particular aspects of the COPM must remain constant across 
contexts if it is to function as intended. While the COPM is partially transformed in 
the process of being adapted, it also introduces a set of fixed roles into the PMDS 
working environment. Thus, like all protocols, it is transformative as well as being 
transformed (Berg, 1998). Protocols embody a script that delegates roles to various 
heterogeneous elements (human and non-human), prescribing a particular 
arrangement of elements and particular actions in space and time. Berg states that 
protocols provide staff members with a set of mandated instructions to which they 
can refer, and thus orientate themselves and act accordingly; staff delegate the role 
of coordination to the protocol, and in turn, the protocol delegates particular roles 
to staff members (Berg, 1998). This enables staff to carry out what can be highly 
complex and variable tasks with some consistency. Indeed for the PMDS the 
COPM provides a script that enables them to carry out the highly complex and 
potentially variable task of managing patient expectations. 
 Each goal setting session follows the same semi-structured interview format. 
First, in the PMDS’ rendition of the COPM, the occupational therapist and the 
physiotherapist are designated as the ‘leaders’ of the goal setting session. It is their 
role to ensure that the session follows the COPM format and that the patient and 
family members adhere to their prescribed roles. At the first interview that takes 
place with family members prior to the patient’s pre-surgical assessments, this role 
entails prompting patients and family members to identify the five daily living tasks 
that they would like to improve. As the COPM manual states: 
It is important that clients identify occupations that they want to do in daily life… 
The therapist should encourage clients to think about a typical day and describe the 
occupations that they typically do…” (Law et al. 2005: 13)  
 
This involves guiding patients through a portion of the COPM score sheet which 
lists a number of possible areas of concern: personal care; functional mobility; 
community management; household management (cleaning and cooking); 
play/school; recreations; and socialization (Law et al. 2005). These ‘areas of 
concern’ are used by the session leaders to prompt the family to think about the 
impact of the patient’s motor disorder on their day-to-day life, and for each area, 
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families and patients are asked to identify specific tasks they would like the patient 
to improve (such as dressing, hygiene, visiting friends, preparing food). The family 
is then asked to identify from these which five are the most important. It is these 
five tasks that the patient will attempt to perform as part of the pre-surgical 
assessments, and it is these five tasks that the team will later use as the basis for 
managing expectations during the goal setting session. 17   
  
Figure 6.1: Floor plan of seating arrangement during goal setting session 
 
 
As ‘leaders’ during the goal setting session, the two therapists have several tasks. If 
adequately performed, the therapists will guide the patient and their family towards 
the creation of five ‘realistic’ goals for DBS, each corresponding to one of the five 
tasks that family has identified as problematic. To illustrate how this occurs we will 
again use an interaction with Carl as an example.  The interaction involves Carl, his 
                                                 
17 It is not unusual for more than five tasks to be chosen. This may occur if patients identify different 
priorities to those of their parents. Rather than have to choose between then, both sets may be 
chosen.  Differences between patient and family members goals are discussed further on. 
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mother (Mm), the occupational therapist (OT), physiotherapist (PT) and the 
psychologist (Psy.).  
 The first role of the leaders is to arrange the meeting space so that it is 
informal and not intimidating in order facilitate honest and open communication (as 
recommended by the COPM manual). Generally this involves arranging the seats so 
that all those involved are sitting in a circle facing one another, and so that one of 
the leaders can easily access a computer. The floor plan in figure 6.1 (page 168) 
shows an example of such a seating arrangement. 
Second, the therapists begin the session by restating the daily living tasks 
that had been identified by the patient and their family prior to the pre-surgical 
assessments. (These are accessed via the computer – the details of the earlier 
interview are kept electronically). This is followed by prompting the patient and/or 
their supporting family members to clarify the specific problem they are having with 
the task: 
 
OT: Now, when I met you last time, we talked about the things that you wanted 
to improve. You identified a number of things... These were handwriting, 
shaving, self-feeding, drinking, and using public transport. 
PT: So with your handwriting, what aspects are you not happy with? Speed? 
accuracy? 
Carl:  Both… I get hand cramps. I would like to be able to handwrite on a clear 
page without making a mark all over the page.   
PT: Okay, what about drinking? 
OT:  I’ve noticed that when you drink from a bottle, you bring it to your mouth 
and tip your whole head back. Is that to make sure your arm doesn’t flick it 
away and spill it? 
Carl: Yeah. 
 
For each one of the five tasks the patient and their family members are encouraged 
to be as specific as possible; to specifically and explicitly outline what it is that the 
patient is having problems with. (The COPM manual states, “it is essential that 
therapists use their skills in interviewing, probing for full responses” (Law et al. 
2005)). As Carl and his mother are prompted to add more and more detail, each 
particular problem becomes more intelligible: each is actively delineated. In effect, 
the resulting ‘five tasks’ are the product of an interaction between the therapists, the 
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patient, their supporting family members, as scripted by the COPM. This 
interaction may also involve the identification and delineation of a new task. Here is 
another example from Carl’s goal setting session: 
 
OT: And another thing is you wanted to use public transport. Is this a problem 
because are you worried that you will attract attention or is it because you 
cannot physically manage?  
Mm: Last time we went out in public, a man laughed at him. The man made 
such a big deal of pointing Carl out. He hasn’t really gone out since. And if 
he gets one of his tics, it can be very difficult on the bus. They throw him 
off his feet. 
OT: Okay, we should keep the two things: confidence in public and being able 
to use public transport.    
  
Here we can see that as a result of the clarification process, one of the difficulties 
identified by Carl and his mother (confidence in public spaces) has been re-
delineated as two (confidence in public places, and physically being able to use 
public transport).   
 While the five tasks are being clarified and rendered intelligible, the role of 
the therapists is to offer their predictions on how the patient’s ability to carry out 
these tasks will be affected by DBS. These predictions are, of course, based on their 
observations from the pre-surgical assessments and their experience of previous 
DBS outcomes within the PMDS. If dystonia (“involuntary movement”) is deemed 
to be the cause of the problem, then the therapists will tentatively predict that there 
will be some improvement: 
 
KT: Carl, tell me about shaving. Why does mum do it for you? 
Carl: It pulls on my hair, it is really sore. 
OT: His arm pulls away and the hair gets caught in the shaver. It is definitely 
the involuntary movements that are making it difficult to shave… Carl – if 
DBS does reduce your voluntary movements, you will find it easier to 
shave.   
 
And if a difficulty is perceived by the therapists to be caused by muscle weakness, 
contractures or spasticity, then they will predict that no improvement will occur. 
Additionally, the therapists may also draw on their knowledge of previous PMDS 
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patients. Here is the occupational therapist’s prediction about how DBS will affect 
Carl’s handwriting: 
 
OT: I think your computer is your best option. DBS may help a bit, but you 
won’t be able to rely on your handwriting. We have noticed some very 
minor improvements in patients, but that is after four or five years. 
 
Once the patient and their family have been prompted to clarify the tasks they 
would like to improve and the therapists have offered their prediction, the COPM 
‘script’ requires that therapists guide the family towards a set of goals for each task. 
This involves negotiation, and it is during these negotiations that particular goals 
will be delineated as ‘realistic’ and others ‘unrealistic’.  Here is an example of the 
physiotherapist negotiating with Carl. Note that she draws on some of the clinical 
information that she and the other physiotherapist produced during the GMFM and 
musculoskeletal screen that we explored in the previous chapter: 
 
PT:  About this problem with stability on public transport. We noticed during 
your [GMFM and muscular-skeletal screen] that you have muscle weakness 
around your pelvis that DBS won’t improve. You could probably improve 
it with a lot of hard work and exercise in the gym, but we shouldn’t set a 
goal that you are not prepared to put in the effort for in the first place. 
Carl:  I’m not motivated, but that is because it takes me so much energy to do 
things! 
PT: Can we agree that we don’t put this as an initial goal? You could tackle it 
when you have some more motivation, but I don’t think we should put it 
down as a goal for DBS. We should aim for other goals.  
 
As result of this negotiation, one potential goal pertaining to the patient’s wish to 
use public transport has been discarded as unobtainable with DBS, and thus 
‘unrealistic’. 
 Below is another example of negotiation, this time involving psychologist 
and Carl. (Team members felt that Carl might be depressed, and thus requested that 
the psychologist participate in the session). 
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Psy: Carl, about your wish to have more confidence in public. We need to 
clarify: What would it take to improve your confidence?  Would it be not 
falling at all? Or falling less?   
Carl:  Just less falls and less jerky movements. 
Psy:  So, would just a little bit of improvement, then, help with your confidence, 
do you think? 
Carl:  Yes. 
Psy:  Because some people might not be happy if they still had some visible 
signs of the movement disorder. It is good that you think that a little 
improvement will help. 
 
Here the psychologist has implied that it is unrealistic to expect DBS to remove all 
visible signs of the movement disorder, and has suggested to Carl that “a little 
improvement” is a more suitable goal.  
The product of these types of negotiations, then, is a set of at least five 
goals, and what exactly counts as ‘realistic’ or ‘unrealistic’ are delineated in the 
process. The resulting five goals, like the ‘five tasks’ that form the basis of the goals, 
are a product of the COPM-scripted interactions between participants. If all goes to 
plan and all participants adhere to the script, the resulting five ‘realistic’ goals for 
DBS will reflect the family’s wishes for meaningful improvement in the patient’s 
day-to-day functioning, and they will reflect the therapists’ educated (but tentative) 
predictions. In short, the five goals will be important to families, and according to 
the therapists they will be achievable with DBS.   
 It is in this way that the COPM is used to manage the expectations of 
patients. The COPM instructs therapists to prompt families to be explicit about 
their difficulties and hopes, and that therapists then communicate the effects of 
DBS in terms that are comprehensible and meaningful to families.  Indeed the 
potential benefits of DBS are explained in terms of the patient’s day-to-day 
activities: as an improved ability to shave with less difficulty, or hold a glass, or 
prepare a bowl of cereal. The effects of DBS are conveyed in specific terms using 
examples familiar to the family. According to team members, this is the advantage 
of the COPM-scripted goal setting session:   
This is the idea of doing these setting sessions, where you’re really critically defining 
a target, you know, there’s no  - we’re not nebulously talking about things getting 
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better, we’re talking about you being able to dress that right arm better. (Clinical 
research fellow, interview).   
 
A ‘well-informed’ family, then, is the ideal product of an interaction that has been 
carefully coordinated according to the COPM.   
 
Quantification 
As discussed above, in addition to managing the expectations of patients, the PMDS 
team also uses the COPM as an outcome measure (as originally intended by its 
authors). This involves a process of quantification, where the family’s perceptions 
of the patient’s abilities are converted into a set of numbers. If the COPM is carried 
out again, perhaps after a DBS system has been implanted, these numbers provide 
an ‘objective’ point of comparison and thus a means of measuring the effect of 
DBS.   
 Once the realistic goals have been negotiated, families are asked by the 
therapists (who are guided by the COPM manual) to provide three scores for each 
of the five daily living tasks which have become the basis of goal setting. Firstly, for 
each task, the patient and their supporting family members are asked to identify 
how important it is to them, on a scale from zero (not important) to ten (very 
important).  Second, they are asked to rate their performance of that task; how good 
they perceive the patient to be at undertaking it. And third, they are asked to rate 
how satisfied they are with their performance. The COPM manual recommends that 
therapists spend time with patients to ensure they understand the rating system, 
“using concrete examples such as the judging of figure skating” if necessary (Law et 
al. 2005: 18).  Consequently three numbers are produced for each task. Here is an 
example of this quantification from Carl’s goal setting session:  
 
PT:  Okay. Let’s go on and score these [daily living] tasks… So firstly, 
confidence to go out in public places. On a scale from zero to ten, how 
important is that to you, ten being the most important? 
Carl: Eight.  
PT:  And how good are you at this? 
C: Zero. 
PT: And how satisfied are you with that? 
C: Two. 




During the interaction the therapist notes each number on the (standardized) 
COPM score sheet. Once all tasks have been rated an overall average is calculated 
for performance and satisfaction. It is these two numbers that will provide a point 
of comparison when the COPM is repeated at a later date.   
 Just as the process of goal setting involved negotiation and guidance from 
the therapists, so too does the process of quantification. Part of the therapist’s role 
(as instructed by the COPM) is to interrogate patients on the numbers they have 
chosen, particularly if the rating appears to conflict with earlier discussions.18  Below 
is an example of such a negotiation from Carl’s goal setting session. Mum has been 
asked to provide ratings for Carl’s ability to drink: 
 
OT: Okay, now it’s Mum’s turn… Drinking. [Importance]? 
Mm: Nine. 
OT:  Performance? 
Mm: Eight. 
OT: Really? You hold his cup for him!  It is really hard to improve from an 
eight! 
Mm: Oh, okay. Well, I was thinking if him using a bottle. But, I suppose, a two.  
 
Quantification, then, is the result of local negotiations between therapists, patients 
and family members: Therapists prompt and guide patients and their families 
toward a set of numbers that are perceived to be appropriate by both parties.  As we 
will now see, this, and the process of negotiating realistic goals, often requires a 
great deal of work from the therapists. 
 
Enrolling patients and family members in the COPM script 
Ensuring that the goal setting session function as both a means to manage 
expectations and as an outcome measure requires that all participants adhere to their 
COPM-scripted roles.  As ‘leaders’ of the session the therapists are responsible for 
ensuring that patients and family members adhere to their particular roles as 
                                                 
18 The COPM manual instructs: “It is suggested that you question if they clients have understood the 
rating scale… further discussion may serve to clarify whether these are truly goals they wish to 
pursue” (Law et al. 2005: 21). 
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prescribed by the COPM. The process of prompting and negotiating with patients is 
part of this ‘enrolling’ process, as is the informal seating arrangement (which 
encourages families to communicate honestly). Generally, however, the task of 
applying the standard COPM protocol to what is often a highly variable group of 
people is a challenging task 
 The COPM protocol permits some forms of variation, so not all variation is 
necessarily problematic. There is large variation in the age of PMDS patients, for 
example, and this can influence the types of goals they hope to achieve with DBS:  
 
[Young children] might be less valuing at that particular age of getting dressed, 
because it doesn’t matter so much that at six, ‘My mum is still dressing me.’  But at 
sixteen, the dressing may take a different priority.  (Physiotherapist, interview).  
 
And as we will see further on it is not unusual for patients to have different 
goals from their supporting family members. Importantly, however the COPM 
allows for this type of variation. It was designed with the belief that different 
patients would have different goals and areas of importance, and that each patient 
should be entitled to identify those goals that were important to them. For the 
therapists, variation among patients and between patients and their families 
regarding the areas of their life that they would like to improve does not create a 
major challenge (We will see further on how the team deals with situations where 
patients and their supporting family members have different goals). 
 Other differences do threaten to derail the COPM session.  Different levels 
of competency between families, for example, present a challenge.   
And then there are just different styles of communicating and different levels of 
understanding [Sometimes] you’re kind of dealing with expert parents. And then 
you have the opposite extreme of somebody that doesn’t understand their child’s 
functional difficulties at any level and therefore can’t be realistic about them either.  
(Phsyiotherapist, interview) 
 
Team members state that cultural beliefs, particularly those around the duties of 
mothers, can present a challenge. In the following interview extract the 
physiotherapist is providing an example where a mother’s sense of duty influences 
her responses during the quantification process.  




JG: Have you noticed any cultural differences in how families rate their child’s 
abilities? 
PT: Very much so. I can think of a one girl where… so the performance scores 
[provided by her mother] are really appropriately scored for – it’s  a 
nightmare to dress her, it’s a nightmare to transfer her, she’s in pain all of 
the time, she doesn’t sleep. All of these things. But satisfaction scores were 
high because [the mother felt] ‘she’s my daughter, and that’s what my role 
is, it’s to care for her and I will never be dissatisfied about doing so.’ 
(Physiotherapist, interview) 
 
Another problem is that, due to the severity of their affliction, some patients have 
great difficulty communicating. This can make the task of identifying their 
perspectives and goals challenging. Many patients will have access to some sort of 
electronic communication aid but those who lack the sufficient dexterity to operate 
such a device may rely on bodily gestures to communicate. The potential for 
families and patients to become upset can also threaten ability of the goal setting 
session to produce realistic goals. The requirement for direct and honest 
communication means that families may have to reflect on terribly upsetting issues 
or consider a bleak, challenge-ridden future.  
 Like all human actors, then, patients and their family members are 
potentially ‘unruly’ and their compliance with the COPM script cannot be 
guaranteed. During the course of goal setting sessions, therapists must engage in a 
great deal of ad-hoc work in order to encourage patients and family members to 
‘follow the script’. In some cases this may involve the use of objects or props. For 
example, team members have devised a vision board that can be used to 
communicate with patients who are unable to access an electronic aid. Depending 
on the age of the patient, the vision board will have a series of numbers, the words 
‘yes’ and ‘no’, happy and sad faces.  
So yes we have a vision board, where we put our numbers from one to ten for the 
importance of a certain goal. Or we have ‘yes’ and ‘no’, smiley face and sad face, in 
terms of the goals… Depends on how able they are. We have had cases when they 
just look at the yes and no answer… we have children who can easily move the 
upper limb and point. (Therapy assistant, interview) 
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Such tools enable the team to explore, at least partially, the patient’s perspectives, as 
prescribed by the COPM. The therapists will also use humour to guide patients and 
families and prevent them from straying from the script. (Indeed, several team 
members felt that being able to laugh with each other and with families was a vital 
skill of the PMDS). Humour may be used throughout a session to help keep the 
situation feeling informal and quell tensions that could potentially disrupt the 
session. The following extract from Carl’s session is an example of this. Toward the 
end of the session, Carl is visibly tired and his mother is beginning to answer on his 
behalf. In order to get Carl to provide a rating without being influenced by this 
mother, she receives the following instruction: 
 
OT: Mum! Don’t influence him!  Hide your face and cover your ears, we need 
to hear from Carl! 
 
The instruction was given at high volume but with obvious jest: the OT was smiling 
as she said it, and Carl along with the physiotherapist and psychologist responded 
with a giggle. The instruction had the intended effect: Mum, also chuckling, turned 
her chair so that she was not facing Carl and covered her ears with her hands, 
enabling Carl to respond.   
 These are examples, then, of the techniques that the therapists use in order 
to encourage families and patients to follow the COPM script. It is this type of 
work that is required to ensure that diverse and variable patients and families will act 
in a sufficiently uniform and stable manner so the goal setting session will generate 
the desired outcomes. It is, as Berg states, part of the work necessary to transform 
heterogeneous elements into the predictable and disciplined entities required for a 
protocol to work as it is intended (Berg 1998). As the example of humour 
demonstrates, much of this work requires a tacit social sensibility; an ability to 
appeal to the emotive capacity of individual patients and family members in order to 
enrol them in the script.   
 Such techniques do not always work and inevitably some goal setting 
sessions will fail.  Below the OT recounts a case where the parents were too upset 
to proceed. Their child’s dystonia was one symptom of a particularly nasty 
progressive metabolic condition, and the future outlook was grim.  
 
6: Managing the expectations of patients & families 
 
 178 
We were just talking to them, you know, the psychologist and I. Because they knew 
what was going to happen [to their child]… [we] made the parents cry. They said ‘I 
don’t want to think about it.  I know what’s going to happen, I just can’t get my 
head around it’ (Occupational therapist, interview). 
 
Encoding Power 
Like all protocols the COPM encodes particular power relations. As elements are 
arranged and coordinated according to a script, some are accorded with more 
authority than others. Specifically, scripts and protocols assign spokespersonship and 
decision making roles to particular elements within the local context.  
Spokespersons (or ‘spokes-things’) are those elements that are designated with the 
authority to ‘speak on behalf of’ or delineate and define some entity or state of 
affairs (Latour 2005: 31), and elements designated as ‘decision makers’ are those that 
are granted the capacity to direct the course of events during the implementation of 
the protocol. Berg states that these roles are designated to those elements that 
exhibit the “most predictable or unequivocal behaviour”, thus enabling the protocol 
to function as intended by its authors (Berg 1998: 240). Berg adds that with clinical 
protocols, which seek to reduce ‘capricious variation in clinical decision making’, 
such authority is often granted to laboratory tests and machines.19  Similarly, in an 
attempt to tame or silence potential sources of contingency, such protocols tend to 
provide little space for a patient’s voice.  
 The power relations encoded within the COPM reflect the ‘patient-centred’ 
philosophy of its original authors.  For Law and her colleagues, it is the impact of an 
affliction on patients’ daily living that is clinically relevant, and the COPM has 
distributed decision-making and spokespersonship roles accordingly. Clearly, the 
COPM endows the therapists with considerable authority, and in this respect it 
reifies a pre-existing hierarchy between the clinician or health professional and the 
patient. The therapists, as we have seen, are instructed to guide and direct patients 
and their family members throughout the interaction, prompting them to offer the 
type of responses that are mandated by the COPM script.  Indeed, during the goal 
setting and quantification processes it is the therapists who are endowed with a 
                                                 
19 The results of a machine-derived white blood cell count, for example, will determine a patient’s 
course of treatment. This is rather than, say, the clinical judgment of the clinician or the viewpoint of 
the patient. 
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decision-making capacity during the interaction: as we saw in the example of Carl’s 
goal setting session, if they perceive the responses to be imprecise, insincere or 
unrealistic, then they can decide to engage in further prompting and negotiation.  
 In the process of being instructed, guided and prompted, however, patients 
and their family members are being called-upon to act as spokespersons. They are 
designated to speak ‘with authority’ on the impact of the movement disorder and to 
delineate which specific aspects of this impact are important and thus should be 
address with an intervention such as DBS. As we saw with Carl’s example, he and 
his mother were encouraged to delineate what they felt were the more pressing 
effects of the dystonia: his confidence in public; his difficulty with shaving and with 
drinking, for instance. The COPM, then, provides space for the voice of families 
and patients; indeed, it requires their active input to function as a patient-centred 
outcome measure. This is not to say that patients and families can say as they please: 
they are constantly directed towards the particular modes of expression required for 
the COPM to function (a good example of this being the expression of ‘satisfaction’ 
with a numerical value during the quantification process). The COPM script then, 
configures a particular a ‘patient voice’, or a particular mode of expression. 
 In PMDS goal setting sessions the therapists will attempt to ensure that 
both the patient and their supporting family members are accorded this 
spokesperson role. It is not uncommon for a patient and their supporting family 
members to have different goals and expectations. For younger patients, for 
example, these revolve around being able to interact with friends, whilst parents are 
often more concerned about long-term care issues:  
The family might have a lot of care type issues and then the kid will be like, ‘Well I 
don’t care about that, I want to access my computer, I want to be able to play with 
my friends” And I think we need to be able to capture that, because the goals are 
different and that’s fine.  We might be able to achieve both the goals.  
(Occupational therapist, interview) 
 
Provided both the patient and family members are willing to negotiate a set of 
‘realistic’ goals, such differences are not considered problematic by the therapists. 
Indeed, in order to engage the patient as much as possible (as stipulated by the 
COPM) it is common for the therapists to negotiate a set of goals with a patient and 
then a separate set of goals with supporting family members. In order to encourage 
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patients to answer honestly and ensure they are not ‘spoken for’ by their family, part 
of the goal setting session may be carried out with the patient alone.  More often, 
though, this will simply involve instructing family members to wait their turn or 
‘hide their faces’ during the interaction (as we saw with Carl and his mother).   
 The therapists, then, will attempt to manage the interaction so that patients, 
as well as their family members are accorded this spokesperson role. In some cases, 
however, the severity of the child’s affliction may prevent this and their family 
members will speak on their behalf (although some attempt will be made to include 
the child): 
If we’re unable to have a whole sentence from the child or get an idea what they 
will want to achieve, then the parents set the goals and we have a yes/no 
conversation with the child. (Therapy assistant, interview).  
 
Thus, like all protocols, the COPM encodes a set of power relations and attributes 
authority to particular elements. By delegating decision-making capacity to the 
therapists it reifies pre-established hierarchy, but by designating patients and family 
members as spokespersons it also encourages active patient and family involvement 
in the goal setting interaction. Patients and family members are provided with a 
space for expression, albeit a highly configured space shaped by the therapists in 
adherence with the COPM. 
 
Enacting a socially-embedded patient 
The COPM script provides no space for MRI images, CAT scans, references to 
defective basal ganglia or nervous-system malfunction. It provides no space for 
talking about DBS electrode replacement, surgical procedure, or stimulation 
parameters.  Indeed, talk about the brain and the aetiology of movement disorders 
is largely absent from the goal setting session. The patient-centred logic of the 
COPM, manifested in the way that it distributes authority among the therapists, 
patients and family, precludes talking about dystonia in this way.  
 Instead patients and their families are encouraged to give their account of 
living with the disorder. As we have seen, they are prompted to explain how the 
disorder impacts upon their day-to-day life in very specific terms, and then identify 
which aspects of this impact they would most like to improve. They are encouraged 
to talk about the mundane, everyday life of the patient: feeding and drinking, 
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hygiene, sleep, pain, playing with friends, writing and using computers, using public 
spaces. As a result, during the course of the goal setting interaction, the movement 
disorder may be understood as an inability to use the bus, having to rely on mum to 
help with shaving or drink from a cup, a fear of being laughed at in public by 
strangers, or an inability to write more than a few sentences before getting cramps. 
It is according to such details that the movement disorder is rendered intelligible 
within the goal setting session. It is, in other words, enacted as social affliction; as a 
hindrance to engaging and acting in the world of people and things that is beyond 
goal setting session and outside of the hospital.   
 Consequently, the patient is enacted as a social being, immersed within a 
network of relations involving other people (family members, friends, strangers), 
and objects (computers, pens, cups, buses). It is these relations, and the patient’s 
capacity to act within this network of people and things, which are closely examined 
within the goal setting session. Via the guiding and prompting of the therapists 
these relations are brought to the forefront of the interaction, and then through a 
process of negotiation they become the basis of the patient’s five goals. As we saw 
with the example of Carl’s goal setting session, the therapists will also refer to these 
social relations as they articulate the likely effects of DBS therapy. In this way, the 
potential effects of DBS are, ideally, rendered comprehensible to patients and 
families: potential benefits are communicated as an improvement in a particular 
aspect of the patient’s day-to-day functioning. Using the COPM to manage 
expectations of patients and families, therefore, entails that the socially-embedded 
nature of the patient will be brought to the forefront.    
 This socially-embedded rendering of the patient is, of course, a temporary 
product of the goal setting session. It is actively produced by the therapist, the 
patient and family members as they attempt to adhere to the COPM script, and as 
Mol (2002) has illustrated, such temporary enactments may be elided by enactments 
or renderings generated in other interactions at other sites within the hospital. At 
the end of the goal setting session, however, part of this ‘socially-embedded’ 
rendering of the patient is granted some durability. The standardized COPM score 
sheet that contains the negotiated goals, the results of the quantification process, 
and a few additional notes, is added to the patient’s records. These are then used a 
point of reference when the patient returns for review after the DBS system has 
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been implanted, thus enabling team members and families to assess its impact on 
the patient’s day-to-day life.  
 
6.5 Discussion: An innovative strategy for managing expectations 
The socio-political trend promoting ‘patient autonomy’ and increased involvement 
of patients in their decision making has put particular pressures on health 
professionals. They have a responsibility to communicate the risks and benefits of 
treatment options to patients, and they have a responsibility to ensure that patients 
understand this information before the intervention takes place. In short, health 
professionals are expected to ensure that patients have realistic expectations before 
they obtain informed consent.   
 For the PMDS team this can be particularly challenging. The team’s 
response to this is to innovate: to adopt a tool from occupational therapy, an 
outcome measure, and modify it to suit the local context of the PMDS.  
Consequently the COPM has become the basis of the goal setting session and the 
therapists’ means of attempting to manage the expectations of patients and their 
families. The team’s inclusion and modification of the COPM can be seen as an 
example of learning-in-practice; it is an example of health professionals developing, 
implementing and modifying a new procedure, while working with patients, in order 
to manage the challenges presented by the introduction of a new technology.  
 As we saw, the therapists must engage in a fair amount of ad-hoc work to 
ensure that patients and families adhere to the script. Families are required to 
communicate honestly and in specific terms and to negotiate reasonably. This 
requires a rapport and degree of trust between the therapists and families. 
According to the therapists, it is often during the earlier pre-surgical assessments 
that they have had a chance to form informal bonds with families and patients, and 
so by the time of the goal setting session, patients and families are more willing to 
speak openly. In this particular setting, then, trust and informal bonds are 
considered an important requirement for managing expectations and thus enabling 
patients and families to make an ‘informed’ decision. The informed consent 
process, then, has not necessarily replaced the more informal, trusting relations 
between health professionals and patients that, according to Wolpe characterized 
clinical contexts in previous times (Wolpe 1998). For the PMDS team, a trusting 
relationship with patients is a crucial part of the disclosure process. Additionally, 
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much of the work required of therapists in order to keep patients and families to the 
COPM script could be described as emotional work.20  In order to encourage patients 
and families to communicate honestly and in order to prevent them from becoming 
distressed and upset in the process, therapists must carefully manage emotions 
during the goal setting session. The use of humour is an example of this, and 
without this type of work the COPM would fail to work as intended. Indeed, 
emotional work can be seen as an important component of the innovation process.  
  I have argued that during the COPM the patient’s movement disorder is 
enacted as a social condition: it is understood in terms of its impact on the day-to-
day life of the patient. The patient, then, is enacted as a socially embedded entity. 
This is another example of the ‘broad clinical gaze’ that was enacted during the team 
meetings. In this case it is a result of the normative stance that has been encoded 
with the COPM: the ‘patient-centred mantra’ that underpins occupational therapy. 
Consequently, this COPM-scripted goal setting session is in noticeable contrast to 
the genetic counselling sessions explored by Morrison (2008), where counsellors’ 
emphasis on patient autonomy tended to obscure mothers’ wider social relations, 
relations that could have provided much needed support and guidance. This 
difference is perhaps no surprise. The COPM-scripted goal setting session is 
another product of the socio-political trend within the UK that is promoting 
multidisciplinary service provision, particularly to in paediatric settings: It has been 
created by a team whose multidisciplinary activities are supported by, for example, 
the NHS tariff structure and the built environment of the hospital within which 
they work.  
The PMDS goal setting session also illustrates the role of non-human 
elements in ethical work. The COPM script requires therapists to draw on their own 
professional and emotional capacities; it requires the use of additional tools, such as 
communication aids; and it requires an informal, comfortably arranged working 
space. Together, these various elements ensure that the script and its patient-centred 
normative orientation are enacted in actual clinical practice, and they are all, 
therefore, implicated in the ethical work of managing expectations and enabling 
informed decision making. 
                                                 
20 Emotional work is the labour undertaken by individuals in order to manage their own and other’s 
emotions so that some institutional aim can be achieved (Bolton 2001).   
6: Managing the expectations of patients & families 
 
 184 
Of course the goal setting session is just a small part of a family’s time with 
the PMDS service, and in other interactions different renderings of the movement 
disorder and different enactments of the patient are produced. Indeed the COPM 
goal setting session is one component of the informed consent process. The 
information session is another component. Once families have participated in both 
these sessions they are given at least several months to make the very difficult 
decision about whether or not to go ahead with DBS. Often team members will put 
them in touch with other families that have gone through with DBS. If a family 
does decide to go ahead, they will be asked read a participant information sheet and 
sign a consent form on the day of surgery.  
 As we have seen, the COPM goal setting session involves quantifying 
patients’ self-perception of their abilities. In effect the COPM translates the specific 
hopes and frustrations of individual patients into a series of numbers. For each 
patient  the COPM will be repeated after the DBS system has been implanted and 
the resulting numbers will be compared to those from their pre-surgical goal-setting 
session. This is part of many data-gathering activities conducted within the PMDS 
aimed at creating an objective body of evidence regarding the efficacy of DBS. 
These activities, we shall see in the following chapter, reflect the socio-political 
trend within healthcare towards evidence-based medicine, and they also constitute 







7 Measuring clinical outcomes 
 
If the scale is insufficient then many patients are going to be unfairly excluded from 
a therapy that can offer them much needed relief. We don’t want people to be 
excluded because an inadequate tool has selectively produced the relevant data, 
thus giving the impression that only a select few will benefit. (Dr Martin, team 
meeting) 
 
7.1 Introduction: the challenge of measuring outcomes 
In chapter 3 we explored the conjunction of historical circumstances that enable 
teams such as the PMDS to exist. In addition to producing novel opportunities for 
managing neurological illnesses, this conjunction of circumstances has also created 
series of constraints that influence how such opportunities can be exploited.  The 
PMDS team operates in a climate of medical device regulation and evidence-based 
medicine, and they are expected to generate appropriate ‘objective’ evidence that 
deep brain stimulation is an effective tool for managing dystonia in children. We 
also saw that this climate necessitated the development of standardized clinical 
assessment tools that could be used to create such evidence. In regards to dystonia, 
there is a precedent for how this evidence should be generated: using the Burke-
Fahn-Marsden Dystonia Rating Scale clinical assessment tool (BFMDRS, or BFM 
for short). It was this tool that was utilized in the multi-centre Medtronic-sponsored 
trials that were used to obtain regulatory approval for DBS as a treatment of 
dystonia in both the US and the European Union, and it has become the standard 
clinical assessment tool for determining the effectiveness of the therapy. Because of 
this, the clinical outcome data reported in the existing body of literature on DBS 
and dystonia has been generated using the BFM.   
 Not surprisingly the BFM is used by the PMDS. If the team wishes to 
compare their outcomes to those in the literature, or if they wish to demonstrate to 
external funders and regulatory agencies or the wider neurological community that 
their therapy is effective, then it is necessary for them to use this standard tool. 
This, however, is problematic for the team. The BFM tool was developed for use 
for adult patients with primary dystonia. Most PMDS patients have secondary 
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dystonia, and consequently the BFM is of limited use.21 Specifically PMDS team 
members argue that the tool fails to capture improvements in many of their patients 
with secondary dystonia; improvements that are relevant and important to patients 
and families.  In this chapter we will see how the team has attempted to ameliorate 
this problem by using another clinical assessment tool which they have adopted 
from occupational therapy called the Assessment of Motor and Process Skills 
(AMPS). PMDS team members argue that it is capable of detecting relevant and 
meaningful changes in patients with secondary dystonia. In effect, the team is 
attempting to redefine ‘what counts as data’ in such a way that it will support their 
activities. Although the team’s use of this tool is unique in tertiary paediatric 
neurology, it can be seen as part of a wider trend towards using clinical assessment 
tools that involve active patient participation.      
 Here we will explore why team members felt that the introduction of this 
AMPS was necessary, and we will see how the tool is actually used in clinical 
practice. Conducting the AMPS requires the occupational therapist to construct an 
assessment space that resembles a typical domestic space within the home, such as a 
kitchen. The patient is then instructed to perform a domestic task, or an Activity of 
Daily Living (ADL). As this is done, the therapist carefully scrutinizes the patient’s 
ability to use their body as an efficient implement, noting how they navigate and 
interact with other objects within the domestic space. First, however, I will give a 
description of clinical assessment tools and state why they are interesting from a 
sociological perspective. 
 
7.2 Conceptualising clinical assessment tools 
Here I will suggest that there are two interrelated reasons why clinical assessment 
tools are worthy of sociological exploration. Firstly, such tools incorporate and 
reproduce specific ways of understanding disease, the body and/or the patient. As 
we saw with the UPDRS in chapter 3, clinical assessment tools function by 
extracting manageable, quantifiable, easily-to-circulate data from highly complex and 
                                                 
21 One team member stated that the BFM was developed in a particular part of the US with large 
Ashkenazy Jewish and Amish-Mennonite populations, both of which have a high frequency of a 
particular genetic abnormalities that cause primary dystonia. Consequently, primary dystonia is more 
common than it would be in other regions of the world. This may have shaped the development of 
the tool – verifying this would make an interesting project in its own right. 
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contingent local contexts. This occurs via a process of filtration, where some bodily 
attributes or phenomena are designated as ‘representative’ of a patient’s condition 
and are subsequently rated, measured and pooled-together, while innumerable other 
phenomena are elided or ignored as irrelevant. This is similar to the process of 
purification that takes place within laboratory clinical work, where particular 
biological parameters are used to represent ‘health’ (Mol 2008). Inevitably this 
filtration process will reflect what Goodwin (1994) has referred to as the professional 
vision of those who created the tool: particular modes of perceiving and 
understanding disease and illness are encoded within clinical assessment tools. They 
do not, then, provide unmediated accounts; rather, they are (to borrow some 
phrasing from Haraway) constructed perceptual systems; highly specific and partial ways 
of seeing and assessing disease and the body (Haraway 1988). As such tools are 
adopted into various clinical and research contexts, these particular modes of 
perceiving health and illness, these partial, highly specific perceptual systems, 
become locally embedded. Indeed, as clinical assessment tools become part of 
clinical infrastructure, particular understandings of health and illness gain 
institutional ‘weight’. 
Within neurological clinical research and practice it is possible to 
characterize clinical assessment tools into four groups, based on the type of 
attributes and phenomena (or ‘outcomes’) that are used to ‘stand in’ for health and 
illness. These include: the underlying disease process; impairment; disability; and 
quality of life (QoL). Not surprisingly some of these tools tend to reify the 
biomedical model of disease and the body. This assessment of underlying disease 
process, for example, may include determining the degree of underlying tissue or 
organ damage, the level of disease-related particles in the blood, or the frequency of 
some sort of disease-related acute event. Similarly, impairment-based tools are those 
that measure the deleterious effects of the disease on the functioning of body parts 
or organs. An example of this is the common Unified Parkinson’s Disease Rating 
Scale which assesses the degree of tremor in various regions of the body (Martínez-
Martín et al. 1994). With such tools it is particular biological or biochemical 
elements, or particular clinical signs, which are deemed to be ‘representative’ of 
‘health’, and it is that these become the basis for measuring the effectiveness of an 
intervention. Such outcome measures provide no allowance for the viewpoint or 
experiences of the patient.  
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 Tools that assess disability or QoL are based upon less reductive 
understandings of health and illness. The measurement of disability involves 
assessing the degree to which a condition reduces or restricts an individual’s ability 
to perform tasks within their physical and social environment. Generally, this is 
done by measuring the individual’s capacity to carryout activities of daily living 
(ADL), such as eating, washing hands, or self-dressing (Buskens and van Gijn 2001). 
QoL-based tools attempt to quantify an individual’s overall sense of well-being and 
life-satisfaction. This is usually done via a questionnaire and/or interviews that 
prompt patients to report on various physical, social and emotional aspects of their 
life. The perceived advantage of such tools is that they measure phenomena that 
patients themselves find meaningful.22   
In addition to incorporating and reproducing particular ways of 
understanding disease, assessment tools also link disease, the body and/or the 
patient into a wider set of relations involving statisticians, commercial institutions, 
regulatory agencies and other ‘macro’ actors. They have become part of what Clarke 
and colleagues have referred to as the integrated infrastructure of biomedicalization; 
infrastructure that enables medical knowledge, technologies and capital to become 
ever more co-constituted (Clarke et al 2010). As we saw in regard to the 
development and dissemination of DBS technology in chapter 3, clinical assessment 
tools transform local, contingent and potential diverse phenomena of particular 
research sites into a set of easy-to-circulate numbers (immutable mobiles) that can 
be pooled-together, compared, and used as a body of evidence to justify the use of 
an intervention. In short, clinical assessment tools are one of the crucial 
technologies that enable populations of individuals to be brought into an 
‘experimental order’ (Petryna 2006).23   
  Given their importance in contemporary healthcare and clinical research, 
therefore, clinical assessment tools are worthy of sociological examination. By 
                                                 
22  The COPM which we explored in previous chapter is another good example of such a tool.   
23 As we saw in chapter 3, clinical assessment tools enable commercial industry to conduct large 
scale, multisite international clinical trials. Not surprisingly pharmaceutical companies tend to prefer 
tools that measure disease process or impairment, as they can be easily quantified by an investigator, 
they are perceived as objective, and even when used with small trials, they ‘lend themselves to 
statistical massage from which some significant advantage can be made to emerge” (Buskens and 
Van Gijn 2001: 37).   
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examining how health professionals use and adapt assessment tools in specific 
contexts, we can explore how various understandings of disease, the body and the 
patient may be perpetuated or disrupted, and we can explore how local contexts can 
become implicated a wider set of relations involving other clinical sites. Here we will 
examine the activities of PMDS team members as they use the AMPS, a disability-
based measure. As we will see, this has implications for how the patient and 
‘dystonia’ are rendered intelligible: the patient is required to carry out a domestic 
task (and ADL) within a mock domestic setting, and consequently the AMPS entails 
an examination of what could be called the patient’s domestic body technique. First, 
however, we will see why the PMDS felt it necessary to adopt the AMPS in the first 
place.  
 
7.3 The problem with the Burke-Fahn-Marsden Dystonia Rating Scale 
The Burke-Fahn-Marsden Dystonia Rating Scale was developed in the early 1980s 
(Burke et al. 1985). It is a composite scale containing two sections: a ‘dystonia 
movement scale’ for quantifying impairment (the effect of dystonia on different 
areas of the body), and a brief ‘disability scale’, which quantifies impact of dystonia 
on a few basic activities.  For the first section, the patient is required to sit upright in 
a chair and perform a series of basic movements. These include, for example:  
“elbows and hands resting on the arms of the chair or the thighs… hold both arms 
out, extended and supinated… opening and closing both hands… touching the 
nose with the index finger” (Burke et al. 1985). As the patient performs these tasks, 
they are video recorded by the clinician or investigator, and at a later time this 
recording will be used to score the patient’s dystonia. This involves noting for each 
region of the body which actions exacerbate the dystonia (‘provoking’ factor), and 
the severity of the dystonia (‘severity factor’).  By multiplying the two score together 
and then adding the result for each body region, an overall score is obtained for that 
individual patient.  For the disability section of the BFM, the patient, or the patient’s 
family, are required to score the patient’s ability to carry out five basic tasks using a 
scale from zero to four. The tasks are speech, feeding, eating, dressing, writing 
hygiene and walking, and patients (or their families) are provided with a description 
of what qualifies as a zero or a one, or a two etc for each task. Ideally the BFM will 
be undertaken with patients as part of a pre-intervention assessment in order to 
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obtain a ‘baseline’ score, and it will subsequently be repeated at regular intervals 
after the intervention, enabling the effectiveness of the intervention to be calculated. 
Generally, as a scale for primary dystonia, the BFM has received positive 
reviews within the field of neurology, rating well for validity, reliability and 
responsiveness (Burke et al, 1985: Krystkowiak et al. 2007). And indeed for the 
PMDS the scale is considered as a useful and effective means of measuring effects 
of DBS on patients with primary dystonia. This is not to say that it is without its 
problems or that it is easy to use. The PMDS therapists who carry out the BFM talk 
of the work required to get impatient, tired, or playful children to sit and carry out 
the tasks as instructed, and they refer to the noticeable lack of specificity in the 
BFM instructions, which, they state, leads to inconsistent application. While these 
challenges are relatively minor and are managed by the therapists,24 using the tool 
with some patients, particularly those with secondary dystonia, is more problematic.  
 First, the movement scale component of the tool can be difficult to 
implement because it is not always clear whether the body area being scored is being 
affected by dystonia alone, or some other component of the patient’s condition. 
Anxiety is common among this group of patients and it can temporarily exacerbate 
dystonic movements. Patients tend to become more anxious and thus more 
dystonic when videotaped.  Here, the occupational therapist illustrates this with 
specific example:  
There was one the other day when the child – it’s so funny because he had no 
dystonia at all during four hours of working with me. But as soon as you put the 
camera on him, he’s like this [mimics involuntary movements]. I say, ‘Can you look at the 
camera?’ And he goes [mimics involuntary facial movements]. And I’m like, ‘Is that a 
plethora spasm?  That’s not a plethora spasm.’  But, ‘Oh his eyes are closed.’ You 
know, and it ends up being such a meaningless measure for some of the kids 
(Occupational therapist, interview). 
 
Second, the tool fails to register improvements that, while they may appear 
minimal, are nonetheless considered important to patients and their family.  This is 
                                                 
24 The therapists deal with the first of these problems by engaging in ad-hoc work to entice children 
to comply, such as using toys as props and humour. In order to deal with the second problem the 
occupational therapist has created a standard guidelines for carrying out the BFM. 
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particularly so with severely affected patients who may be unable to participate in 
the BFM in the first place.  Here is an example from a team meeting discussion 
between the occupational therapist (OT) and a neurologist (neur):  
 
OT:    We have had six cases where there has been no change in their BFM score 
[after DBS system has been implanted]. But, rather than each patient 
needing three people to bath them and two to dress them, they now only 
need one carer. This is a significant improvement, but how do we 
demonstrate this when it cannot be demonstrated with the available scale? 
Neur:  With one patient, we managed to give him the use of a finger and thumb. 
This actually translates into quite an improvement in terms of daily living. 
OT:    That might be so, but how could we demonstrate that to funders?  
 
For a patient, gaining the use of a finger and thumb may have important 
implications for their day-to-day life; it may, for example, enable them to operate a 
communication aid. Such improvements, however, cannot be detected with the 
BFM, and consequently it often fails to generate evidence that could be used to 
justify the use of DBS as a therapy of children with secondary dystonia. With regard 
to the PMDS patient cohort, therefore, the tool fails to meet the ‘responsiveness’ 
criteria of ‘scientific soundness’ requirements of a clinical assessment tool. During 
an academic meeting, team members discussed whether it was worth dropping the 
tool from their assessment regime altogether.  It was decided, however, that for the 
meantime they would continue to use the tool as it was nonetheless a useful 
measure for patients with primary dystonia, and it provided a means of 
communicating with other centres:  
 
PT2 : So why do we need to use an impairment scale anyway? It is because all the 
other research out there uses these scales? 
S&L: And the BFM specifically – what is the point of it? 
CRF: It does enable a common language with other centres.  
Dr M:  The problem is, if we have different scales, different languages for primary 
dystonia and secondary dystonia, that makes it difficult to compare.  
 
The team has therefore retained the use of the tool and at this stage it is generally 
carried out with all capable patients as part of the extensive pre-surgical baseline 
assessment, and at regular intervals after the DBS system has been implanted. The 
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PMDS is not the only team to note the shortcomings of the BFM. Several other 
centres working with children with secondary dystonia have also stated that, while it 
is certainly not useless, it can produce potentially misleading data (Marks et al 2009; 
Monbaliu et al. 2010). Nonetheless, the PMDS’ response to this particular challenge 
is unique: the team has adopted clinical assessment tools from occupational therapy 
into their assessment regime. These adopted tools are used to assess disability, or 
the patient’s ability to carry out activities of daily living (ADL). Team members 
argue that because of this focus on disability rather than impairment, these tools are 
more suitable for capturing and measuring improvements that are relevant to 
patients and their families. They are, in other words, considered more responsive to 
the effects of the DBS intervention. 
 
7.4 The Assessment of Motor and Process Skills (AMPS) 
The main tool that was adopted from occupational therapy for use as an outcome 
measure is the Assessment of Motor and Process Skills, or AMPS. It was developed 
in the early 1990s by the occupational therapist Anne Fisher, and it is designed to 
evaluate the impact of interventions on patients with any form or degree of 
disability (Fisher 1995).  Like the COPM we explored in the previous chapter, its 
design was informed by the patient-centred ‘mantra’ of occupational therapy: it is 
intended to evaluate patients’ capacity to engage in occupational and domestic 
activities that patients themselves feel are important (Fisher, 1997). Generally the 
AMPS is carried out with patients in the community in their ‘natural’ domestic 
setting. It is, nonetheless, designed to be a highly standardized, carefully controlled 
means of evaluation. In order to ensure that it is applied with minimal variation and 
as few inconsistencies as possible across various clinical and research contexts, the 
AMPS is part of a network of actors which attempt to dictate who can use it and 
how it can be used. This network consists of a standard AMPS manual (Fisher 
1995), a ‘regulatory’ agency called the ‘Center for Innovative OT Solutions’, and an 
AMPS computer software program. These elements restrict who can conduct the 
AMPS, and they play a role in coordinating the actions of the therapist and patient 
while the AMPS is being undertaken in specific clinical contexts.  
 Firstly, although patients can choose the occupational or domestic activities 
that they would like to carry out as part of the assessment, they must do so from a 
list of 120 standardised ‘activities of daily living’ provided in the AMPS manual. For 
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each ADL, the manual provides a description of what the patient is required to do if 
they choose that task.  Each ADL has a corresponding code and tasks are divided 
into levels of difficulty, from “Very Easy Tasks” (such as putting on socks and 
shoes), to “Much Harder than Average Tasks” (making fried rice). In order to 
evaluate the patient’s ability to complete a task, the therapist will examine and rate 
(from one to four) 36 specific skills items that constitute all of the ADLs. These 
include sixteen motor skill items (such as walking, reaching, gripping, objects) and 
twenty process skill items (such as choosing objects, pacing), all of which are 
defined by the AMPS manual. The manual also stipulates how these should be rated 
for each task (ie, what constitutes a one or a two and so on).   
 Second, the AMPS can only be conducted by an occupational therapist who 
is a fully certified and calibrated AMPS scorer. In order to become certified, 
therapists must attend an appropriate five-day training course, and in order to 
become calibrated, they must undertake ten AMPS ‘trial’ assessments and send their 
resulting scores to ‘Center for Innovative OT Solutions (previously called ‘AMPS 
Project International’). The Center will then assign each therapist with a calibration 
value indicating their rating ‘severity’, calculated by comparing their ratings with 
those of other therapists. This value will then be used to adjust (or calibrate) the 
therapist’s subsequent AMPS measurements. The certification and calibration can 
be seen as gate-keeping activities: only those therapists with a particular set of 
mandated skills can access and use the AMPS.   
 And third, in order to ensure that only certified, calibrated occupational 
therapists conduct the AMPS, software is required to undertake a critical step in the 
AMPS rating process.  In order to generate an overall score for a particular patient, 
the therapist will input the ADL code scores for each of the 36 skill items into the 
software, which will then generate an overall score for the patient. First, however, 
the therapist must ‘unlock’ the software with a personal code which can only be 
obtained by the Center for Innovative OT Solutions. Importantly this personalized 
code indicates the calibration value of the therapist, which is subsequently used by 
the software when computing a final score. In effect, the software system restricts 
who can conduct the AMPS and it attempts to reduce the influence of individual 
rater idiosyncrasies on their patient’s overall score. Indeed, the AMPS software is an 
example of the materialization of a power relation (Berg 1998): the gate-keeping role 
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of the Center for Innovative OT Solutions has been encoded within the software, 
and non-certified, non-calibrated therapists are ‘locked-out’.   
 The aim of this system of certification and calibration requirements, the 
personalized code and software system is to maintain the inter-rater reliability of the 
AMPS and ensure its ‘scientific soundness’ as an assessment tool. Indeed, as 
Timmermans and Berg have pointed out, the creation of standards and ensuring 
that standards are maintained often requires such strategies and techniques that aim 
to stabilize particular relations of power and control (Timmermans and Berg 2003). 
If such measures are effective, then compliant, correctly configured therapists will 
conduct the AMPS in a manner that is mandated by the Center for Innovative OT 
Solutions. This will mean that the ‘patient-centred’ sensibility that informed the 
construction of the tool will come to have some sort of effect on those local 
contexts in which the tool is applied. 
 The AMPS has become a widespread tool within occupational therapy.  
Advocates claim that it has been validated for use with patients from various 
cultural backgrounds (Goto et al. 1996) and with a range of disorders. This includes 
children with cerebral palsy (Van Zelst et al. 2006), and it was while working with 
this group in the community that the PMDS occupational therapist became familiar 
with the AMPS tool. When the occupational therapist later became part of the 
newly formed PMDS (which works with patients with dystonic cerebral palsy), and 
once she and other team members became aware of the limitations of the BFM, this 
familiarity encouraged her to suggest that the team adopt the AMPS. The tool has 
subsequently been used as a standard part of the team’s regime of assessments for 
the last five years or so. While the tool has been adopted in other clinical settings 
(Nygard et al. 1994), the PMDS is the only team using the AMPS to assess the 
efficacy of a DBS therapy. 
 
7.4.1 Using the AMPS with patients 
It is the occupational therapist (henceforth ‘OT’), then, who undertakes the AMPS 
with patients in the PMDS.  She has undergone the AMPS training course, her 
severity as rater has been calibrated by the Center of Innovative OT Solutions, she 
has access to the appropriate software and a copy of the manual, and in order to 
maintain her skill-set, she attends regular AMPS-based meetings with a local group 
of OTs.  
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 Before the AMPS can begin the patient must choose five daily living tasks. 
In the PMDS these are the same five tasks chosen by the patient and their 
accompanying family members during their initial interview that later became the 
basis of the COPM-scripted goal setting session. The AMPS manual states that 
these must be tasks that the patient “wants and needs to perform” but is having 
difficulty doing so (Fisher 2006). Importantly, each task must also correspond to 
one of the 120 standard ‘Activities of Daily Living’ listed in the AMPS manual. The 
patient will be asked to perform the five tasks during their subsequent assessments, 
and the video recordings of these performances will later be used to score the 
patient. Here I will use extracts from my observation notes of both a performance 
session, during which a patient performed a task, and a scoring session, during 
which the OT analysed video-recordings and the AMPS software to provide an 
overall score. I will argue that conducting the AMPS assessment involves the 
formation of a carefully coordinated assemblage including the patient and various 
domestic objects. This assemblage enables the assessment of body technique: the 
patient’s ability to utilize their body efficiently as an instrument to carry-out 
domestic, cultural practices.    
 
A domestic assemblage 
In many occupational therapy contexts the application of the AMPS takes place in 
the patient’s home. This provides the OT with an opportunity to observe a patient 
as they attempt to perform tasks that are important to them in the environment in 
which they would usually perform these tasks. As the manual states: 
[OTs] need to observe and evaluate ADL task performances in natural spaces: 
bedrooms, family or living rooms, kitchens, gardens – ones like those where the 
client typically would be performing ADL tasks (Fisher and Jones 2010: 4-5). 
 
In the context of the PMDS, where patients and their families may spend several 
days undergoing an assortment of assessments, it is necessary to recreate these 
‘natural’ spaces within the hospital. Thankfully, as we saw in chapter 4, the hospital 
contains a diversity of spaces (such as kitchenettes and play areas), some of which 
provide the OTs with well-equipped settings to undertake AMPS assessments. It is 
in one of the spaces that we will follow the OT as she conducts the assessment of 
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Carl. Carl is again accompanied by his mother and two of the tasks he chose were 
washing the dishes and making a sandwich. 
 Carl’s AMPS assessment takes place in a large room with a kitchenette. His 
mother spends most of the session seated in the corner of the room, knitting, and 
saying very little.  Along one side of the room is a large sliding door that opens to a 
kitchen sink and dish rack, a fridge, an oven with a stovetop, bench-space and 
cupboards both under and above the bench (See figure 7.1, page 198). The OT, 
who is accompanied by the therapy assistant (TA), announces that they will begin 
with the ‘washing the dishes’ task. It transpires that the task was chosen because 
Carl would like to attend university in a few years and this would require him to live 
away from his mother and clean-up after himself.  
 As with the GMFM assessment we followed in chapter 4, the AMPS takes 
place within a layout of objects that has been carefully arranged by the therapists. 
This spatial layout, as we will see, enables particular information to be extracted 
from the patient, in much the same way that the careful arrangement of a laboratory 
assemblage enables information to be obtained from an entity of interest (Latour 
and Woolgar 1986; Mol 2002).  The assemblage created by the OT is, to a degree, 
standardized. The AMPS manual stipulates how the task is to be performed by the 
patient, and in doing so it designates the types of objects to be included and how 
they should be arranged within space: indeed, we could say that the description 
within the AMPS manual is materialised as a specific place, thus (as we will see) 
enabling the creation of standardized knowledge. ‘Washing the dishes’ corresponds 
to ADL task “J-2” in the manual, which states that the task must be performed as 
follows:  
The client is expected to wash and rinse 10 to 15 dishes… Rinsing soap suds off 
the dishes is expected… Appropriate dishes include an assortment of plates, 
glasses, silverware, small pans and related utensils. [After the dishes have been 
cleaned] the client is to drain water from the sink, wipe the counters dry, wring out 
the dishrag or sponge (Fisher 2003: 100). 
 
The task description also outlines the responsibilities of the therapist during the 
performance: 
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The client should be completely familiarized with the set-up of the environment 
including the location of all needed tools and materials (Fisher 2003: 100).   
 
Having checked the manual she has with her, the OT arranges the kitchenette so 
the task can be carried out correctly. She and the assistant have brought with them a 
box of dirty dishes from the staff offices on the upper levels. The dishes (bowls, 
plates and cutlery) are piled on one side of the sink and the dish rack is placed on 
the other. The OT checks that there is dishwashing liquid, a sponge and a tea towel 
in the cupboard below the sink.  In effect, part of the home is brought into the 
clinic. The assemblage created by the OT is intended to mimic the spatial layout of 
objects in an ‘average’ domestic kitchen. The OT then familiarizes Carl with the 
ADL task: 
 
OT:  Carl – The washing up.  How do you normally do it at home? Do you 
normally do it at home?  
Carl:  No. I don’t usually do it.  
OT: For this one, you are going to rinse and wash the dishes, stack them, dry 
them, and then put them away, and then you are going to wipe the bench 
and the sink clean. Got it?  Now, you will put the clean plates here and the 
clean bowls here [in the dish rack] and we will put the cups and utensils 
over here [next to the dish rack]. You can also put the sponge and the tea 
towel where they should go when you have finished.  Happy? 
Carl: Yip.  
 
Before he begins, however, the OT instructs Carl to ignore everyone else in the 
room, particularly his mother.  She adds:  
 
OT:  Now, I’m not going to interfere with you at all, and neither is mum – isn’t 
that right mum! I will step in, though, if it looks like something is going to 
fall or something bad like that happens... Great. Ready when you are. 
  
Here the OT is attempting to limit which entities can become involved in the 
domestic assemblage. Indeed, if an assemblage is to yield particular, sought after 
information, it is necessary to prevent intrusion from unwanted influences that 
create noise or could throw a carefully coordinated interaction off course.  
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Figure 7.1: Room layout during the ‘washing the dishes’ task 
 
 
The built environment of the location where the AMPS is being conducted also 
reduces unwanted intrusion. In laboratories, for example, such intrusion is reduced 
by partitioning of space with physical boundaries, thus creating an ordered place of 
knowledge-production shielded from disorderly outside space (Guggenheim 2011; 
Henke and Gieryn 2008). The room in which Carl performs the task is already 
partitioned from the noisy surrounding ward, and with the door closed, the outside 
world is barely audible. Indeed, those elements and activities that usually constitute 
a hospital environment are shut out from the AMPS assessment.  
 Within this ordered space Carl is encouraged to interact with the other 
elements of the domestic assemblage in much the same way as an ‘average’ 
individual would at their home.  After receiving his instructions, he stands up and 
walks to the bench, sighs loudly, and begins to get on with washing the dishes and 
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putting them on the rack one-by-one. The OT watches closely and takes notes with 
a pad and pen, and the therapy assistant stands nearby recording Carl with a small 
handheld camcorder (The layout of the assessment is illustrated in figure 7.1, page 
198).  Once all the cleaned dishes have been placed on the rack, Carl rinses the 
sponge and wipes the bench and sink. Carl appears tired and moves slowly, and his 
body shakes and jerks due to his movement disorder, but he appears to complete 
the task without much trouble.  
 At the end, the therapy assistant has produced a video recording and the OT 
has created a series of notes. The OT will subsequently use these to closely 
scrutinize Carl’s performance and provide scores for each of the 36 motor and 
process skill items, thus enabling an overall score to be calculated. 
 
7.4.2 An assessment of body technique 
For each of the motor and process items the OT must assign a number between 
one and four, where four equates to “performs skill item readily and consistently”, 
and one equates to “severe deficit or inability to perform skill item” (Fisher 2003). 
In order to illustrate the scoring process and its implications we will follow the OT 
as she uses video recordings to provide scores for patients who had carried out 
various tasks several weeks earlier. One recording is of a patient who had earlier 
performed the preparing ‘Cold cereal and beverage’ ADL task (task C-1).  The 
patient, William, is seven years old and has primary dystonia. This performance was 
one of several conducted as part of a post-surgical review: William has had the DBS 
system implanted for one year.  
 Before scoring each skill item the OT watched the video recording of the 
performance from start to finish. It begins with the OT giving William his 
instructions: He is to get the milk from the fridge, a glass from the top right 
cupboard, and use the jug of water that has been provided. The OT shows William 
where these various objects are. William begins by grabbing a bowl from the 
cupboard and placing it on the bench. He then picks up the box of cereal and 
attempts to pour cereal into the bowl. Nothing comes out so William opens the 
inner bag up some more. After several attempts he gets enough cereal in the bowl 
and uses his fingers to level it.  He then gets a large bottle of milk from the fridge 
and places it in the bench next to the bowl. He stops and looks perplexed, and then 
pours the milk into the cereal.  He over-pours and some splashes onto the bench. 
7: Measuring clinical outcomes 
 
 200 
Using a paper towel he cleans up the mess. Once this is done, he pats the cereal 
down into the milk with his fingers and then stares at the bowl – he has forgotten 
what to do next. He asks the OT, who instructs him to get a glass of water. He 
searches the cupboards looking for a glass, locates one, and places it on the bench. 
He then drags the jug of water across the bench towards himself, lifts it, and then 
pours the water in. He then stops for several seconds before picking up the glass 
and pouring some water into the bowl of milk and cereal. He puts the glass down 
on the bench, pauses, and he then (oddly) picks it up and pours more water into the 
into the cereal until the liquid level reaches the very top of the bowl. At this point 
the recording ends.   
The OT then begins scoring each of the 36 motor and process skill items 
that constitute William’s performance, one by one. In effect, the scoring process 
involves an examination of the way in which William uses his body to negotiate and 
interact with other objects within the domestic assemblage. Each skill item draws 
the OT’s attention to a different aspect of this performance.   
Several motor and process skills, such as ‘Aligns’ and ‘Positions’ relate to the 
position of the body relative to other objects within the domestic assemblage. 
Importantly, body alignment and position are rated according to the degree of 
functionality: a higher score is achieved if the body is orientated is such a way that 
the ADL task can be completed efficiently.  If the body alignment results in 
‘unacceptable delay, unacceptable effort” or “task breakdown”, it is scored as a one 
(Fisher 2003: 189). Here is an example from the scoring of William’s performance 
(as the OT scores each item, she explains her reasoning to me): 
 
OT:   The second [skill item] is ‘Aligns’ – this is also a four. He had no problem 
positioning himself to do the task. [Next skill item is] ‘Positions’ - this is 
something you would notice when their elbow is way up in the air while 
they are trying to pour something for instance. There was a bit of that with 
William. It kind of looks a bit awkward. Lets give him a two. 
 
Some motor and process skill items pertain to specific interactions between the body and 
other objects within the domestic assemblage.  For example, ‘Grips’ refers to the ability 
of the patient to grasp an object (such as a plate or a pan) or to open containers, 
‘Lifts’ refers to the patient’s ability to lift (and not slide) an object from one position 
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to another, and ‘Manipulates’ refers to dexterity or in-hand manipulation of task 
objects. Again, body-object interactions are rated according to their functionality: 
 
OT: ‘Grips’ - there was no grip slip – four. Even if you see a quick grip slip then 
you give him a two, but there was nothing like that here… ‘Lifts’ – If you 
slide an object rather than lift it, then you score it down. Did he do it? I 
think he slid the jug of water across the bench. This is where the video is 
useful [the OT consults the recording]. He did! He gets a two… ‘Manipulates’ – 
there was some fumbling with the cereal when he was trying to get it out of 
the box. He gets a two for this.   
 
Body-object interactions are also graded according to their cultural appropriateness. 
The ‘Uses’ skill item refers to whether or not the correct object has been selected 
for a task: using ‘a plate as a plate, knife as a knife” (Fisher 2003: 207). Here, then, 
the scoring process reflects social conventions regarding the use of particular 
objects. This is illustrated in the following extract, where I am asked for my opinion 
on the appropriateness of an interaction between the body (William’s hand) and an 
object a (bowl of cereal): 
 
OT: ‘Uses’ – this is about hygiene. For instance, does a stroke victim use a 
toothbrush to brush their hair?  There is an issue with William’s hands in 
the cereal.  What do you think? 
JG: For me, seeing him use his hand to adjust the dry cereal in the bowl looked 
quite normal. It is something that I would do. But when he used his hand 
to move the milky cereal, that was different. That seemed unhygienic.  
OT: Yes, I agree.  He gets a two.  
 
Other skill items pertain to the movement of the body as the patient navigates other 
objects within the assemblage. For example: 
 
OT: ‘Reaches’ – he was fine here. Had no problem getting the milk from the 
fridge. He gets a four… ‘Bending’ is also a four. There was no increase in 
effort while picking up the paper towels… ‘Walks’ – no instability when 
walking to the fridge and back, so he gets a four.  
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The fluidity of body movements while performing the task is also graded. ‘Flows’ pertains 
to the ‘fluid quality’ of arm and hand movement. Smooth movement scores highly, 
whereas movement that is disrupted, perhaps from “tremor, stiffness, increased 
tone” is scored down (Fisher 2003: 196): 
 
OT: ‘Flows’ - This is hard, I will look [at the manual]. I don’t think the spillage 
was due to “marked spillage due to tremors”, which would qualify as a one 
in the manual. I think it was due to orientation. So, I will give him a two.  
 
Scoring skill items also involves differentiating ‘erroneous’ movements from functional 
movements. Movements that are not directed towards the completion of the task, or 
hinder the completion of the task, may result in a lower score. For example, a 
“wobbly while walking or interacting with task objects” will result on low score of 
‘Stability’ and ‘Transports’. A patient’s inappropriate persistence with a task will also 
be designated as erroneous movement: 
 
OT: ‘Terminates’ - William gets a one for this. He continued to pour water into 
the bowl of cereal even when it was full of milk. He did it twice! 
 
Other skill items pertain to the patient’s control over their body while moving and 
interacting with other objects. For example: 
 
OT: ‘Calibrates’ – Here we are grading his movement and how he adjusts the 
force of his movement depending on the object. Does he use too much 
force?  Not enough?  Well, you can see how much milk he spilled. He gets 
a one.   
 
The temporal dimension of the performance is also rated. ‘Sequences’ for example, 
is scored highly if various steps are performed “in an effective order for efficient use 
of time” (Fisher 2003: 214) similarly, ‘Gathers’ refers to the patient’s ability to 
efficiently collect the necessary items required for a task: 
 
OT:  ‘Gathers’- He collected everything from the fridge that he needed to in one 
trip. It would be scored down if he made multiple trips. He gets a four.   
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And ‘Paces’ pertains to the overall rate of the task: 
 
OT: ‘Paces’ – I think he is slow.  He is consistent, but he is slow. So, he gets a 
two.   
 
Thus, by the time all 36 skill items have been scored the OT has scrutinized: the 
positioning of the William’s body within the domestic assemblage, the interactions 
between the body and other elements within the assemblage, body movement and 
fluidity of movement, and the rate at which sequences of body movements occur. 
Importantly, as William’s example illustrates, these various aspects of the 
performance are rated according to their functionality and efficiency. It is, therefore, 
the patient’s ability to use the body as an efficient implement that is being examined: an 
implement for carrying out particular domestic tasks in a culturally permissible 
manner. To borrow a term from Marcel Mauss (1973 [1934]), we could say that the 
AMPS is an assessment of specific domestic body technique. Mauss defines body 
techniques as the way in which “from society to society men know how to use their 
bodies” (1973: 70). They have, he argues, three characteristics, all of which are 
scrutinized as part of the AMPS assessment: they involve a specific series of bodily 
movements and forms; they are social in that they are learned within cultural 
contexts; and they are efficient in that they serve a specific purpose or function.  
 Importantly for the PMDS team, the AMPS enables the patient’s 
proficiency in domestic body techniques to be quantified. Once the OT has decided 
upon scores for all 36 items, she enters them into the AMPS software, along with 
the ADL task code, the age of the patient, and, of course, her personal AMPS code 
(which unlocks the software in the first place and ensures the final score will be 
calibrated according to her severity as a rater). The programme combines these 
details with scores from several of William’s other ADL performances. From these 
combined scores the programme generates an overall set of scores for William at 
that point in time. The programme enables the OT to compare these to those of the 
‘average, able-bodied’ seven year-old child, and with those of William’s pre-surgical 
baseline assessment: The OT notes that William’s scores are within the normal 
range of an average seven year old, despite scoring poorly on several skill items (It is 
expected, she states, that an average child of that age would have the same 
difficulties). And, she adds, when compared with his pre-DBS scores, “his motor 
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skills have improved significantly, although his process skills are largely unchanged.” 
It is according to such comparisons of body technique proficiency that that the 
AMPS enables the impact of the motor disorder, and the effectiveness of DBS as 
therapy for managing dystonia, to be assessed for each patient.  
 
7.5 Discussion: The shift towards patient-centred tools 
As we have seen, undertaking an AMPS assessment involves the construction of 
domestic assemblage that is carefully shielded from unwanted influences. Within 
this controlled space the patient is coaxed to perform domestic tasks, to use their 
body as an efficient implement to perform ADL tasks in a culturally permissible 
manner. This, I have illustrated, enables the OT to scrutinize the elements of 
domestic body technique: the sequence of bodily movements and forms employed 
by the patient as they negotiate and interact with the other elements of the 
assemblage. It is, then, the patient’s practical relationship to and involvement in the 
world that is being assessed. As a consequence, dystonia, and the effectiveness of 
DBS in managing dystonia, are rendered intelligible in terms of their impact on this 
practical relationship and involvement. To borrow the language of Annemarie Mol 
(2002) we can say that the domestic assemblage has enacted dystonia as a reduced 
ability to engage in the world, or in other words, as a disability. Perceiving dystonia 
in this way is useful for the team. It enables team members to capture and measure 
clinical improvements that patients themselves find meaningful; improvements that 
may not have been captured with the impairment-based BFM. Of course the AMPS 
is just one data-gathering activity: Results from the AMPS and the BFM, as well as 
the COPM and various cognitive, speech, and pain assessments, are all combined to 
form an overall body of knowledge that will be used to assess the effectiveness of 
DBS.  
  This example of the adoption of the AMPS within the PMDS provides 
another glimpse into the means by which transformations (or innovations) within 
clinical practice can occur. Here, in an attempt to develop a clinical service using 
DBS technology, the PMDS team has incorporated the AMPS tool into their 
routine clinical practice. Like the team’s adaption of the COPM, this is an example 
of learning-in-practice; they have developed a new routine in order to manage a 
specific challenges associated with the integration of DBS technology. And as a 
consequence the perceptual system entrenched within the tool has become 
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embedded within the clinical context of the PMDS. The PMDS subsequently enacts 
a central principle of occupational therapy: that a condition or illness should be 
understood in terms of a patient’s (in)ability to engage in occupational activities 
(which includes domestic and work activities). In a sense, the AMPS tool has 
functioned as a vector, a means of transporting elements of the professional vision 
of occupational therapy into a hospital-based paediatric neurology context.  
We can also see here another example of the broad clinical gaze of the 
PMDS that we saw during the team meeting and during the COPM-scripted goal 
setting session. Again, the clinician’s attention is directed towards various ‘non-
biomedical’ aspects of the patient. As with the COPM-scripted goal setting session, 
it is the consequence of a carefully coordinated interaction (involving a well-trained 
‘mandated’ OT) that enables the ‘patient-centred’ mantra of the tool from 
occupational therapy to be expressed. In the following chapter I will relate this 
insight on the PMDS clinical gaze to current discussions on the implications of new 
neurotechnologies; At this point it suffices to say that it demonstrates that clinicians 
working with new neuro-interventions, like many patients subjected to neuro-
interventions, resist reductive, biomedical brain-based explanations of disease and 
the patient. 
 It is also worth noting here that while the PMDS is the only DBS service to 
have adopted the AMPS so far, it not unique it is adoption of this type of clinical 
assessment tool. Indeed, it is perhaps best seen as part of the shift identified by 
Armstrong and colleagues towards the creation and adoption of QoL measures 
within medical practice more broadly (Armstrong et al. 2007). Despite the 
pharmaceutical industry’s proclivity for easy-to-implement ‘objective’ measures, 
there has been a trend away from methods of data collection that rely exclusively on 
clinician (or investigator) reporting, toward those that employ greater patient 
involvement (Hobart and Thompson 2001). This shift is often explained as a 
consequence of the emergence of ‘patient rights’ movement within healthcare and 
the growing body of evidence illustrating that clinicians and patients often have 
different perceptions of the impact of an illness (Reiser 1993; Hobart et al. 1996). 
Armstrong argues that it represents a deeper transformation within medical 
thinking: an awareness that the underlying pathology of an illness does not 
necessarily correspond to the symptoms experienced by the patient, and if health 
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interventions are to be adequately assessed, it is these ‘distal’ symptoms and 
experiences that must be measured (Armstrong et al 2007, Armstrong 2011).  
While patient-perceived changes are often derided for being ‘less objective’ 
than those measured by investigators or clinicians, they are nonetheless now 
considered an important component of evidence-based health research in 
neurology. In effect, disability-based and QoL-based tools manage a tension 
between evidence-based medicine on the hand and the patient-centred healthcare 
movement on the other: tools such as the AMPS essentially convert particular 
aspects of illness (as experienced by the patient) into a set of ‘objective’ data (May et 
al 2006).  To some degree this shift towards such tools has been institutionalized: 
the FDA has taken the stance that new drugs for neurological diseases will not be 
approved based on measurements of disease process or impairment alone. 
Improvements that patients themselves consider relevant (such as improvement in 
disability) must also be illustrated (Buskens and van Gijn 2001). Similarly in the UK 
it has become standard practice to report patient-based outcomes alongside more 
traditional biomedically-defined outcomes (Fitzpatrick et al. 1998).  
 Despite this apparent sea-change, the adoption of the AMPS tool has 
created additional challenges for the PMDS. The team is, in effect, attempting to 
redefine ‘what counts’ as data in the field of paediatric neurology in such a way that 
it supports their activities. Thus, ensuring the longer term survival of DBS as a 
therapy for secondary dystonia depends on their ability to convince other agents 
that their framing of ‘what counts as data’ is legitimate. Like the COPM, the AMPS 
is prevalent in occupational therapy settings but it is largely unknown within the 
neurology community, where the BFM is still considered the standard tool for 
measuring the effectiveness of interventions for dystonia. So despite successfully 
incorporating the tool into their clinical practice, and despite successfully using it to 
capture clinical improvements that patients and their families feel are meaningful, 
the team must still convince the wider neurological community that the AMPS is a 
scientifically sound, appropriate measure, and that the data it generates therefore 
count as sufficient evidence of DBS effectiveness.25 This can be seen as part of a 
more significant dilemma encountered by the team that I will briefly touch upon in 
the next, final chapter of this thesis: convincing other clinicians that the novel 
                                                 
25 One of the team’s strategies for doing this is to publish peer-reviewed articles that systematically 
demonstrate the shortcomings’ of the BFM while highlighting the utility of AMPS.   
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activities that take place within the PMDS, including the DBS therapy, are indeed 
‘innovative’ and ‘progressive’, and thus worthy dissemination amongst the wider 







8 Discussion: Reconceptualising medical innovation 
 
8.1 A brief recapitulation 
In the introduction to this thesis I argued that the Morlacchi-Nelson model of 
medical innovation would provide a useful starting point for this exploration of 
deep brain stimulation in paediatric neurology. The advantages of using this as an 
underlying conceptual tool should now be apparent. Firstly, it has encouraged us to 
explore the ‘conjunction of circumstances’ that has shaped the development and 
dissemination of DBS technology, and in doing so, we have provided some context 
for the activities of the PMDS.  Deep brain stimulation, as we have seen, has its 
genesis in the knowledge and material infrastructure of stereotactic neurosurgery, 
and the DBS technology emerged from advancements in the development of the 
cardiac pacemaker. The advent of medical device regulation along with the 
development of clinical assessment tools for specific illnesses shunted the 
development of DBS towards specific therapeutic applications, most notably 
Parkinson’s disease. The development of additional clinical assessments tools has 
enabled Medtronic to sponsor additional clinical trials and thus widen the market of 
their technology. Thus, in answer to the first research question of this thesis, (What 
factors have shaped the development and dissemination of DBS technology?) we 
can say that the development and dissemination of DBS technology has been 
shaped by an intertwining of professional and commercial interests, the advent of 
medical device regulation and the co-development of particular clinical assessment 
tools.  
The second advantage of using the Morlacchi-Nelson model of medical 
innovation as a starting point is that it has encouraged me to explore the learning-
in-practice entailed in the implementation DBS technology within an actual clinical 
service. In order to explore this learning-in-practice I identified what PMDS team 
members perceived to be key challenges associated with their work, and examined 
how PMDS clinicians had developed strategies for managing each of these 
challenges through the second research question: ‘What are the challenges 
associated with the integration of DBS technology into a therapy for children and 
young people with dystonia?’;  and the third research question: How do members of 
the PMDS team attempt to overcome these challenges in clinical practice? The first 
challenge we explored was coordinating multidisciplinarity; or ensuring that the 
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diverse professionals who constitute the PMDS work together as a collective. I 
argued that the built environment of the hospital enabled multidisciplinary team 
work, and I also illustrated how the crafting of a team diary and the regular team 
meetings both functioned to coordinate multidisciplinary team work. The meetings, 
for example, provided an opportunity for Dr Martin to discursively unify the team 
and alleviate tensions, as well as providing an opportunity for encouraging team 
members to complete and circulate multidisciplinary documents.  
The second challenge that I focused on was identifying dystonia and 
differentiating it from other manifestations of neurological pathology such as 
spasticity – this is necessary in order to help identify which patients with secondary 
dystonia are suitable deep brain stimulation candidates. I demonstrated that the 
team’s strategy for overcoming this challenge was to utilise the embodied skills of 
the physiotherapists. By engaging in communicative body work and utilising 
carefully-honed tactile skills, the physiotherapists are able to identify dystonia and 
evaluate its impact on the patient’s gross motor function. 
The third challenge that I explored was managing the expectations of 
patients and family members.  Here, I demonstrated how the team had adapted a 
tool from occupational therapy, the COPM, into a goal-setting session. Provided 
that those individuals involved in the session stick to the script, the goal-setting 
session prompts a particular mode of communication: it prompts patients and 
family members to be explicit about their hopes, and it encourages team members 
to convey their expectations in terms that are accessible to patients and families. 
And the fourth challenge we explored was measuring clinical outcomes. Specifically, 
the team considers the standard clinical assessment tool for measuring dystonia (the 
BFM) to be inadequate for measuring improvements that patients and families find 
meaningful. Consequently, the team has adopted an additional tool from 
occupational therapy, the AMPS. The team, therefore, is attempting to redefine 
‘what counts as data’ when assessing interventions in dystonia paediatric neurology. 
These strategies are examples of the varied work that is required to implement an 
emerging medical technology within clinical practice. Obviously a technology on its 
own is useless: if the potential benefits of a promising technology are to be realised 
it will need to become integrated within an actual clinical service. The ability of such 
a service to make the most of a technology will depend upon the ability of clinicians 
to work effectively with one another and with patients, to identify appropriate 
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candidates, to successfully manage expectations, to demonstrate the effectiveness of 
their service, and to manage any other challenges that they encounter. This adaptive 
work, as Morlacchi and Nelson (2011) point out, is a vital component of the 
innovation process. Economists have also made this point. Localised learning 
processes, according to Antonelli, produce technical knowledge which is the 
“primary input in the generation of new knowledge at large, together with the 
scientific advances… and the acquisition of external knowledge spilling in the 
atmosphere” (2009: 632). What I have illustrated in the preceding chapters is the 
diverse nature of this adaptive work; it involves embodied skills and tacit 
knowledge, emotional labour, and a variety of profession-specific knowledge and 
tools.  
This ‘adaptive’ work is transformative. As Hopkins and colleagues point out, 
realising the potential of new technologies requires the construction of “new 
elements and linkages to reconfigure existing socio-technical systems” (Hopkins et 
al 2007: 568). It requires, in other words, the creation of novel assemblages. In the 
case of the PMDS these novel assemblages involve a diverse array of tools, bodies, 
skill-sets, fields of knowledge, and elements of the built environment. Indeed, the 
multidisciplinary nature of the team has enabled it to draw on a diverse array of 
resources from a range of professions, which together have resulted in a service that 
is unique within hospital-based medicine and unique within neurology (paediatric or 
otherwise). The team’s use of the COPM and AMPS are good examples of this: 
both have been adapted somewhat to suit the local clinical context, and both entail 
clinician-patient interactions that are unusual within tertiary neurological services. 
And if the PMDS is successful in convincing the wider neurological community that 
the AMPS is a legitimate assessment tool for dystonia, then the transformative 
effect will not be limited to their local context. We can see here how the 
development and dissemination of a technology can prompt wider changes within 
clinical practice: an emerging technology has enabled the formation of a novel 
collection of professionals; this novel collection of professionals has, by bringing 
together an eclectic array of resources, created a unique service; and this service may 
prompt wider changes among a specialist community.  
It is worth noting here that innovative activities of the PMDS team 
correspond to what some economists, drawing on complexity theory, have referred 
to as the complexity theory of change (Rosser 1999; Foster 2005). According to this 
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model, ‘change’ (some of which may be referred to as innovation) emerges from a 
collective “cluster” of heterogeneous individuals each possessing a distinctive set of 
skills. These individuals are creative: they may adhere to the local rules that 
characterise the cluster, but they also draw-upon their skills and available resources 
(or capacities, if we employ the parlance of material semiotics) to overcome 
constraints in original ways. These individuals also possess bounded rationality 
(rationality resulting from a myopic understanding of the world) rather than 
Olympian rationality (rationality based upon a full awareness of all available tools, 
resources and constraints). According to this model, innovation emerges from the 
many creative activities of these agents within the heterogeneous collective, and can 
be stifled by top-down, imposed decision making: individuals must be provided 
with some ‘creative space’. This has certainly been the case with the PMDS. While it 
was Dr Martin’s explicit intention to create a team of individuals from specific 
professional backgrounds, he did not stipulate which tools and resources these 
professionals were to utilise in their roles (and he would had a limited knowledge of 
the many, profession-specific tools available to them), and team members have been 
left to their own devices to work-out which tools would be most appropriate.26 
 
8.2 The socio-political trends shaping medical innovation 
According to this ‘complexity theory school’ of economics it is not possible to 
predict the form of innovations that will emerge from such clusters: this would 
require an impossible foresight of the many interweaving forces that shape a local 
context. Nevertheless, this school argues, there are discernible patterns of 
innovation. These reflect what complexity theorists have referred to as attractors.  
Attractors are, in effect, the limits of possibility for a given system of activities.27 
Such limits may be the consequence of, for example, government policies, prevalent 
ideologies or existing material infrastructure that subsequently induce patterns of 
                                                 
26 The occupational therapist, for example, made the decision to bring in the COPM as a 
replacement for the Goal Attainment Scale (GAS) that she felt was inadequate: “I started using it by 
myself with the psychologist. So that’s how it started” (Occupational therapist, interview). 
27 The technical definition of an attractor is: “a set of values in phase space to which a system 
migrates over time, or about which the system iterates” (Meade et al 2004). They have what DeLanda 
refers to as a real, virtual existence, rather than an actual existence (DeLanda 2002): Attractors 
influence perceivable phenomena, but they themselves are not directly perceivable. Hence, they have 
a real existence in ‘phase space’.         
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organisation and action. We saw a good example of an attractor in the historical 
development of deep brain stimulation technology:  Medtronic created an extensive 
set of skills, resources and procedures for producing cardiac-pacemakers. This 
embedded ‘technology platform’ presented a pathway for subsequent innovative 
activities; a pathway which closes some possibilities while making others more 
likely, thus providing structure for the development of neurostimulator technology. 
Subsequently the neurostimulator and the cardiac pacemaker share componentry 
and are visually similar: we can say that the technology platform created an 
‘attractor’, around which particular patterns of devices emerge. My point here is not 
to specifically adopt this notion of ‘attractor’ into my account of deep brain 
stimulation and the PMDS, but rather to argue that despite the significant diversity 
that may exist among innovative biomedical sites, particular patterns in innovation 
will nonetheless emerge, patterns that are the result of various structuring 
influences. As I stated earlier, these are what Faulkner has called “powerful 
structuring forces that affect the capacity of groups to shape a technology” (2009: 
24). I have referred to these forces as socio-political trends, and in the preceding 
chapters I have identified several (thus addressing the fourth research question of 
this thesis: What socio-political trends influence the development of PMDS’ DBS 
service?) 
During the historical development and dissemination of deep brain 
stimulation I illustrated that commercial industry and the motivation for profit 
could be considered one such socio-political trend: Medtronic, which formed 
alliances with key clinicians, was a key driver in the dissemination of deep brain 
stimulation. I also argued that this dissemination and stabilization was shaped by the 
emerging prominence of evidence-based medicine and the rationalization of 
healthcare. This trend became ‘encoded’ in legislation that created medical device 
regulation and redefined ‘efficacy’ as something that is objectively verifiable. This 
has created a context where the development of new technologies is directed 
towards therapeutic applications for illnesses which can be quantified with such 
tools.  
Other authors have also noted the transformative effects of commercial 
industry and rationalisation in healthcare. Blume, for example, argues that the 
influence of commercial industry has created a common pattern of medical device 
development: devices typically have their genesis in the ‘tinkering’ activities of an 
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engineer or physicist, or a clinician with some training in these areas who plays 
around with a newly acquired material (Blume 2010: 8; Blume 1992). This 
entrepreneur then seeks guidance from the manufacturing industry, leading to an 
alliance that gradually expands to include other clinicians and hospitals, and during 
which the device undergoes ongoing incremental modification.  Inevitably large 
companies will come to dominate later stages of development and dissemination as 
they possess the necessary capital to obtain regulatory approval. Blume states that 
the artificial hip, the intraocular lens, the artificial kidney, obstetric ultrasound 
technology and the cochlear implant followed this pattern – a pattern that 
characterised the development of deep brain stimulation technology.  
Several commentators have drawn attention to the role of commercial 
industry in facilitating EBM and rationalisation in healthcare. Timmermans and 
Berg argue that pharmaceutical companies, since the advent of pharmaceutical 
regulation, have become strategic supporters in EBM (Timmermans and Berg 2003: 
167). In an effort to secure access to markets, pharmaceutical companies have 
supported the construction and dissemination of standards that can be used to 
‘objectively’ establish the effectiveness and superiority of their drugs. Rationalisation 
creates a degree of uniformity and reduces uncertainty, which provides companies 
with clear ‘pathways’ for accessing markets and thereby enable drug companies to 
construct comprehensive business models and thus secure investment. Clarke et al 
(2003) argue that this alliance between the pharmaceutical industry and 
rationalisation has been ‘greatly facilitated’ by information technologies which have 
enabled distinct, heterogeneous research and clinical sites to become subject to 
centralised management operation.  
We have seen the same phenomenon in regard to the medical device 
industry: Medtronic has facilitated the diffusion and standardization of outcome 
measures (particularly the UPDRS) across research sites in order to access lucrative 
markets for their deep brain stimulation technology. For Clarke and colleagues 
(2003), this alliance between commercial industry and rationalisation is one 
manifestation of the BiomedicalTechnoService Complex Inc; a contemporary form 
of the Medical Industrial Complex identified by Relman (1980). As we will see 
further on, Clarke and colleagues believe that this complex generates particular 
healthcare practices that are producing new bodies and health identities.  
8: Reconceptualising medical innovation 
 
 214 
We also saw that EBM and rationalisation has structuring effects on the learning-in-
practice activities of the PMDS. As we saw in chapter 6, team members have an 
obligation to ‘objectively demonstrate’ the efficacy of DBS, very much in 
accordance with the EBM movement. And, the standard tool for generating this 
evidence (the BFM) was established as such by the activities of Medtronic in its 
attempt to gain regulatory approval. Interestingly, the team’s response to the 
perceived limitation of this clinical assessment tool, namely, to adopt another tool 
and attempt to redefine ‘what counts as evidence’ is not unique. Blume has noted 
the same occurrence in regard to the cochlear implant (Blume 2010). Proponents of 
the controversial implant were able to define the criteria according to which its 
success would be judged: they strategically defined the desired outcome as 
‘improved speech perception and production’ and were thus able to demonstrate its 
effectiveness using tools that were available only to medicine and audiology 
(2010:176). Other more comprehensive ways for measuring the effect of cochlear 
implants on the lives of children were disregarded. Blume suggests the 
dissemination and stabilisation of new therapies in the era of EBM does not 
necessarily entail using evidence to build consensus among agents, it entails creating a 
consensus about what counts as evidence.    
In Blume’s example this consensus was crucial to the success of the cochlear 
implant. It also had the effect of strengthening the authority of the medically-trained 
clinicians who were promoting the device: its success was defined using their tools 
and according to their terms. These tools and terms were, of course, derived from 
an understanding of deafness that was based upon the biomedical model. 
Consequently, this rendering of deafness as a biomedical problem requiring 
technological intervention was perpetuated during the dissemination of the device, 
much to the abhorrence of those who had less-reductive understandings of 
deafness, particularly those who understood deafness an important part of self- and 
collective-identity.  The device, then, was something of a vector for the biomedical 
model of disease. Other commentators have made a similar link between the 
development and dissemination of new medical technologies and the perpetuation 
of reductive, biomedical model-derived understandings of health and illness (eg, 
Corea, 1985; Pasveer 1989; Klein et al 1991). Pickstone has argued that as clinical 
practice has become increasingly reliant on technologies, there has been a shift from 
biographical medicine (where illnesses are understood as disturbances to individuals’ 
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lives) to techno-medicine (Pickstone 2000: 10). Similarly, Brown and Webster 
suggest that new technologies and their innovation networks tend to confirm the 
power of the biomedical model and, more generally, biomedical-based research 
(Brown and Webster 2004: 169). For Clarke and colleagues, this biomedicalization is a 
key feature of the BiomedicalTechnoService Complex Inc. It is a consequence of 
the increasing intermeshing of commercial interests, rationalisation and new medical 
technologies, and it is, they argue, generating new individual and collective identities 
based around biomedically-defined criteria (Clarke et al 2003).  As we will see in 
section 8.4, new neurotechnologies have also been implicated in this trend towards 
reductive understandings of disease and the body. 
Despite the influence of commercial interests and rationalisation, our 
exploration of DBS in paediatric neurology reveals a different picture. In the 
process of exploring the learning-in-practice activities of the team I identified other 
socio-political trends which have, in effect, led them to enact less-reductive 
understandings of disease and the body. I argued that the multidisciplinary structure 
of the team reflects a prevalent belief that multidisciplinary teams can provide better 
health services for patients, particularly children. This belief has been encoded in the 
tariff structure for children’s healthcare services as well as other policies which seek 
to remove financial and structural barriers to multidisciplinarity. It has also been 
encoded in the material, physical form (the structural layout) of the children’s 
hospital. The physical form of the hospital facilitates the multidisciplinary activities 
of the PMDS by providing them with a diversity of spaces for carrying out a 
diversity of interactions with patients. I argued that the team’s activities have been 
influenced by a trend in healthcare that promotes patient-involvement in decision 
making and which aims to protect the autonomy of patients. This is a trend which 
has become embedded in NHS policy and is reflected in the team’s attempts to 
carefully manage the expectations of patients and families, resulting in their 
adoption of the COPM tool. And, I argued, the COPM and AMPS tools reflected a 
‘patient-centred’ approach to health service provision that is prominent in 
occupational therapy, and has subsequently, via the adoption of these tools, become 
embedded in the activities of the PMDS. The multidisciplinary structure of the team 
and the multidisciplinary nature of their tools and activities have brought about a 
clinical gaze that extends far beyond the biomedical elements of the patient’s body. 
In addition to neurological and gross motor function considerations, team members 
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scrutinize a patient’s cognitive abilities, speech and language skills, their capacity to 
carry out tasks of daily living, their expectations regarding the intervention, and as 
we saw during the team meeting, a patient’s relations with peers and family 
members, as well as a patient’s schooling. Team members may draw upon 
knowledge of any number of these elements when deciding upon an appropriate 
course of action.  The PMDS, as I have argued, enacts a clinical gaze that has a 
broad remit. It is for this reason that the PMDS’ attempt to redefine ‘what counts as 
evidence’ stands in striking contrast to that of cochlear implant proponents. The 
PMDS’ extensive assessment regime means that the effectiveness of DBS is defined 
according to a broad array of characteristics: changes in gross motor function, 
impairment and ability to perform ADLs (as we saw in the preceding chapters) and 
changes in cognitive and speech and language abilities (which we did not explore 
here).  As a result, various allied health professionals, particularly the occupational 
therapist and physiotherapists, have been granted considerable authority in defining 
and determining the effectiveness of DBS within the PMDS. 
The development and dissemination of many new biomedical technologies 
may involve a perpetuation of the biomedical model and the elision of other modes 
of understanding disease and the body, but this has not been the case as far as the 
PMDS is concerned. This is because the activities of the PMDS, indeed its very 
structure, have been influenced not only by EBM, rationalisation and commercial 
interests, but also a by pro-multidisciplinary socio-political trend, and by a trend 
towards patient-centred care. Indeed, the PMDS represents a confluence between 
these various trends; a confluence that is unique within hospital-based medicine.  
May and colleagues have explored a similar convergence of trends within the 
practices of UK primary care, where the patient-centred approach to clinical 
practice is more prominent than it is in hospital settings (May et al 2006). 
Increasingly, clinicians working within primary care must manage a potential 
conflict between EBM and its insistence on evidence-guided decision making on the 
one hand, and patient-centred care, which insists on incorporating patient’s 
experiences and narratives of illness into decision making, on the other. 
Interestingly, the potential tension between the two has spawned technological 
solutions: novel tools that embody both approaches. May and colleagues provide 
the example of decision support tools which provide space for patient-input and 
prompt clinicians to divulge available data about an intervention (2006: 1026).  We 
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have seen the generation of such tools within the PMDS: the COPM-scripted goal 
session being a good example of this. In this light, we can see that the novel 
strategies developed within the PMDS parallel strategies developed elsewhere, 
where a similar conjunction of socio-political trends occurs.    
The innovative activities of the PMDS, then, have not occurred in isolation. 
They reflect broader trends in contemporary healthcare; trends that have become 
encoded in legislation, in tools, in architecture, in NHS policy, or in the modes of 
thinking of clinicians. In effect, these trends present pathways for individual teams 
such as the PMDS: they constitute a set of constraints and resources which make 
some innovative activities more likely than others. While the development of deep 
brain stimulation therapy for children with dystonia parallels other innovations in 
medicine, it is also characterised by some divergences: these are a consequence of 
the particular confluence of socio-political trends which structure the activities of 
the PMDS. 
 
8.3 The Complex Model of Medical Innovation 
Shortly I will relate these observations to a current discussion on the implications of 
new neurotechnologies. Firstly, however, I will outline the ‘Complex Model of 
Medical Innovation’, which I believe has been validated by our exploration of deep 
brain stimulation in paediatric neurology. As I stated in the introduction to this 
thesis, the Complex Model being suggested here is largely derived from the 
Morlacchi-Nelson model. The key difference between the two is an additional 
‘sphere of influence’ representing socio-political trends which, to some extent, 
structure the local context within which innovation occurs. This complex model is 
represented below in figure 8.1. I have used the activities of the PMDS team to 
provide detail.  
The ‘sphere of influence’ representing socio-political trends encapsulates all 
three other spheres. This is to indicate that socio-political trends are structuring 
forces that can shape learning-in-practice, technology transfer, and understandings 
of disease and the body. Thus, according to this model, evolution in clinical practice 
(which we might refer to as ‘innovation’) results from the interaction of technology 
transfer, understandings of the disease and the body, and learning-in-practice (as 
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stated by Morlacchi and Nelson), all of which are structured to some degree by 
various socio-political trends.28    
 





Following Morlacchi and Nelson (2011: 512) we can say that the relative influence 
of each sphere in the process of innovation will differ from case to case. The 
development of a DBS service for children and young people with dystonia has 
been heavily influenced by technology transfer, learning-in-practice, and socio-
political trends, but we might imagine other cases where the evolution of a clinical 
                                                 
28 As I stated earlier, Faulkner (2009) has also illustrated that particular ‘macro structuring forces’ 
have shaped the development of several medical devices. He does not, however, put forward a 
model of innovation to conceptualise this relationship between macro forces and local innovative 
practices. Nor does he differentiate the innovation process into ‘technology transfer” “learning in 
practice” and “understandings of disease”.   
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therapy has been radically influenced by the dissemination of new scientific 
understandings of the disease.  It is also important to keep in mind that the 
learning-in-practice activities may lead to new scientific understandings of disease 
(Morlacchi and Nelson 2011: 512), a phenomenon that was not explored in this 
particular case study.29 
A legitimate question here is: why bother producing a model of medical 
innovation? If innovation emerges from a complex intertwining of forces, would it 
not be more appropriate to provide a rich detailed account of a case study, and 
refrain from producing an abstract model that is sufficiently general that it can 
represent all cases of innovation? Surely the generality of such a model would 
render it meaningless?   An answer to this is that such a model can serve to counter 
the prevalent and misleading linear model of innovation that was discussed in the 
introduction. Godin has argued that various agents have used the linear model as a 
rhetorical device to secure funding for basic science, and that its simplicity grants 
administrators with a sense of orientation when allocating funding for research and 
development (Godin 2006). Hence, as Morlacchi and Nelson have suggested, 
research into other important aspects of innovation, aspects that are elided by the 
linear model, has been underfunded. As we have seen, the clinical implementation 
of a novel technology and the creation of a useful clinical service involve 
considerable work on the part of clinicians. A more comprehensive model can be 
used to draw attention to the importance of this work, and possibly help garner 
additional support for clinicians attempting to utilise new technologies. Further on 
(in section 8.5) I will demonstrate the utility of this more comprehensive model: the 
findings from this project’s examination of the innovative activities of the PMDS 
can help inform recommendations on ‘preparing the future for deep brain 
stimulation’.  
 
                                                 
29 PMDS team members, however, are engaged in research activities that are generating new 
understandings of the disease and the body. The clinical research fellow has been attempting to draw 
a correlation between clinical outcome (and reduction of dystonia in various parts of the body) with 
the exact position of the electrodes within the GPi. The goal is to determine if specific regions of the 
GPi are implicated in the movements of particular body regions. So far he has found no meaningful 
correlation, which may suggest that the GPi is not divided in this way.    
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8.4 Neurotechnologies and the march towards neurocentrism? 
According to Peter Keating and Alberto Cambrosio (2003), during the 20th century 
there was a great transformation from medicine to biomedicine. The former was 
characterized by what Pickstone (2000) referred to as biographical medicine (in 
which illnesses are understood as disturbances to individual’s lives), whereas in the 
latter, biology and medicine have become entwined to such an extent that health 
and illness are rendered intelligible in terms of an array of biological entities: 
oncogenes, DNA profiles, cellular markers, viral load counts and so on. Keating and 
Cambrosio describe this transformation as being characterized by the emergence of 
biomedical platforms.30 These are configurations of healthcare policy, architecture, 
machines, infrastructure, reagents and ‘ways of thinking’ that reify and perpetuate 
this biomedical mode of clinical work.  These platforms are embedded within 
hospital settings (in the form of diagnostic laboratories, for example) and have a 
structuring effect on clinical research and clinical practice.  
Importantly, as I have alluded to, these platforms are implicated in the 
formation of new individual and collective identities, in which biological traits have 
become the basis of social life. Rabinow’s term (2006) biosociality is often used to 
capture this phenomenon (Rose and Novas 2004, Novas 2006; Brekke and Sirnes 
2011): Biomedical diagnoses can influence how individuals’ perceive themselves, 
and this altered self-perception prompts individuals to engage in new social and 
political activities that appropriate and perpetuate the language of biomedicine. Rose 
has argued that in this era of biomedicine, our sense of individuality derives from 
our knowledge of biomedical traits and is “increasingly grounded within our fleshy 
corporal existence” (Rose 2007: 26).  The emergence of biomedical platforms, then, 
has involved a change in the way which health and illness are rendered intelligible, 
and it has prompted the formation of new identities and social collectives which 
draw-upon and perpetuate biomedical knowledge. 
                                                 
30 In a sense, the term ‘biomedical platform’ can be seen as a synonym for ‘biomedical paradigm’. 
Keating and Cambrosio use the term platform because they wish to highlight the material and 
institutional basis of this mode of clinical work. The notion of a biomedical ‘paradigm’ could give the 
impression that a biomedical ‘way of thinking’ preceded and brought about biomedical technologies 
and pro-biomedical institutional arrangements, rather than being mutually co-constitutive. 
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In this project, we have seen the emergence of different kind of platform; a 
platform that exists in addition to those identified by Keating and Cambrosio. This 
‘multidisciplinary’ platform is characterized by pro-multidisciplinary healthcare 
policy, architecture (the built environment) that encourages multidisciplinary team 
work, a multidisciplinary team structure, and clinical assessment tools and ‘ways of 
thinking’ that reify and perpetuate what I have referred to as a broad clinical gaze. 
In the process of addressing the fifth research question of this project (how are 
dystonia and the patient rendered intelligible within the PMDS?) we have seen that 
this broad clinical gaze has the effect of foregrounding particular social aspects of 
an illness and aspects of the patient’s experience of illnesses during clinical 
interactions; the team meetings in which a patient’s family dynamics and schooling 
were discussed is a good example of this. It is according to these aspects that 
dystonia is rendered intelligible within the PMDS, and it is according to these 
aspects – as illustrated by team’s use of the Assessment of Motor and Process Skills 
- that the effectiveness of deep brain stimulation is measured and assessed. Whether 
or not such platforms exist in other countries or in non-paediatric contexts is matter 
for further research. But in the setting where I have been doing my fieldwork, this 
platform has shaped the way in which a new neurotechnology has been integrated 
into clinical service, and it is structuring the type of patients, bodies and illnesses 
that are being enacted by within this service.  
Thus, in addressing the fifth research question I argue that, just as Mol 
(2002) illustrated in regards to atherosclerosis, PMDS patients and dystonia are 
enacted in multiple forms. As patients pass through the service they become 
entwined in various assemblages which render the body and dystonia intelligible in 
multiple ways: in the GMFM and musculoskeletal screen, dystonia is enacted as 
impaired gross motor function; during the AMPS and COPM-scripted goal setting 
session, dystonia is enacted as a reduced ability to undertake tasks of daily living, or 
a reduced ability to engage in the world. It is the patient’s practical relationship to 
and involvement in the world that is being assessed, and they are not, then, reduced 
to their biological and biochemical, (or cerebral) composition. And as we saw during 
team meetings the patient was rendered intelligible as an individual who was part of 
a wider network involving family members, peers and schooling. Understanding 
dystonia in this way, and understanding the patient as an agent-in-the-world has a 
utility for the PMDS clinicians: these understandings are drawn-upon during 
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decision making processes. Within this platform that structures the activities of the 
PMDS, the patient and the patient’s illness are not simply reduced to its biomedical 
elements.   
It is important here to relate these findings to some of the emerging 
scholarship on the cultural impact of the neurosciences. As briefly illustrated in the 
introduction to this thesis, social scientists have noted that neuroscience and 
neurotechnologies are increasingly reshaping the way in which health, illness and 
personhood are understood, and are potentially influencing how people understand 
themselves (c.f. Vidal 2009; Pickersgill and Van Keulen 2011; Rose and Abi-Rached 
2013). Indeed, this work explores what could be described as the emergence of 
neurosociality, a form of biosociality in which neuroscience-derived understandings of 
brain networks, brain chemistry and brain functioning are drawn upon by actors to 
make sense of health and illness, and are increasingly used by actors as a basis for 
self-understanding. Psychiatric disorders, for example, are being recast as neuro-
circuit disorders, and problems ‘of the mind’ have become problems ‘of the brain’. 
As Rapp argues, “psychodynamic explanations of human variation and suffering” 
are being eclipsed by “brain-orientated, hyper-materialist explanations” (Rapp 2011: 
8).  
Various sociological studies have explored specific manifestations of this 
neurosociality. Mautoud’s account (2011) of DBS recipients who attributed their 
emotions and behaviours to their neural networks (and the effect of stimulation on 
these networks) is one example. Similarly, during her study of a clinical research 
sites using functional-MRI to study the brains of children with learning disorders, 
Rapp noted (2011) that many mothers saw their children as ‘cerebral subjects’ and 
adopted language from neurology and neuroscience when accounting for their 
children’s behaviour. Other studies have noted that while actors may adopt 
elements of this neurologic discourse, they may nonetheless avoid equating the self 
with the brain. Singh has noted (2013) that children who had received a diagnosis of 
ADHD (and had thus been exposed to neuroscientific discourse) often creatively 
made a distinction between themselves (“I”) and their brain, and some children 
stated that their actions were a consequence of negotiations between the two. Focus 
group research conducted by Pickersgill and colleagues has also illustrated the 
creative ways in which actors draw upon ideas from neuroscience. Participants, who 
came from a variety of backgrounds including the neurosciences, teaching and 
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social care, were encouraged to talk about the relationship between ‘the self’ and the 
brain. For some of these participants (particularly the neuroscientists), neuroscience 
discourse provided a valuable set of tools for understanding personhood and illness, 
but for others (such as those professionals involved in social care or education) it 
was ignored or integrated into already-held understandings that draw on an array of 
resources for making sense of oneself and others. Pickersgill and colleagues suggest 
that individuals are bricoleurs; agents that “assemble frameworks for understanding 
personhood by piecing together different knowledges concerning psyche, soma and 
society” (2011: 361). In this regard, then, neuroscience discourse is simply an 
additional resource that people draw-upon when accounting for their behaviour and 
constructing a sense of self. 
Indeed, many of the participants involved in Pickersgill and colleagues’ 
focus groups produced a complex account of personhood that related neuroscience 
discourse to sociological and psychological explanations of personhood. A number 
of participants believed that brain-based explanations of illness and personhood 
alone were too reductive, and stated that mental illness, for example, should be seen 
has having its origins in early life experience. Here, participants employed a 
neurodevelopmental narrative that drew attention to the importance of nurture and 
social interaction: problematic behaviour is a manifestation of neurological 
abnormalities, but these abnormalities are a consequence of neglect during early 
childhood (Pickersgill et al: 358-359). Personhood is not simply equated with the 
brain: it is seen, at least in part, as product of a person’s childhood social ecology: 
“the multidimensional web of actors, structures and experiences within which they 
[were] situated” (Pickersgill 2009: 58). While this narrative was articulated by 
participants in reference to mental health, it is nonetheless salient to this project as it 
seems to align with the activities of the PMDS team. As we have seen, the team’s 
broad clinical gaze is very much concerned with examining their patients’ social 
ecology, and many of the team’s activities are directed towards ensuring that 
participants can engage more fully in day-to-day activities. Within the PMDS deep 
brain stimulation is understood as a tool for ‘unlocking’ the body and enabling 
patients to engage in the world.31  Here, then, the neural structures of the brain are 
implicated in identity and personhood, but only in so far as they limit an individual’s 
                                                 
31 This point was explicitly stated by the clinical research fellow (see page 96). 
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ability to immerse themselves in culturally-mediated activities. Indeed, the activities 
of the PMDS team would suggest that for them, it is this immersion which is seen 
as the ultimate source of the self.  
Despite the team’s reliance on imaging technologies, and despite that fact that 
they put electrodes in the brains of children, their activities do not, then, appear to 
perpetuate neurocentric discourses in which health, illness and personhood are 
equated with the structures of the brain. This is, as I have argued, because a 
particular ‘multidisciplinary’ platform has shaped the way in which these neuro-
technologies have been integrated into a clinical service; a platform that has 
structured the type of clinical activities that take place, and has thus structured the 
way in which patients, brains and illnesses are enacted.  The case study, then, 
suggests that the social impact of the neurosciences and new neurotechnologies will 
depend very much on the way in which they are integrated within (and hybridized 
with) existing platforms. It is quite possible that new neurotechnologies will 
perpetuate neurocentric, biomedical based understandings of health and 
personhood, but as yet this has not been the case in regards to paediatric deep brain 
stimulation. 
 
8.5 Policy implications: Preparing the future for deep brain stimulation 
The findings from this project can help guide the formation of policy 
recommendations relating to deep brain stimulation. In June 2013 The Nuffield 
Council on Bioethics launched its report Novel Neurotechnologies: Intervening in the Brain 
(the report I referred to at the very beginning of this thesis). The report had several 
principle aims. First, it sought to identify “the economic pressures and regulatory 
controls that shape and challenge the development pathways of novel 
neurotechnologies.” The ‘great need’ for such technologies, the report argues, 
necessitates the formation of a climate that facilitates innovation and directs 
“research, development and investment towards the production of safe and 
effective products” (2013:xix). The report also sought to explore the ethical and 
social issues that arise from the application of novel neurotechnologies. Such 
technologies, the report argues, raise unique social and ethical concerns due to the 
special status of the brain. The brain plays “a central role in the operation of our 
bodies, our capacities for autonomous agency, our conceptions of ourselves and our 
relationships with others” (xix). Technologies that intervene in the brain have the 
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potential to disrupt a person’s sense of self and their ability to exercise autonomy. 
This is complicated by the fact that the workings of the brain are an enigma: the 
processes which underlie a person’s mental functioning are largely unknown and the 
relationship between mind and the brain are the subject of considerable debate. 
Hence, there is “considerable uncertainty” surrounding the potential impact of 
novel neurotechnologies. 
And third, the report sought to develop a series of recommendations that will 
help those developing novel technologies to navigate this tension between great 
need and great uncertainty. These recommendations are the elements of 
“responsible research and innovation” and include (amongst others): 
 
1. Securing safety and efficacy: It is important, the report states, that the risks of a 
novel neurotechnology be assessed relative to their efficacy, and relative to the 
availability of other treatments. 
2. Generating robust evidence: It is important, therefore, that the processes of 
innovation generate robust evidence. Such evidence on efficacy and safety is 
necessary to support autonomous decision making among patients and research 
participants (and therefore bears directly on seeking and obtaining valid, 
informed consent). Additionally, the report states, robust evidence will ensure 
that interventions will only occur when there are sound reasons for doing so. 
3. Co-ordinated interdisciplinarity:  There are valuable advantages, the report 
states, to an interdisciplinary approach to innovation. Groups containing actors 
from different professional backgrounds can deliver outcomes not so readily 
achieved by professions working in isolation. Specifically, such groups may be 
better suited to obtaining a more comprehensive picture of the capabilities and 
limitations of novel neurotechnologies.  
 
These recommendations are sensible and laudable, and hopefully they will guide 
future UK and EU regulatory and funding policy. A potential criticism of the 
report, however is that these recommendations are too general. Indeed, it could be 
argued that they reflect a lack of information on how the tension between “great 
need and great uncertainties” actually manifests in the day-to-day routine research 
and clinical environments of those working with novel neurotechnologies. As this 
project has shown, researchers and clinicians may already be aware of the necessity 
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of ‘securing safety and efficacy’ and ‘generating robust evidence’; indeed, PMDS 
team members spend a great deal of their time attempting to achieve these tasks. 
There are specific contextual factors, however, that make these tasks complex and 
difficult. These are factors that have not been explored in the report and it is for 
this reason, I argue, that the recommendations of the report are perhaps too 
general. Similarly, the recommendation that innovation takes place within 
interdisciplinary groups also lacks specific detail: how, exactly, can a collection of 
individuals from different professions enable a more comprehensive assessment of 
the benefits and effects of a novel technology?  And what professions should be 
involved in these groups?  
In a similar vein, several ethicists have identified what they believe to be the 
ethical challenges associated with DBS, and have put forward a series of 
recommendations on how these challenges should be managed.  Bell and colleagues 
(2009) have identified what they believe to be the five main potentially problematic 
ethical issues of deep brain stimulation based on a review of the emerging clinical 
literature. The first of these is securing informed consent (2009: 580). The authors 
argue that the process of attaining informed consent can be difficult because: 
patients may have cognitive difficulties that affect their capacity to reasonably assess 
the available information; DBS is often a last resort and patients are often desperate 
for therapeutic relief; and it is difficult for clinicians to provide predictions about 
how individual patients will respond. The authors also state that caregivers should 
be included in the decision making process, since patients will inevitably remain 
reliant on their assistance.  
The second issue Bell and colleagues identified as ethically problematic is 
resource allocation (DBS therapy costs around £35,000 per person for the first two 
years, and up to £6000 per person per year from then on). While there is emerging 
evidence to suggest that, in the long run, it is more cost-effective than other, 
medicine-based therapies (Fraix et al 2006), the large up-front cost may mean that it 
has to be rationed in health settings where rationing is central (such as public health 
systems). It is important, therefore, that clinicians do their best to ensure that only 
those patients who are likely to receive the optimum benefit from DBS be offered 
the therapy. Indeed, patient selection is also identified as a potentially problematic 
ethical issue of DBS. The authors argue that it is necessary to establish selection 
criteria that will enable clinicians to identify which candidates will obtain and retain 
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the greatest benefits from DBS. As yet, such criteria have not been established. 
Poorly selected patients will undergo unnecessary hardship and be exposed to 
unnecessary risk: good patient selection is therefore necessary to adhere to the 
principles of beneficence and nonmaleficience (Bell at al 2009: 579). 
The fourth ethical challenge is dispelling miracle-like narratives about DBS.  
The authors point out that the over-optimistic portrayals of DBS in the media 
should, ideally, be counterbalanced with more realistic information. A better 
transfer of information between those working with and developing DBS, the 
media, and the public is needed to ensure that members of the latter do not have 
distorted and fanciful impressions of DBS. The fifth potentially problematic ethical 
issue identified by Bell and colleagues pertains to the apparent psychosocial adverse 
effects experienced by some DBS recipients. If such effects do occur, then any 
appraisal of the effectiveness of DBS therapies must take such changes into 
account: the reduction of motor symptoms must be balanced with any changes in a 
patient’s sense of self and well-being.  
As with the Nuffield Council report, Bell and colleagues suggest that one of 
the best means of managing the ethical issues is for DBS to be delivered by 
multidisciplinary teams. They propose that such teams should include, in addition to 
a neurosurgeon and neurologists, neuropsychologists, psychiatrists and an advanced 
care nurses (2009: 579). Such teams, the authors argue, can draw on a range of 
professional perspectives in order to assess the suitability of patients, and to 
comprehensively identify the effects of DBS therapies on patients’ lives. Indeed, 
other commentators on the ethics of deep brain stimulation and neuro-implants 
have made similar proposals (Agid et al 2006; Ford and Kubu 2006; Kubu and Ford 
2007). And, in a similar vein to the Nuffield Report, Bell and colleagues argue that 
the appropriate means of managing the uncertainties around DBS is to ensure that 
clinicians are committed to the generation of robust evidence on patient outcomes. 
Specifically, they propose the establishment of a registry of deep brain stimulation 
patients. The idea is that every single DBS recipient, along with data on their 
response to DBS and any adverse effects, would be recorded on the registry. 
Again, these recommendations are laudable but their generality may limit 
their utility. The findings of this project, for example, suggest that the formation of 
a registry would pose additional challenges: what type of data should be recorded on 
a registry for patients with dystonia? BFM-derived data? If so, this registry would 
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present misleading evidence (at least according to members of the PMDS team). 
This project has explored how such challenges actually manifest in clinical practice 
and how clinicians attempt to manage them. Because of this we are well-suited to 
build upon the recommendations made by the Nuffield Council and Bell and 
colleagues. Indeed, some of the novel activities developed within the PMDS may be 
worth disseminating – they may help other clinicians working with 
neurotechnologies overcome similar challenges. In this light, I make the following 
recommendations: 
 
1. DBS should be delivered by multidisciplinary services. In accordance with the 
recommendations made by both the Nuffield Council report and Bell and 
colleagues, I suggest that deep brain stimulation be delivered by 
multidisciplinary teams.  However, the selection of professionals involved could 
be widened to include other allied health professionals, particularly occupational 
therapists and physiotherapists. This multidisciplinary team should not only be 
involved in selecting candidates (as stated by Ford and Kubu 2006), but also the 
regular assessment of patient outcomes. Occupational therapists, for instance, 
have access to a pool of resources enabling what could be called a more 
comprehensive assessment of clinical outcomes.  It would be necessary to 
ensure that multidisciplinary teams had access to the appropriate diversity of 
space and resources which is needed for them to undertake the varied 
assessment tasks.  
 
2. Using goal setting session for the management of patient expectations. In this 
project we have witnessed the use of a novel strategy for managing the 
expectations of patients and supporting family members. During the goal setting 
session the COPM tool encouraged a mode of communication between 
clinicians, patients and family members that facilitates informed decision 
making. If we consider informed decision making to be ethically favourable, 
then use of the COPM-scripted goal setting session should be encouraged in 
other settings.  Indeed, it is important to recognise the role of non-human 
elements in facilitating ethical work in biomedical settings, and promote the 
dissemination of such tools. This would also entail training clinicians how to use 
such tools. 




3. Creating a body of evidence using a flexible registry. Following the 
recommendation of Bell and colleagues, I suggest that all DBS cases be 
recorded on a registry. For the registry to be useful, however, it would need to 
provide space for various forms of patient outcome data: for patients with 
dystonia, this could be data generated using the BFM, the AMPS and COPM, 
QoL-based tools, and so on. The danger is that an overly rigid registry would 
prematurely delimit ‘what counts’ as data, thus preventing the generation of 
knowledge that may have been of some use.  As Bell and colleagues point out, it 
is necessary to decipher which patients experience the greatest improvement in 
life satisfaction: A registry containing various forms of data on outcomes is 
more likely to present a more comprehensive picture of the impact of DBS.   
  
8.6 Project limitations and future research possibilities 
In this project I have explored the activities of a specific team over the course of 
twelve months. While this has enabled me to examine key aspects of the innovation 
process, there are, of course, limitations with this project. First, given that one aim 
of this project is to explore how dystonia and the body are rendered intelligible 
within the PMDS, it would have been ideal to observe interactions involving the 
neurosurgeon and the patient, and also interactions in which the patient is subjected 
to various neuro-imaging procedures (such as MRI). Here, no doubt, we would have 
witnessed the enactment of a body based very much on the biomedical model, and 
we would have witnessed the enactment of dystonia as an abnormality of brain 
functioning.  
Secondly, it became clear to me while conducting this project that many 
clinical decision making interactions were made outside of regular weekly team 
meetings. This was particularly the cases for decisions that were medical in nature; 
decisions relating to medications and stimulation parameters and so on that were 
made by the neurologists or the nurse and did not require input from the therapists. 
Presumably many ‘routine’ decisions in which the best course of action is relatively 
straightforward were also made outside of team meetings. Because ethical 
considerations meant that I could not simply follow my participants around the 
hospital, I was not able to observe participants as they made these decisions. Thus, I 
was probably presented with a lop-sided picture of decision making within the 
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PMDS; a picture of decision making that included a high proportion of complex 
cases requiring significant input from the therapists. It may be that many patients 
pass through the PMDS without having their schooling and relationships with 
family members and peers subject to the ‘broad’ PMDS clinical gaze.  
Another limitation of this study is its focus on one case study. Ideally, a 
study that is attempting to generate a general model of medical innovation would do 
so by abstracting from several case studies, not one. The Texan-based DBS service 
for children and young people with dystonia would provide a useful point of 
comparison to the PMDS: it exists within a markedly different healthcare system to 
the NHS and is no doubt subject to a different arrangement of socio-political 
trends. Comparing the two teams would have enabled a more comprehensive 
assessment of how such trends can actually ‘structure’ innovative activities.    
The absence of patients and family member perspectives in this project is a notable 
limitation, as is the relatively short time period that I spent with PMDS team. Both 
of these limitations suggest further research possibilities. 
 
8.6.1 Exploring the perspectives of patients and family members 
In this project I have explored the perspectives of clinicians, and the interactions 
involving clinicians, patients and family members. A logical follow on from this 
would be to explore the perspectives of patient and families who have been 
involved in the PMDS. As I mentioned in the introduction, small studies on the 
perspectives of Parkinson’s patients with DBS have been conducted by a clinical 
team. These studies revealed that while DBS was generally effective in reducing 
many of the symptoms associated with Parkinson’s, it was having a mixed impact 
on their overall sense of well-being: some lamented their reliance on technology, 
many had a negative anticipation of the future, some felt considerable despair over 
the years of their life that they had lost to the illness, and some felt a sense of being 
dehumanised due to their reliance on mechanical technology. These patients 
represent a different cohort to that of the PMDS (they are adults with a progressive 
neurological condition rather than children with generally static conditions), but 
nevertheless, it would be worthwhile to explore whether PMDS patients are having 
similar experiences.  
A particularly interesting avenue would be to explore the impact of DBS on 
a patient’s sense of self. Such a project could explore how their motor disorder is 
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implicated in a patient’s sense of self, and how this is subsequently affected by the 
implantation of a DBS system.  This project would also enable us to explore, from 
the patient’s perspective, whether DBS did actually encourage a ‘cerebral’ sense of 
self. With older and more articulate patients, I envisage that such a project could 
make use of Fox and Ward’s strategy for exploring health identities (Fox and Ward 
2008). Here, in-depth interviews are used to encourage participants to provide 
context to their world and descriptions of their day-to-day life, and they are then 
encouraged to reflect on the meaning of these experiences. The intention of this 
interview method is to identify the assemblages which participants inhabit, and 
identify the affective characteristics of these assemblages as experienced by the 
patient. Similarly, family members could also be included in such a project, enabling 
the impact of DBS on the dynamics of family life and roles of various family 
members to be explored. Such a project, then, would be exploring the wider impact 
of novel-neurotechnologies on health identities and family relations. 
The impact of various PMDS assessments on patients and families could 
also be explored. I have suggested, for example, that the COPM-scripted goal 
session is a useful tool for managing expectations. In order to verify its effectiveness 
it would be necessary to explore the viewpoints of patients and family members: did 
they feel that they were adequately prepared for DBS?  And did they feel that the 
PMDS as a whole provided adequate channels for articulating their own expertise 
about dystonia and well-being?    
 
8.6.2 Creating visions of the future to construct innovation alliances 
This project has explored the activities of one team during a twelve-month period. 
Ideally a comprehensive exploration of medical innovation would explore the 
activities of the team over a longer time frame as they attempt to convince other 
clinicians that their service is indeed ‘innovative’ and ‘progressive’ and thus worth 
maintaining or replicating elsewhere. Indeed, a potential criticism of both the 
Morlacchi-Nelson Model and the Complex Model of Innovation is that they imply 
that any novel therapy emerging from the interactions between learning-in-practice, 
technology transfer and understandings of disease is intrinsically ‘progressive’ and 
‘innovative’.  Yet, as a body of work from the sociology of expectations has made 
clear, whether or not a novel set of practices and/or novel knowledge is indeed 
‘progressive’ or ‘innovative’  depends very much upon the ability of proponents to 
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frame it as such (Brown et al 2000). In short, other actors (clinicians, commissioners 
and funding bodies, regulatory agencies and patients) have to be convinced that a 
novel therapy is necessary.  Proponents, then, must form alliances with such actors 
by enrolling them in a particular vision of the future in which the novel therapy 
does indeed offer much needed relief to patients in need. Any number of techniques 
may be used to construct futures and form such alliances: proponents, for example, 
may employ ‘breakthrough’ narratives (Brown 2000) and the use of future-
orientated metaphors (Wyatt 2000) to create performative expectations. And, as 
Borup and colleagues points out (2006), expectations can be either rhetorical or 
material in nature: they may be expressed as utterances, or inscribed in texts, bodies 
or objects. According to this body of work the process of innovation involves the 
active and collective construction of the future.  
A fruitful avenue of research would be to explore how PMDS team members 
actively ‘construct’ the future in order to consolidate and possibly disseminate their 
innovations. Such a project would provide a window into an aspect of medical 
innovation that has not been addressed in this current project. Interestingly, the 
PMDS team is about to begin working on a proposal to conduct an international, 
multi-centre clinical trial exploring the effects of deep brain stimulation to manage 
children with secondary dystonia. The goal is to produce an overwhelming body of 
evidence that indicates the effectiveness of DBS for secondary dystonia, and thus 
encourage the formation of other DBS teams in paediatric neurology. I observed a 
team meeting where initial plans for the trial were discussed: ideally, the team would 
like to enrol Danish, Belgium and French research groups working with children 
with cerebral palsy to help recruit and assess participants, and they would like the 
trial to utilise the regime of assessments developed by the PMDS. In other words, 
the PMDS is attempting to determine how data should be collected within these 
sites, and thus define ‘what counts as evidence’. If the team is successful in having 
their regime adopted, then their ‘local’ innovations will have become more 
widespread within the paediatric neurology community, and importantly, their 
framing of ‘what counts as data’ will have become something of a standard. Thus, 
the process of producing a proposal and bringing these other teams ‘on-board’ 
would provide a fascinating study into the dynamics of medical innovation. Such a 
project could explore how the PMDS constructs a future and creates a set of 
expectations in order to create alliances between the groups; that is, what 
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concessions need to be made for such groups to be brought into the project; how 
the PMDS regime of assessments is altered or reconfigured when ‘transported’ to 
other clinical sites; and how the definition of ‘what counts as data’ is altered during 
the formation of alliances.    
 
8.7 Concluding comments 
In this project I have used deep brain stimulation as a case study to explore the 
dynamics of medical innovation. I have explored the historical development and 
dissemination of the deep brain stimulation technique, and the activities of clinicians 
as they develop a clinical service providing deep brain stimulation for children and 
young people with dystonia. I have argued that innovation emerges from 
technology transfer, the dissemination of new knowledge, and the learning-in-
practice activities of clinicians. In the case of the PMDS, learning-in-practice has 
been shaped by elements of the built environment and it has involved utilizing 
embodied know-how, tools and knowledge from several professions, reflecting the 
multidisciplinary structure of the team.  
In the process of exploring the history of deep brain stimulation and the 
activities of PMDS clinicians, this project has also identified several socio-political 
factors which have shaped the innovation process. These include the evidence-
based medicine movement and rationalization in healthcare more broadly, the 
influence of commercial interest and the profit motive, a prevalent pro-
multidisciplinarity sentiment, the patient-centred healthcare movement, and (related 
to this patient-centred approach) a trend towards shared-decision making. Using 
these as examples, this project has put forward a conceptualisation of innovation 
which I have called the Complex Model of Innovation. By situating ‘technology 
transfer’, ‘understandings of disease’ and ‘learning-in-practice’ within a broader 
socio-political context, this conceptualisation builds upon the Morlacchi-Nelson 
model of medical innovation.  
 This project has also illustrated that the PMDS clinicians utilise what could 
be called a broad clinical gaze. In additional to various biomedical concerns, the 
PMDS clinicians scrutinize many aspects of the patient and the patient’s relationship 
with the world, such as their ability to carry out domestic tasks, their relationship 
with peers and family members, and their schooling. Thus, during their time with 
the PMDS patients and dystonia are enacted (or ‘constructed’) in multiple ways. For 
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example, dystonia is enacted as impaired gross motor function, and as reduced 
ability to perform domestic tasks. Using this insight, I have argued that new 
neurotechnologies do not necessarily reify reductive, biomedical model-derived 
understandings of the patient and illness. 
 I have also suggested that the findings of this project can provide some 
guidance on preparing the future for deep brain stimulation. Some of the activities 
conducted by the team may be worth replicating in other clinical contexts. In 
particular, these include the multidisciplinary structure of the team which enables 
access to a vast array of tools and resources for overcoming day-to-day challenges, 
and the goal setting session used by the team to manage the expectations of patients 
and young people.   
 
No doubt the reader has noted that I have adopted what could be described as a 
positive tone throughout this thesis. By emphasizing the innovative aspects of the 
PMDS, I have represented team members in a favourable light. Thus, some 
commentators may suggest that I have ‘sided with the clinicians’ and failed to 
maintain the critical, or at least the impartial, perspective that is often expected from 
a social scientist. At the risk of prompting a debate on the role of the social sciences 
more generally, it is worth explicitly stating that I have been, and still are, knowingly 
supportive of the team’s activities.   
I will justify this position by drawing upon the Nuffield Council’s report on 
neurotechnologies (2013) that I referred to at the very beginning of this thesis. 
There is, as the report states, a genuine and urgent need for new therapies for 
debilitating neurological disorders such as dystonia, and there is a need to encourage 
responsible research and innovation. The PMDS team is, in my opinion, one good 
example of how responsible research and innovation may be undertaken at the level 
of service provision – as I have suggested, several of their innovations are worth 
perpetuating among other groups working in similar situations where “great need 
meets great uncertainty”. The PMDS team is innovative, but this did come at the 
expense of compassionate care: During my fieldwork I witnessed some horrendous 
examples of suffering – children with some of the worst, most complex cases of 
neurological pathology, in severe pain, with very poor prognoses. Yet, I also 
witnessed some very admirable examples of human interaction. These children were 
at the centre of an enormous amount of care, attention and affection from parents 
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and staff members, and a great deal of resources were directed towards improving 
their quality of life. It was because of this that I came from fieldwork excursions 
feeling hopeful and inspired. This type of clinical environment and the support they 
offer should be encouraged.   
  236 
Appendices 
 
List of Appendices 
Appendix 1: Notification of favourable opinion from NRES Committee 237 
Appendix 2: Participant information leaflets (PILs) 
  Children and young people 
  Participants over 16 years of age (non-clinicians) 
  Health professionals (consultation observations) 
  Health professionals (team meeting observations) 







Appendix 3: Assent and consent forms 
  Assent form for children and young people 
Form for people over 16 years of age (non-clinicians) 
  Form for health professionals (consultation observations) 
  Form for health professionals (team meeting observations) 








































Appendix 2: Participant information leaflets  
 
Leaflet 1: Children and young people, for consultation observations  
















































































































Appendix 3: Consent forms 
 

















































Appendix 4: Interview topic guide 
 

























List of references 
 
4 News (2012). Revealed: Postcode Lottery for Dystonia Treatment. [online] 
Available at: http://www.channel4.com/news/revealed-the-postcode-lottery-
for-dystonia-treatment [Accessed on 29 June 2013].  
1997 Premarket Notification: Implantable Deep Brain Stimulation for the Treatment of Tremor 
due to Parkinson’s and Essential Tremor. Neurological Devices Panel of the 
Medical Devices Advisory Committee. Washington D.C.: Miller Reporting 
Company. 
2012-13 Tariff Information Spreadsheet (2012). The Department of Health. 
[Accessed 8th of August 2013] Available from: 
https://www.gov.uk/government/publications /confirmation-of-payment-  
by-results-pbr-arrangements-for-2012-13  
Ackerman, S. (2006). Hard Science, Hard Choices: Facts, Ethics and Policies Guiding Brain 
Science Today. New York: Dana Press. 
Agid, Y., Schüpbach, M., Gargiulo, M., Mallet, L., Houeto, J. L., Behar, C., et al. 
(2006). Neurosurgery in Parkinson’s disease: the doctor is happy, the patient 
less so? In P. Riederer, H. Reichmann, M. B. H. Youdim & M. Gerlach (Eds.), 
Parkinson’s Disease and Related Disorders Vol. 70, Springer Vienna. pp. 409-414:  
Akrich, M. and Latour, B. (1992). A summary of a convenient vocabulary for the 
semiotics of human and nonhuman assemblies. In Bijker, W. and Law, J. 
(Eds.). Shaping Technology, Building Society. Cambridge MA: MIT University Press. 
Pp. 259-265. 
Alcadipani, R. and Hassard, J. (2010). Actor-Network Theory, organizations and 
critique: towards a politics of organizing. Organization. 17(4): 419-435. 
Andy O. (1983). Thalamic stimulation for control of movement disorders. Applied 
Neurophysiology 46: 107-111. 
Annandale, E. (2002). The Sociology of Health and Medicine: A Critical Introduction. 
Cambridge UK: Polity Press.  
Antonelli, C. (2007). The economics of innovation: from the classical legacies to the 
economics of complexity. Economics of Innovation and New Technology 18(7): 611-
646. 
Antonelli, C. and Ferraris, G. (2011). Innovation as an emerging system property: 
and agent based simulation model. Journal of Artificial Societies and Social 
Simulation 14(2) 
  261 
Alderson, P., & Morrow, V. (2011). The Ethics of Research with Children and Young 
People: A Practical Handbook. London: Sage. 
D’Amour, D., Ferrada-Videla, M., San Martin Rodriguez, L., & Beaulieu, M.-D. 
(2005). The conceptual basis for interprofessional collaboration: Core concepts 
and theoretical frameworks. Journal of Interprofessional Care 19(Suppl. 1): 116 – 
131. 
Ardouin, C., Pillon, B., Peiffer, E., Bejjani, P., Limousin, P., Damier, P., et al. (1999). 
Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects 
neither memory nor executive functions: A consecutive series of 62 patients. 
Annals of Neurology, 46(2): 217-223. 
Armstong, D. (2011). The invention of patient-centred care. Social Theory and Health 
9(4): 410-418. 
Armstrong, D., Lilford, R., Ogden, J. and Wessely, S. (2007). Health-related quality 
of life and the transformation of symptoms. Sociology of Health & Illness 29(4): 
570-583.  
Bagby, RM., Ryder, A., Schuller, D. and Marshall, M. (2004).  The Hamilton 
Depression Rating Scale: Has the Gold Standard Become a Lead Weight? The 
American Journal of Psychiatry 61(12): 2163-2177. 
Beauchamp, T. and Childress, J. (2001). Principles of Biomedical Ethics. New York: 
Oxford University Press. 
Bell, E, Mathieu, G, Racine, E, (2009). Preparing the ethical future of deep brain 
stimulation. Surgical Neurology 72: 577-586. 
Benabid AL, Pollak P., Louveau A., Henry S. and de Rougemont J. (1987) 
Combined (thalamotomy and stimulation) stereotactic surgery of the VIM 
thalamic nucleus for bilateral Parkinson disease. Applied Neurophysiology 50: 344-
346. 
Benabid, A. L., Pollak, P., Hoffmann, D., Gervason, C., Hommel, M., Perret, J. E., 
et al. (1991). Long-term suppression of tremor by chronic stimulation of the 
ventral intermediate thalamic nucleus. The Lancet, 337(8738): 403-406. 
Berg, M. (1998). Order(s) and disorder(s): of protocols and medical practices. In M. 
Berg, and A. Mol (Eds.). Differences in medicine: unraveling practices, techniques and 
bodies. (pp. 227-246). Durham: Duke University Press. 
Bergman, H., Wichmann, T. and DeLong, M. (1990). Reversal of experimental 
parkinsonism by lesions of the subthalamic nucleus. Science 249: 1436-1438. 
  262 
Blomstedt, P. and Haris, M. (2010). Deep brain stimulation for movement disorders 
before DBS for movement disorders. Parkinsonism & Related Disorders 16: 429-
433. 
Blume, S. (2010). The Artificial Ear: Cochlear Implants and the Culture of Deafness.  
London: Rutgers University Press. 
Blume, S (1992). Insight and Industry: On the Dynamics of Technological Change in Medicine. 
Cambridge MA: MIT Press 
Bodewitz, H., Buurma, H. and De Vries, G. (1989). Regulatory Science and the 
Social Management of Trust in Medicine. In: Bijker, W., Hughes, T. & Pinch, 
T. (Eds.) The Social Construction of Technological Systems: New Directions in the 
Sociology and History of Technology. London: MIT Press. 
Bolton, S. (2001). Changing faces: nurses as emotional jugglers. Sociology of Health and 
Illness 23(1): 85-100.   
Borges, G. L. (1970). ‘Funes the Memorious’ In Labyrinths. Penguin Classics: 
London. 
Borup, M., Brown, N., Konrad, K. and Van Lente, H. (2006). The Sociology of 
Expectations in Science and Technology. Technological Analysis & Strategic 
Management 18(3/4): 285-298 
Bourret, P. (2005). BRCA Patients and Clinical Collectives: New Configurations of 
Action in Cancer Genetics Practices. Social Studies of Science 35(1): 41-68.  
Breggin, P. (1972). The Return of Lobotomy and Psychosurgery. Congressional Record Feb 
24, 1972.  
Brekke, O. and Sirnes, T. (2011). Biosociality, biocitizenship and the new regime of 
hope and despair: interpreting “Portraits of Hope” and the Mehmet Case”. 
New Genetics and Society 30(4): 347-374.  
Brewer, John. (2000). Ethnography. Buckingham: Open University Press 
Brice, J. and McLellan, L. (1980). Suppression of Intention Tremor by Contingent 
Deep-Brain Stimulation. The Lancet 315(8180): 1221-1222. 
Broer, C. and Heerings, M. (2013). Neurobiology in public and private discourse: 
The case of adults with ADHD. Sociology of Health and Illness 35(1): 49-65. 
Brown, N. and Webster, A. (2004). New Medical Technologies and Society: Reordering Life. 
Cambridge: Polity Press. 
  263 
Brown, P., Alaszewski, A., Swift, T. and Nordin, A. (2011). Actions speak louder 
than words: the embodiment of trust by healthcare professionals in gynae-
oncology. Sociology of Health and Illness 33(2): 280-295. 
Burke, D., Gilles, J. and Lance, J. (1970). The quadriceps stretch reflex in human 
spasticity. Journal of Neurology, Neurosurgery and Psychiatry 33: 216-223.  
Burke, E., Fahn, S., Marsden, C., Bressman, S., Moskowitz, C. and Friedman, J. 
(1985). Validity and reliability of a rating scale for the primary torsion 
dystonias. Neurology 35(1): 73-77.  
Callon, M., 1987. Society in the making: the study of technology as a tool for 
sociological analysis. In: Bijker, W.E., Hughes, T.P., Pinch, T.J. (Eds.), The 
Social Construction of Technological Systems. New Directions in the Sociology and History 
of Technology. MIT Press, Cambridge, MA, pp. 83–103. 
Callon, M (1995). Four models of the dynamics of science. In Jasanoff, S., Markle, 
G., Peterson, J. and Pinch, T. (Eds.). Handbook of Science and Technology Studies. 
London: Sage. pp. 29-63.  
Callon, M. (1999). Actor-Network Theory - The Market Test. In J. Law & J. 
Hassard (Eds.), Actor-Network Theory and After (pp. 181-195). Oxford: Blackwell 
Publishing. 
Cambrosio, A. and Keating, P. (1988). “Going monoclonal”: art, science, and magic 
in the day-to-day use of hybridoma technology. Social Problems 35(3): 244-260.  
Carmel, S. (2006). Boundaries obscured and boundaries reinforced: incorporation as 
a strategy of occupational enhancement for intensive care. Sociology of Health and 
Illness 28(2): 154–77. 
Centellas, K. Smardon, R. and Fifield, S. (In press). Calibrating translational cancer 
research: Collaboration without consensus in interdisciplinary laboratory 
meetings. Science, Technology and Human Values.  
Chiueh C., Markey S., Burns R., Johannessen J., Jacobowitz D. and Kopin I. (1984). 
Neurochemical and behavioral effects of MPTP in rat, guinea pig and monkey. 
Psychopharmacology Bullitin 20: 548–553. 
Choudhury, S., & Ortega, F. (2011). ‘Wired up differently’: Autism, adolescence and 
the politics of neurological identities. Subjectivity 4(3): 323-345. 
Cicourel, A. (1994). Method and Measurement in Sociology. New York: Free Press. 
  264 
Chou, K., Grube, S. and Patel, P. (2012). Deep Brain Stimulation: A New Life for People 
with Parkinson's Dystonia and Essential Tremor. New York: Demos Medical 
Publishing. 
Clarke, A., Shim, J., Mamo, L., Fosket, J. and Fisman, J. (2003). Biomedicalization: 
Technoscientific transformation of health, illness and US biomedicine. 
American Sociological Review 68(2): 161-194. 
Clarke, A., Shim, J., Mamo, L., Fosket, J. and Fishman, J. (2010). Biomedicalization: 
a theoretical and substantive introduction. In Clarke, A., Mamo, L., Fosket, J., 
Fishman, J. and Shim, J. (Eds.). Biomedicalisation: Technoscience, Health and Illness in 
the US. London: Duke University Press. pp. 1-46.   
Coffey, R. (2001). Deep Brain Stimulation for Chronic Pain: Results of Two 
Multicentre Trials and a Structured Review. Pain Medicine 2(3): 183-192. 
Coffey, R. (2009). Deep Brain Stimulation Devices: A Brief Technical History and 
Review. Artificial Organs 33: 208-220. 
Coffey, R. and Lozano, A. (2006). Neurostimulation for chronic noncancer pain: an 
evaluation of the clinical evidence and recommendations for future trial 
designs. Journal of Neurosurgery 105: 175-189. 
Collins, H. (1987). Expert-systems and the science of knowledge. In Bijker, W., 
Hughes, T. and Pinch, T. (Eds.). The Social Construction of Technological Systems: 
New Directions in the Sociology and History of Technology Cambridge MA: MIT Press. 
pp 329-348. 
Collins, H. and Evans, R. (2002) The Third Wave of Science Studies: Studies of 
Expertise and Experience. Social Studies of Science 32(2): 235-296. 
Coombs, M. (2004). Power and conflict in intensive care clinical decision making. 
Intensive and Critical Care Nursing 19: 125-135 
Coombs M. and Ersser. J. (2004) Medical hegemony in decision-making – a barrier 
to interdisciplinary working in intensive care? Journal of Advanced Nursing 46(3): 
245–252 
Cooper, I. and Upton, A. (1978). Use of chronic cerebellar stimulation for disorders 
of disinhibition. The Lancet 311: 595-600. 
Cooper, I., Upton, A. and Amin, I. (1980). Reversibility of chronic neurologic 
deficits. Some effects of electrical stimulation of the thalamus and internal 
capsule in man. Applied Neurophysiology 43(3-5): 224-258. 
Corea, G. (1985). The Mother Machine. New York: Harper & Row. 
  265 
Corrigan, O. (2003). Empty ethics: the problem with informed consent. Sociology of 
Health and Illness. 25(3): 768-792. 
Coulter, A., Entwistle, V. and Gilbert, D. (1998). Informing patients: an assessment of the 
quality of patient information and materials. London: King’s Fund Publishing.  
Crossley, N. (2001). The phenomenological habitus and its construction. Theory and 
Society 30(1): 81-120.  
Crossley, N. (2012). Phenomenology and the body. In Turner, B. (Ed.). Routledge 
Handbook of Body Studies. New York: Routledge. pp. 130-143.  
Defazio, G. (2010). The epidemiology of primary dystonia: current evidence and 
perspectives. European Journal of Neurology, 17(Suppl. 1): 9-14.  
DeLanda, M. (2002). Intensive Science, Virtual Philosophy. London: Continuum. 
DeLanda, M. (2006). A New Philosophy of Society: Assemblage Theory and 
Complexity. London: Continuum. 
DeLong, M. (1990). Primate Models of Movement Disorders of Basal Ganglia 
Origin. Trends in Neurosciences 3(7): 281-285. 
Department of Health. (2000). The NHS plan. London: HMSO. 
Department of Health. (2008). NHS next stage review: A high quality workforce. London: 
HMSO. 
Department of Health (2009). NHS Cancer Action Team: The Characteristics of an 
Effective Multidisciplinary Team (MDT). London: HMSO. 
Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., 
et al. (2006). A Randomized Trial of Deep-Brain Stimulation for Parkinson's 
Disease. New England Journal of Medicine, 355(9): 896-908. 
Dey, Ian. (1993). Qualitative Data Analysis: A User Friendly Guide for Social 
Scientists. London: Routledge. 
Dworkin, R. H., Turk, D. C., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., 
Katz, N. P., Kerns, R. D., Stucki, G., Allen, R. R., Bellamy, N., Carr, D. B., 
Chandler, J., Cowan, P., Dionne, R., Galer, B. S., Hertz, S., Jadad, A. R., 
Kramer, L. D., Manning, D. C., Martin, S., McCormick, C. G., McDermott, M. 
P., McGrath, P., Quessy, S., Rappaport, B. A., Robbins, W., Robinson, J. P., 
Rothman, M., Royal, M. A., Simon, L., Stauffer, J. W., Stein, W., Tollet, J., 
Wernicke, J. and Witter, J. (2005). Core outcome measures for chronic pain 
clinical trials: IMMPACT recommendations. Pain 113: 9-19. 
Durkheim, E. (1982). The Rules of Sociological Method. Basingstoke: Macmillan. 
  266 
Dystonia Medical Research Foundation (2010). Deep Brain Stimulation. [online]. 
Available at: http://www.dystonia-
foundation.org/pages/deep_brain_stimulation /151.php [Accessed on 1 July 
2013].  
The Dystonia Society. (2013). Deep Brain Stimulation: The Campaign Continues. [online] 
Available at: 
http://www.dystonia.org.uk/index.php/component/content/article/ 7-about-
us/266-deep-brain-stimulation-the-campaign-continues [Accessed on 29 June 
2013] 
East Midlands Specialised Commissioning Group. (2011). A Commissioning Policy 
for the Use of Deep Brain Stimulation (DBS). National Health Service [online] 
Available at: www.derbycitypct.nhs.uk/UserFiles/.../policies/P037V1% 
20EMSCG%20 [Accessed on 29 June 2013).  
Fahn S. & Elton, R. (1987). Unified Parkinson’s Rating Scale (UPDRS). In: Fahn, S., 
Marsedn, C., Calne, D. an Goldstein, M. (Eds.) Recent Developments in Parkinson’s. 
Florham Park: Macmillan Health Care Information. 
Faulkner, A. (2009). Medical Technology into Healthcare and Society: A Sociology of Devices, 
Innovation and Governance. New York: Pargrave Macmillan. 
Fein, E. (2011). Innocent machines: Asperger’s Syndrome and the neurostructural 
self. In (Pickersgill, M. and Van Keulen, I. (Eds.). Sociological Reflections on the 
Neurosciences. Bingley UK: Emerald Group Publishing. pp. 27-50. 
Finn, R., Learmonth, M. and Reedy, P. (2010). Some unintended effects of 
teamwork in healthcare. Social Science & Medicine 70: 1148-1154. 
Fins, J. and Schiff, N. (2010). Conflicts of interest in deep brain stimulation research 
and the ethics of transparency. Journal of Clinical Ethics, 21(2): 125-132. 
Fins, J. Mayberg, H., Nuttin, B., Kubu, C., Galert, T., Sturm, V., Stoppenbrink, K., 
Merker, R. and Schlaepfer, T. (2011). Misuse Of The FDA’s Humanitarian 
Device Exemption In Deep Brain Stimulation For Obsessive-Compulsive 
Disorder. Health Affairs 30(2): 302-311. 
Fisher, A. (1995).  Assessment of Motor and Process Skills (1st ed).  Fort Collins, CO: 
Three Star Press. 
Fisher, A. (1997). Assessment of Motor and Process Skills. (2nd ed.). Fort Collins, CO: 
Three Star Press.  
  267 
Fisher, A. (2006). Assessment of Motor and Process Skills. Vol. 1: Development, 
Standardization, and Administration Manual (6th ed.) Fort Collins, CO: Three 
Star Press 
Fitzpatrick, R., Davey, C., Buxton, M. and Jones, D. (1998) Evaluating patient-based 
outcome measures for use in clinical trials. Health Technology Assessment 2(14): 1-
73. 
Foote, S. B. (1978). Loops and Loopholes: Hazardous Device Regulation Under the 
1976 Medical Device Amendments to the Food, Drug and Cosmetic Act. 
Ecology Law Quarterly 7: 101-135. 
Foster, J. (2005). From simplistic to complex systems in economics. Cambridge 
Journal of Economics 29: 873–92. 
Foucault, M. (1963/2003). The Birth of the Clinic: An Archaeology of Medical Perception. 
London: Routledge Classics.  
Foucault, M. (1978). Politics and the Study of Discourse. Ideology and Consciousness 
3:7-26.   
Foucault, M., Kriegel, B., Thalamy, A., Beguin, F. and Fortier, B. (1979). Les 
Machines a guerir. Aux Origines de l’Hospital Moderne. Brussels: Pierre Mardaga.  
Fournier, V. (2000). Boundary work and the (un)making of the professions. In 
Malin, N. Professionalism, Boundaries and the Workplace. London: Routledge. pp. 
67-86. 
Fox, N. and Ward, K. (2008). What are health identities and how may we study 
them? Sociology of Health and Illness 30(7): 1007-1021. 
Fox, N. (2012). The Body. Cambridge UK: Polity Press.  
Fox, R. and Swazey, P. (1984). Medical morality is not bioethics – Medical ethics in 
China and the United States. Perspectives in Biology and Medicine 34: 226-236.  
Fraix, V., Houeto, J.-L., Lagrange, C., Le Pen, C., Krystkowiak, P., Guehl, D., et al. 
(2006). Clinical and economic results of bilateral subthalamic nucleus 
stimulation in Parkinson’s disease. Journal of Neurology, Neurosurgery & 
Psychiatry, 77(4): 443-449. 
French, L., Story., Galicich, J. and Schultz, E. (1962). Some Aspects of Stimulation 
and Recording from the Basal Ganglia in Patients with Abnormal Movements. 
Confinia Neurologica 22: 265-273. 
Freund, P., McGuire, M. and Podhurst, L. (2003). Health, Illness, and the Social Body: A 
Critical Sociology. New Jersey: Prentice Hall.  
  268 
Gardner, J. (2013). A history of deep brain stimulation: technological innovation 
and the role of clinical assessment tools. Social Studies of Science 43(5): 707-728. 
Gardner, J., Dew, K., Stubbe, M., Dowell, A. and Macdonald, L. (2011). Patchwork 
diagnoses: The production of coherence, uncertainty, and manageable bodies. 
Social Science and Medicine 73(6): 843-850. 
Garfkinel, H. (1963). A conception of, and experiments with, ‘trust’ as a condition 
of stable interactions. In Harvey, O. J. (Ed.). Motivation and Social Interaction, 
New York: Ronald Press. pp. 187-238. 
Gelijns, A. and Rosenberg, N. (1994). The dynamics of technical change in 
medicine. Health Affairs 13(3): 28-46 
Geyer, H. and Bressman, S. (2006). The diagnosis of dystonia. Lancet Neurology. 5: 
780-790. 
Gieryn, T. (1983) Boundary work and the demarcation of science from non-science: 
strains and interests in professional ideologies of scientists. American Sociological 
Review 48: 781–95. 
Gieryn, T. (2002). What buildings do. Theory and Society. 31: 35-74. 
Gilbert, F. and Ovadia, D. (2011). Deep brain stimulation in the media: over-
optimistic portrayals call for a new strategy involving journalists and scientists 
in ethical debates. [Perspective]. Frontiers in Integrative Neuroscience, 5. 
Gildenberg, P. (2000). Fifty Years of Stereotactic and Functional Neurosurgery. In 
Barrow, D., D. Kondziolka, E. Laws, and V. Traynelis (Eds.). Fifty Years of 
Neurosurgery. (pp. 295-320). New York: Lippincott Williams & Wilkins.  
Gildenberg, P. (2005). Evolution of Neuromodulation. Stereotactic and Functional 
Neurosurgery 83(2-3), 71-79. 
Gildenberg, P. (2009). Neuromodulation: A Historical Perspective. In E. Krames, P. 
Peckham & A. Rezai (Eds.), Neuromodulation pp. 9-20. Amsterdam: Elsevier and 
Academic Press. 
Gillett, G. (2011). The Gold-Plated Leucotomy Standard and Deep Brain 
Stimulation, Bioethical Inquiry 8: 35-44. 
Gisquet, E. (2008). Cerebral implants and Parkinson's disease: A unique form of 
biographical disruption? Social Science & Medicine, 67(11): 1847-1851. 
Glannon, W. (2009). Stimulating brains, altering minds. Journal of Medical Ethics, 
35(5): 289-292. 
  269 
Godin, B. (2006). The linear model of innovation: The historical construction of an 
analytical framework. Science, Technology and Human Values 31(6): 639-67. 
Goetz, C., Poewe, W., Rascol, O., Sampaio, C., Stebbins, G., Fahn, S., Lang, A. E., 
Martinez-Martin, P., Tilley, B. and Van Hilten, B. J. (2003). The Unified 
Parkinson’s Disease Rating Scale (UPDRS): Status and recommendations. 
Movement Disorders 18: 738-750. 
Goetz, C, Stebins, G. T., Chmura, T. A., Fahn, S., Klawans, H. L. & Marsden, C. D. 
(1995). Teaching tape for the motor section of the unified Parkinson’s Disease 
rating scale. Movement Disorders 10: 263-266. 
Goodwin, C. (1994). Professional vision. American Anthropologist 96(3): 606-633. 
Gordon, L., Keller, J., Stashinko, E., Hoon, A. and Bastian, A. (2006). Can spasticity 
and dystonia be independently measured in cerebral palsy? Pediatric Neurology 
35(6): 375-381.  
Goto, S., Fisher, A. and Mayberry, W. (1996). The Assessment of Motor and 
Process Skills Applied Cross-Culturally to the Japanese. The American Journal of 
Occupational Therapy 50(10): 798-806.  
Gregory, A. and Hayflick, S. (2005). Neurodegeneration with brain iron 
accumulation. Folia Neuropathol, 43 (4): 286-296.  
Guggenheim, M. (2012). Laboratorizing and de-laboratorizing the world: changing 
sociological concepts for places of knowledge production. History of the Human 
Sciences 25(1):  99-118. 
Hammersley, M. and Atkinson, P. Ethnography: Principles and Practice. Third Edition. 
London: Routledge.  
Haraway, D. (1988). Situated knowledges: the science question in feminism and the 
privilege of partial perspective. Feminist Studies 14(3): 575-599.  
Hardy, B., Turrell, A., and Wistow, G. (1992). Innovations in Community Care 
Management. Aldershot: Avebury.  
Hariz, M., Blomstedt, P. and Zrinzo, L. (2010). Deep Brain Stimulation Between 
1947 and 1987: The Untold Story. Neurosurgical Focus 29(2): E1. 
Health Commission Wales (Specialist Services). (2009). Deep brain stimulation for 
movement disorders. Commissioning policy. Welsh Assembly Government 
[online] Available at: www.wales.nhs.uk/sites3/docopen.cfm?orgid=898 
&id=223309 [Accessed 29 June 2013).   
  270 
Heath, R. (1977). Modulation of emotion with a brain pacemaker: Treatment for 
intractable psychiatric illness. Journal of Nervous and Mental Disease 165: 300-317. 
Heath, R., Llewellyn, R. and Rouchell. (1980). The Cerebellar Pacemaker for 
Intractable Behavioral Disorders and Epilepsy: Follow Up Report. Biological 
Psychiatry 15(2): 243-256.  
Henkel, C. and Gieryn, T. (2008). Sites if scientific practice: the enduring 
importance of place. In Hackett, E., Amsterdamska, O., Lynch, M. and 
Wajcman, J. The Handbook of Science and Technology Studies (3rd Edition). 
Cambridge MA: MIT Press. pp. 353-376. 
Hester, M. (2007). Special Section: Technology and the Body Guest Editorial: 
Linking Life and Technology.  Cambridge Quarterly of Healthcare Ethics 16: 254-
256. 
Hobart, J., Freeman, J. and Lamping, D. (1996). Physician and patient orientated 
outcomes in chronic and progressive neurological disease: which to measure? 
Current Opinion in Neurology  9(6): 441-444. 
Hobart, J. and Thompson, A. (2001). Assessment measures and clinical scales. In 
Guiloff, J. (Ed.). Clinical Trials in Neurology. London: Springer. pp. 17-28 
Hopkins, M., Martin, P., Nightingale, P. and Kraft, A. and Mahdi, S. (2007). The 
myth of the biotech revolution: An assessment of technological, clinical and 
organizational change. Research Policy 36(4): 566-567.  
Hosbuchi, Y., Adams, J. E. and Rutkin, B. (1973). Chronic thalamic stimulation for 
the control of facial anesthesia dolorosa. Archives of Neurology 29: 158-61. 
Housley, W. (2005). Interaction in Multidisciplinary Teams. Hants UK: Ashgate.  
Hunter, D. (2003). Public Health Policy. Cambridge: Cambridge University Press.  
Jankovic J. (2007) Dystonic disorders. In: Jankovic J, Tolosa E, (Eds.). Parkinson’s 
disease and movement disorders. 5th edn. Philadelphia, PA: Lippincott Williams and 
Wilkins, pp.321–47. 
Joyce, K. (2006). From numbers to pictures: The development of magnetic 
resonance imaging and the visual turn in medicine. Science as Culture 15(1): 1-22. 
Keating, P. and Cambrosio, A. (2003). Biomedical Platforms: Realigning the Normal 
and the Pathological in Late-twentieth-Century Medicine. Cambridge MA: MIT 
Press. 
  271 
Kennedy, I (2001). Kennedy, I (2001) Learning from Bristol: The Report of the 
Public Inquiry into children’s heart surgery at the Bristol Royal Infirmary 
1984–1995. London: The Stationery Office. 
Klein, R. Raymond, J. and Dumble, L. (1991.) RU486: Misconceptions, Myths and 
Morals. Melbourne: Spinifex. 
Kringelbach, M. and Aziz, T. (2009). Deep Brain Stimulation: Avoiding the Errors 
of Psychosurgery. Journal of the American Medical Association 301(16): 1705-1707. 
Krystkowiak, P., du Montcel, S., Vercueil, L., Houeto, J-L. Lagrange, C., Cornu, P., 
Blond, S., Benabid, A-L. Pollak, P. and Vidailhet, M. (2007). Reliability of the 
Burke-Fahn-Marsden Scale in a Multicenter Trial for Dystonia. Movement 
Disorders  22(5): 685– 689. 
de Laat, B. (2000). Scripts for the future: Using innovation studies to design 
foresight tools. In Brown, N., Rappert, B. and Webster, A. (Eds.). Contested 
Futures: A Sociology of Prospective Techno-Science. Aldershot: Ashgate. pp. 175-208. 
de Laet, M. and Mol, A. (2000).  The Zimbabwe Bush Pump Mechanics of a Fluid 
Technology. Social Studies of Science 30(2): 225-263. 
Laitinen, L. V., Bergenheim, A. T. and Hariz, M. I. (1992). Leksell's posteroventral 
pallidotomy in the treatment of Parkinson’s. Journal of Neurosurgery 76: 53-61. 
Langston J., Forno L., Rebert C. and Irwin I. (1984). Selective nigral toxicity after 
systemic administration of 1-methyl-4-phenyl 1-1,2,3,6, tetrahydropyridine 
(MPTP) in the squirrel monkey. Brain Research 292: 390–394. 
Lampland, M. & Star, L. (2009). Standards and Their Stories: How Quantifying, Classifying, 
and Formalizing Practices Shape Everyday Life, New York: Cornell Press. 
Latour, B. (1987). Science in action: how to follow scientists and engineers through 
society. Cambridge MA: Harvard University Press. 
Latour, B. (1992). Where are the missing masses? The sociology of a few mundane 
artifacts. In Bijker, W. and Law, J. (Eds.). Shaping Technology, Building Society. 
Cambridge MA: MIT University Presspp. 225-258.  
Latour, B. (1993). We Have Never Been Modern. Cambridge MA: Harvard University 
Press. 
Latour, B. (2001). Gabriel Tarde and the End of the Social 
http://www.brunolatour.fr/ articles /article/082.html. 
Latour, B. (2004). How to talk about the body: the normative dimension of science 
studies. Body and Society 10(2-3): 205-229. 
  272 
Latour, B. (2005). Reassembling the Social: An Introduction to Actor-Network 
Theory. Oxford: Oxford University Press. 
Latour, B. and Woolgar, S. (1986). Laboratory Life: The Construction of Scientific Facts. 
Princeton NJ: Princeton University Press.   
Law, J. (1992). Notes on the theory of the actor-network: Ordering, strategy, and 
heterogeneity. Systems Practice.  5(4): 376-393. 
Law, J. (2004) After method: Mess in social science research. New York: Routledge. 
Law, J. (2007) Actor Network Theory and Material Semiotics. Available at 
http://www.heterogeneities.net/publications/Law2007ANTandMaterialSemio
tics.pdf 
Law, M., Babtiste, S., Carswell, A., McColl, MA., Polotajko, H. and Pollock, N. 
(2005). Canadian Occupational Performance Measure. Ottowa: CAOT Publications 
ACE.  
Leathard, A. (2003). Policy Overview. In Leathard, A. (Ed.). Interprofessional 
Collaboration: From Policy to Practice in Health and Social Care. New York: Brunner-
Routledge. 
Lebiedowska M., Gaebler-Spira, D., Burns, R. and Fisk, J. (2004). Biomechanic 
characteristics of patients with spastic and dystonic hypertonia in cerebral 
palsy. Archives of Physical Medical Rehabilitation. 85: 876-880.  
Limousin, P., Pollak, P., Benazzouz, A., Hoffmann, D., Le Bas, J. F., Perret, J. E., et 
al. (1995). Effect on parkinsonian signs and symptoms of bilateral subthalamic 
nucleus stimulation. The Lancet, 345(8942): 91-95. 
Lynch, M. (1982). Technological work and critical inquiry: investigations in a 
scientific laboratory. Social Studies of Science 12: 499-533 
Lynch, M. (1985). Art and Artifact in Laboratory Science. London: Routledge & Kegan 
Paul.  
Manji, H., Howard, R., Miller, D., Hirsch, P., Carr, L., Bahtia, K., Quinn, N., and 
Marsden, C. (1998). Status dystonicus: the syndrome and its management. 
Brain, 121: 243-252.  
Marks, W., Honeycutt, J., Acosta, F. and Reed, M. (2009). Deep Brain Stimulation 
for Pediatric Movement Disorders. Seminars in Pediatric Neurology, 16(2): 90-
98.  
Marsden, C. D., and Parkes, J. D. (1977). Success and problems of long-term 
levodopa therapy in Parkinson’s disease. The Lancet, 309(8007): 345-349. 
  273 
Martin, P. (1999). Genes as drugs: the social shaping of gene therapy and the 
reconstruction of genetic disease. Sociology of Health and Illness 21(5): 517-538. 
Martínez-Martín, P., Gil-Nagel, A., Gracia, L., Gomez, J., Martinez-Sarries and 
Bermejo, F. (1994). Unified Parkinson’s disease rating scale characteristics and 
structure. Movement Disorders 9(1): 76-83. 
Maseida, D. (2011). Body work in respiratory physiological examinations. Sociology of 
Health and Illness. 33(2): 296-277.  
Mashour, G., Walker, E. and Robert, M. (2005). Psychosurgery: past, present, and 
future. Brain Research Reviews. 48: 409-419. 
Mauss, M. (1977 [1934]). Techniques of the body. Economy and Society 2(1): 70-88. 
May, C. Rapley, T. Moreira, T., Finch, T. and Heaven. (2006). Technogovernance: 
Evidence, subjectivity, and the clinical encounter in primary care. Social Science 
and Medicine 62: 1022-1030. 
Mayberg, H., Lozano, A., Voon, V., McNeely, H., Seminowicz, D., Hamani, C., 
Schwalb, J. and Kennedy, S. (2005). Deep Brain Stimulation for Treatment-
Resistant Depression. Neuron 45: 651–660. 
McClelland, V., Mills, K., Siddiqui, A., Selway, R. and Lin, J-P. (2011) Central motor 
conduction studies and diagnostic magnetic resonance imaging in children with 
severe primary and secondary dystonia. Developmental Medicine and Child Neurology 
53: 757-763. 
McConachie, H., Salty, A., Chaduryz, Y., McLachlanz, A. and Logan, S. (1999). 
How do Child Development Teams work? Findings from a UK national 
survey.  Child: Care, Health and Development.  25(2): 157-168. 
McGee, E. and Maguire, G. (2007). Becoming Borg to Become Immortal: 
Regulating Brain Implant Technologies. Cambridge Quarterly of Healthcare Ethics 
16: 291-302. 
Medical Services Advisory Committee. (2008). Deep brain stimulation for dystonia and 
essential tremor. Canberra, Australia: MSAC; Report No.: 1092. 
Medtronic (2010). Innovating for Life: 2010 Annual Report. Minneapolis: Medtronic. 
Medtronic (2013). Delivering Solutions. Advancing Healthcare: 2013 Annual Report. 
Minneapolis: Medtronic. 
Medtronic (2014). Benefits and Risks. Parkinson’s Disease. Available at: 
www.medtronic.com/patients/parkinsons-disease/therapy/benefits-and-
risks/index.htm#  [Accessed on 3rd February 2014] 
  274 
Merleau-Ponty, M. (1962). The Phenomenology of Perception. London: Routledge.  
Miller, F. (2007). Physical Therapy of Cerebral Palsy. New York: Springer. 
Monbaliu, E., Ortibus, F., Desloovere, K., Deklerck, J., de Cock, P. and Feys, H. 
(2010). Rating scales for dystonia in cerebral palsy: reliability and validity. 
Developmental Medicine and Child Neurology 52(6): 570-575.  
Montgomery, E. B., & Gale, J. T. (2008). Mechanisms of action of deep brain 
stimulation (DBS). Neuroscience & Biobehavioral Reviews, 32(3): 388-407. 
Montgomery, E. and Gale, J. (2008). Mechanisms of action of deep brain 
stimulation (DBS). Neuroscience & Biobehavioral Reviews 32: 388-407. 
Mol, A. (1999). Ontological Politics: A Word and Some Questions. In Law, J. 
Hassard, J. (Ed.). Actor Network Theory and After. Oxford: Blackwell 
Publishing.pp74-89. 
Mol, A. (2002). The body multiple: ontology in medical practice.  Duke University 
Press. 
Mol, A. (2008). The Logic of Care: Health and the Problem of Patient Choice. London: 
Routledge. 
Moriera, T. (2004). Coordination and embodiment in the operating room. Body and 
Society 10(1): 109-129. 
Morlacchi, P. and Nelson, P. (2011). How medical practice evolves: Learning to 
treat failing hearts with an implantable device, Research Policy. 40: 511-525. 
Morrison, D. (2008). Making the autonomous client: how genetic counselors 
construct autonomous subjects. In B. Rothman, E. Armstrong and R. Tiger. 
(Eds.). Bioethical Issues: Sociological Perspectives (pp. 179-198). Oxford: Elsevier.   
Morrison, D.  and Bliton, M. J. (2011). Exploring Layers of Meaning with Deep 
Brain Stimulation Patients. AJOB Neuroscience, 2(1): 26-28. 
Morgan, (2008). The doctor-patient relationship. In G. Scambler (Ed.). Sociology as 
applied to medicine. London: Saunders Elsevier 
Moutaud, B. (2011). Are we receptive to naturalistic explanatory models of our 
disease experience? Applications of deep brain stimulation to obsessive 
compulsive disorder and parkinson’s disease. In (Pickersgill, M. and Van 
Keulen, I. (Eds.). Sociological Reflections on the Neurosciences. Bingley UK: Emerald 
Group Publishing. pp. 179-202.   
  275 
Mundinger F. (1965). Stereotaxic interventions on the zona incerta area for 
treatment of extrapyramidal motor disturbances and their results. Confinia 
Neurologica 26(3): 222-230. 
Mundinger F. (1977). New stereotactic treatment of spasmodic torticollis with a 
brain stimulation system. Med Klin 72: 1982-1986 
Mullett, K. (1987). State of the Art in Neurostimulation. PACE 10: 162-175.  
Nashold, B. and Slaughter, D. (1969). Effects of Stimulating or Destroying the 
Deep Cerebellar Regions in Man. Journal of Neurosurgery 31:172-186. 
NHS Commissioning Board (2013). Clinical Commissioning Policy: Deep Brain 
Stimulation (DBS) In Movement Disorders(Parkinson’s Disease, Tremor and Dystonia). 
National Commissioning Board.   
NHS: National Institute for Health and Clinical Excellence (2006). Deep Brain 
Stimulation for Tremor and Dystonia (Excluding Parkinson’s disease). NHS: 
National Institute for Health and Clinical Excellence. [online] Available at: 
http://guidance.nice.org.uk/IPG188 [Accessed on 29 June 2013] 
NHS England commitment to shared decision making (2013). NHS. Available from: 
http://www.england.nhs.uk/ourwork/pe/sdm/commitment/ [Accessed on 
October 10, 2013].  
NHS Choices (2012). Consent to treatment: Children and teenagers.  Available at: 
http://www.nhs.uk/Conditions/Consent-to-treatment/Pages/Children-under-
16.aspx.  [Accessed on February 17, 2014].  
Nightingale, P. and Martin, P. (2004). The myth of the biotech revolution. 
TRENDS in Biotechnology 22(11): 564-569. 
Novas, C. (2006). The political economy of hope: patients organisations, science 
and biovalue. Biosocieties 1(3): 289-305. 
Nuffield Council on Bioethics. (2013). Novel Neurotechnologies: Intervening in the Brain. 
Nuffield Council on Bioethics: London. 
Nygard, L., Bernspang, B., Fisher, A. and Winblad, B. (1994). Comparing motor and 
process ability of persons with suspected dementia in home and clinic settings. 
American Journal of Occupational Therapy 49(8): 689-696.  
Ortega, F. (2009). The cerebral subject and the challenge of neurodiversity. 
BioSocieties 4: 346-365. 
Ostrem, J. L., & Starr, P. A. (2008). Treatment of Dystonia with Deep Brain 
Stimulation.  Neurotherapeutics 5(2): 320-330. 
  276 
Pawson, R. (1999). ‘Methodology’ In S. Taylor (Ed.). Sociology: Issues and Debates 
London: MacMillian.  
Pasveer, B. (1989). Knowledge of the shadows: the introduction of X-ray images in 
medicine. Sociology of Health and Illness 11(4): 360-381.  
Penfield, W. (1936). Epilepsy and Surgical Therapy. Archives of Neurology and Psychiatry 
36: 449-484. 
Petryna, A. (2006). Globalising human subjects in human research. In Petryna, A., 
Lakoff, A. and Kleinman, A. (Eds.). Global Pharmacueticals: Ethics, Markets, 
Practices.  Durham: Duke University Press. pp. 33-60.  
Pickersgill, M. (2009). Between soma and society: Neuroscience and the ontology of 
psychopathy. BioSocieties 4(1): 45-60.  
Pickersgill, M. and Van Keulen, I. Sociological Reflections on the Neurosciences Bingley 
UK: Emerald Group Publishing.  
Pickersgill, M., Cunningham-Burley, S., & Martin, P. (2011). Constituting 
neurological subjects: Neuroscience, subjectivity and the mundane significance 
of the brain. Subjectivity 4: 346-365. 
Pickstone, J. (2000). Ways of Knowing: A New Science, Technology and Medicine. 
Manchester: Manchester University Press. 
Pietroni, P. (1992). Towards reflective practice – the languages of health and social 
care. Journal of Interprofessional Care 1: 7-16. 
Porras, G., Li, Q., and Bezard, E (2012). Modeling Parkinson’s in Primates: The 
MPTP Model. Cold Spring Harbor Perspectives in Medicine. 2(3).  
Porter, T. (1994). Making Things Quantitative. Science in Context 7: 389-407. 
Porter, T. (1995). Trust in Numbers: The Pursuit of Objectivity in Science and Daily Life. 
Princeton: Princeton University Press.  
Polanyi, M. (1962). Tacit knowing. Review of Modern Physics 34: 601-616. 
Popper, K. (1959). The Logic of Scientific Discovery. London: Unwin Hyman. 
Rabinow, P. (Ed.). (1991). The Foucault Reader: An Introduction to Foucault's Thought. 
London: Penguin. 
Rabinow, P. (1996). Essays in the Anthropology of Reason. Princeton  NJ: Princeton 
University Press.  
Racine, E., Waldman, S., Palmour, N., Risse, D. & Illes, J. (2007). “Currents of 
Hope”: Neurostimulation Techniques in U.S and U.K. Print Media. Cambridge 
Quarterly of Healthcare Ethics 16: 312-316. 
  277 
Rapp, R. (2011). A child surrounds this brain: the future of neurological difference 
according to scientists, parents and diagnosed young adults. In Pickersgill, M. 
and Van Keulen (Eds.). Sociological Reflections on the Neurosciences Bingley UK: 
Emerald Group Publishing. pp. 3-26. 
Reichenbach, H. (1938). Experience and Prediction: An Analysis of the 
Foundations and the Structure of Knowledge. Chicago: University Press of 
Chicago. 
Reiser, S. (1993). The Era of the Patient. Journal of the American Medical Association 
269(8): 1012-1017.  
Relman, A. (1980). The New Medical Industrial Complex. New England Journal of 
Medicine 303: 963-970.  
Rhodes, L., McPhillips-Tangum, C., Markham, C. and Klenk, R. (1999). The power 
of the visible: the meaning of diagnostic tests in chronic back pain. Social Science 
& Medicine, 48(9): 1189-1203. 
Ritzer, G. (1996). The McDonalsization of Society: An Investigation into the Changing 
Character of Contemporary Social Life. Thousand Oaks CA: Pine Forge Press.  
Rose, N. (2003). Neurochemical selves. Society 41: 46-59. 
Rose, N. (2007). The Politics of Life Itself: Biomedicine, Power, and Subjectivity in the Twenty-
First Century. Princeton NJ: Princeton University Press. 
Rose, N. and Abi-Rached, J. (2013). Neuro: The New Brain Sciences and the Management 
of the Mind. Woodstock UK: Princeton University Press. 
Rose, N and Novas, C. (2004). Biological citizenship. In Ong, a and Collier, S. 
(Eds.). Global Assemblages: Technology, Politics and Ethics as Anthropological Problems. 
New York: Blackwell, 439-463. 
Rosenow, J., Das, K., Rovit, R. L. and Couldwell, W. T. (2002). Irving S. Cooper 
and His Role in Intracranial Stimulation for Movement Disorders and 
Epilepsy. Stereotactic and Functional Neurosurgery 78: 95-112. 
Ross. L. Children in Medical Research: Access Versus Protection. New York: Oxford 
University Press.  
Rossi, U. (2003). The History of Electrical Stimulation of the Nervous System for 
the Control of Pain. In B. Simpson (Ed.), Electrical Stimulation and the Relief of 
Pain (pp. 5-16). Amsterdam: Elsevier. 
Rosser, J. (1999). On the complexities of complex economic dynamics. Journal of 
Economic Perspectives 13: 169–92. 
  278 
Rothman, B. (1986). The Tentative pregnancy: Prenatal diagnosis and the future of motherhood. 
New York: Viking.  
Russell, D., Rosenbaum, P., Cadman, D., Gowland, C., Hardy, S. and Jarvis, S. 
(1989). The gross motor function measure: a means to evaluate the effects of 
physical therapy. Developmental Medicine and Child Neurology 31: 341-352.  
Russell, D., Rosenbaum, P., Avery, L. and Lane, M. (2002). Gross Motor Function 
Measure (GMFM-66 and GMFM-88) User’s Manual. London: MacKeith Press.  
Schermer, M. (2011). Ethical Issues in Deep Brain Stimulation. Frontiers in 
Intergrative Neuroscience 5: 17 
Schupbach, M., Gargiulo, M., Welter, M., Mallet, L., Behar, C., Houeto, J., Maltete, 
D., Mesnage, V., and Agid, Y. (2006) Neurosurgery in Parkinson’s disease: A 
distressed mind in a repaired body? Neurology 66(12): 1811-1816. 
Schlaepfer, T. E., & Fins, J. J. (2010). Deep Brain Stimulation and the Neuroethics 
of Responsible Publishing. JAMA: The Journal of the American Medical Association, 
303(8): 775-776. 
Schlaepfer, T., Cohen, M., Frick, C., Kosel, M. and Brodesser, D., Axmacher, N., 
Young Joe, A., Kreft, M., Lenarts, D. and Sturm, V. (2008).Deep Brain 
Stimulation to Reward Circuitry Alleviates Anhedonia in Refractory Major 
Depression. Neuropsychopharmacology  33: 368–377.  
Schlaepfer, T. and Fins, J. (2010). Deep Brain Stimulation and the Neuroethics of 
Responsible Publishing: When One is Not Enough. Journal of the American 
Medical Association 303(8): 775-776. 
Sem-Jacobsen C. (1966). Depth-electrographic observations related to Parkinson’s 
Disease. Recording and electrical stimulation in the area around the third 
ventricle. Journal of Neurosurgery  24: 388-402. 
Shatin, D., Mullet, K. and Hults, G. (1986). Totally Implantable Spinal Cord 
Stimulation for Chronic Pain: Design and Efficacy. PACE 9: 577-583.  
Shealy, N., Mortimier, J. & Reswick, J. (1967). Electrical Inhibition of Pain by 
Stimulation of the Dorsal Columns: Preliminary Clinical Report. Anesthesia and 
Analgesia 44: 489-491. 
Shilling, C. (2007). Sociology and the body: classical traditions and new agendas. In 
Shilling, C. (Ed.). Embodying Sociology: Retrospect, Progress and Prospects. Oxford: 
Blackwell Publishing. pp. 1-18. 
  279 
Shusterman, R. (2012). Pragmatism’s embodied philosophy: from immediate 
experience to somaesthetics. In Turner, B. (Ed.). Routledge Handbook of Body 
Studies. New York: Routledge. pp. 34-48.  
Siegfried, J. and Shulman J. (1987). Deep Brain Stimulation. PACE  10: 271-272. 
Singh, I. (2012). Brain talk: power and negotiation in children’s discourse about self, 
brain and behaviour. Sociology of Health & Illness 35(6): 813-827. 
Silverman, D. (2001). Interpreting Qualitative Data: Methods for Analysing Talk, 
Text and Interaction. London: Sage Publications 
Spiegel EA., Wycis HT., Marks, M. and Lee AJ. (1947) Stereotaxic apparatus for 
operations on the human brain. Science. 106: 349-50 
Stuart, M. (2012). Deep Brain Provides Stimulating Market. Medtech Insight 14(4)  
Synofzik, M., & Schlaepfer, T. E. (2011). Electrodes in the brain--Ethical criteria for 
research and treatment with deep brain stimulation for neuropsychiatric 
disorders. Brain Stimulation, 4(1): 7-16. 
Taghva, A., Corrigan, J. & Rezai, A. (2012). Obesity and Brain Addiction Circuitry: 
Implications for Deep Brain Stimulation. Neurosurgery 71(2): 224-238. 
Talan, J. (2009). Deep Brain Stimulation: A New Treatment Shows Promise in the Most 
Difficult Cases, New York, Dana Press. 
Tarde, G. (2010). The Laws of Imitation. New York: Henry Holt and Company. 
Tieman, B., Palisano, R. and Sutlive, A. (2005). Assessment of motor development 
and function in preschool children. Mental Retardation and Developmental 
Disabilities Research News 11: 189-196.  
Timmermans, S. and Berg, M. (2003). The Gold Standard: The Challenge of Evidence-
Based Medicine and Standardization in Health Care. Philadelphia: Temple University 
Press.  
Twigg, J., Wolkowitz, C., Cohen, R. and Nettleton, S. (2011). Conceptualising body 
work in health and social care. Sociology of Health and Illness 33(2): 171-188.  
United Nations (1989). Convention on the Rights of the Child. New York: UNHCHR. 
Upton, A. (1986). Biostimulation. Pacing and Clinical Electrophysiology, 9, 3-7. 
Upton, A. and Lazorthes, Y. (1987). Editorial. Pacing and Clinical Electrophysiology 10: 
161. 
U.S. Food and Drug Adminstration (2010). Humanitarian Device Exemption. 
[online] Available at: 
http://www.fda.gov/MedicalDevices/DeviceRegulationand 
  280 
Guidance/HowtoMarketYourDevice/PremarketSubmissions/Humanitarian 
DeviceExemption/ [Accessed on 30 June 2013].  
Valenstein, E. (1997). The History of Psychosurgery. In Greenblatt (Ed.).  The 
History of Neurosurgery. (pp. 499-516).  Park Ridge: AANS.  
Van Zelst, B., Miller, M. and Russo, R (2006). Activities of daily living in children 
with hemiplegic cerebral palsy: a cross-sectional evaluation using the 
Assessment of Motor and Process Skills. Developmental Medicine & Child 
Neurology 48(9): 723-727. 
Vidailhet, M., Vercueil, L., Houeto, J-L., Krystkowiak, P., Benabid., Cornu, P., 
Lagrange, C., du Montcel, S., Dormont, D., Grand, S., Blond, S., Detante, O., 
Pillon, B., Ardouin, C., Agid, Y., Destee, A. and Pollak, P. (2005). Bilateral 
deep-brain stimulation of the globus pallidus in primary generalised dystonia. 
The New England Journal of Medicine 352(5): 459-467.  
Vidal, F. (2009) Brainhood, anthropological figure of modernity. History of the 
Human Sciences 22: (1): 5–36. 
Webster, A. (2002). Innovative health technologies and the social: Redefining 
health, medicine and the body. Current Sociology 50(3): 443-457.  
Wehrens, R. and Bal, R. (2012). Health Programes Struggling with Complexity: A 
Case Study of the Dutch ‘PreCare’ Project. Social Science & Medicine 75(2): 274-
282. 
Williams, S. and Bendelow, G. (1998) The Lived Body: Sociological Themes, Embodied 
Issues. London: Routledge. 
Wolpe, P. (1998). The triumph of autonomy in American Bioethics: A sociological 
view. In R deVries and J. Subedi (Eds.). Bioethics and Society: Constructing the 
Ethical Enterprise. New Jersey: Prentice Hall. Pp 38-59. 
Yianni, J., Green, A., McIntosh, E., Bittar, R. Joint, C., Scott, R, Gregory, R., Bain, 
P. and Tipu, A. (2005) The costs and benefits of deep brain stimulation surgery 
for patients with dystonia: an initial exploration. Neuromodulation 8(3): 155-61. 
Zeisel, J. (2006). Inquiry by Design: Environment/Bahaviour/Neuroscience in 
Architecture, Interiors, Landscape and Planning. New York: WW Norton & 
Company 
 
 
 
